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Preface
Inflammatory bowel disease (IBD) is a term for a two very different and yet in many
characteristics congruent chronic inflammatory disorder of the intestinal tract. Crohn’s
disease (CD) and ulcerative colitis are two principal components of IBD. Both CD and
ulcerative colitis are considered as multifactoral diseases. For long period of time we keep
these inflammatory intestinal disorders as the result of environmental factors and
immunological disturbances manifested in persons with genetic predisposition. The
pathogenesis of IBD has remained largely unknown, but surely involves environmental
factors, immunological factors in a complex form. Increasing disease prevalence and
gathered lot of new research data on IBD suggested the pretence for review.
Epidemiological studies have shown that prevalence of IDB has dramatically increases in
western world probably due to western lifestyle. Environmental factors are suggested to
have major role in development of diseases connected to westernalization of the lifestyle.
These factors include smoking, use of antibiotics and non-steroidal anti-inflammatory
drugs, stress, various infections and diet. The initiating mechanisms of their actions are still
not understood. Research has revealed several genetic factors contributing to IDB
pathogenesis; more than a hundred IDB genes, loci and their allele variation have been
defined (e.g. NOD2/CARD15, IL23, ATG16L1, IRGM, ICAM-1, CCR5, TLR4, TNFα).
Intestinal stricture is a serious and late complication of CD. Recent studies have identified
certain disease specific characteristics that may be used in identifying individuals having
higher risk for stricture development. These are lower age at initial diagnosis of CD, need
for steroid therapy at the diagnosis, perianal fistulizing disease or small intestinal localized
disease. Anti-Saccharomyces cerevisiae antibody (ASCA) levels were also found to be
correlated to fibrostenosing or penetrating disease behaviour. Recently, other serological
markers (anti-I2 and anti-CBir1), fibronectin, bFGF and YKL-40 glycoprotein of the chitinase
family have been shown to lead to the hyperplasia of the intestinal muscle layers and
deposition of collagen.
Determination of gene polymorphism can also be important in regarding the prediction of
therapy response. Since no curative therapy for IBD exists, pharmacological therapy mainly
focuses on inflammation control. IBD pharmacotherapy utilizes a wide scale of drugs for
inflammation reduction including aminosalicylates, glicocorticoids, immunomodulators and
biological therapy. Their pharmocodinamics and pharmacokinetics can be altered by
polymorphisms of certain gene coding proteins resulting faster drug elimination, tolerance
or more side affect development. Namely, the form of N-acetyltransferase in slow
acetylators can develop more side effects for sulfasalazine, mutation of glucocorticoid
receptor-β lead to decreased affinity to exogenous glucocorticoids, mutations of thiopurine
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markers (anti-I2 and anti-CBir1), fibronectin, bFGF and YKL-40 glycoprotein of the chitinase
family have been shown to lead to the hyperplasia of the intestinal muscle layers and
deposition of collagen.
Determination of gene polymorphism can also be important in regarding the prediction of
therapy response. Since no curative therapy for IBD exists, pharmacological therapy mainly
focuses on inflammation control. IBD pharmacotherapy utilizes a wide scale of drugs for
inflammation reduction including aminosalicylates, glicocorticoids, immunomodulators and
biological therapy. Their pharmocodinamics and pharmacokinetics can be altered by
polymorphisms of certain gene coding proteins resulting faster drug elimination, tolerance
or more side affect development. Namely, the form of N-acetyltransferase in slow
acetylators can develop more side effects for sulfasalazine, mutation of glucocorticoid
receptor-β lead to decreased affinity to exogenous glucocorticoids, mutations of thiopurine
S-methyltransferase defining allelic variations determine the likeliness of leucopenia and
thrombocytopenia development during azathioprine or 6-mercaptopurine treatment.
Patients who are homozygous for certain standard alleles of NOD2, TLR4 and TNFα are
more often resistant to infliximab therapy.
The role of altered composition in intestinal microbiota has also been emphasized in the
development of IBD over the years. The gut microbiota composition varies upon individual
but remains highly stable containing large amount of Bacteroidetes, Firmicutes, Acinetobacter,
Proteobacteria and Fusobacteria containing 150 times larger genetic information than the
human genome. This changed composition in IBD surely affects normal barrier function, cell
metabolism, antibiotic function and inflammatory responses. This book is trying to give
further research data to answer the main question whether altered microbiota composition
is a cause of or a consequence of the inflammatory state.
In the first part of this book you can read chapters for outstanding researchers on the
ethiopathogenesis of IBD including a reviews on environmental factors, genetic
predisposition (including gene polymorphisms influencing disease development, efficacy of
therapy with standard aminosalicylates, glucocorticoids and immunomodulators as well as
biological therapy), altered immune response effecting various components of the innate
and acquired immune system leading to loss of tolerance to commersal enteral bacteria and
to gut dysbiosis.
In the second part of the book clinicians show the management of IBD including the
presentation of use of modern radiological diagnostic modalities in the diagnosis and
identification of extent and activity of IBD. The place of surgical therapy in the management
of IBD patients will be discussed by showing up-to-date minimally invasive techniques
along with the long-term results of classical surgical options.
The last part of the book focuses on future directions of IBD therapy utilizing new
pharmacological methods for more effective drug delivery. Potential role of liposomes and
nanoparticules (NP) will be highlighted in the treatment of IBD and colon cancer. Data will
show that certain nanopaticules, like Ag-NPs or chitosan, may enhance the epithelial
permeability and could therefore serve as an effective carrier for drug delivery, but also
might favour the systemic absorption of toxins or other NPs that would likely cause
immune activation. You can find more interesting data on the beneficial role and night-side
of colon targeting drug delivery systems in this last part of the book.
I am sure together with the Commissioning Editors and the Publisher that all readers,
researcher, clinicians and novice readers, will receive lot of new scientific information by
reading this book.
I wish to thank the outstanding work of all authors, the invitation to the publisher and the
excellent support throughout the publishing process to the commissioning editors, Ms.
Ivona Lovric, Ms. Danijela Duric and Mr. Vedran Greblo.
Imre Szabo MD, PhD
Division of Gastroenterology
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Chapter 1
Insights to the Ethiopathogenesis of the Inflammatory
Bowel Disease
Ana Brajdić and Brankica Mijandrušić-Sinčić
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52970
1. Introduction
Inflammatory bowel disease (IBD) is a term that refers to two very different yet in many
ways related phenotypes, Crohn’s disease (CD) and ulcerative colitis (UC). It is well known
that both of the two primary human inflammatory bowel diseases are characterized by
chronic inflammation of the intestinal tract, yet their etiology still remains unclear.
CD and UC are considered to be multifactorial diseases and the underlying pathological
process seems to be a combination of genetic predisposition and immunologic disturbances.
Being the largest surface in the human body and since it is constantly colonized by a highly
diverse community of microbes that are in normal circumstances either commensal or bene‐
ficial to human health, the role of the intestinal microbiota in development of IBD has been
thoroughly investigated over the years. It is now generally accepted that the commensal
flora plays a central role in triggering and perpetuating the disease process. [1] Even though
there are several logical arguments contributing to the theory that the intestinal microbiota
plays a major role in the IBD development, the types of microbes involved have not been
adequately described. Studies of experimental animal models of IBD uncover that the pres‐
ence of gut bacteria is essential in inflammation initiation and there is no disease onset in
germ-free mice [2]. Furthermore, decreasing bacterial numbers in the intestine by using anti‐
biotics, can lead to clinical improvement and decreased inflammation in both humans [3]
and animal models of IBD [4, 5].
Pathogenesis of the IBD is characterized by various genetic abnormalities that lead to overly
aggressive altered immune response, triggered by heterogeneous environmental factors un‐
der the influence of the commensal intestinal microbiota. There is no single abnormality of
the gastro intestinal tract that would lead to development of CD or UC. Only in correlation
of those four mentioned main factors a dysbalance of the gastrointestinal tract develops,
© 2012 Brajdić and Mijandrušić-Sinčić; licensee InTech. This is an open access article distributed under the
terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
 2012 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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leading to chronic inflammation with all its consequences and complications. Schematized
and simplified pathogenesis involving correlation between environmental factors, genetic
predisposition, host immune response and intestinal microbiota is shown in Figure 1.
Figure 1. Schematized correlation of main factors involved in the IBD pathogenesis. Each of the mentioned factors fit
together as separate pieces of puzzle, together creating a complex clinical and pathological image of the IBD.
In this review, we discuss recent insights in the ethiopathogenesis of the inflammatory bow‐
el diseases.
2. Etiology and pathophysiology
2.1. Environmental factors
Epidemiological studies show that the prevalence of IBD dramatically increased in northern
Europe, the United Kingdom and North America in the second half of the twentieth century
and is also increasing in the rest of the world, proportionally to the adoption of western life‐
style [6]. This process, known as “westernization” of lifestyle [7], includes environmental
triggers such as smoking (shown to be protective in UC but detrimental in CD), use of anti‐
biotics and nonsteroidal anti-inflammatory drugs (NSAIDs), stress, infection and diet. Stud‐
ies have also reported an association between early life exposure to antibiotics (in the first
year of subject’s life) and CD development due to early childhood dysbiosis [8].
Inflammatory Bowel Disease4
The mechanisms by which these factors initiate the onset of IBD are still not well under‐
stood. There is some evidence that infection and NSAIDs can transiently initiate nonspecific
inflammation, break the mucosal barrier and activate innate immune response [9]. This
process may lead to enhanced uptake of commensal bacterial antigens and in combination
with genetic susceptibility, in this way stimulate protracted T-cell mediated inflammation.
Up until now, only smoking and appendectomy have been clearly linked with the risk of
developing IBD. A recent cohort study concerning autophagy-related genes and granuloma
formation in surgically treated CD patients has showed that there is a significant association
between smoking and granuloma formation [10]. This observation could be a result of in‐
flammation promoting effects of smoking, resulting in more severe inflammation with gran‐
ulomas in smokers with CD [10]. Appendectomy and smoking reduce risk for UC but on the
other hand, active smoking increases risk for CD [11]. Even though proven to be valid, these
facts cannot be held answerable for all variations in IBD incidence and prevalence.
There is also a hypothesis known as the “hygiene hypothesis”, that could be the fundamen‐
tal reason for the switch from infectious to chronic inflammatory diseases. This hypothesis
proposes that there has been a lifestyle change from one with high microbial exposure to
one with low microbial exposure [12]. There are numerous environmental factors that could
be assigned to the hygiene hypothesis, some of which being better housing, safer food,
cleaner water, vaccines, dietary changes, fewer infections, improved hygiene and sanitation
and widespread use of antibiotics [12].
Even though there are many firm epidemiological studies and evidence linking certain envi‐
ronmental factors to greater probability of developing IBD, it is still widely believed that
there is no one simple environmental factor that could alone cause CD or UC. Based on the
fact that differences in geographic distribution combined with changes in incidence over
time within one observed area could provide insights into possible etiologic factors, a pro‐
spective population based study investigated the incidence of UC and CD in Primorsko-gor‐
anska County, Croatia (January 2000 to December 2004) was performed by the authors [13].
The study included a total of 170 patients residing a county with a stable, ethnic and racially
homogeneous population and the results showed an increase in UC and CD incidence, in
comparison to an earlier prospective study for the county of Zagreb, with a similar popula‐
tion and similar environmental circumstances [13]. It is considered that the rapid “westerni‐
zation” of the country combined with the improved awareness of the disease play a role in
the reported increase. Annual age-standardized incidence rate was 4,3/105 for UC and
7,0/105 for CD. Croatian results concerning UC were similar to those reported in Belgium,
Northern France and Germany and those concerning CD reach the mean incidence value re‐
ported in European multicentric study of CD [13].
2.2. Genetic predisposition
There have recently been great advances in understanding the very complex genetics of the
IBD, from studies based on single nucleotide polymorphism and candidate gene approaches
to studies based on transgenic and deletion techniques [14]. It is thought that UC and CD
may be heterogeneous polygenic disorders, sharing some but not all susceptibility loci and
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there are most likely several factors determining the disease phenotype [15]. Presence of a
mutated gene in a host does not guarantee that IBD will develop and we cannot use it as a
predicting factor for later development of IBD.
In order to prove that genetic factors contribute to the pathogenesis of IBD, studies have
shown that the concordance rate between twins is much lower for UC than for CD, which
may indicate that the genetic penetrance in CD is much greater than in UC. Reported con‐
cordance rate for UC in monozygotic twins is 15,4% vs. 3,9% in dizygotic twins and for CD
30,3% in monozygotic vs. 3,6% in dizygotic twins [16]. These findings may be considered
valuable evidence that there is genetic susceptibility for IBD, particularly CD. Also, studies
have shown that there is linkage between certain genetic disorders and incidence of IBD. In
infants born to consanguineous parents there is a risk of developing extremely rare autoso‐
mal recessive mutations in genes encoding interleukin (IL)-10 receptor and the IL-10 cyto‐
kine [17, 18]. IL-10 is an anti-inflammatory cytokine and its primary purpose is to limit and
ultimately terminate inflammatory responses [19]. Disturbance in either IL-10 or IL-10 recep‐
tor function via autosomal, recessive mutations are sufficient to cause severe forms of CD,
which have been successfully treated by bone marrow transplantation [20].
There have been over a hundred IBD genes and loci defined and one of the most important
genes associated with CD is nucleotide binding oligomerization domain protein 2 (NOD 2), also
known as the caspase recruitment domain family member 15 (CARD15) gene [21, 22]. The NOD2
gene is expressed mainly in monocyte/macrophage cell lines where it plays an important
role in host-signaling pathways. One of its main effects is the activation of the NF-κB pro‐
tein, a transcription factor involved in cellular inflammatory pathways and an important
regulator in cell fate decisions, such as programmed cell death and proliferation control, and
also a critical factor in tumorigenesis.
The NOD2 mutations have been observed in individuals of European and African-American
ancestry and studies have shown that in individuals of European ancestry heterozygous car‐
riage of one of the major risk alleles bargain a 2,4-fold increase in risk for CD while homozy‐
gous or compound heterozygous carriage bargains 17,1-fold increase in risk for CD [22]. In
those of African American origin, mutations are only heterozygous with similar risk for CD
among carriers as mentioned above. When it comes to Asian populations, studies show that
NOD2 mutation has not been associated with CD in studies of IBD patients form Hong
Kong, China, Japan and Korea [23]. Mutations in the NOD2 gene, unexpectedly, reduce
macrophage activation of NF- κB protein, which is why one would expect inflammation to
weaken, instead of the increase of inflammation, which can be seen in IBD. In the absence of
NOD-2 expression by epithelial cells, microbial products that normally induce these cells to
secrete chemokines fail to do so, leading to potential loss of barrier function [7].
It is known that in about 70% of patients suffering from CD, the disease affects the small
intestine. The human intestinal epithelial wall exceeds all other tissues of the human organ‐
ism in its cell-renewal rate [24]. The intestinal adult stem cells self-renew and produce
daughter cells. Daughter cells form an adjacent zone of rapidly cycling progenitors and un‐
dergo 4-6 rounds of division before differentiating into multiple lineages, fabricating up to
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300 cells/crypt per day [25]. In this way, post-mitotic cells covering the biggest area of the
intestinal epithelium are formed.
Besides absorptive cells, there are three classes of secretory cells: goblet cells (secrete mainly
mucus), enteroendocrine cells (secreting different hormones) and Paneth cells [26]. Current‐
ly, the most acceptable role of Paneth cells in the small intestine is the production of a
stream of antibacterial secretions, responsible for the sterile environment of the small intesti‐
nal lumen and in this way, protection of the vital stem cells in the neighborhood. Two most
frequent defensins found in Paneth cells are the α defensins, human defensin 5 and 6 (DE‐
FA5 and DEFA6) and in addition to DEFA5 and DEFA6, Paneth cells store several other an‐
tibiotic peptides (for example regenerating islet-derived 3-γ and phospholipase A2group
IIA) [27]. Investigations on human α defensins have shown that DEFA5 has a very effective
antibacterial activity against S. aureus, while DEFA6 expressed some antibacterial potential
in vitro and there are ongoing investigations on their antiviral potential [28, 29]. There is nu‐
merous evidence for a link between the Paneth cell and ileal Crohn’s disease. It is reported
that NOD 2 is heavily expressed in Paneth cells and ileal CD is associated with a diminished
synthesis of Paneth cell defensins [30, 31]. The role of NOD2 as an intracellular receptor for
bacterial dipeptide in regulating Paneth cell defensin formation was confirmed in NOD-2
knockout mice and in patients after small intestinal transplantation [32, 33].
Being a genetically complex system, pathogenesis of IBD can be closely linked to numerous
other genomic regions. Autophagy 16-like 1 (ATG16L1) is responsible for encoding a protein
component of the autophagy complex and it has been strongly related to CD [34]. ATG16L1
is extensively expressed, including in Paneth cells, where it has a role in exocytosis of secre‐
tory granules containing antimicrobial products [35].
Other genes that regulate autophagy and that have been closely related to CD in genome-
wide association studies are immunity-related guanosine triphosphotase M (IRGM) and leu‐
cine-rich repeat kinase 2 (LRRK2) [36, 37]. A recent study by Brinar et al. [10] investigated a
relationship between variants in autophagy genes and granuloma formation in CD. The au‐
thors hypothesized that genetic variants in autophagy genes in CD patients may lead to im‐
paired processing of intracellular bacterial components, thus contributing to granuloma
formation. [10]. This cohort study detected an association in four autophagy genes, ATG4A,
ATG4D, FNBP1L and ATG2A. The study has also shown that granuloma positive patients
were significantly younger at diagnosis, that they had surgery at significantly younger age
after a shorter duration of the disease. These findings suggest that there is a significant rela‐
tionship between earlier mentioned variants in autophagy genes and granuloma formation,
which could be a marker of a more aggressive disease course. [10]
After variants in NOD2, most significantly associated with CD is the amino acid change
Arg381Gln variant in the IL-23 receptor (IL23). In comparison to Arg381 carriers, Glutamine
381 reduces risk for IBD by nearly 3-fold and studies on the proinflammatory role of IL-23
prioritize its signaling pathway as a therapeutic target in inflammatory bowel disease [38].
Many genes that encode factors in the IL-23 pathway have been associated with both psoria‐
sis and IBD and numerous loci have been associated with both IBD and celiac disease [39,
Insights to the Ethiopathogenesis of the Inflammatory Bowel Disease
http://dx.doi.org/10.5772/52970
7
there are most likely several factors determining the disease phenotype [15]. Presence of a
mutated gene in a host does not guarantee that IBD will develop and we cannot use it as a
predicting factor for later development of IBD.
In order to prove that genetic factors contribute to the pathogenesis of IBD, studies have
shown that the concordance rate between twins is much lower for UC than for CD, which
may indicate that the genetic penetrance in CD is much greater than in UC. Reported con‐
cordance rate for UC in monozygotic twins is 15,4% vs. 3,9% in dizygotic twins and for CD
30,3% in monozygotic vs. 3,6% in dizygotic twins [16]. These findings may be considered
valuable evidence that there is genetic susceptibility for IBD, particularly CD. Also, studies
have shown that there is linkage between certain genetic disorders and incidence of IBD. In
infants born to consanguineous parents there is a risk of developing extremely rare autoso‐
mal recessive mutations in genes encoding interleukin (IL)-10 receptor and the IL-10 cyto‐
kine [17, 18]. IL-10 is an anti-inflammatory cytokine and its primary purpose is to limit and
ultimately terminate inflammatory responses [19]. Disturbance in either IL-10 or IL-10 recep‐
tor function via autosomal, recessive mutations are sufficient to cause severe forms of CD,
which have been successfully treated by bone marrow transplantation [20].
There have been over a hundred IBD genes and loci defined and one of the most important
genes associated with CD is nucleotide binding oligomerization domain protein 2 (NOD 2), also
known as the caspase recruitment domain family member 15 (CARD15) gene [21, 22]. The NOD2
gene is expressed mainly in monocyte/macrophage cell lines where it plays an important
role in host-signaling pathways. One of its main effects is the activation of the NF-κB pro‐
tein, a transcription factor involved in cellular inflammatory pathways and an important
regulator in cell fate decisions, such as programmed cell death and proliferation control, and
also a critical factor in tumorigenesis.
The NOD2 mutations have been observed in individuals of European and African-American
ancestry and studies have shown that in individuals of European ancestry heterozygous car‐
riage of one of the major risk alleles bargain a 2,4-fold increase in risk for CD while homozy‐
gous or compound heterozygous carriage bargains 17,1-fold increase in risk for CD [22]. In
those of African American origin, mutations are only heterozygous with similar risk for CD
among carriers as mentioned above. When it comes to Asian populations, studies show that
NOD2 mutation has not been associated with CD in studies of IBD patients form Hong
Kong, China, Japan and Korea [23]. Mutations in the NOD2 gene, unexpectedly, reduce
macrophage activation of NF- κB protein, which is why one would expect inflammation to
weaken, instead of the increase of inflammation, which can be seen in IBD. In the absence of
NOD-2 expression by epithelial cells, microbial products that normally induce these cells to
secrete chemokines fail to do so, leading to potential loss of barrier function [7].
It is known that in about 70% of patients suffering from CD, the disease affects the small
intestine. The human intestinal epithelial wall exceeds all other tissues of the human organ‐
ism in its cell-renewal rate [24]. The intestinal adult stem cells self-renew and produce
daughter cells. Daughter cells form an adjacent zone of rapidly cycling progenitors and un‐
dergo 4-6 rounds of division before differentiating into multiple lineages, fabricating up to
Inflammatory Bowel Disease6
300 cells/crypt per day [25]. In this way, post-mitotic cells covering the biggest area of the
intestinal epithelium are formed.
Besides absorptive cells, there are three classes of secretory cells: goblet cells (secrete mainly
mucus), enteroendocrine cells (secreting different hormones) and Paneth cells [26]. Current‐
ly, the most acceptable role of Paneth cells in the small intestine is the production of a
stream of antibacterial secretions, responsible for the sterile environment of the small intesti‐
nal lumen and in this way, protection of the vital stem cells in the neighborhood. Two most
frequent defensins found in Paneth cells are the α defensins, human defensin 5 and 6 (DE‐
FA5 and DEFA6) and in addition to DEFA5 and DEFA6, Paneth cells store several other an‐
tibiotic peptides (for example regenerating islet-derived 3-γ and phospholipase A2group
IIA) [27]. Investigations on human α defensins have shown that DEFA5 has a very effective
antibacterial activity against S. aureus, while DEFA6 expressed some antibacterial potential
in vitro and there are ongoing investigations on their antiviral potential [28, 29]. There is nu‐
merous evidence for a link between the Paneth cell and ileal Crohn’s disease. It is reported
that NOD 2 is heavily expressed in Paneth cells and ileal CD is associated with a diminished
synthesis of Paneth cell defensins [30, 31]. The role of NOD2 as an intracellular receptor for
bacterial dipeptide in regulating Paneth cell defensin formation was confirmed in NOD-2
knockout mice and in patients after small intestinal transplantation [32, 33].
Being a genetically complex system, pathogenesis of IBD can be closely linked to numerous
other genomic regions. Autophagy 16-like 1 (ATG16L1) is responsible for encoding a protein
component of the autophagy complex and it has been strongly related to CD [34]. ATG16L1
is extensively expressed, including in Paneth cells, where it has a role in exocytosis of secre‐
tory granules containing antimicrobial products [35].
Other genes that regulate autophagy and that have been closely related to CD in genome-
wide association studies are immunity-related guanosine triphosphotase M (IRGM) and leu‐
cine-rich repeat kinase 2 (LRRK2) [36, 37]. A recent study by Brinar et al. [10] investigated a
relationship between variants in autophagy genes and granuloma formation in CD. The au‐
thors hypothesized that genetic variants in autophagy genes in CD patients may lead to im‐
paired processing of intracellular bacterial components, thus contributing to granuloma
formation. [10]. This cohort study detected an association in four autophagy genes, ATG4A,
ATG4D, FNBP1L and ATG2A. The study has also shown that granuloma positive patients
were significantly younger at diagnosis, that they had surgery at significantly younger age
after a shorter duration of the disease. These findings suggest that there is a significant rela‐
tionship between earlier mentioned variants in autophagy genes and granuloma formation,
which could be a marker of a more aggressive disease course. [10]
After variants in NOD2, most significantly associated with CD is the amino acid change
Arg381Gln variant in the IL-23 receptor (IL23). In comparison to Arg381 carriers, Glutamine
381 reduces risk for IBD by nearly 3-fold and studies on the proinflammatory role of IL-23
prioritize its signaling pathway as a therapeutic target in inflammatory bowel disease [38].
Many genes that encode factors in the IL-23 pathway have been associated with both psoria‐
sis and IBD and numerous loci have been associated with both IBD and celiac disease [39,
Insights to the Ethiopathogenesis of the Inflammatory Bowel Disease
http://dx.doi.org/10.5772/52970
7
40]. Studies show that neither IL23 nor ATG16L1 genes are associated with CD in Japanese
and Korean patients [41].
There are numerous other loci associated with both CD and UC and the number of potential
IBD genes continues to increase and searching for other genotype-phenotype correlations in
the matter of IBD continues to be an important step in future studies. Despite all the facts
specified, indications for genetic tests in everyday clinical practice still do not exist.
2.3. Host immune response
In order to develop IBD, both innate (macrophage, neutrophil) and acquired (T and B cells)
immune responses combined with loss of tolerance to enteric commensal bacteria need to be
activated in a host.
2.3.1. Innate immune responses
Studies have shown that there is an increase in the absolute number of macrophages and
dendritic cells in both forms of IBD, with an enhanced production of proinflammatory cyto‐
kines and chemokines and an increase in the expression of adhesion molecules and co-stim‐
ulatory molecules [41].
Adhesion molecules (such as intracellular cell adhesion molecule 1, ICAM1 ) are crucial
when it comes to binding circulating cells to the activated endothelium [42]. These mole‐
cules also have an important role in later mediation of migration of the extravagated im‐
mune cells through the stroma to the source of optimum chemokine production as well as
through the epithelium to the lumen [43]. Mucosal dendritic cells are activated, express
higher levels of the toll like receptors (TLR) 2 and 4, (which have an important role in recog‐
nition of bacterial products) and CD40, all of which is followed by increased production of
IL-12 and IL-6 [44]. TLRs are profusely expressed on the surface of monocytes, macrophag‐
es, dendritic and epithelial cells and are responsible in identification of the commensal mi‐
croflora as well as maintenance of the intestinal homeostasis [45]. Like NOD2, they
selectively bind to specific microbial adjuvants and initiate signaling through nuclear factor
kappa-light-chain-enhancer of activated B cell, NF-κB. Activation of NF-κB triggers expres‐
sion of various molecules involved in the inflammatory response (such as IL-1β, TNF, IL-6,
IL-8, ICAM1, CD 40, CD 80 and other chemokines, adhesion molecules and co-stimulatory
molecules), all of which have an increased expression in IBD [41]. NF-κB is activated in tis‐
sues of IBD patients and its inhibition can attenuate experimental colitis [46].
In both forms of IBD, alterations of TLR 3 and 4 have been described, suggesting that abnor‐
mal bacterial sensing has a role in the disease pathogenesis [47]. As explained earlier, ileal
Paneth cells also express the NOD-2 protein, and their production of mucosal α-defensins is
decreased in CD patients with NOD-2 mutations.
2.3.2. Adaptive immune responses
Adaptive immune responses should be considered separately for CD and UC, due to their
distinct profiles in those two entities.
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2.3.2.1. Crohn’s disease
Crohn’s disease is predominantly TH1 and TH17 mediated process. Antigen presenting cells
produce IL-12, which is responsible for stimulation of IFN-γ. IFN-γ then mediates tradition‐
al TH1 responses. As the inflammatory response matures, in several models TH1 responses
can change into TH2 responses [48]. On the other hand, IL-17 mediates TH17 responses [49].
The production of IL-17 is impacted by innate immune cells and antigen presenting cells,
which produce Il-6, IL-23 and TGFB [50].
When it comes to estimating the importance between TH1 and TH17 responses in CD devel‐
opment, studies have shown that even though Th17 responses play a role in the inflamma‐
tion, the Th1 response is quantitatively greater [51]. This conclusion agrees with the
intestinal pathologic effects of IFN-γ and the relation of Th1 responses to granulomatous
disease [51]. In contribution, double blinded clinical trial of anti IL-17 in patients with CD
has been carried out recently and the study showed that blockage of IL-17A is ineffective in
tested subjects [51]. The role of IL-17 in patients suffering from CD is still under intense in‐
vestigation.
2.3.2.2. Ulcerative colitis
Ulcerative colitis is considered to have an atypical TH2 response, mediated by natural killer
T cells that secrete IL-13 and IL-5 [52]. The TH2 response is an atypical one due to the fact
that concentrations of IL-4 and IL-5, which are normally elevated in TH2 response, have been
found to be variable in UC tissues [53]. Recent studies have shown an increase in IL-17 lev‐
els in UC (in compare to control groups), but that increase was found to be far less than the
one found in CD patients. T-cell subsets are stimulated by antigen presenting cells, particu‐
larly dendritic cells, which have a unique capacity to activate naïve T cells. Dendritic cells
are found in the lamina propria and Peyer’s patches of normal intestine. Interaction between
antigen presenting cells and T cells occurs by presenting an antigen on the surface of the ma‐
jor histocompatibility complex, which is then recognized by the appropriate T-cell receptor,
followed by secretion of cytokines ( such as IL-6, IL-10, IL-12, IL-23, TGF β).
The results of this pathway are increased levels of dendritic cells in patients with active IBD
and in experimental colitis models [44, 54]. Peyer’s patches, which can be considered as the
immune senses of the intestine, seem to play a key organ in the relationship between innate
and adaptive immunity in the human gut [55].
2.4. Intestinal microbiota
The understanding of the development of gastrointestinal (GI) tract microbiota has greatly
developed, due to decreased costs of DNA sequencing and evolution of bioinformatics.
The human intestinal microbiota can be defined as a community of microbes that is either
commensal or beneficial to human health. The adult human gut contains around 1014 bacte‐
rial cells and up to a 1000 different bacterial species [56]. The most abundant bacterial phyla
in the healthy human large intestine are Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria,
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Fusobacteria and Verrucomicrobia [56]. The gut microbiota composition varies between indi‐
viduals and remains highly stable over time. A recent study performed by Arumugam et al.
combined 22 newly sequenced faecal metagenomes of individuals from Denmark, France,
Italy and Spain, resulting in three distinctive enterotypes. Furthermore, these results were
combined with existing gut data-sets, 13 Japanese and four American, returning the same
three clusters. These isolated bacterial communities were dominated by one of the three
main distinct bacterial genera – Bacteroides, Prevotella and Ruminococcus [56]. In terms of
function, it is indicated that drivers of each of the three enterotypes use different routes to
generate energy from substrates available in the colon. Bacteroides seem to derive energy pri‐
marily from carbohydrates and proteins through fermentation, Prevotella is a known mucin
degrader and Ruminococcus is linked to both mucin and sugar [56].
Numerous studies have shown that colonization of the GI tract in infants depends upon de‐
livery mode and that the vagina has evolved to serve the fundamental inoculum for all
mammals [57]. If a baby is exposed to vaginal microbes during birth, its initial gut bacteria
will consist dominantly of Lactobacillus and Prevotella spp [58]. The bacteria, acquired from
their mother’s vaginal canal, can be found in the skin and mouth and the meconium of the
baby. Many babies are not exposed to their mother’s vaginal flora, due to the cesarean sec‐
tion-birth method (C-section). In contrast to vaginally delivered babies, those delivered by
C-section accommodate bacterial communities that resemble bacteria of the skin: Staphylo‐
coccus, Corynebacterium and Propionibacterium spp [59]. In early childhood, the initial strains
of GI bacteria are outcompeted by other bacterial strains, of a less certain origin, which rap‐
idly increase in diversity and shift in response to dietary changes and/or illness [60, 61].
During early childhood, when peas and other plant-derived foods are introduced, the bacte‐
rial phyla of the GI tract changes and Firmicutes and Bacteroidetes are now dominant [62]. Mi‐
crobial community can change, but the changes are now of a much slower rate than in early
childhood and with unknown effects on health. The mentioned data and the development of










Table 1. Development of the GI tract colonization in infants and early childhood
Children from different parts of the world have different gut microbiota (for example Burki‐
na Faso and Italy) [63], and when it comes to elderly, their GI tract microbiota is substantial‐
ly different than in young adults [64]. According to Zoetendal et al., the gut microbiota
composition of spouses showed the least degree of species similarity, while siblings showed
increased degree of similarity in species make up [65].
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The gut microbiota acts as a metabolic organ via production of short chain fatty acids and
vitamins and it contributes to the barrier effect by preventing colonisation by pathogens. Re‐
cent studies have shown that a modulation of a gut microbiota using prebiotics increases ep‐
ithelial barrier integrity by increasing expression of tight junction proteins [66]. The gut
microbiota also helps to shape and maintain normal mucosal immunity.
The human gut microbiome consists of 150x more genes than the human genome [67]. In 2010,
initiative called Meta-HIT (Metagenomics of the Human Intestinal Tract) published a cata‐
logue of the microbial genomes strained from 124 faecal samples. The results found that the
gene set was approximately 150 times larger than the human gene complement with 3,3 mil‐
lion different microbial genes [68]. Recent studies have shown that the intestine is home to spe‐
cialized dendrytic cells, whose function is to induce a highly tolerogenic response from T and B
cells, through induction of regulatory T cells and secretion of IgA [69]. Activated immune cells,
such as mucosal dendrytic cells, constantly sample luminal microbial antigens and present
them to adaptive immune cells [70]. There are three main ways by which flagellin from com‐
mensal microbes may play a role in IBD. Flagellin from commensal microbes may cross the al‐
tered epithelial barrier that occurs in IBD. Such flagellin can, via Toll-like receptor 5 (TLR5),
induce the epithelium to secrete cytokines that recruit polymorphonuclear neutrophils (PMN)
[71]. Such cytokines may promote adaptive immunity and/or, alternatively, flagellin may acti‐
vate dendritic cells and directly promote adaptive immune immunity. Flagellin is also target‐
ed by the CD-associated adaptive immune response [71].
In healthy hosts the pro-inflammatory pathways associated with TLR and NLR are sup‐
pressed by inhibitory molecules of both human and bacterial origin, such as COX-2 inhibi‐
tors, NF-κβ inhibitor, IL-10, TGF-β, IFN-α/β etc. [72, 73]. A disruption of this homeostasis
threatens the state of immune tolerance and may result in gut inflammation. How the host
tolerates resident bacteria whilst being able to mount an effective inflammatory response to
invading pathogens is still not fully understood.
Gut microbiota and activity in IBD patients are proven to be abnormal. IBD patients are
characterized by a reduced abundance of dominant members of the gut microbiota. Accord‐
ing to Frank et al., mucosal biopsies taken from CD and UC patients showed reduced abun‐
dance of Firmicutes and Bacteroidetes and a concomitant increase of Proteobacteria and
Actinobacteria, compared to non-IBD control [74]. As a consequence of this dysbiosis, the rel‐
ative abundance of Enterobacteriaceae was increased in IBD patients compared to healthy
control [75, 76]. Significantly lower counts of Bifidobacterium populations were found in rec‐
tal biopsies of patients with UC [77]. Study performed by Macfarlane et al. showed that Clos‐
tridium leptum (Firmicutes) is less abundant in fecal samples of CD patients (Table 2) [77].
Clostridium and Bacteroides species are the cardinal producers of short chain fatty acids (SCFA)
in the human colon [66]. There were decreased SCFA concentrations found in fecal samples of
IBD patients, which could be explained by decreased clostridia of groups IV and XIVa (a broad
phylogenetic classification comprised of several genera and species of gram positive bacteria).
Among the SCFA produced upon carbohydrate fermentation, butyrate has an important role
as a major source of energy for colonic epithelial cells, an inhibitor of pro-inflammatory cyto‐
kine expression in the intestinal mucosa and an inductor of production of mucin and antimi‐
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idly increase in diversity and shift in response to dietary changes and/or illness [60, 61].
During early childhood, when peas and other plant-derived foods are introduced, the bacte‐
rial phyla of the GI tract changes and Firmicutes and Bacteroidetes are now dominant [62]. Mi‐
crobial community can change, but the changes are now of a much slower rate than in early
childhood and with unknown effects on health. The mentioned data and the development of










Table 1. Development of the GI tract colonization in infants and early childhood
Children from different parts of the world have different gut microbiota (for example Burki‐
na Faso and Italy) [63], and when it comes to elderly, their GI tract microbiota is substantial‐
ly different than in young adults [64]. According to Zoetendal et al., the gut microbiota
composition of spouses showed the least degree of species similarity, while siblings showed
increased degree of similarity in species make up [65].
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The gut microbiota acts as a metabolic organ via production of short chain fatty acids and
vitamins and it contributes to the barrier effect by preventing colonisation by pathogens. Re‐
cent studies have shown that a modulation of a gut microbiota using prebiotics increases ep‐
ithelial barrier integrity by increasing expression of tight junction proteins [66]. The gut
microbiota also helps to shape and maintain normal mucosal immunity.
The human gut microbiome consists of 150x more genes than the human genome [67]. In 2010,
initiative called Meta-HIT (Metagenomics of the Human Intestinal Tract) published a cata‐
logue of the microbial genomes strained from 124 faecal samples. The results found that the
gene set was approximately 150 times larger than the human gene complement with 3,3 mil‐
lion different microbial genes [68]. Recent studies have shown that the intestine is home to spe‐
cialized dendrytic cells, whose function is to induce a highly tolerogenic response from T and B
cells, through induction of regulatory T cells and secretion of IgA [69]. Activated immune cells,
such as mucosal dendrytic cells, constantly sample luminal microbial antigens and present
them to adaptive immune cells [70]. There are three main ways by which flagellin from com‐
mensal microbes may play a role in IBD. Flagellin from commensal microbes may cross the al‐
tered epithelial barrier that occurs in IBD. Such flagellin can, via Toll-like receptor 5 (TLR5),
induce the epithelium to secrete cytokines that recruit polymorphonuclear neutrophils (PMN)
[71]. Such cytokines may promote adaptive immunity and/or, alternatively, flagellin may acti‐
vate dendritic cells and directly promote adaptive immune immunity. Flagellin is also target‐
ed by the CD-associated adaptive immune response [71].
In healthy hosts the pro-inflammatory pathways associated with TLR and NLR are sup‐
pressed by inhibitory molecules of both human and bacterial origin, such as COX-2 inhibi‐
tors, NF-κβ inhibitor, IL-10, TGF-β, IFN-α/β etc. [72, 73]. A disruption of this homeostasis
threatens the state of immune tolerance and may result in gut inflammation. How the host
tolerates resident bacteria whilst being able to mount an effective inflammatory response to
invading pathogens is still not fully understood.
Gut microbiota and activity in IBD patients are proven to be abnormal. IBD patients are
characterized by a reduced abundance of dominant members of the gut microbiota. Accord‐
ing to Frank et al., mucosal biopsies taken from CD and UC patients showed reduced abun‐
dance of Firmicutes and Bacteroidetes and a concomitant increase of Proteobacteria and
Actinobacteria, compared to non-IBD control [74]. As a consequence of this dysbiosis, the rel‐
ative abundance of Enterobacteriaceae was increased in IBD patients compared to healthy
control [75, 76]. Significantly lower counts of Bifidobacterium populations were found in rec‐
tal biopsies of patients with UC [77]. Study performed by Macfarlane et al. showed that Clos‐
tridium leptum (Firmicutes) is less abundant in fecal samples of CD patients (Table 2) [77].
Clostridium and Bacteroides species are the cardinal producers of short chain fatty acids (SCFA)
in the human colon [66]. There were decreased SCFA concentrations found in fecal samples of
IBD patients, which could be explained by decreased clostridia of groups IV and XIVa (a broad
phylogenetic classification comprised of several genera and species of gram positive bacteria).
Among the SCFA produced upon carbohydrate fermentation, butyrate has an important role
as a major source of energy for colonic epithelial cells, an inhibitor of pro-inflammatory cyto‐
kine expression in the intestinal mucosa and an inductor of production of mucin and antimi‐
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crobial peptides, thus strengthening epithelial barrier [66, 78]. A decrease of butyrate levels
could be involved in the increased inflammatory state characteristic of IBD. Stimulation of bu‐
tyric acid production could be achieved through repopulation of clostridial clusters IV and XI‐
Va,  or  even through probiotic  therapy with lactic  acid bacteria  [79].  Some evidence has
indicated a promising therapeutic effect of pro, pre and synbiotics in IBD.
BACTERIAL COMMUNITIES
MOST ABUNDANT BACTERIAL PHYLA











↓Clostridium leptem (Firmicutes) in CD
↓Bifidobacterium in UC
Table 2. Most abundant bacterial communities in healthy human large intestine and its alterations in IBD
Paneth cells of the small intestine also have an important role in the human gut microbiota,
as they are a source of α defensins 5 and 6, which may regulate and maintain microbial bal‐
ance in the intestinal lumen. The α defensins 5 and 6 are efficacious against Enterobacteriaceae
and Bacteroides vulgatus and studies have shown their levels are increased in chronic inflam‐
matory conditions [80, 81]. In association with ileal CD, they are significantly reduced, par‐
ticularly in patients with NOD-2 mutations. Colonic CD (but not UC) is associated with β
defensins 2 and 3, which are secreted by leukocytes and epithelial cells of many kinds [82].
As explained above, it is a widely accepted hypothesis that the bacteria play an important
role in the pathogenesis of IBD. There are several ways in which the microbiota might be
linked to IBD. The microbiota as a whole could act as a surrogate pathogen, or specific mem‐
bers of the microbiota could be overt pathogens.
It remains unclear whether the altered gut microbiota composition is a cause of the disease
or a consequence of the inflammatory state, but it is most likely that microbial dysbiosis and
lack of beneficial bacteria, together with genetically predisposed increased epithelial perme‐
ability, bacterial translocation into the lamina propria, defective innate immunity and loss of
tolerance to the resident microbiota eventually lead to IBD.
3. Conclusion
Chronic intestinal inflammation in inflammatory bowel disease develops under the influ‐
ence of environmental triggers in genetically susceptible individuals with an altered im‐
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mune response. The role of the intestinal microbiota in the pathogenesis of IBD still remains
unclear, but even though some enteric bacteria are detrimental and some are protective,
their involvement in the pathogenesis of IBD is unquestionable. Table 3 lists main factors as‐
sociated with IBD development, including known differences between UC and CD ethiopa‐
thogenesis.
Since we currently lack complete understanding of the mechanisms leading to the disease,
this topic remains to be exceedingly interesting and enigmatic and most certainly a challeng‐
ing clinical entity that yet remains to be further investigated and unraveled.
ULCERATIVE COLITIS CROHN’S DISEASE
ENVIRONMENTAL FACTORS
‘westernization of lifestyle’
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Table 3. Interaction of environmental factors, genetic predisposition, host immune response and intestinal
microbiota, main factors associated with CD and UC ethiopathogenesis
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1. Introduction
1.1. What is it a gene polymorphism?
Every protein is coded by a gene and every human gene exists in several allelic variants,
which occur due to mutations and are inherited together with other genetic characteristics
from parents to children. If a certain allelic variant occurs within the population with at least
a 1% frequency, it is known as a common gene polymorphism. However, if the frequency in
the given population is below 1%, it is referred to as a rare allelic variant.
An allele having a majority within a population is called a wild type or standard. Allele(s),
which are a minority within a population, are known as a variant, non-standard or some‐
times a mutant allele.
Percentage frequencies of individual alleles for the same gene polymorphisms in various
populations  are  often significantly  different,  which makes  many clinical  studies  compli‐
cated. For example, variant allele asterisk *10 of gene coding for cytochrome CYP2D6 co‐
des an unstable enzyme with decreasing activity.  It  can result in the slower metabolism
of some drugs, e.g. antidepressants. The frequency of this variant allele is from 1 - 2% in
the Caucasian population but  51% in the Asian population.  The gene CYP2D6 can also
be duplicated or multiplicated. The amount of enzyme is from 2 to 13 times higher com‐
pared to the standard gene allele, which leads to ultra rapid metabolism. The occurrence
of this polymorphism differs.  For example,  in Central Europe, the occurrence is 4% and
in Saudi Arabia it is 29%.
© 2012 Ladislava et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 2012 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
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1.2. Molecular biological basis of gene polymorphism
The molecular biological basis of gene polymorphism is a mutation of the given gene, in
which individual variant alleles occur. Mutations can have a form of replacement or substi‐
tution when one or more nucleotides in a gene are replaced by another one; or they can have
a form of frameshift mutations, including deletions or insertions, when one or more nucleo‐
tides in a gene are missing (=deletion) or are redundant (=insertion). Frameshift mutations
lead to frameshift changes, and from the position of the mutation other amino acids can be
incorporated in the protein chain or a stop codon is generated, which prematurely termi‐
nates transcription of the protein chain.
The most common mutation in gene polymorphisms is the replacement of a single nucleo‐
tide, or the so-called single nucleotide polymorphism or SNP.
SNP represents 90% of all gene polymorphisms in humans. There is a freely accessible data‐
base (http://www.ncbi.nlm.nih.gov/SNP/index.html), which lists over 38 million identified
and validated SNPs, and their number grows every day. SNPs are also associated into
blocks - haplotypes, which are usually inherited together. Therefore, the identification of a
single SNP can theoretically identify the whole haplotype.
1.3. Methods of gene polymorphisms detection
Presently, the basic method of molecular diagnostics is a polymerase chain reaction, PCR. A
basic PCR reaction contains two primers and serves for the detection of one specific locus in
the form of amplicon of a pre-calculated size.
For the purposes of finding simple nucleotide polymorphisms, the products of amplification
can be further digested by restriction endonuclease, and this arrangement is marked PCR-
REA (PCR-restriction enzyme analysis), PRA (primer restriction analysis) or PCR-RFLP
(PCR-restriction fragment length polymorphism) [1]. This method allows for the analysis of
any gene up to a length of approximately 5 kbp. Amplicons of the same length are the result
of PCR amplification. These amplicons are further digested by a suitable restriction endonu‐
clease and the resulting products analyzed by gel electrophoresis. It is a very simple, fast
and highly sensitive detection method for single gene polymorphisms. However, it can only
be used for determining gene polymorphism when two alleles in the given locus differ in
such a way that one contains a restriction locus for the given endonuclease and the other
does not.
DNA sequencing is the determination of the primary structure of nucleotide chain, i.e. the
sequence of nucleotides in DNA molecules. It is a final and definite determination of the ba‐
sic information which DNA carries. Knowledge of the DNA sequence allows to find the
reading frames of potential genes, to analyse exons and introns in structural genes, and to
determine the sequences of amino acid-coded proteins, and is usable for the detection of
regulatory genes and regulatory areas, repetitive sequences and all simple nucleotide poly‐
morphisms. There are two fundamentally different methods which are commonly used for
sequencing. The first method is based on terminating DNA chains using chemical substan‐
ces and is called Maxam-Gilbert Sequencing [2]. The second method uses the inhibition of
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the enzymatic synthesis of DNA by dideoxyterminators, and is known as Sanger’s Sequenc‐
ing Method [3]. Both methods use the same original material, i.e. DNA fragments obtained,
for example, by restriction or cloned in vector. They can also be products of polymerase
chain reaction. The most recent development in sequencing methods has been the introduc‐
tion of devices for automatic sequencing. This method uses enzymatic Sanger’s method and
allows for the determination and processing of DNA sequences at a much faster rate as well
as being more economical than standard techniques [4].
1.4. Clinical consequences of gene polymorphism
The clinical consequences of mutations on the function and the amount of coding protein
(phenotype) depend on their localization and can influence the development of certain dis‐
eases or a patient’s response to a particular drug regarding their effectiveness, as well as the
safety of a chosen pharmacotherapy.
A mutation can be located in the coding areas of a gene (exons), in the regulatory areas (pro‐
moter or generally in the 5´ region of gene) or at the exon–intron interface, i.e. in the exon-
intron primary transcript splicing site.
Mutation in the exon area (the coding part of a gene), is manifested by the substitution of
amino acids or from a change of the amino acid sequence in the protein chain.
If a gene codes for an enzyme, the result of the mutation is a change in the pharmacokinetic
parameters at the drug metabolization level, i.e. leading to the altered activity of this en‐
zyme, or to its complete inactivation and consequent acceleration or deceleration of the met‐
abolic processes leading to the degradation of the active substance in the drug or, on the
other hand, to the formation of the active substance in case of the “prodrug”. If a gene codes
for a receptor protein, the mutation can lead to a change of the receptor’s ability to bind a
ligand and to activate the signaling cascade. This can cause changes in the pharmacodynam‐
ic parameters of the drug. Membrane carriers, protein and P-glycoprotein transporters cod‐
ed by a variant allele of a gene can have an altered affinity to its substrates; variant channel
proteins can create channels with different electrical and chemical characteristics, and this
can result in a change of ionic homeostasis.
Mutation in the regulatory areas of a gene leads to changes in gene expression, i.e. to either
upregulation or downregulation. It is manifested by the lack or excess of protein coded by
this gene. If the mutation is located in the interface area between intron and exon in the pri‐
mary transcript splicing site, this can result in the faulty splicing of the primary transcript,
and can cause a shortening or lengthening of a protein chain, which leads to the loss or re‐
striction of functions of the coding protein.The splicing site is distinguishable by specific ri‐
bonucleoproteins. If the nucleotide sequences in this area differ from the standard gene as a
result of mutation, incorrect splicing of primary transcript hnRNA to mRNA occurs.
The presence of variant alleles can have an impact not only on metabolic processes (absorp‐
tion, distribution and drug elimination), it can also influence the effectiveness and safety of
the chosen pharmacotherapy. Furthermore, it represents an increased risk of the develop‐
ment of certain diseases due to the changing structures or functions of several regulatory
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proteins, which influence the physiological processes of the body. Disease development is
caused by both genetic and environmental factors. Additionally, a patient’s sensitivity to ex‐
ternal factors is varied and this variability is again, genetically conditioned.
2. The role of candidate genes in etiopathogenesis of inflammatory
bowel diseases
Inflammatory bowel diseases (IBD) are chronic inflammatory diseases of the gastrointestinal
tract. The term covers two specific conditions – Crohn’s disease (CD) and ulcerative colitis
(UC), which differ in their anatomic location, intensity and the scope of their affect on the
intestinal mucosa. The etiopathogenesis of these two conditions is not fully understood to
date. However, several studies have confirmed that there are external factors, together with
genetic predisposition, which contribute to the diseases’ onset [5]. The significant role of ge‐
netic predisposition is supported by a relatively high familial occurrence of Crohn’s disease,
a high concordance in monozygotic twins up to 67% a connection with patients’ ethnic or
racial character, and parallel incidences of other rare genetic syndromes. The risk of Crohn’s
disease is 3–5 times higher in the first degree relatives, and a familial occurrence was found
in 15–20% of cases. However, genetic predisposition is more important in CD than in UC [6–
8]. Genes whose products somehow influence the development of the inflammatory reaction
are called “candidate genes,” and they are located at different places on the genome marked
from IBD1 to IBD9 [9]. These candidate genomic loci include NOD2/CARD15, ICAM-1,
CCR5, MDR1, TLR4 and other genes [10–12]. At present, the correlation between the genetic
makeup of an individual and the predisposition to contract a disease has been studied as
well as its connection with the clinical characteristic of a disease.
2.1. NOD2/CARD15 gene
NOD2 (nucleotide-binding oligomerization domain) is a protein expressed by several im‐
mune system cells (monocytes, macrophages and dendritic cells). It is a key molecule that
reacts to the intracellular presence of peptidoglycans of bacterial origin [13]. The binding of
peptidoglycans initiates the signalling cascade, ending with NF-κB activation and the ex‐
pression of pro-inflammatory genes including TNFα [14,15]. In the gene for the protein
NOD2, several polymorphisms were described. Substitutions at positions 702Arg>Trp,
908Gly>Arg and the frameshift mutation (cytosine nucleotide insertion) at position 1007
(3020fsinsC) are most often linked with the disruption of receptor functions. These three
mutations represent 81% mutations of NOD2 in CD patients [16]. The presence of the latter
mutation leads to the disruption of the reading frame during the transcription and to the ter‐
mination of proteosynthesis due to a newly formed stop codon [17]. For the polymorphisms
at positions 702 and 908 was described a comparable or just a slightly increased NF-κB in‐
duction [18]. Furthermore, the presence of the frameshift mutation at position 1007 limits the
structure and function of the NOD2 protein to such an extent that the NF-κB activation in
the presence of peptidoglycan is (MDP used as a standard inductor) undetectable [15] and
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TNFα expression is decreased [19–21]. The described polymorphisms have a relatively high
frequency in the Caucasian population. Carriers of one mutant allele have a 2 to 4 times
higher risk of CD outbreak and recessive homozygotes at 20–40 times higher [20]. An associ‐
ation between the occurrence of the 1007fs frameshift mutation in the NOD2 gene and the
IBD incidence has also been confirmed. A similar association, somewhat less significant, was
also discovered in the 908Gly>Arg polymorphism [21]. Patients with mutations in the gene
CARD15/NOD2 also showed a decreased expression of defensines [22]. Mutations can there‐
fore be predisposed to CD not only directly, but indirectly as well, i.e. by obstructing the
natural antimicrobial immunity mediated by defensines.
2.2. ICAM-1 gene
Lately, the association between IBD and the ICAM-1 gene has also been intensively studied.
This gene codes for the intracellular adhesive molecule ICAM-1 which performs many phys‐
iological functions. It controls the migration of inflammatory elements, participates in the
presentation of antigen, and because it is expressed by various cell types, it is involved in
many signalling cascades [23]. Its significantly increased expression in the intestinal mucosa
was observed in inflammatory bowel diseases. In the ICAM-1 gene, at least 20 SNPs were
identified. A SNP marked 469Lys>Glu has also been linked with IBD [24]. A substitution of
nucleotides leads to the substitution of amino acid in the 5th immunoglobulin domain of
ICAM-1, which is important for the adhesion of B cells and dendritic cells [25]. An altered
function of the protein ICAM-1 potentially contributes to the genetic predisposition for in‐
flammatory diseases and immunity disorders. The prevalence of the 469Lys>Glu polymor‐
phism has also been linked with multiple sclerosis [26], Behcet’s disease [27], psoriatic and
rheumatic arthritis [28] and other chronic inflammatory diseases [29].
2.3. CCR5 gene
Another gene, which intervenes in the reactions of the immune system, is the gene that co‐
des for the receptor CCR5, whose ligands are CC chemokines. The endogenous functions of
this receptor include the mobilization of the relevant immune system cells and the targeting
of their chemotaxis into the inflamed area. The CCR5 receptor is responsible for the trans‐
port of chemokine CC and participates in the entering of virus particles of the human immu‐
nodeficiency virus (HIV-1) into macrophages [30].
Its regulatory role lies in the preference of the Th1 immune response and suppression of the
Th2 immune pathway. It participates, for example, in the immune defence against Mycobac‐
terium tuberculosis, [31]. In the 1990s, it was discovered that the gene for this receptor occurs
in various allelic forms in the population. In particular, a 32 base pairs deletion in the gene
CCR5 was studied because it leads to the expression of a shorter, and therefore non-func‐
tional receptor in the cell membrane and consequently to the disrupted communication be‐
tween cells of the immune system. This deletion mutation is associated with the onset of
pathological inflammatory conditions, such as sarcoidosis [32], rheumatoid arthritis [33] and
periodontitis [34]. A cellular immunity disorder caused by the non-functional receptor
CCR5 could play some role in IBD development.
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genetic predisposition, which contribute to the diseases’ onset [5]. The significant role of ge‐
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a high concordance in monozygotic twins up to 67% a connection with patients’ ethnic or
racial character, and parallel incidences of other rare genetic syndromes. The risk of Crohn’s
disease is 3–5 times higher in the first degree relatives, and a familial occurrence was found
in 15–20% of cases. However, genetic predisposition is more important in CD than in UC [6–
8]. Genes whose products somehow influence the development of the inflammatory reaction
are called “candidate genes,” and they are located at different places on the genome marked
from IBD1 to IBD9 [9]. These candidate genomic loci include NOD2/CARD15, ICAM-1,
CCR5, MDR1, TLR4 and other genes [10–12]. At present, the correlation between the genetic
makeup of an individual and the predisposition to contract a disease has been studied as
well as its connection with the clinical characteristic of a disease.
2.1. NOD2/CARD15 gene
NOD2 (nucleotide-binding oligomerization domain) is a protein expressed by several im‐
mune system cells (monocytes, macrophages and dendritic cells). It is a key molecule that
reacts to the intracellular presence of peptidoglycans of bacterial origin [13]. The binding of
peptidoglycans initiates the signalling cascade, ending with NF-κB activation and the ex‐
pression of pro-inflammatory genes including TNFα [14,15]. In the gene for the protein
NOD2, several polymorphisms were described. Substitutions at positions 702Arg>Trp,
908Gly>Arg and the frameshift mutation (cytosine nucleotide insertion) at position 1007
(3020fsinsC) are most often linked with the disruption of receptor functions. These three
mutations represent 81% mutations of NOD2 in CD patients [16]. The presence of the latter
mutation leads to the disruption of the reading frame during the transcription and to the ter‐
mination of proteosynthesis due to a newly formed stop codon [17]. For the polymorphisms
at positions 702 and 908 was described a comparable or just a slightly increased NF-κB in‐
duction [18]. Furthermore, the presence of the frameshift mutation at position 1007 limits the
structure and function of the NOD2 protein to such an extent that the NF-κB activation in
the presence of peptidoglycan is (MDP used as a standard inductor) undetectable [15] and
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TNFα expression is decreased [19–21]. The described polymorphisms have a relatively high
frequency in the Caucasian population. Carriers of one mutant allele have a 2 to 4 times
higher risk of CD outbreak and recessive homozygotes at 20–40 times higher [20]. An associ‐
ation between the occurrence of the 1007fs frameshift mutation in the NOD2 gene and the
IBD incidence has also been confirmed. A similar association, somewhat less significant, was
also discovered in the 908Gly>Arg polymorphism [21]. Patients with mutations in the gene
CARD15/NOD2 also showed a decreased expression of defensines [22]. Mutations can there‐
fore be predisposed to CD not only directly, but indirectly as well, i.e. by obstructing the
natural antimicrobial immunity mediated by defensines.
2.2. ICAM-1 gene
Lately, the association between IBD and the ICAM-1 gene has also been intensively studied.
This gene codes for the intracellular adhesive molecule ICAM-1 which performs many phys‐
iological functions. It controls the migration of inflammatory elements, participates in the
presentation of antigen, and because it is expressed by various cell types, it is involved in
many signalling cascades [23]. Its significantly increased expression in the intestinal mucosa
was observed in inflammatory bowel diseases. In the ICAM-1 gene, at least 20 SNPs were
identified. A SNP marked 469Lys>Glu has also been linked with IBD [24]. A substitution of
nucleotides leads to the substitution of amino acid in the 5th immunoglobulin domain of
ICAM-1, which is important for the adhesion of B cells and dendritic cells [25]. An altered
function of the protein ICAM-1 potentially contributes to the genetic predisposition for in‐
flammatory diseases and immunity disorders. The prevalence of the 469Lys>Glu polymor‐
phism has also been linked with multiple sclerosis [26], Behcet’s disease [27], psoriatic and
rheumatic arthritis [28] and other chronic inflammatory diseases [29].
2.3. CCR5 gene
Another gene, which intervenes in the reactions of the immune system, is the gene that co‐
des for the receptor CCR5, whose ligands are CC chemokines. The endogenous functions of
this receptor include the mobilization of the relevant immune system cells and the targeting
of their chemotaxis into the inflamed area. The CCR5 receptor is responsible for the trans‐
port of chemokine CC and participates in the entering of virus particles of the human immu‐
nodeficiency virus (HIV-1) into macrophages [30].
Its regulatory role lies in the preference of the Th1 immune response and suppression of the
Th2 immune pathway. It participates, for example, in the immune defence against Mycobac‐
terium tuberculosis, [31]. In the 1990s, it was discovered that the gene for this receptor occurs
in various allelic forms in the population. In particular, a 32 base pairs deletion in the gene
CCR5 was studied because it leads to the expression of a shorter, and therefore non-func‐
tional receptor in the cell membrane and consequently to the disrupted communication be‐
tween cells of the immune system. This deletion mutation is associated with the onset of
pathological inflammatory conditions, such as sarcoidosis [32], rheumatoid arthritis [33] and
periodontitis [34]. A cellular immunity disorder caused by the non-functional receptor
CCR5 could play some role in IBD development.




The Toll receptor was originally described in Drosophila, where its function lies in the im‐
mune defence against fungal and yeast infections in adults. It was found that the intracellu‐
lar part of this receptor molecule often resembles parts similar to a completely different
receptor – for cytokine interleukin-1 (IL-1). In humans, a total of 10 receptors have been de‐
scribed in which their amino acid sequence is similar to the original Toll receptor of Droso‐
phila [35]. Thus, they were named Toll-like receptors. Individual TLR receptors differ in
their presence in various cell populations and in their affinity for various ligands. TLR4 in
particular is a model ligand of lipopolysaccharide (LPS), which activates the NF-κB expres‐
sion after binding to the extracellular domain of a receptor, and, in the next step, the expres‐
sion of pro-inflammatory cytokines (TNFα, IL). The gene for TLR4 is located on
chromosome 9, in the area 9q32-33, and is expressed by monocytes, macrophages, masto‐
cytes and immature dendritic cells, as well as by intestinal cells in a small amount in the api‐
cal part of epithelium, and also by renal, corneal and pulmonary epithelial cells [36]. A
substitution of adenine for guanine at position 896 (896A>G) was detected by direct se‐
quencing. This substitution is manifested on the amino acid sequence level by the substitu‐
tion of a conservative aspargic acid with glycine at position 299 (299Asp>Gly). This single
nucleotide polymorphism (SNP) is located in exon 4 of the gene for TLR4 and results in pro‐
duction of an altered extracellular domain of this receptor.
Another SNP was found at position 399 of the amino acid sequence, where non-conservative
threonine was replaced by isoleucine (399Thr>Ile). This mutation cosegregates with muta‐
tion 299Asp>Gly [37]. Polymorphisms in the gene for TLR4 are linked with various diseases
such as chronic periodontitis [38], COPD [39], Behcet’s disease [40], septic shock [41] or IBD
[42] and are associated with the disruption of intracellular processes leading to NF-κB in‐
duction and TNFα expression.
2.5. TNFα gene
Several SNPs have been described in the TNFα gene sequence; in the promoter, intron, as well as
exon areas. In the promoter area, the following polymorphisms have been described: substitu‐
tions at nucleotide positions –1031T>C, –863 C>A, –857 C>A, –851C>T, –419 G>C, –376 G>A, –
308 G>A, –238 G>A, –163 G>A, and –49 G>A. In the intron 1 sequence, there is the substitution of
488G>A [43]. The mutation in the gene TNFα results in a changed level of the gene expression
and therefore a different amount of active cytokine. As was mentioned before, the physiological
or pathological manifestations of its effect are based on TNFα quantity. In this context, the poly‐
morphisms in the promoter area of the gene, which interacts with the transcription factors, are
highlighted. Nucleotide polymorphisms at positions –376, –308 and –238 are most often men‐
tioned in connection with the change of the gene expression level.
2.5.1. Polymorphism –376G>A
Transcription factor OCT-1 binds at position –376. It was proved that the transcription factor
binds with a higher preference to the variant allele –376A [44].
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2.5.2. Polymorphism –308G>A
This polymorphism is most often mentioned in connection with increased TNFα produc‐
tion. At the same time, it is the most closely studied predisposition factor for chronic inflam‐
matory diseases including IBD. Braun et al. [45] as well as Sashio et al. [46] confirmed in
vitro a higher transcription activity of the variant allele –308A. In his study of the Czech pop‐
ulation, Sykora et al. [47] stated that a statistically significant association existed between the
–308G>A polymorphism and the occurrence of UC in child patients. He also discovered that
patients who were carriers of at least one variant allele, i.e. carriers of the genotype G/A or
A/A, had significantly higher levels of C-reactive protein (CRP) compared with carriers of
the standard G/G genotype [47]. A study of the Mexican population confirmed that there
was a significantly higher frequency of the variant allele –308A in the gene for TNFα in pa‐
tients with UC, compared with a healthy population [48,49] found a significantly higher risk
of pancolitis in carriers of the variant allele –308A. The risk is 1.91 times higher in compari‐
son with carriers of the standard genotype [49]. A meta-analysis of 27 studies confirmed a
significantly higher risk of the onset of ulcerative colitis and Crohn’s disease in carriers of
the non-standard A/A genotype polymorphism –308G>A in the European population [50].
2.5.3. Polymorphism –238G>A
Some authors stated that the variant allele –238A is associated with a high expression of
TNFα, but other groups of scientists have not confirmed this statement [51,52]. It is also as‐
sumed that the levels of the TNFα transcription are influenced by DNA sections situated
outside the promoter area.
3. Gene polymorphisms associated with inflammatory bowel diseases:
Differences between CD and UC patients
At present, it is generally considered that IBDs have a genetic background and that there are
environmental factors which can trigger the disease [53].
The locus IBD1 is the most often linked with a genetic predisposition to IBD. It is situated,
along with others, in the gene NOD2/CARD15. In our study, we studied three polymor‐
phisms in this gene (702Arg>Trp, 908Gly>Arg and 1007fs insC) in 101 patients with CD, 35
patients with UC and 78 healthy volunteers. At least one variant allele was found in 56.3%
of the patients with CD, whereas in patients with UC it was found in only 14.6%, and in
healthy volunteers, 20%. Recessive homozygotes (carriers of two non-standard alleles in the
gene NOD2/CARD15) were found only in the group of patients with CD. The most serious
clinical impact and therefore the strongest association with CD, was confirmed in the frame‐
shift mutation (Leu1007fs insC) in this gene – see Table 1. Similar results were reported by
other authors [5, 54 - 56] and also by our research team in their previous works [21,8]
The second monitored mutation in this gene (702Arg>Trp) was significantly less frequent in
patients with UC compared with patients with CD. In the third mutation of the gene, substi‐
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tution 908Gly>Arg, we did not find any statistical association with CD or UC. The frequency
of this allele in Czech and Slovak populations is very low; the allele frequency in the group
of healthy volunteers was 2%. Brant et al. [54], unlike our results, found a significant connec‐
tion between Crohn’s disease and the mutation Gly908Arg in a larger set of patients.
Gene Variant allele Patients with CD Patients with UC Health volunteers
NOD2/CARD15
702Trp 9.90• 2.86• 8.97
908Arg 3.96 1.43 1.92
Leu1007fs 16.83* 8.57 5.77*
ICAM-1 469Glu 48.02** 37.14Δ 26.28**, Δ
CCR5 Δ32 8.91• 17.14• 14.74
Table 1. Frequency (in %) of variant allele of all tested genes and statistically significant differences among groups.
Statistical analysis by Fisher test *P<0.01; **P<0.05 - statistical significant differences between group of CD patients and
group of healt volunteers ΔP<0.01; ΔΔP<0.05 - statistical significant differences between group of UC patients and
group of healt volunteers •P<0.01; ••P<0.05 - statistical significant differences between group of CD patients and UC
patients.
All present studies imply that the genetic predisposition to IBD is polygenic, i.e. the process
of pathogenesis includes more genes, and the presence of individual mutations is cumula‐
tive, which means that the occurrence of a larger number of mutations in the same gene in‐
creases the probability of a phenotype change, or, i.e., the loss of function of a protein coded
by this particular gene. We found a highly significant difference between the group of pa‐
tients with Crohn’s disease and the control group (P = 0.0019) in the total number of moni‐
tored mutations. Our results also confirmed that the average number of mutations in the
gene NOD2/CARD15 calculated in one person is significantly (P < 0.05) higher in the group
of patients with CD, when compared with UC or the control group. Furthermore, patients
with UC revealed a lower frequency of these mutations than the control group, but the re‐
sult was not significant. It seems that the occurrence of variant alleles in the gene NOD2/
CARD15 is really typical for patients with Crohn’s disease [5].
The ICAM-1 gene plays a key role in the migration of neutrophils to the inflammation area
and is connected with several inflammatory diseases. Matsuzawa [29] reported a significant‐
ly increased frequency of the variant allele for the polymorphism 469Lys>Glu in this gene
among Japanese patients with CD. We also confirmed a strong association between the oc‐
currence of a non-standard allele for this polymorphism and CD (P = 0.0002) in our set (pa‐
tients of Caucasian population). Carriers of two non-standard alleles in this gene were up to
83% in patients with Crohn’s disease, but only 0.6% in patients with UC and less than one
percent in healthy individuals. The odds ratio implies that the risk of CD in these recessive
homozygotes is 10.6 times (95% CI = 2.9–38.7) higher than in people with standard alleles in
the gene ICAM-1, and the risk of UC is 3.1times (95% CI = 0.55–17.35) higher.
Herfarth et al. [57] suggested that the mutation in chemokine receptors CCR5 could play a
key role in the regulation of the intestinal immune response in CD. They did not succeed in
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finding a higher frequency of the deletion allele Δ32 in patients with CD, but they found out
that the polymorphism in the gene for the CCR5 receptor can contribute to the disease pro‐
gression and its location. The results of our study suggest that patients with CD have a dele‐
tion allele Δ32 in the gene CCR5 significantly less often compared with patients having UC.
The deletion allele is found in patients with UC insignificantly more often compared with
healthy volunteers.
Polymorphism –308G>A in the gene for TNFα is most often mentioned in connection with
the increased production of this cytokine, therefore it is studied as a predisposition factor for
chronic inflammatory diseases, including IBD. The highest frequency of the non-standard al‐
lele of this polymorphism (25%) was found in the group of patients with indeterminated col‐
itis. In the groups of patients diagnosed with CD and UC, the allele frequency was almost
identical – 13.96% and 14.29%. To compare the occurrence of the variant allele in the evalu‐
ated group of patients, a control group of healthy individuals was used. The overall fre‐
quency of the variant allele for the polymorphism –308G>A in the control group of healthy
individuals reached 8.46%. When comparing the allele frequencies in both groups, i.e.
healthy volunteers to the group of patients with IBD, it is obvious that the variant allele of
the monitored polymorphism occurs 1.86 times more frequently in the group of patients
compared with the group of healthy individuals, and this probability is highly significant (P
= 0.0002). In the group of patients with indeterminate colitis, the variant allele occurs 3.95
times more often compared with the group of healthy volunteers.
The allelic frequency of the monitored polymorphism in the entire Caucasian population is
generally about 11% [58]. The results indicate a possible role of the variant allele of the poly‐
morphism –308G>A in the gene TNFα as a predisposing factor for the onset of IBD. An in‐
creased level of TNFα can lead to a predisposition to a more intense inflammatory reaction
and represents one of the risk factors contributing to the development of this disease [49,50].
From the available data it is obvious that genetic factors can determine the IBD character,
especially in case of CD. In monozygous twins with CD, 7 out of 9 cases showed a corre‐
spondence to the disease location, and in 6 out of 9 cases the disease was diagnosed within 2
years. However, the disease behaviour did not reveal any correspondence [60]. Available
data imply that the mutation in the gene CARD15/NOD2 can be connected with the affected
ileum, or preferential occurrence of inflammation in the ileocaecal area [6] and with the sten‐
otic form of the disease [59,60]. There has also been a discussion regarding the impact of mu‐
tation in this gene on the onset age of Crohn’s disease [61]. Herfarth [57] reported that
carriers of the deletion mutation Δ32 in the gene CCR5 are less often affected in the upper
part of gastro intestinal tract (GIT), but they are more susceptible to the development of
strictures. Due to the absence of CCR5 receptors and decreased ability of a cell to initiate an
inflammatory response [57], carriers of the deletion mutation Δ32 experience less often the
aggressive progress of the disease (perforating or fistula type of CD) [57].
However, our results revealed that the perforating type of CD occurs significantly more of‐
ten in patients with the deletion allele Δ32, compared with patients with the non-stenotic
form of the disease, in whom the occurrence of this deletion allele was significantly lower.
Therefore we did not confirm the results of Herfarth et al. [57].
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Statistical analyses of our results confirmed an association between the polymorphism in the
gene ICAM-1 and CD outbreak. The occurrence of the variant allele 469Glu in the gene
ICAM-1, both in heterozygous and homozygous state, is statistically significantly higher in
patiens, in whom CD broke out before 16 years of age, compared with patients, in whom the
disease broke out between 16 and 40 years of age [8] – see Figure 1. However, we did not
confirm the results of Hradský et al. [56] that the frameshift mutation 1007fs in the gene
NOD2/CARD15 occurs more often in child patients with CD than in adult patients. This was
probably caused by the fact that the group of patients with a very early clinical manifesta‐
tion of the disease consisted of only 10 individuals. Nevertheless, even our results imply
that the greater the genetic predisposition is, the earlier the age of manifestation and disease
diagnosis. For example, three or more mutations in all of the monitored candidate genes
were detected in 46.2% of young patients, in whom the clinical manifestations of the disease
appeared before 16 years of age, but only in 26.3% of patients did the disease manifested
from 16 to 40 years of age and in 0% of patients with CD after 40 years of age [8].
Figure 1. Influence of ICAM-1 gene mutation on the age of CD manifestation. Note: +/+: standard homozygote (carri‐
er of two wild type alleles); +/- : heterozygote (carrier of one variant allele); -/- : variant homozygote (carrier of two
variant alleles).
4. Pharmacotherapy of inflammatory bowel diseases and genes affecting
drug metabolism, the occurrence of adverse effects and response to
therapy
At the present time, there is no curative therapy and hence the pharmacological treatment
focuses on inflammation control, eliminating disease symptoms and improving of the quali‐
ty of life. IBD pharmacology utilises a wide scale of drugs including salicylates, glucocorti‐
coids, and immunosuppressives (e.g. thioguanine derivatives, methotrexate and
cyclosporine).
In clinical practice, IBD therapy, using a step-by step system, is influenced by the intensity
of the disease and the effectiveness of previous therapy.
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At present, aminosalicylates constitute the substantial part of the conservative treatment of
IBD. When this therapy is insufficient, corticoid or immunosuppressive therapy is applied,
either separately or combined. The highest level is biological therapy. Many authors indicate
that TNFα as a pro-inflammatory cytokine plays a crucial role in the pathogenesis of many
diseases, including IBD. The use of monoclonal antibodies, which neutralize TNFα, seems to
be a very effective method of treatment. IBD requires long-term treatment. It is also necessa‐
ry to mention surgical resection of the affected part of the intestine, which is used as an al‐
ternative method or pharmacotherapy supplement.
Patients are potentially exposed to the side effects of many drugs. Some toxic effects could
be caused by overdose induced by a low metabolism and the elimination of effective sub‐
stances. However, mechanisms of metabolism and elimination are complex; there are some
crucial enzymatic proteins whose activity affects metabolism on an important therapeutical
level. Single nucleotide polymorphisms (SNPs) of these genes affect enzyme structure and
activity and are therefore, therapeutically significant.
4.1. Aminosalicylates
Aminosalicylates has been used in IBD therapy since the 1940s. Historically, the first prepa‐
ration in this drug group was Sulfasalazine. It is a prodrug, which is dissociated in the intes‐
tine by bacteria into the active substance 5-ASA and pharmacologically inactive
sulfapyridine.
During this therapy, adverse effects develop in 5 to 50% of individuals (most common are
nausea, vomiting, general asthenia, headache, abdominal discomfort and rarely haemolytic
anaemia and rash), in which some patients require termination of the therapy. The cause of
these undesired effects is considered to be the sulfonamide component of the substance. Sul‐
fapyridine released in the intestine is absorbed into the systemic circulation and acetylated
in the liver by N-acetyltransferase (NAT) into N-acetylsulfapyridine. N-acetyltransferase is a
cytosol enzyme with broad distribution into various tissues. The highest activity was ob‐
served in liver cells, intestinal epithelium and the urinary bladder. In contrast, an insignifi‐
cant activity of this enzyme was found in plasma, brain and muscle [62]. N-acetyltransferase
exists in two different and independently regulated isoforms: NAT1 and NAT2, which differ
in their affinity to various substrates. The NAT2 isoenzyme in the liver is a lot more impor‐
tant for sulfapyridine acetylation than NAT1 present in the liver and gut.
4.1.1. Polymorphisms influencing aminosalicylates therapy
The genes for NAT1 and NAT2 are located on chromosome 8p22. The NAT2 gene is poly‐
morphous and to date, several allelic variants have been identified with various impacts on
the acetylation activity of these enzymes. Any population can be divided into fast, inter‐
mediate and slow acetylators, where over 50% of the Caucasian population represent the
slow acetylator phenotype. Slow acetylators, unlike the fast ones, have higher concentra‐
tions of plasma sulfapyridine and its elimination half-time is longer. Sulfapyridine is re‐
sponsible for various adverse effects; therefore, the NAT2 acetylation phenotype/genotype
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appeared before 16 years of age, but only in 26.3% of patients did the disease manifested
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4. Pharmacotherapy of inflammatory bowel diseases and genes affecting
drug metabolism, the occurrence of adverse effects and response to
therapy
At the present time, there is no curative therapy and hence the pharmacological treatment
focuses on inflammation control, eliminating disease symptoms and improving of the quali‐
ty of life. IBD pharmacology utilises a wide scale of drugs including salicylates, glucocorti‐
coids, and immunosuppressives (e.g. thioguanine derivatives, methotrexate and
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diseases, including IBD. The use of monoclonal antibodies, which neutralize TNFα, seems to
be a very effective method of treatment. IBD requires long-term treatment. It is also necessa‐
ry to mention surgical resection of the affected part of the intestine, which is used as an al‐
ternative method or pharmacotherapy supplement.
Patients are potentially exposed to the side effects of many drugs. Some toxic effects could
be caused by overdose induced by a low metabolism and the elimination of effective sub‐
stances. However, mechanisms of metabolism and elimination are complex; there are some
crucial enzymatic proteins whose activity affects metabolism on an important therapeutical
level. Single nucleotide polymorphisms (SNPs) of these genes affect enzyme structure and
activity and are therefore, therapeutically significant.
4.1. Aminosalicylates
Aminosalicylates has been used in IBD therapy since the 1940s. Historically, the first prepa‐
ration in this drug group was Sulfasalazine. It is a prodrug, which is dissociated in the intes‐
tine by bacteria into the active substance 5-ASA and pharmacologically inactive
sulfapyridine.
During this therapy, adverse effects develop in 5 to 50% of individuals (most common are
nausea, vomiting, general asthenia, headache, abdominal discomfort and rarely haemolytic
anaemia and rash), in which some patients require termination of the therapy. The cause of
these undesired effects is considered to be the sulfonamide component of the substance. Sul‐
fapyridine released in the intestine is absorbed into the systemic circulation and acetylated
in the liver by N-acetyltransferase (NAT) into N-acetylsulfapyridine. N-acetyltransferase is a
cytosol enzyme with broad distribution into various tissues. The highest activity was ob‐
served in liver cells, intestinal epithelium and the urinary bladder. In contrast, an insignifi‐
cant activity of this enzyme was found in plasma, brain and muscle [62]. N-acetyltransferase
exists in two different and independently regulated isoforms: NAT1 and NAT2, which differ
in their affinity to various substrates. The NAT2 isoenzyme in the liver is a lot more impor‐
tant for sulfapyridine acetylation than NAT1 present in the liver and gut.
4.1.1. Polymorphisms influencing aminosalicylates therapy
The genes for NAT1 and NAT2 are located on chromosome 8p22. The NAT2 gene is poly‐
morphous and to date, several allelic variants have been identified with various impacts on
the acetylation activity of these enzymes. Any population can be divided into fast, inter‐
mediate and slow acetylators, where over 50% of the Caucasian population represent the
slow acetylator phenotype. Slow acetylators, unlike the fast ones, have higher concentra‐
tions of plasma sulfapyridine and its elimination half-time is longer. Sulfapyridine is re‐
sponsible for various adverse effects; therefore, the NAT2 acetylation phenotype/genotype
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could be important for the prediction of toxicity. Several studies confirmed higher inciden‐
ces of adverse effects in slow acetylators [63–65]. Nevertheless, acetylation status is not the
only factor regulating plasma concentration. Sulfapyridine is not only acetylated, it is also
metabolised by the hydroxylation of an unknown polymorphous enzyme [66,67] and the
high hydroxylation capacity can, in some individuals, compensate for the low level of acety‐
lation. Due to the frequent occurrence of adverse effects, Sulfasalazine has been replaced by
the active component alone, i.e. 5-aminosalicylic acid (5-ASA). 5-ASA is acetylated by poly‐
morphous NAT1 into the pharmacologically inactive metabolite, therefore, there is a hy‐
pothesis that the increased acetylation capacity of NAT1 could be causing the decreased
effectiveness of 5-ASA. Studies in patients with ulcerous colitis did not confirm the correla‐
tion between the NAT1 and NAT2 genotypes and the therapeutic response to aminosalicy‐
lates [68,69].
4.2. Glucocorticoids
Glucocorticoids (GCs) play an important role in the IBD therapy but like other drug groups,
they are now used not in the causal therapy but in the symptomatic therapy. Glucocorti‐
coids (GCs) are broadly used to inhibit common inflammatory and autoimmune reactions of
the body. They play a crucial role in the CD therapy, especially during the high activity of
the disease. GCs are effective for the treatment of active inflammation but not for the main‐
taining of remission and prevention of relapses. Despite the massive boom of other drugs,
they keep their position of golden standard in the IBD therapy.
Corticosteroids have anti-inflammatory and immunomodulating properties – mainly immu‐
nosuppressive. Their anti-inflammatory effect is partly immediate; peaking within 6 hours
of the GCs injection application and subsiding within 24 hours. This is connected with quan‐
titative changes in circulating leucocytes. GCs are at high doses affecting B-lymphocytes.
Furthermore, they can lead to the decreased production of IgA and IgG 2-3 weeks after the
onset of the therapy. Anti-inflammatory effect, which starts later, is a long-term with an im‐
pact on T-lymphocytes, especially Th-lymphocytes, and substantially less on Ts-lympho‐
cytes [70]. However, quite limiting factors in the therapeutic use of GCs are various adverse
effects during a long-term use, which are mainly connected with their numerous physiologi‐
cal functions in the body. The toxicity of corticosteroids is insignificant and physiological
doses are administered during the substitution therapy, adverse effects do not develop.
They only occur after administering of high doses during anti-inflammatory and immuno‐
suppressive therapy.
GCs are highly lipophilic substances, which easily penetrate membranes of target cells and
bind to specific glucocorticoid receptors. GCs complexes + receptor form homodimers,
which are transported into the cell nucleus. Here they bind to specific responsive DNA
structures of various genes. The result of this interaction is a changed gene transcription.
The inhibition of promoters for the AP-1 gene (activator protein 1) or NF-κB (nuclear factor
kappa B), which are transcription factors for pro-inflammatory cytokines, and then induc‐
tion of IκBα (inhibitor kappa B alfa), which is able to bind and therefore inhibit NF-κB, are
important for the immunosuppressive and anti-inflammatory effect of GCs.
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Terminating of the corticoidsteroid therapy leads in a part of patients to the disease relapse.
To maintain the remission state, their long-term administering is therefore necessary; we
talk about the so-called corticodependence. The opposite problem is corticoresistance, i.e.
condition, when administering of GCs does not lead to the calming down of the disease or
remission. Corticoresistance occurs in 16-20% of patients; corticodependence in 28-36% of
treated patients [71,72]. Corticoresistance is not only the problem of Crohn’s disease and has
been intensively studied [73].
4.2.1. Polymorphisms influencing glucocorticoid therapy
Corticoresistance is mainly associated with polymorphisms in the MDR1 gene (multidrug
resistance gene). P-glycoprotein (P-gp) coded by this gene is a membrane protein serving
as  an  ATP-dependent  transporter  of  xenobiotics  from cells.  Polymorphism in  this  gene
was described for the first time in tumour cells in connection with the occurrence of the
multidrug resistance of  anticancer  drugs [74].  However,  the  MDR1  gene is  also  present
in normal tissue with excretion functions,  i.e.  the intestines,  liver,  kidneys,  placenta and
testes.  It  is  also  formed in  brain  capillary  endothelial  cells,  where  it  participates  in  the
function  of  the  blood-brain  barrier  [75].  P-glycoprotein  in  these  tissues  is  probably
formed as  a  defence  mechanism against  xenobiotics.  It  is  an important  regulator  of  the
biological  activity  and  tissue  distribution  of  various  drugs,  and  it  participates  in  their
transport  from cells  into  the  extracellular  environment.  The  increased activity  of  the  P-
glycoprotein  pump is  one  of  the  reasons  for  the  multidrug resistance  of  cancer  cells  to
cytostatic  drugs,  and it  is  assumed that  it  could cause the non-responsiveness to gluco‐
corticoids.
MDR1  gene  is  located  on  the  7q  chromosome  and  consists  of  28  exons.  Farrell  et  al.
proved the increased expression of this gene in T-lymphocytes and in the cells of the in‐
testinal epithelium in patients with UC and CD, who had to undergo an intestine resec‐
tion  after  the  failure  of  drug  therapy  [76].  Therefore,  the  level  of  the  MDR1  gene
expression significantly influences the therapeutic response to the administered glucocor‐
ticoides (GCs).  An indirect  dependence between the cells’  sensitivity to GCs and MDR1
expression was also described [77].
The presence of polymorphisms in the MDR1 gene can influence the gene expression, its
amount and also the function of the P-glycoprotein pump, based on the mutation place and
character. Substitutions of amino acids in the primary protein structure can result in changes
of the substrate spectrum and the effectiveness of transport or pump sensitivity to specific
inhibitors. These two mechanisms can also be combined.
Polymorphism in  the  MDR1  gene  was  described  for  the  first  time  in  1989  [78].  MDR1
variants and their  functional  impact  are still  being studied intensively.  To date,  50 SNP
and 3 deletion and insertion mutations has been described [79,80].  From the perspective
of the biological availability of glucocorticoids, mutations in exon 12 (e.g. 1236C>T), exon
21 (2677G>T/A) and exon 26 (3435C>T) have been studied more predominantly [81].The
most  frequent  polymorphisms  have  a  character  of  substitution  at  position  2677,  where
guanine  usually  occurs,  or  possibly  thymine  and  less  frequently,  alanine  (2677G>T/A).
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could be important for the prediction of toxicity. Several studies confirmed higher inciden‐
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tion between the NAT1 and NAT2 genotypes and the therapeutic response to aminosalicy‐
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the disease. GCs are effective for the treatment of active inflammation but not for the main‐
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they keep their position of golden standard in the IBD therapy.
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of the GCs injection application and subsiding within 24 hours. This is connected with quan‐
titative changes in circulating leucocytes. GCs are at high doses affecting B-lymphocytes.
Furthermore, they can lead to the decreased production of IgA and IgG 2-3 weeks after the
onset of the therapy. Anti-inflammatory effect, which starts later, is a long-term with an im‐
pact on T-lymphocytes, especially Th-lymphocytes, and substantially less on Ts-lympho‐
cytes [70]. However, quite limiting factors in the therapeutic use of GCs are various adverse
effects during a long-term use, which are mainly connected with their numerous physiologi‐
cal functions in the body. The toxicity of corticosteroids is insignificant and physiological
doses are administered during the substitution therapy, adverse effects do not develop.
They only occur after administering of high doses during anti-inflammatory and immuno‐
suppressive therapy.
GCs are highly lipophilic substances, which easily penetrate membranes of target cells and
bind to specific glucocorticoid receptors. GCs complexes + receptor form homodimers,
which are transported into the cell nucleus. Here they bind to specific responsive DNA
structures of various genes. The result of this interaction is a changed gene transcription.
The inhibition of promoters for the AP-1 gene (activator protein 1) or NF-κB (nuclear factor
kappa B), which are transcription factors for pro-inflammatory cytokines, and then induc‐
tion of IκBα (inhibitor kappa B alfa), which is able to bind and therefore inhibit NF-κB, are
important for the immunosuppressive and anti-inflammatory effect of GCs.
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tion  after  the  failure  of  drug  therapy  [76].  Therefore,  the  level  of  the  MDR1  gene
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expression was also described [77].
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variants and their  functional  impact  are still  being studied intensively.  To date,  50 SNP
and 3 deletion and insertion mutations has been described [79,80].  From the perspective
of the biological availability of glucocorticoids, mutations in exon 12 (e.g. 1236C>T), exon
21 (2677G>T/A) and exon 26 (3435C>T) have been studied more predominantly [81].The
most  frequent  polymorphisms  have  a  character  of  substitution  at  position  2677,  where
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Some authors assume that the reason for the increased transport activity of MDR1 is be‐
cause of this polymorphism [83].  In contrast,  mutation 3435C>T in exon 26 is  connected
with a low expression of P-glycoprotein in the small intestine. The frequency of this mu‐
tation in the Caucasian population reaches 28.6% [83].  Carriers  of  the homozygous var‐
iant  genotype  TT  showed  a  lower  production  of  intestinal  P-glycoprotein,  when
compared  with  standard  homozygotes  of  the  CC  genotype.  Several  studies  imply  that
the  frequency  of  the  CC genotype  is  significantly  higher  in  African  populations,  when
compared with  Caucasian  and Asian  populations  [84,85].  It  could  be  speculated  that  it
might provide the African population with a certain selective advantage against GIT in‐
fections,  which  are  endemic  in  tropical  regions,  because  P-glycoprotein  plays  a  crucial
role in the defence against bacterial and viral infections. The physiological role of P-gly‐
coprotein lies in the protection against entering bacterial toxins into the intestinal muco‐
sa. This hypothesis is supported by Panwala [86], who demonstrated that knockout mice
are sensitive to the development of severe spontaneous intestinal inflammations.The am‐
biguous results of the studies focusing on the impact of individual SNPs on the expres‐
sion or function of the P-glycoprotein pump were brought into consonance by the results
of  haplotype  analysis,  which  found a  correlation  between  mutations  3435C>T,  2677G>T
and 1236C>T. Potocnik [87] demonstrated a significantly higher risk of resistance to glu‐
cocorticoids in carriers of the haplotype marked as T/T/T.
The MDR1 gene is also included in the group of so-called candidate genes for IBD. At
present, the relationship is being studied between the polymorphism 3435C>T, which re‐
sults in the decreased expression of P-glycoprotein and the increased susceptibility to the
development of IBD... Another cause of corticoresistance is examined on the level of the glu‐
cocorticoid receptor (GR). It could be because of the disturbed receptor function or the
change of its expression.
Glucocorticoid receptor (GR) exists in two isoforms (GR-α, and GR-β), which are formed by
an alternate splicing of hnRNA to mRNA. Only the GR-α isoform, whose expression many
times exceeds the expression of GR-β, is able to bind glucocorticoids and mediate their ef‐
fect. Corticoresistant patients showed a higher expression of the GR-β isoform, but when
compared with GR-α, this amount was still very little [88,89]. In-vitro obtained data imply
that the formation of GR-β isoform is inducible and can be influenced by cytokines IL-2 and
IL-4 [90,91] as well as by glucocorticoids [92]. The question is, how GR-β participates in
modulating the sensitivity of an organism to glucocorticoids.
Polymorphisms ER22/23EK, located in exon 2, consist of two point mutations - substitutions
in codons 22 and 23. The first mutation is silent, changing codon 22 from GAG to GAA (both
code glutamic acid). The consequent mutation in codon 23, AGG→AAG, leads to the substi‐
tution of arginine for lysine [93]. ER22/23EK is associated with the decreased sensitivity (rel‐
ative resistance) to glucocorticoids [94]. Its mechanism probably lies in the changed ratio
between the forming translation isoforms GR-α and GR-β, in favour of the weaker transacti‐
vator GR-A α [93]. Two other polymorphisms in the gene GR, 363Asn>Ser in exon 2 and Bcl
I, are associated with hypersensitivity to GCs [95–97]. A study in 119 IBD patients observed
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a more frequent occurrence of the Bcl I polymorphism in individuals responsive to GCs
therapy [97].
Mutation 641Arg>Val and 729Ile>Val, that lead to the expression of receptors with a de‐
creased affinity for exogenously supplemented corticosteroids, including Dexametasone,
were described in the binding domain for the glucocorticoid receptor. The negative feedback
induced by glucocorticoid resistance leads to the increased production of cortisol in the
adrenal gland. This increased adrenal activity also leads to an increased production of an‐
drogens and mineralocorticoids [95,98,99]. In contrast, a polymorphism (363Asn>Ser) in
exon 2 leading to an increased sensitivity to dexamethasone was also observed [100]. Yet an‐
other potential predictor of glucocorticoids’ effectiveness from the group of polymorphisms
of the gene for the corticoid receptor seems to be polymorphism BcI I, in which an associa‐
tion between hypersensitivity and glucocorticoids [97].
Since corticoresistance is most often observed in severely afflicted patients, it is still unclear
whether corticoresistance is a singular phenomenon or whether it is caused by an exhaus‐
tion of the anti-inflammatory capacity of glucocorticoids due to an excessive production of
pro-inflammatory cytokines, which, in turn, is caused by the excessive activity of several in‐
tracellular transcription factors that can also reduce the affinity of the glucocorticoid recep‐
tor for its intracellular ligands [101]. The results of several studies imply that the relative
corticoresistance of T-lymphocytes could possibly be conditioned by their contact with pro-
inflammatory cytokines and the consequential decrease of GR affinity for ligands [91]. How‐
ever, this explanation of corticoresistance is not satisfactory because state of remission can
be achieved in a substantial number of patients with a severe form of the disease by cortico‐
therapy, even though their T-lymphocytes are exposed to the same conditions as the non-
responders.
So far, no clinical or genetic marker exists which could be used to predict whether glucocor‐
ticoid therapy would lead to the desired therapeutic response, or that the inflammation
would be corticoresistant.
4.3. Thiopurines
Thiopurine analogues (azathioprine, 6-mercaptopurine) were therapeutically used as immu‐
nosuppressives in the early 1950s for the first time. They are chemical thiol analogues of en‐
dogenous purine compounds. Azathioprine is one of the most commonly used drug in this
group. The effect of azathioprine, just like its potential toxicity, depends on the amount of its
active metabolites or the administered dose. Azathioprine metabolism is so complex that it
is obvious that the levels of active and inactive metabolites correlate with the activity of met‐
abolic enzymes. Scientific teams focused on the research of variant alleles of the genes for
TPMT, ITPA and XDH, which are key enzymes for the metabolism of thiopurines, in which
it is possible to expect an impact on the phenotype or on the decreased enzymatic activity of
the native protein. Variant alleles can indirectly influence azathioprine’s effect and incidence
of its toxicity manifestations by this mechanism.
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Some authors assume that the reason for the increased transport activity of MDR1 is be‐
cause of this polymorphism [83].  In contrast,  mutation 3435C>T in exon 26 is  connected
with a low expression of P-glycoprotein in the small intestine. The frequency of this mu‐
tation in the Caucasian population reaches 28.6% [83].  Carriers  of  the homozygous var‐
iant  genotype  TT  showed  a  lower  production  of  intestinal  P-glycoprotein,  when
compared  with  standard  homozygotes  of  the  CC  genotype.  Several  studies  imply  that
the  frequency  of  the  CC genotype  is  significantly  higher  in  African  populations,  when
compared with  Caucasian  and Asian  populations  [84,85].  It  could  be  speculated  that  it
might provide the African population with a certain selective advantage against GIT in‐
fections,  which  are  endemic  in  tropical  regions,  because  P-glycoprotein  plays  a  crucial
role in the defence against bacterial and viral infections. The physiological role of P-gly‐
coprotein lies in the protection against entering bacterial toxins into the intestinal muco‐
sa. This hypothesis is supported by Panwala [86], who demonstrated that knockout mice
are sensitive to the development of severe spontaneous intestinal inflammations.The am‐
biguous results of the studies focusing on the impact of individual SNPs on the expres‐
sion or function of the P-glycoprotein pump were brought into consonance by the results
of  haplotype  analysis,  which  found a  correlation  between  mutations  3435C>T,  2677G>T
and 1236C>T. Potocnik [87] demonstrated a significantly higher risk of resistance to glu‐
cocorticoids in carriers of the haplotype marked as T/T/T.
The MDR1 gene is also included in the group of so-called candidate genes for IBD. At
present, the relationship is being studied between the polymorphism 3435C>T, which re‐
sults in the decreased expression of P-glycoprotein and the increased susceptibility to the
development of IBD... Another cause of corticoresistance is examined on the level of the glu‐
cocorticoid receptor (GR). It could be because of the disturbed receptor function or the
change of its expression.
Glucocorticoid receptor (GR) exists in two isoforms (GR-α, and GR-β), which are formed by
an alternate splicing of hnRNA to mRNA. Only the GR-α isoform, whose expression many
times exceeds the expression of GR-β, is able to bind glucocorticoids and mediate their ef‐
fect. Corticoresistant patients showed a higher expression of the GR-β isoform, but when
compared with GR-α, this amount was still very little [88,89]. In-vitro obtained data imply
that the formation of GR-β isoform is inducible and can be influenced by cytokines IL-2 and
IL-4 [90,91] as well as by glucocorticoids [92]. The question is, how GR-β participates in
modulating the sensitivity of an organism to glucocorticoids.
Polymorphisms ER22/23EK, located in exon 2, consist of two point mutations - substitutions
in codons 22 and 23. The first mutation is silent, changing codon 22 from GAG to GAA (both
code glutamic acid). The consequent mutation in codon 23, AGG→AAG, leads to the substi‐
tution of arginine for lysine [93]. ER22/23EK is associated with the decreased sensitivity (rel‐
ative resistance) to glucocorticoids [94]. Its mechanism probably lies in the changed ratio
between the forming translation isoforms GR-α and GR-β, in favour of the weaker transacti‐
vator GR-A α [93]. Two other polymorphisms in the gene GR, 363Asn>Ser in exon 2 and Bcl
I, are associated with hypersensitivity to GCs [95–97]. A study in 119 IBD patients observed
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a more frequent occurrence of the Bcl I polymorphism in individuals responsive to GCs
therapy [97].
Mutation 641Arg>Val and 729Ile>Val, that lead to the expression of receptors with a de‐
creased affinity for exogenously supplemented corticosteroids, including Dexametasone,
were described in the binding domain for the glucocorticoid receptor. The negative feedback
induced by glucocorticoid resistance leads to the increased production of cortisol in the
adrenal gland. This increased adrenal activity also leads to an increased production of an‐
drogens and mineralocorticoids [95,98,99]. In contrast, a polymorphism (363Asn>Ser) in
exon 2 leading to an increased sensitivity to dexamethasone was also observed [100]. Yet an‐
other potential predictor of glucocorticoids’ effectiveness from the group of polymorphisms
of the gene for the corticoid receptor seems to be polymorphism BcI I, in which an associa‐
tion between hypersensitivity and glucocorticoids [97].
Since corticoresistance is most often observed in severely afflicted patients, it is still unclear
whether corticoresistance is a singular phenomenon or whether it is caused by an exhaus‐
tion of the anti-inflammatory capacity of glucocorticoids due to an excessive production of
pro-inflammatory cytokines, which, in turn, is caused by the excessive activity of several in‐
tracellular transcription factors that can also reduce the affinity of the glucocorticoid recep‐
tor for its intracellular ligands [101]. The results of several studies imply that the relative
corticoresistance of T-lymphocytes could possibly be conditioned by their contact with pro-
inflammatory cytokines and the consequential decrease of GR affinity for ligands [91]. How‐
ever, this explanation of corticoresistance is not satisfactory because state of remission can
be achieved in a substantial number of patients with a severe form of the disease by cortico‐
therapy, even though their T-lymphocytes are exposed to the same conditions as the non-
responders.
So far, no clinical or genetic marker exists which could be used to predict whether glucocor‐
ticoid therapy would lead to the desired therapeutic response, or that the inflammation
would be corticoresistant.
4.3. Thiopurines
Thiopurine analogues (azathioprine, 6-mercaptopurine) were therapeutically used as immu‐
nosuppressives in the early 1950s for the first time. They are chemical thiol analogues of en‐
dogenous purine compounds. Azathioprine is one of the most commonly used drug in this
group. The effect of azathioprine, just like its potential toxicity, depends on the amount of its
active metabolites or the administered dose. Azathioprine metabolism is so complex that it
is obvious that the levels of active and inactive metabolites correlate with the activity of met‐
abolic enzymes. Scientific teams focused on the research of variant alleles of the genes for
TPMT, ITPA and XDH, which are key enzymes for the metabolism of thiopurines, in which
it is possible to expect an impact on the phenotype or on the decreased enzymatic activity of
the native protein. Variant alleles can indirectly influence azathioprine’s effect and incidence
of its toxicity manifestations by this mechanism.
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Azathioprine has a wide therapeutic spectrum and therefore it is considered to be a relative‐
ly safe drug. Despite this, adverse effects are common during therapy. Pharmacovigilance
studies have noted them in up to 15-25% of patients [102]. Thiopurines are associated with
two types of adverse effects, i.e. reactions, which are independent of the dosage and occur in
up to 25% patients (nausea, fever, rash, flu-like syndrome, arthralgia), or adverse effects
which are connected with the drug dosage and induced by a different mechanism. The latter
is represented mainly by thiopurine-induced myelosupression, which is usually manifested
by leukopenia and thrombocytopenia [102]. Basically it is a manifestation of the therapy tox‐
icity caused by a high level of active metabolites when exceeding the therapeutic dose or
due to ineffective metabolization and elimination processes. Myelosupression induced by
these drugs is reversible; however, for a patient, in whom the therapeutic objective was only
immunosuppression, this means a risk of life-threatening infection. Another problem is the
fact that the thiopurine-induced myelosupression is manifested after a certain latency period
and in most cases it also means termination of the azathioprine medication. However, some
works state that a moderate myelosupression is associated with better clinical results from
the therapy [103].
4.3.1. Polymorphisms influencing the thiopurines therapy
4.3.1.1. The gene for thiopurine S-methyltransferase (TPMT)
In the 1960s, this enzyme, which catalyzes the methylation of the thiol functional group, was
described in several cell populations. Activity of S-adenosyl-L-methionine: thiopurin S-
methyltransferase (TPMT; EC 2.1.1.67) was demonstrated in cytoplasm of prokaryotic as
well as eukaryotic cells. In humans, the activity of this enzyme was mainly described in er‐
ythrocytes, leukocytes, renal parenchyma, hepatocytes and intestinal cells. Its occurrence
was also confirmed in mammalian placenta [104].
The human gene for TPMT is located in the short arm of chromosome 6 (6p22.3). It consists
of 9 exon and 8 intron regions [105]. Its length (including introns) is about 25 kbp [106]. In
the sequence of this gene, there were 21 SNPs identified, which facilitated the formation of
22 variant allelic form of the gene. In compliance with the agreed rules, nomenclature of the
non-standard TPMT alleles is marked by a number, or a number and a letter. Variant alleles
are listed in Table 2.
Even though the differences in the catalytic activity of the TPMT enzyme has been known
for several decades, the first proof of the association of this phenotype with gene polymor‐
phism was provided by Krynetski [107]. It was evidence that a variant allele TPMT*2 is
present in individuals with low enzymatic activity [107].
Since then, many gene alleles for TPMT have been discovered. They differ not only in the
nucleotide sequence but also in the activity of enzymes transcribed from such sequence. The
fact that many variant alleles lead to a decreased enzymatic activity resulted in the belief
that gene polymorphisms of this gene substantially influence pharmacokinetic parameters
of the drug with a thiopurine structure.
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Allele SNP Substitution of AA Reference
TPMT*1 Standard allele - wild type (wt)
TPMT*1S 474T>C Silent [108]
TPMT*1A -178C>T [108]
TPMT*2 238G>C Ala80Pro [107]
TPMT*3A 460G>A Ala154Thr [109]
719A>G Tyr240Cys
TPMT*3B 460G>A Ala154Thr [110]
TPMT*3C 719A>G Tyr240Cys [111]
TPMT*3D 460G>A Ala154Thr [110]
719A>G Tyr240Cys
292G>T Glu92Stop
TPMT*4 _1G>A (intron 9) Splicing defect [111]
TPMT*5 146T>C Leu49Ser [110]
TPMT*6 539A>T Tyr180Phe [110]
TPMT*7 681T>G His227Gln [110]
TPMT*8 644G>A Arg215His [112]
TPMT*9 356A>C Lys119Thr [110]
TPMT*10 430G>C Gly144Arg [110]
TPMT*11 395G>A Cys132Tyr [113]
TPMT*12 374C>T Ser125Leu [110]
TPMT*13 83A>T Glu28Val [110]
TPMT*14 1A>G Met1Val [110]
TPMT*15 _1G>A (intron 7) Splicing defect [114]
TPMT*16 488G>A Arg163His [115]
TPMT*17 124C>G Gln42Glu [110]
TPMT*18 211G>A Gly71Arg [110]
TPMT*19 365A>C Lys122Thr [115]
Table 2. Listing of variant alleles of the gene for TPMT including the location of the nucleotide polymorphism and
changes in the protein primary structure.
Variant TPMT alleles occurring in Caucasian population and their phenotype
About 90% of the Caucasian population shows standard enzymatic activity. Medium enzy‐
matic activity correlates with the heterozygous genotype, i.e. the presence of some variant
alleles, and is found in less than 10% of the population. Enzymatic activity is virtually unde‐
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Azathioprine has a wide therapeutic spectrum and therefore it is considered to be a relative‐
ly safe drug. Despite this, adverse effects are common during therapy. Pharmacovigilance
studies have noted them in up to 15-25% of patients [102]. Thiopurines are associated with
two types of adverse effects, i.e. reactions, which are independent of the dosage and occur in
up to 25% patients (nausea, fever, rash, flu-like syndrome, arthralgia), or adverse effects
which are connected with the drug dosage and induced by a different mechanism. The latter
is represented mainly by thiopurine-induced myelosupression, which is usually manifested
by leukopenia and thrombocytopenia [102]. Basically it is a manifestation of the therapy tox‐
icity caused by a high level of active metabolites when exceeding the therapeutic dose or
due to ineffective metabolization and elimination processes. Myelosupression induced by
these drugs is reversible; however, for a patient, in whom the therapeutic objective was only
immunosuppression, this means a risk of life-threatening infection. Another problem is the
fact that the thiopurine-induced myelosupression is manifested after a certain latency period
and in most cases it also means termination of the azathioprine medication. However, some
works state that a moderate myelosupression is associated with better clinical results from
the therapy [103].
4.3.1. Polymorphisms influencing the thiopurines therapy
4.3.1.1. The gene for thiopurine S-methyltransferase (TPMT)
In the 1960s, this enzyme, which catalyzes the methylation of the thiol functional group, was
described in several cell populations. Activity of S-adenosyl-L-methionine: thiopurin S-
methyltransferase (TPMT; EC 2.1.1.67) was demonstrated in cytoplasm of prokaryotic as
well as eukaryotic cells. In humans, the activity of this enzyme was mainly described in er‐
ythrocytes, leukocytes, renal parenchyma, hepatocytes and intestinal cells. Its occurrence
was also confirmed in mammalian placenta [104].
The human gene for TPMT is located in the short arm of chromosome 6 (6p22.3). It consists
of 9 exon and 8 intron regions [105]. Its length (including introns) is about 25 kbp [106]. In
the sequence of this gene, there were 21 SNPs identified, which facilitated the formation of
22 variant allelic form of the gene. In compliance with the agreed rules, nomenclature of the
non-standard TPMT alleles is marked by a number, or a number and a letter. Variant alleles
are listed in Table 2.
Even though the differences in the catalytic activity of the TPMT enzyme has been known
for several decades, the first proof of the association of this phenotype with gene polymor‐
phism was provided by Krynetski [107]. It was evidence that a variant allele TPMT*2 is
present in individuals with low enzymatic activity [107].
Since then, many gene alleles for TPMT have been discovered. They differ not only in the
nucleotide sequence but also in the activity of enzymes transcribed from such sequence. The
fact that many variant alleles lead to a decreased enzymatic activity resulted in the belief
that gene polymorphisms of this gene substantially influence pharmacokinetic parameters
of the drug with a thiopurine structure.
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Allele SNP Substitution of AA Reference
TPMT*1 Standard allele - wild type (wt)
TPMT*1S 474T>C Silent [108]
TPMT*1A -178C>T [108]
TPMT*2 238G>C Ala80Pro [107]
TPMT*3A 460G>A Ala154Thr [109]
719A>G Tyr240Cys
TPMT*3B 460G>A Ala154Thr [110]
TPMT*3C 719A>G Tyr240Cys [111]
TPMT*3D 460G>A Ala154Thr [110]
719A>G Tyr240Cys
292G>T Glu92Stop
TPMT*4 _1G>A (intron 9) Splicing defect [111]
TPMT*5 146T>C Leu49Ser [110]
TPMT*6 539A>T Tyr180Phe [110]
TPMT*7 681T>G His227Gln [110]
TPMT*8 644G>A Arg215His [112]
TPMT*9 356A>C Lys119Thr [110]
TPMT*10 430G>C Gly144Arg [110]
TPMT*11 395G>A Cys132Tyr [113]
TPMT*12 374C>T Ser125Leu [110]
TPMT*13 83A>T Glu28Val [110]
TPMT*14 1A>G Met1Val [110]
TPMT*15 _1G>A (intron 7) Splicing defect [114]
TPMT*16 488G>A Arg163His [115]
TPMT*17 124C>G Gln42Glu [110]
TPMT*18 211G>A Gly71Arg [110]
TPMT*19 365A>C Lys122Thr [115]
Table 2. Listing of variant alleles of the gene for TPMT including the location of the nucleotide polymorphism and
changes in the protein primary structure.
Variant TPMT alleles occurring in Caucasian population and their phenotype
About 90% of the Caucasian population shows standard enzymatic activity. Medium enzy‐
matic activity correlates with the heterozygous genotype, i.e. the presence of some variant
alleles, and is found in less than 10% of the population. Enzymatic activity is virtually unde‐
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tectable in one of 300 individuals. This condition is related with the occurrence of a homozy‐
gous genotype for variant alleles [116]. It is sufficient to administer to these patients just
6-10% of the standard azathioprine dose. In heterozygotes, the activity of an enzyme tran‐
scribed according to the matrix of a standard allele is metabolically sufficient. In these pa‐
tients, however, it is necessary to consider the increased hematotoxicity of the therapy.
Allele TPMT*1 (wt)
Marking TPMT*1 belongs to the standard allele (wild type, wt), which is the most frequent
in population. Enzymatic protein, which is expressed on the basis of this nucleotide se‐
quence, has a high, which means standard activity.
Allele TPMT*2 (238G>C; 80Pro>Ala)
Allele TPMT*2 carries a substitution 238G>C (exon 5). This nucleotide transversion leads to
a change of the primary structure of the protein, in which the rigid amino acid proline (at
position 80) is substituted for alanine, an amino acid which is chemically more flexible. This
results in altered intermolecular interactions, a disturbed tertiary structure and also the cata‐
lytic activity and stability of the protein [107], and a decreased enzymatic activity of up to a
100 times is expected [116].
Allele TPMT*3A (460G>A, 719A>G; 154Ala>Thr, 240Tyr>Cys)
Allele TPMT*3A includes two nucleotide substitutions in the gene sequence. Substitutions at
positions 460G>A (exon 7) and 719A>G (exon 10) lead to the substitution of alanine for
threonine at position 154, and tyrosine for cysteine at position 240 of the peptide chain.
Based on this mutation, a very unstable protein is formed during the protein synthesis [110].
Enzymatic activity is decreased up to 200 times [116].
Allele TPMT*3B (460G>A; 154Ala>Thr)
Allele TPMT*3B carries only one nucleotide substitution, at position 460G>A, resulting in
the change of the primary protein structure due to the substitution of alanine for theonine at
position 154. The expressed protein has an extremely unstable structure and is rapidly de‐
graded by cell proteases.
Allele TPMT*3C (719A>G; 240Tyr>Cys)
The nucleotide substitution at position 719 (exon 10) and the consequential amino acid sub‐
stitution at position 240 have a similar effect on protein stability [111].
The above variant alleles are present in 85-90% of individuals with a low enzymatic activity
of the TPMT enzyme. Other gene polymorphisms occur in the Caucasian population with
such a low frequency that their low incidence in the population makes them quite difficult
to detect, and the possibility to use them in clinical practice is minimal.
Among non-standard alleles of the gene for TPMT, variant alleles TPMT*3A, TPMT*3C and
TPMT*2 have the highest frequency. Population testing revealed substantial racial and eth‐
nic differences in the occurrence of variant alleles. For example, the inhabitants of South
Asia (India, Pakistan) reveal a smaller incidence of variant alleles – from detected non-
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standard alleles, only the TPMT*3A was confirmed [117]. On the other hand, the African
population has an overall frequency of variant alleles comparable with Caucasian popula‐
tion, but the highest representation among non-standard alleles has TPMT*3C [118]. This al‐
lele (TPMT*3C) represents 50% of variant alleles in Afro-Americans, compared with only 5%
in Americans of European origin [104]. The most common variant allele in the Caucasian
population is TPMT*3A (some papers state that up to 10% of the population carries the het‐
erozygous genotype; [119]. The occurrence of individual variant alleles in various popula‐
tions is shown in Table 3.
Ethnic group TPMT*2 TPMT*3A TPMT*3B TPMT*3C Reference
Caucasian - France 0.7 3 0 0.4 [119]
Caucasian - Germany 0.5 8.6 0 0.8 [113]
Caucasian - Norway 0 3.4 0 0.3 [120]
Caucasian - America 0.2 3.2 - 0.2 [112]
Afro - American 0.4 0 - 2.4 [112]
Afro - Kenya 0 0 - 5.4 [118]
African - Ghana 0 0 - 7.6 [121]
Asian - Southeast Asia 0 0 - 1 [122]
Asian - Japan 0 0 0 1.6 [123]
Asian - China 0 0 0 1 [124]
Table 3. Occurrence of variant alleles TPMT*2, TPMT*3A, TPMT*3B and TPMT*3C in various populations (in %).
Legend: 0 – occurrence of alleles was not confirmed; - allele was not detected.
An important outcome of these population studies is that clinically significant variant alleles
or their polymorphisms are present in all populations; therefore, the same diagnostic meth‐
ods based on the determination of genotype can be used. [106]. From the phenotype per‐
spective, the overall protein stability of TPMT is the most important. In vitro and in vivo
studies confirm that the quantity of expression of variant alleles is comparable with the ex‐
pression of the variant allele TPMT*1. It is the shorter biological halftime of the protein ex‐
pressed on the basis of the variant allele which is responsible for the decreased metabolic
activity of the enzyme [109]. Experiments assessing protein quality using the Western blot
procedure imply that enzymatic protein produced by the transcription of the variant allele
has a significantly shorter halftime compared with proteins translated according to the wt
allele. Western blot analysis in cells with two copies of a variant allele did not confirm the
presence of enzymatic protein. This fact directly correlates with the phenotype feature – un‐
detectable TPMT activity. Tai et al. [109] determined protein quantity in vitro and found that
the amount of enzymatic protein at a particular time after the expression decreased the most
in the variant allele TPMT*3A, (200 times lower compared to TPMT*1). In the variant allele
TPMT*2, the decrease of protein density was smaller by one order (20 times). In the allele
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tectable in one of 300 individuals. This condition is related with the occurrence of a homozy‐
gous genotype for variant alleles [116]. It is sufficient to administer to these patients just
6-10% of the standard azathioprine dose. In heterozygotes, the activity of an enzyme tran‐
scribed according to the matrix of a standard allele is metabolically sufficient. In these pa‐
tients, however, it is necessary to consider the increased hematotoxicity of the therapy.
Allele TPMT*1 (wt)
Marking TPMT*1 belongs to the standard allele (wild type, wt), which is the most frequent
in population. Enzymatic protein, which is expressed on the basis of this nucleotide se‐
quence, has a high, which means standard activity.
Allele TPMT*2 (238G>C; 80Pro>Ala)
Allele TPMT*2 carries a substitution 238G>C (exon 5). This nucleotide transversion leads to
a change of the primary structure of the protein, in which the rigid amino acid proline (at
position 80) is substituted for alanine, an amino acid which is chemically more flexible. This
results in altered intermolecular interactions, a disturbed tertiary structure and also the cata‐
lytic activity and stability of the protein [107], and a decreased enzymatic activity of up to a
100 times is expected [116].
Allele TPMT*3A (460G>A, 719A>G; 154Ala>Thr, 240Tyr>Cys)
Allele TPMT*3A includes two nucleotide substitutions in the gene sequence. Substitutions at
positions 460G>A (exon 7) and 719A>G (exon 10) lead to the substitution of alanine for
threonine at position 154, and tyrosine for cysteine at position 240 of the peptide chain.
Based on this mutation, a very unstable protein is formed during the protein synthesis [110].
Enzymatic activity is decreased up to 200 times [116].
Allele TPMT*3B (460G>A; 154Ala>Thr)
Allele TPMT*3B carries only one nucleotide substitution, at position 460G>A, resulting in
the change of the primary protein structure due to the substitution of alanine for theonine at
position 154. The expressed protein has an extremely unstable structure and is rapidly de‐
graded by cell proteases.
Allele TPMT*3C (719A>G; 240Tyr>Cys)
The nucleotide substitution at position 719 (exon 10) and the consequential amino acid sub‐
stitution at position 240 have a similar effect on protein stability [111].
The above variant alleles are present in 85-90% of individuals with a low enzymatic activity
of the TPMT enzyme. Other gene polymorphisms occur in the Caucasian population with
such a low frequency that their low incidence in the population makes them quite difficult
to detect, and the possibility to use them in clinical practice is minimal.
Among non-standard alleles of the gene for TPMT, variant alleles TPMT*3A, TPMT*3C and
TPMT*2 have the highest frequency. Population testing revealed substantial racial and eth‐
nic differences in the occurrence of variant alleles. For example, the inhabitants of South
Asia (India, Pakistan) reveal a smaller incidence of variant alleles – from detected non-
Inflammatory Bowel Disease40
standard alleles, only the TPMT*3A was confirmed [117]. On the other hand, the African
population has an overall frequency of variant alleles comparable with Caucasian popula‐
tion, but the highest representation among non-standard alleles has TPMT*3C [118]. This al‐
lele (TPMT*3C) represents 50% of variant alleles in Afro-Americans, compared with only 5%
in Americans of European origin [104]. The most common variant allele in the Caucasian
population is TPMT*3A (some papers state that up to 10% of the population carries the het‐
erozygous genotype; [119]. The occurrence of individual variant alleles in various popula‐
tions is shown in Table 3.
Ethnic group TPMT*2 TPMT*3A TPMT*3B TPMT*3C Reference
Caucasian - France 0.7 3 0 0.4 [119]
Caucasian - Germany 0.5 8.6 0 0.8 [113]
Caucasian - Norway 0 3.4 0 0.3 [120]
Caucasian - America 0.2 3.2 - 0.2 [112]
Afro - American 0.4 0 - 2.4 [112]
Afro - Kenya 0 0 - 5.4 [118]
African - Ghana 0 0 - 7.6 [121]
Asian - Southeast Asia 0 0 - 1 [122]
Asian - Japan 0 0 0 1.6 [123]
Asian - China 0 0 0 1 [124]
Table 3. Occurrence of variant alleles TPMT*2, TPMT*3A, TPMT*3B and TPMT*3C in various populations (in %).
Legend: 0 – occurrence of alleles was not confirmed; - allele was not detected.
An important outcome of these population studies is that clinically significant variant alleles
or their polymorphisms are present in all populations; therefore, the same diagnostic meth‐
ods based on the determination of genotype can be used. [106]. From the phenotype per‐
spective, the overall protein stability of TPMT is the most important. In vitro and in vivo
studies confirm that the quantity of expression of variant alleles is comparable with the ex‐
pression of the variant allele TPMT*1. It is the shorter biological halftime of the protein ex‐
pressed on the basis of the variant allele which is responsible for the decreased metabolic
activity of the enzyme [109]. Experiments assessing protein quality using the Western blot
procedure imply that enzymatic protein produced by the transcription of the variant allele
has a significantly shorter halftime compared with proteins translated according to the wt
allele. Western blot analysis in cells with two copies of a variant allele did not confirm the
presence of enzymatic protein. This fact directly correlates with the phenotype feature – un‐
detectable TPMT activity. Tai et al. [109] determined protein quantity in vitro and found that
the amount of enzymatic protein at a particular time after the expression decreased the most
in the variant allele TPMT*3A, (200 times lower compared to TPMT*1). In the variant allele
TPMT*2, the decrease of protein density was smaller by one order (20 times). In the allele
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TPMT*3B, in which only one nucleotide substitution is present, the protein density was de‐
creased 4 times; in the variant allele TPMT*3C, the density determined by Western blotting
was comparable with the wt allele [109]. Furthermore, the amount of protein determined by
Western blotting after 24-hour cultivation also corresponds with the results of degradation
halftimes for native proteins. It was confirmed that the halftime of a protein expressed from
a wt allele is about 18 hours. A comparable halftime can be observed in case of the protein, if
it was expressed from the allele TPMT*3C Degradation halftimes in the alleles TPMT*3B
(6h) and TPMT*2 (0.2h) are significantly shorter. The shortest degradation halftime detected
in a protein expressed according to the sequence corresponds with the allele TPMT*3A
(0.25h; [109]). These results imply that the lowest enzymatic activity, resulting from the fast
degradation of a protein, is connected with the alleles TPMT*3A and TPMT*2. This hypothe‐
sis is supported by the phenotype-undetectable metabolic activity of enzymes in patients
with the variant alleles TPMT*3A and TPMT*2 in their genotype.
4.3.1.2. The gene for Inosine Triphosphate Pyrophosphatase (ITPA)
Inosine triphosphate pyrophosphatase (ITPA; EC 3.6.1.19) is one of the ubiquitous cytosol
enzymes. It catalyzes the reaction of inosine triphosphates hydrolysis to inosine monophos‐
phate. Even though the activity in various types of cells is different and the role of the en‐
zyme in the cell is not clearly understood; it is supposed that it prevents the accumulation of
false nucleotides, which could be incorporated in the DNA and RNA molecules instead of
standard nucleotides, and therefore damage these macromolecules. Another possible role of
these nucleotides can be their competition with GTP during cell signalling processes [125].
The role of ITPA in azathioprine biotransformation lies in the hydrolytic breakdown of po‐
tentially hepatotoxic 6-thio-ITP.
The gene coding for ITPA is situated on the short arm of chromosome 20 (20p13) and con‐
tains 8 exon sequences [126]. Several nucleotide polymorphisms were identified in its se‐
quence; in 5 of these polymorphisms, a correlation with a low activity of the native protein
was proven [127]. The lowest enzymatic activity was discovered in individuals who carry
the nucleotide substitution of cytosine for adenine at position 94 in the sequence of the exon
2 (94C>A). At the protein primary structure level, this substitution is manifested by the sub‐
stitution of proline for threonine at position 32, which decreases its affinity for the produc‐
tion of active dimer in ITPA proteins, decreases the protein stability and leads to a non-
specific mRNA splicing [128,125,129]. The heterozygous genotype for the variant allele 94A
is from the phenotype perspective manifested by the decrease of ITPA activity up to 22.5%
of the activity of a standard form. ITPA activity was not detectable in individuals who are
homozygous for this variant allele [128]. The frequency of the variant allele 94A in the ITPA
gene is 5–7% in the Caucasian population [130–133]. Another nucleotide substitution in
which an impact on the enzymatic activity was confirmed, is the substitution of adenine for
cytosine at the sequence of intron 2 (IVS2+21A>C). The presence of this substitution leads to
a faulty mRNA splicing during post-transcriptional modifications and the formation of a
protein, which reaches 61% activity in heterozygous individuals, when compared to the na‐
tive form of the enzyme [134,125]. Homozygous carriers of this variant allele have their en‐
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zymatic activity at 30% of the activity of a standard form [132]. The frequency of this variant
allele in the Caucasian population reaches 10-13% [128,134]. Individuals who have the var‐
iant allele 94A in their genome as well as the variant allele IVS2+21C, showed 10% activity of
ITPA [128]. A connection between the decreased ITPA activity and the occurrence of pan‐
creatitis, a rash, a flu-like syndrome and leukopenia was identified in patients treated by
azathioprine [135,136].
4.3.1.3. The gene for Xanthine Dehydrogenase (XDH)
Xanthine dehydrogenase (XDH, XO; EC 1.17.1.4) also belongs among cytosol enzymes,
which participate in the metabolism of endogenous purine and pyrimidine nucleotides, as
well as exogenous substances with this chemical structure [137]. The enzyme activity has
been observed mainly in hepatocytes, enterocytes and renal parenchyma cells. XDH cataly‐
ses the oxidation of hypoxanthine to xanthine and consequently to uric acid. This enzyme is
a crucial element of the biological availability of drugs containing the thiopurine molecule
[138]. XDH activity significantly fluctuates depending on the ethnicity, sex and tissue type
[139–141]. The administering of the competitive XDH inhibitor allopurinol leads to a higher
biological availability of 6-MP (6-mercaptopurine) and in some cases to a better therapeutic
response to thiopurine therapy [138,142].
The gene coding for the enzyme XDH is situated on the short arm of chromosome 2 (2p23).
In humans, several polymorphisms have been identified, which facilitate the formation of 21
allelic variants [143]. Several of these allelic variants are associated with the occurrence of
adverse effects during azathioprine therapy and with higher levels of toxic metabolites 6-
MP [133,144]. Several of the noted single nucleotide polymorphisms influence XDH enzy‐
matic activity. However, many of these variant alleles have only been discovered within the
Japanese or Asian populations. A potential clinical importance can be expected in example
of polymorphisms 837C>T, which has a 6% frequency in the Caucasian population. At the
primary protein structure level, there is no amino acid substitution. Nevertheless, this poly‐
morphism somehow influences enzymatic activity and its occurrence correlates with higher
levels of thiopurine metabolites. A possible explanation may be the coincidence with an un‐
known polymorphism [144] or RNA interferency. During the reaction of the catalyzed XDH,
free oxygen radicals are generated, which are expected to participate in the hepatotoxic ef‐
fect of thiopurines [145].
4.4. Biological therapy
Biological therapy represents a completely new therapeutic approach to chronic inflamma‐
tory diseases. This therapeutic approach has proved useful not only in IBD therapy, but also
in the therapy of other chronic inflammatory diseases, such as rheumatoid arthritis, ankylos‐
ing spondylarthritis and psoriasis. In IBD, the most common drugs intervene in the TNFα
cytokine-mediated signalling at the molecular level (infliximab, adalimumab and etaner‐
cept).The main mechanism of these “anti-TNFα” antibodies is the binding of a drug to the
TNFα soluble form (sTNFα) and blocking biological functions, which are mediated by it.
Some studies demonstrated that individual antibodies have a different neutralisation poten‐
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TPMT*3B, in which only one nucleotide substitution is present, the protein density was de‐
creased 4 times; in the variant allele TPMT*3C, the density determined by Western blotting
was comparable with the wt allele [109]. Furthermore, the amount of protein determined by
Western blotting after 24-hour cultivation also corresponds with the results of degradation
halftimes for native proteins. It was confirmed that the halftime of a protein expressed from
a wt allele is about 18 hours. A comparable halftime can be observed in case of the protein, if
it was expressed from the allele TPMT*3C Degradation halftimes in the alleles TPMT*3B
(6h) and TPMT*2 (0.2h) are significantly shorter. The shortest degradation halftime detected
in a protein expressed according to the sequence corresponds with the allele TPMT*3A
(0.25h; [109]). These results imply that the lowest enzymatic activity, resulting from the fast
degradation of a protein, is connected with the alleles TPMT*3A and TPMT*2. This hypothe‐
sis is supported by the phenotype-undetectable metabolic activity of enzymes in patients
with the variant alleles TPMT*3A and TPMT*2 in their genotype.
4.3.1.2. The gene for Inosine Triphosphate Pyrophosphatase (ITPA)
Inosine triphosphate pyrophosphatase (ITPA; EC 3.6.1.19) is one of the ubiquitous cytosol
enzymes. It catalyzes the reaction of inosine triphosphates hydrolysis to inosine monophos‐
phate. Even though the activity in various types of cells is different and the role of the en‐
zyme in the cell is not clearly understood; it is supposed that it prevents the accumulation of
false nucleotides, which could be incorporated in the DNA and RNA molecules instead of
standard nucleotides, and therefore damage these macromolecules. Another possible role of
these nucleotides can be their competition with GTP during cell signalling processes [125].
The role of ITPA in azathioprine biotransformation lies in the hydrolytic breakdown of po‐
tentially hepatotoxic 6-thio-ITP.
The gene coding for ITPA is situated on the short arm of chromosome 20 (20p13) and con‐
tains 8 exon sequences [126]. Several nucleotide polymorphisms were identified in its se‐
quence; in 5 of these polymorphisms, a correlation with a low activity of the native protein
was proven [127]. The lowest enzymatic activity was discovered in individuals who carry
the nucleotide substitution of cytosine for adenine at position 94 in the sequence of the exon
2 (94C>A). At the protein primary structure level, this substitution is manifested by the sub‐
stitution of proline for threonine at position 32, which decreases its affinity for the produc‐
tion of active dimer in ITPA proteins, decreases the protein stability and leads to a non-
specific mRNA splicing [128,125,129]. The heterozygous genotype for the variant allele 94A
is from the phenotype perspective manifested by the decrease of ITPA activity up to 22.5%
of the activity of a standard form. ITPA activity was not detectable in individuals who are
homozygous for this variant allele [128]. The frequency of the variant allele 94A in the ITPA
gene is 5–7% in the Caucasian population [130–133]. Another nucleotide substitution in
which an impact on the enzymatic activity was confirmed, is the substitution of adenine for
cytosine at the sequence of intron 2 (IVS2+21A>C). The presence of this substitution leads to
a faulty mRNA splicing during post-transcriptional modifications and the formation of a
protein, which reaches 61% activity in heterozygous individuals, when compared to the na‐
tive form of the enzyme [134,125]. Homozygous carriers of this variant allele have their en‐
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well as exogenous substances with this chemical structure [137]. The enzyme activity has
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ses the oxidation of hypoxanthine to xanthine and consequently to uric acid. This enzyme is
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In humans, several polymorphisms have been identified, which facilitate the formation of 21
allelic variants [143]. Several of these allelic variants are associated with the occurrence of
adverse effects during azathioprine therapy and with higher levels of toxic metabolites 6-
MP [133,144]. Several of the noted single nucleotide polymorphisms influence XDH enzy‐
matic activity. However, many of these variant alleles have only been discovered within the
Japanese or Asian populations. A potential clinical importance can be expected in example
of polymorphisms 837C>T, which has a 6% frequency in the Caucasian population. At the
primary protein structure level, there is no amino acid substitution. Nevertheless, this poly‐
morphism somehow influences enzymatic activity and its occurrence correlates with higher
levels of thiopurine metabolites. A possible explanation may be the coincidence with an un‐
known polymorphism [144] or RNA interferency. During the reaction of the catalyzed XDH,
free oxygen radicals are generated, which are expected to participate in the hepatotoxic ef‐
fect of thiopurines [145].
4.4. Biological therapy
Biological therapy represents a completely new therapeutic approach to chronic inflamma‐
tory diseases. This therapeutic approach has proved useful not only in IBD therapy, but also
in the therapy of other chronic inflammatory diseases, such as rheumatoid arthritis, ankylos‐
ing spondylarthritis and psoriasis. In IBD, the most common drugs intervene in the TNFα
cytokine-mediated signalling at the molecular level (infliximab, adalimumab and etaner‐
cept).The main mechanism of these “anti-TNFα” antibodies is the binding of a drug to the
TNFα soluble form (sTNFα) and blocking biological functions, which are mediated by it.
Some studies demonstrated that individual antibodies have a different neutralisation poten‐
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tial and that this ability is also dependent on the TNFα concentration. At high sTNFα con‐
centrations, the neutralising potential of infliximab, adalimumab and etanercept is
comparable [146]. However, if the sTNFα concentration in the tissue is small, etanercept is
about 20 times more effective than other antibodies. Two mechanisms are employed during
the binding of the antibody to the membrane-bound TNFα form (tmTNFα). The first is an‐
tagonism, preventing the interaction between tmTNFα and its receptor (TNFR). The second
is agonism; the binding of the drug to tmTNFα activates the reverse signalling cascade
which leads to the suppression of TNFα production, other pro-inflammatory cytokines and
apoptosis [147].
The cytotoxicity of anti-TNFα antibodies is caused by two mechanisms. The first lies in the
binding of antibodies to tmTNFα and the apoptosis activation. The second mechanism is
based on the initiation of complement-dependent cytotoxicity through the antibody Fc frag‐
ment. The antibody Fc fragment has the function of effector mediated by the Fc receptor in
immunocompetent cells of monocytes and macrophages, NK cells and some types of T lym‐
phocytes. Activation initiates a cascade of intracellular processes leading to phagocytosis,
degranulation, activation of the complement and cytokines release [148]. Monoclonal sub‐
stances with an Fc fragment in its structure (infliximab, adalimumab, and etanercept) have
the ability to interact with these receptors. The antibody or the complex anti-TNFα Ig-TNFα
can bind to the receptor [147]. One of the major risks of biological therapy is the production
of antibodies against the drug. No of anti-TNFα drugs, in which the sequences are fully hu‐
man, have this undesired property suppressed. Infliximab is the most immunogenic chimer‐
ic antibody [149]. The production of antibodies targeted against the drug decreases its
therapeutic effect and increases the drug clearance. Due to this, the anti-TNFα therapy is
supplemented by immunosuppressives (MTX, AZA) with the goal to prevent the induction
of immune reactions [150].
4.4.1. Polymorphisms, which influence the anti-TNFα antibodies therapy
Mutations in the gene TNFα, especially mutations in the promoter area of this gene, lead to
an altered expression of the gene and subsequently to a change in the amount of active
TNFα. Its increased level result not only in pathological manifestations of chronic inflamma‐
tion, but also in the effectiveness of the biological therapy,which at the molecular level influ‐
ence the TNFα cytokine-mediated signalling (infliximab, adalimumab and etanercept).
Therefore, the gene coding for the cytokine TNFα is classified among candidate genes as
well as therapeutic genes, whose protein products influence the effectiveness and safety of
drug therapy. More information on polymorphisms in this gene can be found in Chapter 2.5.
TNFα production is strictly controlled. Most of the regulatory mechanisms are embedded
into the post-transcription processes [148]. The amount of the TNFα active form (both s and
tm forms) is therefore dependent not only on the presence of the above mentioned SNPs,
but also on the stimulation of cytokine-producing cells, TACE activity (TNF-α-converting
enzyme) and intracellular regulatory processes and mRNA stability [151]. The initiating fac‐
tor is the presence of gram-negative and gram-positive microorganisms (lipopolysacchar‐
ide,LPS, is one of the strongest stimulators), viral antigens or tumour-transformed cells.
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Receptor molecules such as NOD2/CARD15 (receptor for muramyl dipeptide, MDP) and
transmembrane receptor structures of the TLR family (receptor for lipopolysaccharides,
LPS) play a key role in this step. The system of gradual activation of intracellular elements
of signal pathways leads to the activation of NF-κB, which is common for both of these path‐
ways and leads to the activation of the expression of TNFα and other pro-inflammatory cy‐
tokines. Another area, which influences the level of TNFα expression, is the promoter area
of the gene coding for this cytokine.
There are also other cytokines which influence TNFα production (e.g. IL-1, IL-17, GM-CSF
and interferon-γ), the antigen-antibody complexes and complements. TNFα release is also
stimulated by pathological damage to tissue due to trauma or ischemia/hypoxia [148].
Factors which quantitatively influence the TNFα expression as well as molecules, which are
inductors of this expression, seem to be potential predictors of the therapeutic response to
biological therapy. One of the key molecules which regulate the gene expression of many
cytokines is the nuclear factor κB (NF-κB) [14,15]. Its activation is closely linked with com‐
plex intracellular processes, by which the immune system recognizes bacterial antigens and
reacts to their presence. In mammalian cells, there are NOD proteins and Toll-like receptors
(also the so-called pattern recognition receptors, PRRs), which recognize these bacterial
structures. More information about polymorphisms in the NOD2/CARD15 and TLR4 genes
is given in Chapters 2.1 and 2.4.
During the infliximab therapy, the growth of apoptosis was confirmed in immune cells. As
described above, it is one of the effect mechanisms which lead to the suppression of the im‐
mune reaction. A Belgium group of scientists led by Mr. Hlavaty [152] based their research
on this finding and demonstrated the possible impact of polymorphisms in genes for indi‐
vidual proteins of the pro-apoptotic pathway (Fas-ligand and caspase 9) on the infliximab
therapy effectiveness in patients with Crohn’s disease. Apoptosis can be induced in cells by
the “extrinsic pathway”, where TNFα molecules, Fas ligand and TRAIL (TNF-related apop‐
tosis-inducing ligand) work as inductors of the apoptosis. There is also an intrinsic pathway,
which includes the release of cytochrome c from mitochondria in a reaction to DNA dam‐
age. Both of these pathways are connected in the area of activation of cysteinyl-aspartate-
specific protease (Caspase 3). Fas ligand is expressed in many immune system cells and, via
the apoptosis induction, maintains the balance between the production and death of T lym‐
phocytes and B lymphocytes. In this manner it contributes to immune tolerance [153]. The
gene for Fas ligand is situated on the long arm of chromosome 1 (1q23). It consists of 4 exons
and its length is approximately 8kb [153]. Polymorphism located in the promoter area (–
844C>T) is at a position where a transcription enhancer has bonded. Variant allele T is re‐
sponsible for the decreased binding affinity of this transcription factor. Individual homozy‐
gous for variant T allele have a decreased expression activity and a decreased quantity of
the native protein in the membrane [154]. Patients with such polymorphism have a de‐
creased activation of the pro-apoptotic pathway.
The intrinsic pathway for apoptosis activation is formed by individual cytosol proteases,
which are activated in cascades. Caspase 9 (Casp9) is one of them. The primary stimulus for
the activation of intrinsic pro-apoptotic pathway is damage to mitochondria and cyto‐
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based on the initiation of complement-dependent cytotoxicity through the antibody Fc frag‐
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phocytes. Activation initiates a cascade of intracellular processes leading to phagocytosis,
degranulation, activation of the complement and cytokines release [148]. Monoclonal sub‐
stances with an Fc fragment in its structure (infliximab, adalimumab, and etanercept) have
the ability to interact with these receptors. The antibody or the complex anti-TNFα Ig-TNFα
can bind to the receptor [147]. One of the major risks of biological therapy is the production
of antibodies against the drug. No of anti-TNFα drugs, in which the sequences are fully hu‐
man, have this undesired property suppressed. Infliximab is the most immunogenic chimer‐
ic antibody [149]. The production of antibodies targeted against the drug decreases its
therapeutic effect and increases the drug clearance. Due to this, the anti-TNFα therapy is
supplemented by immunosuppressives (MTX, AZA) with the goal to prevent the induction
of immune reactions [150].
4.4.1. Polymorphisms, which influence the anti-TNFα antibodies therapy
Mutations in the gene TNFα, especially mutations in the promoter area of this gene, lead to
an altered expression of the gene and subsequently to a change in the amount of active
TNFα. Its increased level result not only in pathological manifestations of chronic inflamma‐
tion, but also in the effectiveness of the biological therapy,which at the molecular level influ‐
ence the TNFα cytokine-mediated signalling (infliximab, adalimumab and etanercept).
Therefore, the gene coding for the cytokine TNFα is classified among candidate genes as
well as therapeutic genes, whose protein products influence the effectiveness and safety of
drug therapy. More information on polymorphisms in this gene can be found in Chapter 2.5.
TNFα production is strictly controlled. Most of the regulatory mechanisms are embedded
into the post-transcription processes [148]. The amount of the TNFα active form (both s and
tm forms) is therefore dependent not only on the presence of the above mentioned SNPs,
but also on the stimulation of cytokine-producing cells, TACE activity (TNF-α-converting
enzyme) and intracellular regulatory processes and mRNA stability [151]. The initiating fac‐
tor is the presence of gram-negative and gram-positive microorganisms (lipopolysacchar‐
ide,LPS, is one of the strongest stimulators), viral antigens or tumour-transformed cells.
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Factors which quantitatively influence the TNFα expression as well as molecules, which are
inductors of this expression, seem to be potential predictors of the therapeutic response to
biological therapy. One of the key molecules which regulate the gene expression of many
cytokines is the nuclear factor κB (NF-κB) [14,15]. Its activation is closely linked with com‐
plex intracellular processes, by which the immune system recognizes bacterial antigens and
reacts to their presence. In mammalian cells, there are NOD proteins and Toll-like receptors
(also the so-called pattern recognition receptors, PRRs), which recognize these bacterial
structures. More information about polymorphisms in the NOD2/CARD15 and TLR4 genes
is given in Chapters 2.1 and 2.4.
During the infliximab therapy, the growth of apoptosis was confirmed in immune cells. As
described above, it is one of the effect mechanisms which lead to the suppression of the im‐
mune reaction. A Belgium group of scientists led by Mr. Hlavaty [152] based their research
on this finding and demonstrated the possible impact of polymorphisms in genes for indi‐
vidual proteins of the pro-apoptotic pathway (Fas-ligand and caspase 9) on the infliximab
therapy effectiveness in patients with Crohn’s disease. Apoptosis can be induced in cells by
the “extrinsic pathway”, where TNFα molecules, Fas ligand and TRAIL (TNF-related apop‐
tosis-inducing ligand) work as inductors of the apoptosis. There is also an intrinsic pathway,
which includes the release of cytochrome c from mitochondria in a reaction to DNA dam‐
age. Both of these pathways are connected in the area of activation of cysteinyl-aspartate-
specific protease (Caspase 3). Fas ligand is expressed in many immune system cells and, via
the apoptosis induction, maintains the balance between the production and death of T lym‐
phocytes and B lymphocytes. In this manner it contributes to immune tolerance [153]. The
gene for Fas ligand is situated on the long arm of chromosome 1 (1q23). It consists of 4 exons
and its length is approximately 8kb [153]. Polymorphism located in the promoter area (–
844C>T) is at a position where a transcription enhancer has bonded. Variant allele T is re‐
sponsible for the decreased binding affinity of this transcription factor. Individual homozy‐
gous for variant T allele have a decreased expression activity and a decreased quantity of
the native protein in the membrane [154]. Patients with such polymorphism have a de‐
creased activation of the pro-apoptotic pathway.
The intrinsic pathway for apoptosis activation is formed by individual cytosol proteases,
which are activated in cascades. Caspase 9 (Casp9) is one of them. The primary stimulus for
the activation of intrinsic pro-apoptotic pathway is damage to mitochondria and cyto‐
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chrome c release. This, after binding to APAF-1, forms a complex with caspase 9 [155]. The
consequential chain of reactions results in the activation of other proteases - caspase 3, 6 and
7, which cause the disruption of the nuclear membrane, the fragmentation of nucleic DNA
and the production of apoptotic vesicles [156]. Even though there has been some research
focusing on the possible association between the 93C>T polymorphism and infliximab thera‐
py effectiveness or the predisposition to Crohn’s disease and the disease activity [157], its
role at the molecular level has not been exactly understood to date. However, it was demon‐
strated that this polymorphism does not result in the amino acid substitution at the level of
the protein primary structure.
5. Gene polymorphisms and adverse effects of azathioprine treatment
During azathioprine therapy, about 10-28% of patients experience adverse effects [158–160].
The most serious of these is myelosupression, which is most often manifested as leukopenia.
In their study, Katsanos [161] found the myelosupression incidence totalling 7%. Other com‐
mon adverse effects, which may result in the termination of the therapy, are hepatotoxicity
(9.7%), pancreatitis (10.5%) and digestive intolerance (17.5%), and to a lesser degree, extend‐
ed infections (6.1%) or flu-like symptoms (5.7%) [162]. Most of these adverse effects are
dose-dependent reactions.
The occurrence of myelosupression correlates with high levels of active azathioprine metab‐
olites (6-thioguanine nucleotide, 6-TGN) [163], which result from a deficient azathioprine
metabolism in individuals with a variant TPMT genotype. There are many experiments
which confirm this dependence [136,164–167].
We tested a group of 188 patients treated with azathioprine for inflammatory bowel disease
(IBD). During the therapy, 34 individuals experienced leukopenia (WBCs count <4 x 109 /L),
hepatotoxicity (alanine aminotransferase or aspartate aminotransferase > 3times upper limit
of normal) was confirmed in 4 patients, digestive intolerance was revealed in 4 individuals
(nausea, vomiting, abdominal pain associated with treatment; ceased after AZA withdraw‐
al) and pancreatitis developed in 2 patients. The variant TPMT allele was confirmed in 8
(23.5%) patients with leukopenia. Within the group of patients who did not experience leu‐
kopenia, the variant TPMT allele was confirmed in 8 people (5.2%). Fisher test confirmed an
association between the variant TPMT genotype and leukopenia (P=0.003) – see Figures 2,
and 3.
Patients with a variant TPMT genotype (heterozygotes) were five times at risk of developing
leukopenia than patients with a standard genotype (P = 0.003, CI 95%, 1.8058–13.8444) [168].
These findings comply with previously published findings [136,164–167].
The FDA recommends a large-scale TPMT genotype testing prior to the azathioprine thera‐
py [169]. Nevertheless, the presence of the variant TPMT genotype does not imply an abso‐
lute azathioprine contraindication in these patients. There were even earlier works, which
reported the desired therapeutic effects without the manifestation of myelotoxicity in pa‐
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tients with variant TPMT genotypes achieved by a proportionate decrease of the dose [170].
Carriers of variant TPMT alleles were recommended to decrease the AZA dosing to 30-70%
or to 10% of standard doses in heterozygotes and in variant homozygotes, respectively
[165,171]. In these patients, the dosage should be carefully subjected to titration and regular
checking of WBCs counts [170,172 –174].
Figure 2. Occurence of leukopenia in patients with different genotypes. Note: +/+: carrier of two wild type alleles
TPMT*1; +/- : carrier of one variant allele: TPMT*2 or *3A,*3B or *3C.
Figure 3. Frequency of variant alleles in patient with / without adverse effects
A similar association between deficient azathioprine metabolism and the occurrence of leu‐
kopenia can be expected in the case of the polymorphism in the gene for XDH. Even though
our set revealed a tendency for a higher frequency of the variant allele 837T in patients with
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olites (6-thioguanine nucleotide, 6-TGN) [163], which result from a deficient azathioprine
metabolism in individuals with a variant TPMT genotype. There are many experiments
which confirm this dependence [136,164–167].
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hepatotoxicity (alanine aminotransferase or aspartate aminotransferase > 3times upper limit
of normal) was confirmed in 4 patients, digestive intolerance was revealed in 4 individuals
(nausea, vomiting, abdominal pain associated with treatment; ceased after AZA withdraw‐
al) and pancreatitis developed in 2 patients. The variant TPMT allele was confirmed in 8
(23.5%) patients with leukopenia. Within the group of patients who did not experience leu‐
kopenia, the variant TPMT allele was confirmed in 8 people (5.2%). Fisher test confirmed an
association between the variant TPMT genotype and leukopenia (P=0.003) – see Figures 2,
and 3.
Patients with a variant TPMT genotype (heterozygotes) were five times at risk of developing
leukopenia than patients with a standard genotype (P = 0.003, CI 95%, 1.8058–13.8444) [168].
These findings comply with previously published findings [136,164–167].
The FDA recommends a large-scale TPMT genotype testing prior to the azathioprine thera‐
py [169]. Nevertheless, the presence of the variant TPMT genotype does not imply an abso‐
lute azathioprine contraindication in these patients. There were even earlier works, which
reported the desired therapeutic effects without the manifestation of myelotoxicity in pa‐
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or to 10% of standard doses in heterozygotes and in variant homozygotes, respectively
[165,171]. In these patients, the dosage should be carefully subjected to titration and regular
checking of WBCs counts [170,172 –174].
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TPMT*1; +/- : carrier of one variant allele: TPMT*2 or *3A,*3B or *3C.
Figure 3. Frequency of variant alleles in patient with / without adverse effects
A similar association between deficient azathioprine metabolism and the occurrence of leu‐
kopenia can be expected in the case of the polymorphism in the gene for XDH. Even though
our set revealed a tendency for a higher frequency of the variant allele 837T in patients with
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leukopenia (4.4%) compared with patients without this adverse effect (2.6%), this difference
was not statistically significant [168,175]. Unlike the TPMT enzyme, whose activity is well
described and quantified in individuals with standard and variant genotypes, the relation‐
ship between the genotype and phenotype activity of XDH is not so clear. It is supposed that
despite the decrease of metabolic activity, this decrease is not as striking as in case of TPMT.
Furthermore, the decreased XDH activity can be better compensated for by the activity of
other enzymes, which participate in azathioprine metabolising. However, the situation is
different if XDH is inhibited by allopurinol. In this case, there is probably an extensive com‐
petition that would result in the 6-TGN levels having a toxic effect (343 pmol/8x108) [163].
To date, no pathological condition connected with decreased ITPA activity has been descri‐
bed. Similarly, available data regarding the association between polymorphisms in the gene
for this enzyme and the occurrence of adverse effects of azathioprine therapy are contradic‐
tory. Some studies describe the association between decreased ITPA activity and the occur‐
rence of pancreatitis, rash, flu-like syndrome and leukopenia [135,136]. There are no other
studies confirming the association between the ITPA polymorphism and the occurrence of
adverse effects [166,176,177]. Our test group included 4 patients who experienced digestive
intolerance during azathioprine therapy; 2 of these patients were heterozygous for the var‐
iant allele 94A in the gene ITPA. The frequency of the variant allele in patients with diges‐
tive intolerance reached 25% (compared with 6.5% in patients without digestive intolerance)
but due to a low number of individuals its statistical interpretation is difficult – see Figure 3.
However, we confirmed that patients, who are carriers of the variant allele, have a 3.33
times greater probability of digestive intolerance (CI 95%, 1.09-13.5) than patients with a
standard allele [168,175]. The association between the variant allele 94A and the occurrence
of digestive intolerance must be confirmed in a larger set of patients. The occurrence of pan‐
creatitis was similarly rare (n=4) in our set. In these patients, the variant allele XDH 837T
had a frequency of 25% (compared with 2.7% in patients without pancreatitis). It is expected
that the presence of this variant allele leads to the decreased activity of the XDH enzyme
[168,175] – see Figure 3. Because of this, 6-MP is subsequently metabolised and the levels of
its cytotoxic metabolites increase, which can cause pancreatitis [133]. In the group of indi‐
viduals, in whom the variant genotype was confirmed, there were 12.1 individuals with
pancreatitis per one individual without this adverse effect (CI 95%; 1.15-126.4). However,
even in this case it is necessary to confirm or disprove these results in a larger set of patients.
The most important polymorphisms with a significant impact on the azathioprine therapy
are SNPs in the gene for TPMT. The impact of other genetic variants must be verified in a
larger set of patients.
6. Gene polymorphisms as predictors of the effectiveness of infliximab
therapy
Infliximab, a chimeric monoclonal antibody, was the first biological agent registered for the
treatment of CD by FDA in 1998. Presently, infliximab, adalimumab and cetrolizumab pegol
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are used in the therapy of CD. Subsequently, the effectiveness of biological therapy was also
confirmed in moderate to severe active UC [178–180].
The effect of biological therapy is based on the suppression of the anti-inflammatory effect
of cytokines, which are inflammation mediators. In patients with IBD, it is assumed that
TNFα has the main role in the induction and prolonging of the inflammatory reaction. The
use of monoclonal antibodies inhibiting this cytokine has been a great therapeutic benefit to
the therapy. Biotechnologically produced monoclonal antibodies have already demonstrat‐
ed its significant position in the therapy of IBD as well as other chronic inflammatory diseas‐
es. Infliximab was firstly used for Crohn’s disease therapy and later Rutgeerts et al.
confirmed its effect in patients with UC [179]. Infliximab as a monoclonal antibody has an
affinity for both soluble and membrane-bound forms of TNFα. Binding to soluble cytokine
inhibits its pro-inflammatory effect, and the affinity for the membrane form of TNFα indu‐
ces apoptosis. Today, biological therapy in IBD has a significant position in the treatment of
patients who do not respond to the conventional pharmacological approach, or in corticoid-
dependent patients and in patients with severely active Crohn’s disease with fistulas and in
serious active ulcerative colitis. The high therapeutic effectiveness of infliximab was con‐
firmed by large-scale clinical studies [179,181,182].
During infliximab therapy, several adverse effects were described. However, except for the
allergic reaction, which occurs immediately after the infliximab is administered, they occur
with low frequency (183). Biological therapy can therefore be considered highly effective.
Still, there are about 20-30% of patients in whom no therapeutic effect occurs. At first, it was
thought that the reason for the absence of any clinical effect was the presence of autoanti‐
bodies against infliximab [184]. However, this hypothesis has not been fully confirmed. Oth‐
er possible causes are the subject of the study [185,186]. Factors which quantitatively
influence TNFα expression seem to be among the potential predictors for the therapeutic re‐
sponse. They are molecules, which participate in the activation of NF-κB, the inductor of the
TNFα expression. Nuclear factor κB (NF-κB) is a key component in the regulation of expres‐
sion in the area of genome-carrying genes for cytokines [14,15]. Its activation is closely con‐
nected with complex intracellular processes, by which the immune system responds to the
presence of bacterial antigens. For example, the presence of muramyl dipeptide (MDP) is
detected by the interaction with NOD2. This cytosol protein is a component of cascade,
which leads to local activation of the immune system in response to the presence of patho‐
gen, and consequently to the expression and release of cytokines including TNFα. The gene
for NOD2 lies in the area of the genome, which was earlier associated with incidences of
IBD and which is linked to the occurrence of IBD [21,8]. In the Caucasian population, there
are two single nucleotide polymorphisms marked 702Arg>Trp and 908Gly>Arg and a fra‐
meshift mutation 1007fs (3020fsinsC), which occur with a relatively high frequency. In vitro
studies confirmed that a cell, which carries in its genome an allelic form corresponding to
variant alleles 702Trp and 908Arg, is able to release TNFα after the induction by muramyl
dipeptide in a quantitatively comparable amount like a cell with wild alleles in these poly‐
morphisms [187–189]. These nucleotide substitutions lead to the change of the primary
structure, but not so significant a change at the level of the secondary and tertiary protein
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leukopenia (4.4%) compared with patients without this adverse effect (2.6%), this difference
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for this enzyme and the occurrence of adverse effects of azathioprine therapy are contradic‐
tory. Some studies describe the association between decreased ITPA activity and the occur‐
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studies confirming the association between the ITPA polymorphism and the occurrence of
adverse effects [166,176,177]. Our test group included 4 patients who experienced digestive
intolerance during azathioprine therapy; 2 of these patients were heterozygous for the var‐
iant allele 94A in the gene ITPA. The frequency of the variant allele in patients with diges‐
tive intolerance reached 25% (compared with 6.5% in patients without digestive intolerance)
but due to a low number of individuals its statistical interpretation is difficult – see Figure 3.
However, we confirmed that patients, who are carriers of the variant allele, have a 3.33
times greater probability of digestive intolerance (CI 95%, 1.09-13.5) than patients with a
standard allele [168,175]. The association between the variant allele 94A and the occurrence
of digestive intolerance must be confirmed in a larger set of patients. The occurrence of pan‐
creatitis was similarly rare (n=4) in our set. In these patients, the variant allele XDH 837T
had a frequency of 25% (compared with 2.7% in patients without pancreatitis). It is expected
that the presence of this variant allele leads to the decreased activity of the XDH enzyme
[168,175] – see Figure 3. Because of this, 6-MP is subsequently metabolised and the levels of
its cytotoxic metabolites increase, which can cause pancreatitis [133]. In the group of indi‐
viduals, in whom the variant genotype was confirmed, there were 12.1 individuals with
pancreatitis per one individual without this adverse effect (CI 95%; 1.15-126.4). However,
even in this case it is necessary to confirm or disprove these results in a larger set of patients.
The most important polymorphisms with a significant impact on the azathioprine therapy
are SNPs in the gene for TPMT. The impact of other genetic variants must be verified in a
larger set of patients.
6. Gene polymorphisms as predictors of the effectiveness of infliximab
therapy
Infliximab, a chimeric monoclonal antibody, was the first biological agent registered for the
treatment of CD by FDA in 1998. Presently, infliximab, adalimumab and cetrolizumab pegol
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are used in the therapy of CD. Subsequently, the effectiveness of biological therapy was also
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The effect of biological therapy is based on the suppression of the anti-inflammatory effect
of cytokines, which are inflammation mediators. In patients with IBD, it is assumed that
TNFα has the main role in the induction and prolonging of the inflammatory reaction. The
use of monoclonal antibodies inhibiting this cytokine has been a great therapeutic benefit to
the therapy. Biotechnologically produced monoclonal antibodies have already demonstrat‐
ed its significant position in the therapy of IBD as well as other chronic inflammatory diseas‐
es. Infliximab was firstly used for Crohn’s disease therapy and later Rutgeerts et al.
confirmed its effect in patients with UC [179]. Infliximab as a monoclonal antibody has an
affinity for both soluble and membrane-bound forms of TNFα. Binding to soluble cytokine
inhibits its pro-inflammatory effect, and the affinity for the membrane form of TNFα indu‐
ces apoptosis. Today, biological therapy in IBD has a significant position in the treatment of
patients who do not respond to the conventional pharmacological approach, or in corticoid-
dependent patients and in patients with severely active Crohn’s disease with fistulas and in
serious active ulcerative colitis. The high therapeutic effectiveness of infliximab was con‐
firmed by large-scale clinical studies [179,181,182].
During infliximab therapy, several adverse effects were described. However, except for the
allergic reaction, which occurs immediately after the infliximab is administered, they occur
with low frequency (183). Biological therapy can therefore be considered highly effective.
Still, there are about 20-30% of patients in whom no therapeutic effect occurs. At first, it was
thought that the reason for the absence of any clinical effect was the presence of autoanti‐
bodies against infliximab [184]. However, this hypothesis has not been fully confirmed. Oth‐
er possible causes are the subject of the study [185,186]. Factors which quantitatively
influence TNFα expression seem to be among the potential predictors for the therapeutic re‐
sponse. They are molecules, which participate in the activation of NF-κB, the inductor of the
TNFα expression. Nuclear factor κB (NF-κB) is a key component in the regulation of expres‐
sion in the area of genome-carrying genes for cytokines [14,15]. Its activation is closely con‐
nected with complex intracellular processes, by which the immune system responds to the
presence of bacterial antigens. For example, the presence of muramyl dipeptide (MDP) is
detected by the interaction with NOD2. This cytosol protein is a component of cascade,
which leads to local activation of the immune system in response to the presence of patho‐
gen, and consequently to the expression and release of cytokines including TNFα. The gene
for NOD2 lies in the area of the genome, which was earlier associated with incidences of
IBD and which is linked to the occurrence of IBD [21,8]. In the Caucasian population, there
are two single nucleotide polymorphisms marked 702Arg>Trp and 908Gly>Arg and a fra‐
meshift mutation 1007fs (3020fsinsC), which occur with a relatively high frequency. In vitro
studies confirmed that a cell, which carries in its genome an allelic form corresponding to
variant alleles 702Trp and 908Arg, is able to release TNFα after the induction by muramyl
dipeptide in a quantitatively comparable amount like a cell with wild alleles in these poly‐
morphisms [187–189]. These nucleotide substitutions lead to the change of the primary
structure, but not so significant a change at the level of the secondary and tertiary protein
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structures. Therefore, the impact on the biological functions of the coded protein is minimal
[188]. The insertion of cytosine nucleotide in the case of the frameshift mutation leads to the
shift of the reading frame during the translation and the formation of a premature stop co‐
don [190]. The transcription of the variant allele results in the production of a protein, which
is shorter by the area coded behind the stop codon. Due to this, the biological activity of the
shortened protein NOD2 is strongly disturbed, which was confirmed by in vitro and in vivo
studies, which discovered that the production of TNFα was not detected after the stimula‐
tion of MDP [187–189]. The presence of the frameshift mutation therefore results in the ab‐
sence of the TNFα expression via NF-κB [15].
If we accept the hypothesis that a higher effectiveness of infliximab therapy correlates with
lower levels of TNFα, then carriers of the alleles, which are connected with the lower expres‐
sion of this cytokine, should also respond favorably to the therapy. Our results confirm this
hypothesis, even though we did not study the phenotype (plasma or tissue levels of TNFα)
but only the genotype. The frequency of variant alleles, in which the significant influence on
the quantity of the TNFα expression (702W and 908R) was not confirmed in vitro, was com‐
parable in patients with a therapeutic response and in patients resistant to the therapy. On
the other hand, the frequency of the frameshift mutation, which leads to a significant de‐
crease of the TNFα expression after the MDP induction, was statistically and significantly
higher (15.2%) in patients who reacted positively to the therapy, compared to patients that
were resistant to the therapy (3.6%). Patients, who are carriers of the frameshift mutation,
have a 4.25 times higher probability that the infliximab therapy will be effective (CI 95%;
1.06-17.07). The frequency of the frameshift mutation (variant allele 1007fs) was virtually
identical in patients who responded to the infliximab therapy by mucosal healing, and in
patients who revealed only clinical improvement of parameters (15.15% and 15.22%, respec‐
tively).
The TNFα expression via NF-κB occurs also after the binding of a specific ligand, e.g. lipo‐
polysaccharide (LPS), to the membrane TLR4 receptor. The activation of the intracellular sig‐
nalling cascade and the expression of pro-inflammatory cytokines occur in cooperation with
the molecule CD14 [191]. In the TLR4 gene, there are nucleotide polymorphisms, which in‐
fluence its biological functions [192,193]. One of these is a substitution of adenine by gua‐
nine at the position 896 of the nucleotide chain. The variant allele 896G has a lower ability to
induce TNFα production in reaction to LPS stimulation in the in vitro experiments [192,193].
Analogically to the variant genotype NOD2, there is a possible hypothesis that the variant
allele 896G is associated with a better therapeutic response. The occurrence of variant allele
in our set was the highest in patients who responded best to infliximab therapy, i.e. those
who showed both a clinical and morphological response to the therapy (9.9%). In patients
with only a clinical response, the frequency of the variant allele was lower (3.6%), and
among patients resistant to the therapy, there were only 1.8% of carriers of the variant allele.
We can describe a certain tendency that a carrier of the variant allele has a greater probabili‐
ty that infliximab therapy will be effective. However, differences in the frequencies of the
variant allele 896G in the TLR4 gene between individual groups of patients were not statisti‐
cally significant. According to the odds ratio, there are 2.59 patients with both a clinical and
Inflammatory Bowel Disease50
morphological reaction per one patient, with a clinical reaction in the group of patients with
a variant allele 896G in the gene TLR4 (CI 95%; 1.01-8.39) [175].
Several polymorphisms influencing the expression degree were described in the promoter
area of the gene coding for TNFα. A single nucleotide substitution –308G>A is often men‐
tioned. Production of TNFα can be increased by this mechanism even under the standard
stimulation conditions. The variant allele –308A occurred with a 14.03% frequency in the set
of patients. Even though according to the in vitro testing, this variant allele means a higher
production of TNFα due to a higher transcription activity of the gene [194], it could be ex‐
pected that it will be more frequent in patients resistant to the therapy. Our results did not
confirm statistically significant differences between individual groups of patients.
Based on the above information, it can be concluded that a patient who is a carrier of a geno‐
type containing variant allele 1007fs in the gene NOD2, variant allele 896A in the gene TLR4
and the standard allele –308A in the gene TNFα, they will have the greatest probability that
the infliximab therapy will be effective for them. Individuals who are homozygous for the
standard (wild type) alleles of the listed polymorphisms in the gene NOD2, TLR4 and TNFα,
are more often resistant to the infliximab therapy. This standard genotype was in our study
of 163 infliximab-administered patients confirmed in up to 75% of resistant patients, com‐
pared with 46.7% in the group with a therapeutic response. In patients with the best re‐
sponse to infliximab, (i.e. both clinical and morphological) the frequency of this allele
combination was even lower (43.9%) – see Figure 4.
Figure 4. Occurrence (in %) of genotype consisted from wild type alleles in polymorphisms NOD2:1007fs, TLR4:
896A>G and TNFα: –308G>A in groups of patients with different response to infliximab therapy. Legend: C - M re‐
sponse - patients with clinical and morphological response to infliximab therapy; C response - patients with clinical
response, but without morphological response; Therapeutic response - total number of patients in both groups (CM +
C); Resistant patients = patients without clinical and without morphological response to infliximab therapy
Gene Polymorphisms and Inflammatory Bowel Diseases
http://dx.doi.org/10.5772/53465
51
structures. Therefore, the impact on the biological functions of the coded protein is minimal
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shortened protein NOD2 is strongly disturbed, which was confirmed by in vitro and in vivo
studies, which discovered that the production of TNFα was not detected after the stimula‐
tion of MDP [187–189]. The presence of the frameshift mutation therefore results in the ab‐
sence of the TNFα expression via NF-κB [15].
If we accept the hypothesis that a higher effectiveness of infliximab therapy correlates with
lower levels of TNFα, then carriers of the alleles, which are connected with the lower expres‐
sion of this cytokine, should also respond favorably to the therapy. Our results confirm this
hypothesis, even though we did not study the phenotype (plasma or tissue levels of TNFα)
but only the genotype. The frequency of variant alleles, in which the significant influence on
the quantity of the TNFα expression (702W and 908R) was not confirmed in vitro, was com‐
parable in patients with a therapeutic response and in patients resistant to the therapy. On
the other hand, the frequency of the frameshift mutation, which leads to a significant de‐
crease of the TNFα expression after the MDP induction, was statistically and significantly
higher (15.2%) in patients who reacted positively to the therapy, compared to patients that
were resistant to the therapy (3.6%). Patients, who are carriers of the frameshift mutation,
have a 4.25 times higher probability that the infliximab therapy will be effective (CI 95%;
1.06-17.07). The frequency of the frameshift mutation (variant allele 1007fs) was virtually
identical in patients who responded to the infliximab therapy by mucosal healing, and in
patients who revealed only clinical improvement of parameters (15.15% and 15.22%, respec‐
tively).
The TNFα expression via NF-κB occurs also after the binding of a specific ligand, e.g. lipo‐
polysaccharide (LPS), to the membrane TLR4 receptor. The activation of the intracellular sig‐
nalling cascade and the expression of pro-inflammatory cytokines occur in cooperation with
the molecule CD14 [191]. In the TLR4 gene, there are nucleotide polymorphisms, which in‐
fluence its biological functions [192,193]. One of these is a substitution of adenine by gua‐
nine at the position 896 of the nucleotide chain. The variant allele 896G has a lower ability to
induce TNFα production in reaction to LPS stimulation in the in vitro experiments [192,193].
Analogically to the variant genotype NOD2, there is a possible hypothesis that the variant
allele 896G is associated with a better therapeutic response. The occurrence of variant allele
in our set was the highest in patients who responded best to infliximab therapy, i.e. those
who showed both a clinical and morphological response to the therapy (9.9%). In patients
with only a clinical response, the frequency of the variant allele was lower (3.6%), and
among patients resistant to the therapy, there were only 1.8% of carriers of the variant allele.
We can describe a certain tendency that a carrier of the variant allele has a greater probabili‐
ty that infliximab therapy will be effective. However, differences in the frequencies of the
variant allele 896G in the TLR4 gene between individual groups of patients were not statisti‐
cally significant. According to the odds ratio, there are 2.59 patients with both a clinical and
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morphological reaction per one patient, with a clinical reaction in the group of patients with
a variant allele 896G in the gene TLR4 (CI 95%; 1.01-8.39) [175].
Several polymorphisms influencing the expression degree were described in the promoter
area of the gene coding for TNFα. A single nucleotide substitution –308G>A is often men‐
tioned. Production of TNFα can be increased by this mechanism even under the standard
stimulation conditions. The variant allele –308A occurred with a 14.03% frequency in the set
of patients. Even though according to the in vitro testing, this variant allele means a higher
production of TNFα due to a higher transcription activity of the gene [194], it could be ex‐
pected that it will be more frequent in patients resistant to the therapy. Our results did not
confirm statistically significant differences between individual groups of patients.
Based on the above information, it can be concluded that a patient who is a carrier of a geno‐
type containing variant allele 1007fs in the gene NOD2, variant allele 896A in the gene TLR4
and the standard allele –308A in the gene TNFα, they will have the greatest probability that
the infliximab therapy will be effective for them. Individuals who are homozygous for the
standard (wild type) alleles of the listed polymorphisms in the gene NOD2, TLR4 and TNFα,
are more often resistant to the infliximab therapy. This standard genotype was in our study
of 163 infliximab-administered patients confirmed in up to 75% of resistant patients, com‐
pared with 46.7% in the group with a therapeutic response. In patients with the best re‐
sponse to infliximab, (i.e. both clinical and morphological) the frequency of this allele
combination was even lower (43.9%) – see Figure 4.
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Patients who are carriers of the standard genotype, are 2.13 times more probable to be resist‐
ant to the infliximab therapy (CI 95%; 1.10-4.13) compared with patients with other allele
combinations [175].
In the group of patients with the genotype containing standard alleles of the monitored
polymorphisms, there were 3.43% of individuals resistant to the therapy per one individual
with a therapeutic response (CI 95%; 1.37-8.60). Patients, in whom the infliximab administer‐
ing resulted in a therapeutic response, were also most often carriers of the combination
1007fs mut in NOD2 gene, wt allele in TLR4 gene and wt allele in TNFα gene (17%). The
genotype containing standard alleles (wt) of NOD2 and TLR4 genes, i.e. the genotype corre‐
sponding to the standard expression activity of TNFα, was significantly more often present‐
ed in individuals resistant to the therapy (89.3%). The genotype composed of at least one
variant allele responsible for the lower expression activity of TNFα was significantly more
common in patients with a therapeutic response (32.6%; P=0.02).
In the group of patients with the greatest therapeutic benefits (clinical and morphological
response), they most often represented carriers of at least one of the monitored variant al‐
leles (39.4%) [175].
7. Conclusion of chapter – The potential of genotyping of IBD patients in
clinical practice: The importance of gene polymorphisms for
individualisation of IBD pharmacotherapy
Pharmacogenetics is a relatively young branch of pharmacology, which deals with the re‐
search of genetic backgrounds of individual differences in the patient’s response to thera‐
peutic drugs, both from the perspective of drug effectiveness and its safety. Its origin and
development is closely connected with new knowledge in the area of the human genome
and the development of molecular biology methods, which are used in this branch. The first,
partly euphoric visions regarding the use of pharmacogenomic findings for pharmacothera‐
py individualisation and personalised medicine were later revised thanks to the empirical
experience from applying theoretical hypotheses into medical practice. The difference be‐
tween theoretical hypothesis and empirical findings results from the complicated biological
system both at the level of genome and its regulatory mechanisms, and at the level of pro‐
teosynthesis, signalling pathways and interactions of intracellular molecules. The more we
know about the human genome, the more we realise that we can only guess how many of its
regions are activated in a decisive moment, and how complex the regulatory mechanisms
are which influence the final effect, and resulted in phenotype.
The clinical application of pharmacogenetic findings can be limited by the existence of non-
genetic factors. Even though genome cannot be influenced by external factors, the drug to
drug interaction which occurs in the organism can influence not only the onset and develop‐
ment of a disease, but also the patient’s response to the drug. Furthermore, it is necessary to
remember that the patient’s sensitivity to external factors is also a variable and that it is also
Inflammatory Bowel Disease52
genetically conditioned. Because of this, pharmacogenetic information alone cannot predict
exactly the effectiveness or safety of a drug. Despite this, pharmacogenetic studies have pro‐
vided much significant information regarding the different rate of drug metabolisation in in‐
dividuals as well as in populations, the effectiveness of various therapies and the
development of serious adverse effects. Pharmacogenetics is a promising tool in the indi‐
vidualisation of the doctor-patient approach.
The characteristic presence of some polymorphisms in the “candidate genes” is connected
with a predisposition to IBD. It seems that Crohn’s disease is more genetically conditioned
than ulcerative colitis. Some polymorphisms are typical for CD, others for UC. In patients
with CD, the frameshift mutation is statistically more often present in the gene NOD2/
CARD15 (Leu1007fs insC) and the substitution mutation 469Lys>Glu in the gene ICAM-1
than in a healthy population. Unlike patients with UC, they less often carry the substitution
mutation 702Arg>Trp in the gene NOD2/CARD15. All three studied mutations in the gene
NOD2/CARD15 (Leu1007fs insC, 702Arg>Trp and 908Gly>Arg) are statistically more fre‐
quent in patients diagnosed with CD than in patients with UC. Genetic analysis could there‐
fore help find individuals with a genetic predisposition that would require more frequent
check-ups, or to inform physicians when to use additional endoscopic and laboratory tests
or to help specify ambiguous diagnosis.
IBD therapy is lengthy; therefore it requires an individual choice of a drug with an aim to
reduce or completely eliminate adverse effects, while at the same time maintain the therapy
effectiveness. The aim is to achieve a maximum pharmacotherapeutic effect as well as the
effective use of finance. The presence of variant alleles of polymorphisms in “therapeutic
genes” can be of significant help in predicting the adverse effects of a given therapy. The
relationship between myelosupression and the presence of variant alleles in the gene for
TPMT is of the greatest interest. The frequency of variant alleles is significantly higher in pa‐
tients who experience leukopenia during azathioprine therapy, than in patients in whom
leukopenia does not develop. TPMT genotyping can therefore serve as a marker which will
notify clinicians of a significantly increased potential risk in patients with a certain geno‐
type, and on the necessity of increased surveillance over the patient or the need to adjust the
dosage. In clinical practice, it is now common to determine variant alleles in the TPMT gene
prior to the azathioprine therapy. This allows individualisation of the therapy and prevents
serious complications.
Another desired goal is to find genetic markers which can potentially influence the effective‐
ness of pharmacotherapy, especially a therapy which is costly, such biological therapy for
example. Our experimental data imply that patients who are carriers of a genotype com‐
posed from the variant allele 1007fs in the gene NOD2, variant allele 896A in the gene TLR4
and standard allele –308A in the gene for TNFα will have the highest probability that inflixi‐
mab therapy will be effective. On the other hand, individuals who are homozygous for
standard (wild type) alleles of the given polymorphisms in the gene NOD2, TLR4 and TNFα,
are more often resistant to infliximab therapy. This standard genotype was confirmed in up
to 75% of patients resistant to the therapy. Patients who are carriers of the standard geno‐
type are 2.13 times more probable to be resistant to infliximab therapy (CI 95%; 1.10-4.13)
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common in patients with a therapeutic response (32.6%; P=0.02).
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response), they most often represented carriers of at least one of the monitored variant al‐
leles (39.4%) [175].
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and the development of molecular biology methods, which are used in this branch. The first,
partly euphoric visions regarding the use of pharmacogenomic findings for pharmacothera‐
py individualisation and personalised medicine were later revised thanks to the empirical
experience from applying theoretical hypotheses into medical practice. The difference be‐
tween theoretical hypothesis and empirical findings results from the complicated biological
system both at the level of genome and its regulatory mechanisms, and at the level of pro‐
teosynthesis, signalling pathways and interactions of intracellular molecules. The more we
know about the human genome, the more we realise that we can only guess how many of its
regions are activated in a decisive moment, and how complex the regulatory mechanisms
are which influence the final effect, and resulted in phenotype.
The clinical application of pharmacogenetic findings can be limited by the existence of non-
genetic factors. Even though genome cannot be influenced by external factors, the drug to
drug interaction which occurs in the organism can influence not only the onset and develop‐
ment of a disease, but also the patient’s response to the drug. Furthermore, it is necessary to
remember that the patient’s sensitivity to external factors is also a variable and that it is also
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genetically conditioned. Because of this, pharmacogenetic information alone cannot predict
exactly the effectiveness or safety of a drug. Despite this, pharmacogenetic studies have pro‐
vided much significant information regarding the different rate of drug metabolisation in in‐
dividuals as well as in populations, the effectiveness of various therapies and the
development of serious adverse effects. Pharmacogenetics is a promising tool in the indi‐
vidualisation of the doctor-patient approach.
The characteristic presence of some polymorphisms in the “candidate genes” is connected
with a predisposition to IBD. It seems that Crohn’s disease is more genetically conditioned
than ulcerative colitis. Some polymorphisms are typical for CD, others for UC. In patients
with CD, the frameshift mutation is statistically more often present in the gene NOD2/
CARD15 (Leu1007fs insC) and the substitution mutation 469Lys>Glu in the gene ICAM-1
than in a healthy population. Unlike patients with UC, they less often carry the substitution
mutation 702Arg>Trp in the gene NOD2/CARD15. All three studied mutations in the gene
NOD2/CARD15 (Leu1007fs insC, 702Arg>Trp and 908Gly>Arg) are statistically more fre‐
quent in patients diagnosed with CD than in patients with UC. Genetic analysis could there‐
fore help find individuals with a genetic predisposition that would require more frequent
check-ups, or to inform physicians when to use additional endoscopic and laboratory tests
or to help specify ambiguous diagnosis.
IBD therapy is lengthy; therefore it requires an individual choice of a drug with an aim to
reduce or completely eliminate adverse effects, while at the same time maintain the therapy
effectiveness. The aim is to achieve a maximum pharmacotherapeutic effect as well as the
effective use of finance. The presence of variant alleles of polymorphisms in “therapeutic
genes” can be of significant help in predicting the adverse effects of a given therapy. The
relationship between myelosupression and the presence of variant alleles in the gene for
TPMT is of the greatest interest. The frequency of variant alleles is significantly higher in pa‐
tients who experience leukopenia during azathioprine therapy, than in patients in whom
leukopenia does not develop. TPMT genotyping can therefore serve as a marker which will
notify clinicians of a significantly increased potential risk in patients with a certain geno‐
type, and on the necessity of increased surveillance over the patient or the need to adjust the
dosage. In clinical practice, it is now common to determine variant alleles in the TPMT gene
prior to the azathioprine therapy. This allows individualisation of the therapy and prevents
serious complications.
Another desired goal is to find genetic markers which can potentially influence the effective‐
ness of pharmacotherapy, especially a therapy which is costly, such biological therapy for
example. Our experimental data imply that patients who are carriers of a genotype com‐
posed from the variant allele 1007fs in the gene NOD2, variant allele 896A in the gene TLR4
and standard allele –308A in the gene for TNFα will have the highest probability that inflixi‐
mab therapy will be effective. On the other hand, individuals who are homozygous for
standard (wild type) alleles of the given polymorphisms in the gene NOD2, TLR4 and TNFα,
are more often resistant to infliximab therapy. This standard genotype was confirmed in up
to 75% of patients resistant to the therapy. Patients who are carriers of the standard geno‐
type are 2.13 times more probable to be resistant to infliximab therapy (CI 95%; 1.10-4.13)
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than patients with different allelic combinations. A more complex genotyping of a larger set
of patients could help define the “risk genotype”, whose carriers have statistically and sig‐
nificantly decreased the probability of a full morphological response to anti-TNF therapy, or
in contrast, to define a “positive genotype”, where the probability of a successful therapy
would be very high.
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1. Introduction
Antony van Leeuwenhoek’s observation of “animalcules” in the tarter of teeth in 1683 marked
the beginning of humans trying to understand their relationship with microbes. Now com‐
monly referred to as “bacteria” or the “microbiota”, we share our inner and outer space with
these single-celled organisms. They are present all around us in the oceans, soil, leaves, and
even air [1]. One of the microbial niches that has recently garnered much attention is the human
body. In this niche, we share the table with 1014 microbial cells, which outnumber our eukary‐
otic cells ten to one [1, 2]. These organisms colonize most body sites, including the skin, oral
cavity, gastrointestinal, urogenital and respiratory tracts. Additionally, there is 150 times more
genetic material associated with our resident bacteria when compared to our own DNA and
comprise what is known as our body’s “second genome,” a concept recently reviewed by Zhu
et al. [3]. In an effort to understand the role that these organisms have on human development,
health and disease, the National Institutes of Health launched the “Human Microbiome
Project” in 2007 in an effort to elucidate this host-microbe interaction [4-6].
The role of bacteria is most obvious in the gastrointestinal tract (GIT). Bacteria in this niche
have the ability to break down substances that otherwise could not be digested by GIT cells;
they also produce metabolites needed by the body such as vitamin K (menaquinones), folate,
B12, and riboflavin [7-12]. The GIT has a surface area the size of a tennis court and is home to
1011-1012 organisms per gram of colonic content [1, 13]. The predominant bacterial phyla present
in the GIT include the Firmicutes and Bacteroidetes with low levels of Proteobacteria, Actino‐
bacteria, Fusobacteria, and Verrucomicrobia [14-16]. It has been noted that members of the
predominant factions (the Firmicutes and Bacteroidetes) belong to only three groups,
Bacteroides, Clostridium coccoides (cluster XIVa) and Clostridium leptum (cluster IV) [15, 17, 18].
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There are also Archaea present in the GIT and have been found to belong to one phylotype,
Methanobrevibacter smithii [14, 19].
1.1. Initial colonization of the gastrointestinal tract
Infants are born sterile and establishment of the GI microbiota begins shortly thereafter.
Studies in mice have revealed that the first organisms to colonize include lactobacilli,fFlavo‐
bacteria and Group N Streptococci [20]. These three groups were found in the stomach and
the small and large intestine. When the mice were 12 days of age, the flavobacteria disappeared
from all three sites. Concurrently, there was a rapid increase in the presence of enterococci and
slow lactose fermenting coliform bacilli reaching 109 bacteria per gram of tissue in the large
intestine. This spike was transient however, and as the mice aged, a shift toward a more strict
anaerobic population occurred in the large intestine. This ordered colonization occurs because
aerotolerant organisms are able to colonize the GIT early in the presence of oxygen. Through
their metabolism, they reduce the redox potential and allow for the later colonization and
replication of strict anaerobes [21].
1.2. Impact of the method of delivery on colonization
In humans, the method of delivery impacts the initial microbiota of the infant [22-24]. In a
study of Venezuelan women, vaginal delivery was associated with initial colonization by
Lactobacillus, Prevotella, Atopobium, and Sneathia spp.; in contrast Cesarean delivery was
associated with colonization of Staphylococcus, Propionibacterium, and Corynebacterium spp.
(organisms typically found on skin). It was also noted that the initial bacteria present in infants
born vaginally were vertically transferred from the mother. This was not the case for those
born via Cesarean. A Finnish study analyzed infant fecal samples collected between three days
of age and six months of age to evaluate temporal colonization [23]. The results revealed that
at three days of age, all but one infant, regardless of the delivery method, were colonized with
aerobic bacteria. However, a higher percentage of vaginally delivered infants were colonized
with Bifidobacterium-like (BLB) and Lactobacillus-like (LBB) bacteria as compared to Cesarean
delivered infants. These differential colonization patterns were corrected by day ten for LBB
and by day 30 for BLB. Additional characterization of the fecal microbiota revealed that at one
month of age, infants born via Cesarean had a significant increase in Clostridium perfringens
(25% to 56%); an increase not seen in vaginally delivered infants. This is an important obser‐
vation, as C. perfringens has been thought to play a role in sudden infant death syndrome (SIDS)
[25]. Also of note, significant differences in the levels of Bacteroides fragilis were observed
between the two methods of delivery [23]. Specifically, this bacterium was present at statisti‐
cally higher numbers in vaginally delivered infants as compared to Cesarean delivered infants
at all time points throughout the six months of the study.
These differences in initial colonizers have been associated with adverse effects, as infants born
via Cesarean are more susceptible to skin infections with methicillin resistant Staphylococcus
aureus (MRSA). A 2004 report indicated that 82% of infant MRSA cases in Chicago and 64% in
Los Angeles were delivered via Cesarean , all of which involved healthy, full-term infants [26].
An additional prospective cohort study indicated a link between Cesarean delivery and
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Clostridium difficile infection, which was further associated with the development of wheeze,
asthma, eczema, and food allergies throughout the first seven years of life [27]. Consistent with
these findings, a Norwegian study documented an association between asthma and Cesarean
delivered children [28]. Although the epidemiological connections between Cesarean delivery,
the composition of the microbiota, and disease are still being studied, strong evidence exists
that early colonization of the intestines with aerobic skin microbes is associated with health
risks.
1.3. Impact of feeding method on colonization
Another factor affecting early colonization of the human gut is determined by feeding method
[29]. In one study of vaginally delivered infants, the fecal microbiota of breast-fed compared
to formula-fed infants within the first month of life was analyzed using fluorescence in situ
hybridization (FISH) to evaluate 11 separate groups of organisms [29]. Bifidobacterium spp.
were the most prominent organisms found to colonize infants fed breast milk, comprising 69%
of the bacterial population, with the next most prevalent group being the Bacteroides and
Prevotella spp. making up 12%. With respect to the fecal microbiota of formula-fed infants, the
microbiota was actually more diverse than that found in the breast-fed babies. Formula-fed
infants had Bifidobacterium spp. as the most predominant group, however, they only comprised
32% of the bacterial population while Bacteroides and Prevotella spp. comprised 29% of the
composition. Additionally, Atopbium spp. were found to account for 8% of the microbiota in
formula-fed infants, but only comprised 1% of the community in the breast-fed infants.
1.4. Microbial changes that occur after weaning
The next major shift in the microbial population occurs during weaning. In a study consisting
of infants from five European countries, the composition of the fecal microbiota at four weeks
post-weaning was analyzed via FISH using 10 different probes [30]. When considering the
results from all of the infants, it was noted that the microbial communities consisted primarily
of Bifidobacterium (37%), C. coccoides (14%) and Bacteroides (14%). When samples were obtained
from infants that were separated by geographic location, differences among the groups were
noticeable. Infants from Spain had significantly greater Lactobacillus spp. and less Bifidobacte‐
rium spp. as compared to infants from the UK, Sweden, Germany, and Italy. The Spanish fecal
samples also had significantly greater presence of Bacteroides spp. and C. leptum compared to
those from the UK, Sweden, or Italy. The numbers of C. leptum was highest in samples obtained
from German infants. The microbiota of infants from Spain also had significantly greater
amounts of enterobacteria when compared to those from the UK, Sweden, or Germany, and
higher numbers of Streptococcus spp. compared to those from Germany. The infants with the
highest amount of Bifidobacterium spp. were from Sweden and the UK. Further separation of
the data revealed that breast-fed infants had an increased percentage of Bifidobacterium spp.
while Bacteroides spp. and C. coccoides were reduced post-weaning. Additionally, delivery
method also influenced the microbiota composition, with vaginally delivered infants having
higher numbers of Bacteroides present.
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while Bacteroides spp. and C. coccoides were reduced post-weaning. Additionally, delivery
method also influenced the microbiota composition, with vaginally delivered infants having
higher numbers of Bacteroides present.
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This study also reported results from infants who provided samples before (at six weeks
of  age)  and  four  weeks  after  weaning  [30].  Switching  to  solid  food  during  this  time
caused a significant reduction in the presence of bifidobactera, enterobacteria, and C. diffi‐
cile/C. perfringens  proportions. These reductions were accompanied by significant increas‐
es in both C. leptum and C. coccoides clusters. Again, location also played a significant role
in the microbial differences at weaning. Spanish infants had the greatest increase in both
C. coccoides and C. leptum post-weaning compared to the other four countries, while enter‐
obacteria was significantly decreased in the Spanish samples compared to those from the
other  countries.  The samples from Spanish infants  also had significant  increases in Ato‐
pobium  spp.  compared to  those from Sweden and Germany and Streptococcus  spp.  com‐
pared to Germany and Italy.  The authors also report  significant decreases post-weaning
in the enterobacteria present in the Italian infant samples as compared to samples from
Sweden  and  the  UK.  As  mentioned  previously,  feeding  and  delivery  method  alter  the
composition  of  the  microbiota  at  birth;  this  is  also  true  after  weaning.  Formula-fed  in‐
fants  had  higher  proportions  of  C.  leptum  in  their  feces  compared  to  breast-fed  infants
post-weaning. Infants born via Cesarean section possessed increased levels of Bacteroides
spp. after weaning, whereas there was no change in the abundance of this group in vagi‐
nally delivered infants. Additionally, Atopobium spp. decreased in vaginally delivered chil‐
dren but increased in Cesarean delivered children post-weaning [30].
Studies describing development or maturation of the human microbiota reveal that as an
individual ages, the microbiota shifts from predominantly facultative anaerobes to strict
anaerobes, just as previously observed in rodents [20]. Notably, variations in initial coloniza‐
tion associated with different delivery and feeding methods seems to profoundly impact the
microbial community post-weaning. Additionally, geographic location plays an important
role in the initial colonization of the (GIT). In spite of all these variables, several themes for
colonization can be described. Initially, Bifidobacterium spp. are the primary colonizers of the
infant GIT along with other species such as Bacteroides, Lactobacillus, Prevotella, and Atopobi‐
um. As the infant matures, the oxygen presence in the gut is reduced and the infant begins
eating solid food, which promotes a transition towards the growth and maintenance of the
anaerobes found in the C. coccoides and C. leptum clusters.
1.5. The microbiota and gastrointestinal homeostasis
The commensal microbiota has a tremendous influence on the development and functional
capabilities of the GIT of its host. Numerous studies have documented the effects that the
microbiota has on GIT development in mice. Specifically, the morphology of the intestines
differs significantly in animals devoid of microbes (i.e., germfree) compared to conventionally-
reared (CONVR) mice [31]. The mucus layer is thinner and epithelial cells have a slower rate
of turnover compared to those from conventional animals, primarily because of extended time
in the S and G1 phases of the cell cycle [32]. This can be corrected by bacterial colonization. In
Figure 1, panel A shows intestinal tissue from germfree (GF) mice and panel B shows tissue
from a mouse colonized with Brachyspira hyodysenteriae. Colonization with B. hyodysenteriae
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elicits the production of goblet cells and increases the heights of the mucosa, resembling what
is seen in CONVR mice.
(a) (b) 
Figure 1. Photomicrographs of cecal tissue from a) a germfree mouse and b) a mouse monoassociated with Brachy‐
spira hyodysenteriae. Note the changes in the cellularity, presence of goblet cells, and height of the mucosa in the ceca
from the monoassociated mouse 28 days after colonization with B. hyodysenteriae.
In the small intestine, this change in epithelial cell transit time is doubled, going from 53 hours
in a CONVR mouse to 115 hours in a GF mouse [33]. The most noticeable gross change in GF
mice is the enlargement of the cecum, which can comprise up to 19% of the mouse’s body
weight [34]. The cecum of a GF mouse can assume a more normal size (4.5% body weight)
following colonization with a mixture of Lactobacillus spp., Group N streptococci , Bacteroides
spp., enterococci and coliform bacilli recovered from CONVR mice [34]. As shown in Figure
2, monoassociation with B. hyodysenteriae also returns the cecum to a more normal size.
Of interest, not all bacteria tested were able to return the cecum to a normal size. It was noted
that colonizing mice with Lactobacillus spp. and Group N streptococci only was not sufficient
to change the morphology of the cecum. However, when Bacteroides spp. colonized the mice,
the morphology assumed a more normal size. Other differences between GF and CONVR mice
include the consistency of the cecal contents, with the contents from a GF mouse being more
liquid, hypotonic and alkaline than in a CONVR mouse [35]. Additionally, GI transit time is
slower in GF mice, which are also prone to vitamin deficiency due to a lack of bacterial
metabolism [36-38]. In GF rats, monoassociation with either a rat-derived Escherichia coli strain
or a sarcina-like micrococcus was able to reverse the vitamin K deficiency. Research identifying
the response to Salmonella enteritis serovar Typhimurium challenge indicated that there was a
50-fold greater translocation of bacteria to the mesenteric lymph node, and organisms were
present in the blood of GF mice, something not seen in CONVR mice [37]. This phenomenon
occurred due to the decreased transit time in the small intestine of GF mice, thereby allowing
the Salmonella to multiply in the host and translocate to other tissue sites.
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tion associated with different delivery and feeding methods seems to profoundly impact the
microbial community post-weaning. Additionally, geographic location plays an important
role in the initial colonization of the (GIT). In spite of all these variables, several themes for
colonization can be described. Initially, Bifidobacterium spp. are the primary colonizers of the
infant GIT along with other species such as Bacteroides, Lactobacillus, Prevotella, and Atopobi‐
um. As the infant matures, the oxygen presence in the gut is reduced and the infant begins
eating solid food, which promotes a transition towards the growth and maintenance of the
anaerobes found in the C. coccoides and C. leptum clusters.
1.5. The microbiota and gastrointestinal homeostasis
The commensal microbiota has a tremendous influence on the development and functional
capabilities of the GIT of its host. Numerous studies have documented the effects that the
microbiota has on GIT development in mice. Specifically, the morphology of the intestines
differs significantly in animals devoid of microbes (i.e., germfree) compared to conventionally-
reared (CONVR) mice [31]. The mucus layer is thinner and epithelial cells have a slower rate
of turnover compared to those from conventional animals, primarily because of extended time
in the S and G1 phases of the cell cycle [32]. This can be corrected by bacterial colonization. In
Figure 1, panel A shows intestinal tissue from germfree (GF) mice and panel B shows tissue
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Figure 1. Photomicrographs of cecal tissue from a) a germfree mouse and b) a mouse monoassociated with Brachy‐
spira hyodysenteriae. Note the changes in the cellularity, presence of goblet cells, and height of the mucosa in the ceca
from the monoassociated mouse 28 days after colonization with B. hyodysenteriae.
In the small intestine, this change in epithelial cell transit time is doubled, going from 53 hours
in a CONVR mouse to 115 hours in a GF mouse [33]. The most noticeable gross change in GF
mice is the enlargement of the cecum, which can comprise up to 19% of the mouse’s body
weight [34]. The cecum of a GF mouse can assume a more normal size (4.5% body weight)
following colonization with a mixture of Lactobacillus spp., Group N streptococci , Bacteroides
spp., enterococci and coliform bacilli recovered from CONVR mice [34]. As shown in Figure
2, monoassociation with B. hyodysenteriae also returns the cecum to a more normal size.
Of interest, not all bacteria tested were able to return the cecum to a normal size. It was noted
that colonizing mice with Lactobacillus spp. and Group N streptococci only was not sufficient
to change the morphology of the cecum. However, when Bacteroides spp. colonized the mice,
the morphology assumed a more normal size. Other differences between GF and CONVR mice
include the consistency of the cecal contents, with the contents from a GF mouse being more
liquid, hypotonic and alkaline than in a CONVR mouse [35]. Additionally, GI transit time is
slower in GF mice, which are also prone to vitamin deficiency due to a lack of bacterial
metabolism [36-38]. In GF rats, monoassociation with either a rat-derived Escherichia coli strain
or a sarcina-like micrococcus was able to reverse the vitamin K deficiency. Research identifying
the response to Salmonella enteritis serovar Typhimurium challenge indicated that there was a
50-fold greater translocation of bacteria to the mesenteric lymph node, and organisms were
present in the blood of GF mice, something not seen in CONVR mice [37]. This phenomenon
occurred due to the decreased transit time in the small intestine of GF mice, thereby allowing
the Salmonella to multiply in the host and translocate to other tissue sites.
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Figure 2. Physical and morphological changes associated with microbial colonization. Shown here are ceca from a
germfree mouse (left), monoassociated mouse (center), and conventional microbiota mouse (right). Note the in‐
creased size of the cecum from the GF mouse. The distal end of the cecum (appendix) of the monoassociated mouse
has begun to undergo morphological changes, including the development of a lymphoid tissue known as a cecal ton‐
sil.
1.6. Effect of bacterial colonization on immune development
In addition to its importance in maintaining gut homeostasis, the GI microbiota is also critical
for normal priming and development of the immune system [39-41]. GF mice have reduced
numbers of immune cells present in the lamina propria and have smaller Peyer’s patches
compared to CONVR mice. They also have a diminished capacity for antibody production,
fewer plasma cells, smaller mesenteric lymph nodes, and reduced numbers of germinal centers
compared to CONVR mice [39]. However, this underdeveloped immune system is fully
capable of mounting a response comparable to that of a CONVR mouse when stimulated with
bacterial antigen or protein [40, 41]. Macrophages from CONVR mice process antigen faster
than those from GF mice, likely because the continued exposure of CONVR macrophages to
bacterial antigen allows them to be “primed” for antigen degradation; a phenomenon that does
not occur in GF mice [41]. The presence of bacteria in the GIT promotes decreased immunor‐
eactivity towards commensal organisms. The barrier between the gut microbiota and the
underlying gastrointestinal associated lymphoid tissue consists of a single layer of epithelial
cells covered by two layers of mucus [42, 43]. The inner layer of mucus is approximately 100
μm thick while the outer layer is approximately 700 μm in the rat colon [43]. The inner layer
is firmly attached to the epithelial cells and devoid of bacteria, while the outer layer is
“loose”and contains commensal organisms [44]. The major constituent of these layers is a
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protein known as Muc2 [42]. The importance of Muc2 has been highlighted by the development
of Muc2-/- mice. These mice fail to gain weight, have diarrhea by seven weeks of age, occult
blood present in their feces by eight weeks of age, and the majority of mice had gross bleeding
and reversible rectal prolapse by nine weeks of age [45]. These mice also develop microscopic
evidence of colitis as early as five weeks of age.
Underneath the mucus layers lay the intestinal epithelial cells, which are held together by tight
junction proteins such as occludins, claudins, and junctional adhesion molecules [46]. These
proteins seal the paracellular junction between the cells and regulate the entry of nutrients,
ions and water. They also act as a barrier against bacterial entry. Loss of epithelial barrier
function promotes a break in immunological tolerance and facilitates immunoreactivity
towards the normal commensal microbiota (Figure 3). This phenomenon has been demon‐
strated in mouse studies employing 2,4,6 trinitrobenzensulfonic acid (TNBS), a chemical that
disrupts the epithelial barrier to allow translocation of bacteria, resulting in the induction of
both innate inflammatory responses and antigen-specific immune responses [47]. Subsequent
to the loss of epithelial barrier function, these mice develop severe gastrointestinal inflamma‐
tion, which can be ameliorated by pretreating with antibiotics to reduce the microbial load [47].
The role of the commensal bacteria in regulating the immune response was elegantly demon‐
strated in a study by Wlodarska et al. [48]. Mice administered metronidazole were more
susceptible to subsequent infection with the pathogen, Citrobacter rodentium. Metronidazole-
treated mice had increased submucosal edema, ulcerations, mucosal hyperplasia and de‐
creased numbers of goblet cells. The author also noted enhanced expression of IL-25 and Reg3γ
mRNA and an increased presence of NK cells and macrophages in the lamina propria of these
mice, indicating an increase in microbial stimulation. The inner mucous layer of metronida‐
zole-treated mice was significantly thinner and mRNA expression of genes encoding for the
goblet-cell specific proteins Muc2, TFF3, and RelmB was also decreased in these mice [49, 50].
The thinning of the inner mucous layer following metronidazole treatment allowed for C.
rodentium to more closely associate with the epithelium and promote production of the pro-
inflammatory cytokines and chemokines TNF-α, IFN-γ, and MCP-1. This study highlights the
contribution of the commensal microbiota in the production of the mucus barrier and subse‐
quently in maintaining mucosal homeostasis [48].
It has also been noted that specific members of the resident microbiota are able to illicit specific
immune functions. Colonization with Bacteroides fragilis expressing polysaccharide A (PSA)
suppressed development of T helper 17 (Th17) CD4+ T cells by promoting the development of
Foxp3+ T regulatory (Treg) CD4+ T cells and inducing IL-10 expression via TLR2 signaling [51].
Additional studies have demonstrated that purified PSA is sufficient to expand the numbers
of Foxp3+ Treg cells [52]. B. fragilis inhabits colonic crypts. This niche puts the organism in close
contact with the immune system but its production of PSA ensures that no inflammatory
response is induced. Both prophylactic and therapeutic treatment of mice with PSA has been
shown to ameliorate TNBS-induced colitis in mice [52]. More recently, work from Atarashi et
al., eloquently demonstrated a role for indigenous Clostridium species in the induction of
colonic Treg cells [53]. Colonization of GF mice with a cocktail of 46 Clostridium strains enriched
for clusters IV and XIVa promoted TGF-β production from intestinal epithelial cells and
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strated in mouse studies employing 2,4,6 trinitrobenzensulfonic acid (TNBS), a chemical that
disrupts the epithelial barrier to allow translocation of bacteria, resulting in the induction of
both innate inflammatory responses and antigen-specific immune responses [47]. Subsequent
to the loss of epithelial barrier function, these mice develop severe gastrointestinal inflamma‐
tion, which can be ameliorated by pretreating with antibiotics to reduce the microbial load [47].
The role of the commensal bacteria in regulating the immune response was elegantly demon‐
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susceptible to subsequent infection with the pathogen, Citrobacter rodentium. Metronidazole-
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creased numbers of goblet cells. The author also noted enhanced expression of IL-25 and Reg3γ
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mice, indicating an increase in microbial stimulation. The inner mucous layer of metronida‐
zole-treated mice was significantly thinner and mRNA expression of genes encoding for the
goblet-cell specific proteins Muc2, TFF3, and RelmB was also decreased in these mice [49, 50].
The thinning of the inner mucous layer following metronidazole treatment allowed for C.
rodentium to more closely associate with the epithelium and promote production of the pro-
inflammatory cytokines and chemokines TNF-α, IFN-γ, and MCP-1. This study highlights the
contribution of the commensal microbiota in the production of the mucus barrier and subse‐
quently in maintaining mucosal homeostasis [48].
It has also been noted that specific members of the resident microbiota are able to illicit specific
immune functions. Colonization with Bacteroides fragilis expressing polysaccharide A (PSA)
suppressed development of T helper 17 (Th17) CD4+ T cells by promoting the development of
Foxp3+ T regulatory (Treg) CD4+ T cells and inducing IL-10 expression via TLR2 signaling [51].
Additional studies have demonstrated that purified PSA is sufficient to expand the numbers
of Foxp3+ Treg cells [52]. B. fragilis inhabits colonic crypts. This niche puts the organism in close
contact with the immune system but its production of PSA ensures that no inflammatory
response is induced. Both prophylactic and therapeutic treatment of mice with PSA has been
shown to ameliorate TNBS-induced colitis in mice [52]. More recently, work from Atarashi et
al., eloquently demonstrated a role for indigenous Clostridium species in the induction of
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increased the number of Foxp3+ Treg cells in the colon. Furthermore, inoculation of young
CONVR mice with Clostridium species facilitated resistance to both dextran sodium sulfate
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Figure 3 Panel A shows normal mucosal homeostasis. The epithelial cells provide a barrier 
between the commensal bacteria and the underlying immune cells. Panel B depicts acute 
inflammation. The epithelial cell barrier has been breached, allowing bacteria to be readily 
detected by the immune system and promote a pro-inflammatory immune response. 
Figure 3. Panel A sh ws norm mucosal homeostasis. The epithelial cells provide a barrier between the commensal
bacteria and the underlying immune cells. Panel B depicts acute inflammation. The pithelial cell barrier has been
breach d, allowing bacteria to be readily detected by the immune system and promote a ro-inflammatory immune
response.
The segmented filamentous bacteria  (SFB)  is  another  microorganism of  interest  that  has
been implicated in the induction of Th17 responses [54]. Ivanov et al. found that C57BL/6
mice purchased from the Jackson Laboratory had significantly less IL-17-producing CD4+
T  cells  in  the  small  intestine  compared  to  those  from Taconic  Farms.  This  discrepancy
could  be  corrected  via  intragastric  gavage  of  the  Jackson  mice  with  contents  from  the
small intestines of the Taconic mice. Using a 16S ribosomal RNA PhyloChip analysis, SFB
were identified in the microbiota of mice from Taconic Farms but not in those from the
Jackson  Laboratory.  Monoassociation  of  mice  with  SFB induced the  production  of  Th17
cells  and  up-regulated  genes  encoding  antimicrobial  peptides  and  serum  amyloid  A
(SAA).  SAA co-cultured  with  naive  CD4+  T  cells  and  lamina  propria  derived  dendritic
cells  induced  Th17  cell  differentiation  in  vitro.  The  authors  concluded  that  SFB,  which
tightly adheres to and imbeds itself among the microvilli on the epithelial cell surface, in‐
duces the production of SAA by intestinal epithelial cells. In turn, the SAA acts on lami‐
na propria dendritic cells to stimulate the induction of Th17 cells.  Colonization with SFB
has  also  been  shown  to  protect  against  C.  rodentium  infection.  Th17  cytokines  such  as
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IL-22  likely  stimulate  intestinal  epithelial  cells  to  secrete  antimicrobial  peptides  to  limit
the growth of the pathogen and its infiltration into the colonic wall [54].
1.7. Effect of bacterial colonization on other aspects of the body
In  addition  to  promoting  immune  maturation,  the  commensal  microbiota  also  helps  to
regulate  fat  storage.  GF mice  eat  29% more  food than conventional  mice  yet  have 42%
less body fat and a decreased metabolic rate [55]. Colonization of GF mice with cecal con‐
tents from conventional mice for 14 days caused a 57% increase in total body fat with a
concomitant  27%  reduction  in  food  intake.  These  “conventionalized”  mice  also  had  in‐
creases in leptin, fasting glucose, and insulin levels compared to GF mice; they also devel‐
oped insulin  resistance.  Levels  of  mRNA specific  for  the  transcription  factors,  SREBP-1
and ChREBP,  were also elevated leading to  increased production of  lipogenic  enzymes.
Fat formation is aided by the regulator lipoprotein lipase (LPL) and is inhibited by the fiaf
gene  product  whose  expression  is  suppressed  in  microbiota-bearing  conventional  mice.
The authors  suggest  that  the bacteria  in  the gut  breakdown dietary polysaccharide into
monosaccharaides  that  are  then  transported  to  the  liver  to  activate  lipogenic  enzymes.
This  process promotes fat  formation in the peripheral  tissues due to the suppression of
fiaf. In addition to the production of white adipose tissue, the microbiota may also play a
role in eye health [56]. A recent study revealed differences in the lipid profiles in the lens
and retinas  of  GF mice  as  compared to  CONVR mice.  The  CONVR mice  had reduced
concentrations of multiple phosphatidylcholines and an overall reduced presence of phos‐
pholipids in the lens.  The authors postulate these changes may be due to the increased
exposure  of  the  CONVR mice  to  more  oxidative  stress  than their  GF counterparts  [56].
Together,  these  studies  help us  realize  the  effects  that  the  gut  microbiota  may have on
host systems that, at the surface, seem to have limited or no connection to the GIT.
1.8. Bacterial production of short chain fatty acids
Another health benefit that the microbiota provides its host revolves around the produc‐
tion  of  short-chain  fatty  acids  (SCFA)  such  as  acetate,  propionate,  and butyrate  as  end
products of anaerobic fermentation [57]. These SCFA (predominantly butyrate) can be uti‐
lized as energy sources by eukaryotic cells.  Members of the Clostridium  clusters IV (e.g.,
Faecalibacterium prausnitzii)  and XIVa (e.g.,  Roseburia  spp. and Eubacterium rectale)  are the
primary butyrate producers in the GIT, and they comprise approximately 2-15% of the to‐
tal gut microbiota [14, 58-61].  Butyrate, a four-carbon fatty acid, is produced by bacteria
via one of two metabolic pathways. The first pathway utilizes the enzymes phosphotrans‐
butyrylase and butyrate kinase to form butyrate from butyryl-CoA to yield one ATP per
one  molecule  of  butyrate  produced [62,  63].  The  second pathway,  which  is  utilized  by
most  organisms  in  the  gut,  uses  butyryl-CoA acetate  CoA transferase  to  form butyrate
and acetyl-CoA from butyryl-CoA [64, 65].
Once produced, butyrate has multiple effects on gut health. A primary use is as a prefer‐
red energy source for colonocytes,  and the mechanisms by which butyrate is utilized in
the GIT is summarized in Figure 4 [66-69]. Two biomarkers of energy homeostasis, ATP
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The segmented filamentous bacteria  (SFB)  is  another  microorganism of  interest  that  has
been implicated in the induction of Th17 responses [54]. Ivanov et al. found that C57BL/6
mice purchased from the Jackson Laboratory had significantly less IL-17-producing CD4+
T  cells  in  the  small  intestine  compared  to  those  from Taconic  Farms.  This  discrepancy
could  be  corrected  via  intragastric  gavage  of  the  Jackson  mice  with  contents  from  the
small intestines of the Taconic mice. Using a 16S ribosomal RNA PhyloChip analysis, SFB
were identified in the microbiota of mice from Taconic Farms but not in those from the
Jackson  Laboratory.  Monoassociation  of  mice  with  SFB induced the  production  of  Th17
cells  and  up-regulated  genes  encoding  antimicrobial  peptides  and  serum  amyloid  A
(SAA).  SAA co-cultured  with  naive  CD4+  T  cells  and  lamina  propria  derived  dendritic
cells  induced  Th17  cell  differentiation  in  vitro.  The  authors  concluded  that  SFB,  which
tightly adheres to and imbeds itself among the microvilli on the epithelial cell surface, in‐
duces the production of SAA by intestinal epithelial cells. In turn, the SAA acts on lami‐
na propria dendritic cells to stimulate the induction of Th17 cells.  Colonization with SFB
has  also  been  shown  to  protect  against  C.  rodentium  infection.  Th17  cytokines  such  as
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IL-22  likely  stimulate  intestinal  epithelial  cells  to  secrete  antimicrobial  peptides  to  limit
the growth of the pathogen and its infiltration into the colonic wall [54].
1.7. Effect of bacterial colonization on other aspects of the body
In  addition  to  promoting  immune  maturation,  the  commensal  microbiota  also  helps  to
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and ChREBP,  were also elevated leading to  increased production of  lipogenic  enzymes.
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gene  product  whose  expression  is  suppressed  in  microbiota-bearing  conventional  mice.
The authors  suggest  that  the bacteria  in  the gut  breakdown dietary polysaccharide into
monosaccharaides  that  are  then  transported  to  the  liver  to  activate  lipogenic  enzymes.
This  process promotes fat  formation in the peripheral  tissues due to the suppression of
fiaf. In addition to the production of white adipose tissue, the microbiota may also play a
role in eye health [56]. A recent study revealed differences in the lipid profiles in the lens
and retinas  of  GF mice  as  compared to  CONVR mice.  The  CONVR mice  had reduced
concentrations of multiple phosphatidylcholines and an overall reduced presence of phos‐
pholipids in the lens.  The authors postulate these changes may be due to the increased
exposure  of  the  CONVR mice  to  more  oxidative  stress  than their  GF counterparts  [56].
Together,  these  studies  help us  realize  the  effects  that  the  gut  microbiota  may have on
host systems that, at the surface, seem to have limited or no connection to the GIT.
1.8. Bacterial production of short chain fatty acids
Another health benefit that the microbiota provides its host revolves around the produc‐
tion  of  short-chain  fatty  acids  (SCFA)  such  as  acetate,  propionate,  and butyrate  as  end
products of anaerobic fermentation [57]. These SCFA (predominantly butyrate) can be uti‐
lized as energy sources by eukaryotic cells.  Members of the Clostridium  clusters IV (e.g.,
Faecalibacterium prausnitzii)  and XIVa (e.g.,  Roseburia  spp. and Eubacterium rectale)  are the
primary butyrate producers in the GIT, and they comprise approximately 2-15% of the to‐
tal gut microbiota [14, 58-61].  Butyrate, a four-carbon fatty acid, is produced by bacteria
via one of two metabolic pathways. The first pathway utilizes the enzymes phosphotrans‐
butyrylase and butyrate kinase to form butyrate from butyryl-CoA to yield one ATP per
one  molecule  of  butyrate  produced [62,  63].  The  second pathway,  which  is  utilized  by
most  organisms  in  the  gut,  uses  butyryl-CoA acetate  CoA transferase  to  form butyrate
and acetyl-CoA from butyryl-CoA [64, 65].
Once produced, butyrate has multiple effects on gut health. A primary use is as a prefer‐
red energy source for colonocytes,  and the mechanisms by which butyrate is utilized in
the GIT is summarized in Figure 4 [66-69]. Two biomarkers of energy homeostasis, ATP
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and NADH/NAD+ levels, are both significantly reduced in only the colonic tissues of GF
mice as compared to CONVR mice [70].  This observation indicates that GF mice have a
reduction in TCA cycle activity, and subsequently less ATP is generated for cellular ener‐
gy.  Moreover,  this  reduction  in  ATP  was  correlated  with  increased  signs  of  energetic
stress in colonocytes, including increased expression of 5’-adenosine monophosphate-acti‐
vated  protein  kinase  (AMPK).  Consistent  with  previous  reports  describing  a  role  for
AMPK in  inducing autophagy [71],  GF coloncytes  also  expressed elevated levels  of  the
autophagosome marker LC3-11. Transmission election microscopic analysis revealed that
significantly  more  GF  colonocytes  were  undergoing  autophagy  than  colonocytes  from
CONVR mice. Colonizing GF mice with a conventional microbiota reversed these effects,
as did incubation of isolated colonocytes with butyrate.  Additional experiments employ‐
ing  the  fatty-acid  oxidation  blocker,  etomoxir,  demonstrated  that  colonocytes  consume
butyrate as an energy source and not as a histone deacetylase (HDAC) inhibitor, another
known function of butyrate [72, 73].
Butyrate functions as an HDAC inhibitor by blocking cellular deacetylase activity and al‐
lowing histone acetylation [72,  73].  Histone modification causes changes in cellular gene
expression patterns; compounds and molecules that can elicit these modifications are be‐
ing  studied  as  potential  anti-cancer  therapeutics  [74].  A  comparative  study  of  gene  ex‐
pression patterns in HT-29 cells (a colon carcinoma-derived cell line), treated with either
butyrate  or  trichostain A (a  known HDAC inhibitor)  revealed that  both substances  had
similar effects on gene expression [75]. Upregulated genes (21 total) were found to regu‐
late the cell  cycle,  signal transduction,  DNA repair and genome transcription.  Only two
genes  were  down-regulated—lactoferrinδ  and  MAPKAP  kinase.  It  is  also  important  to
note that both butyrate and trichostain A inhibited the growth of HT-29 cells by creating
an arrest in the G1  phase of the cell  cycle [76].  Butyrate may also down-regulate pro-in‐
flammatory responses via its HDAC activity, as incubation of butyrate with inflamed bi‐
opsy samples  or  LPS-induced peripheral  blood mononuclear  cells  (PBMCs)  reduced the
mRNA expression of IL-6, TNF-α, TNF-β, and IL-1β [77]. Additionally, in murine studies
of TNBS- and DSS-induced colitis,  and in ulcerative colitis  (UC) patients,  administration
of butyrate enemas ameliorates disease activity via NFκB inhibition [77-79]. Butyrate has
been shown to decrease both COX-2 and PGE2 expression in HT-29 cells stimulated with
TNF-α [80].
The information presented in this section clearly defines a central role for the gut micro‐
biota in many physiological processes;  the microbiota even has a tremendous impact on
the host’s  health status.  Causal  links likely exist  between the methods by which infants
are  delivered,  their  gut  microbial  colonization patterns  and subsequent  health  concerns,
including  asthma,  eczema  and,  food  allergies.  Associations  between  gut  bacterial  com‐
munities  and  obesity,  diabetes,  and  cardiovascular  disease  have  also  been  documented
[81-83].  A significant body of literature also links changes in the composition of the gut
microbiota  with  inflammatory  bowel  disease  (IBD),  which  is  discussed  in  detail  in  the
following section [84-89].
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Figure 4. Microbial regulation of colonocyte metabolism. Schematic depicting how dietary fiber is fermented by
microbes into butyrate in the lumen of the colon, which is then transported into the colonocyte. In the colonocyte,
butyrate promotes oxidative metabolism and inhibits autophagy. Based on transcriptome and proteome experiments,
enzymes regulated by microbes are shown in boxes. In all cases, boxed enzymes that function in β-oxidation and the
TCA cycle are downregulated in GF colonocytes, revealing that microbes positively regulate their expression. Diminish‐
ed ATP results in phosphorylation of AMPK and p27, which culminates in autophagy. (Cell Metab. 2011 May 4;13(5):
517-5) Reprinted with permission from the publisher license number 2977121495018
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biota in many physiological processes;  the microbiota even has a tremendous impact on
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2. Introduction to inflammatory bowel disease
In 1932, three physicians, Burrill Crohn, Leon Ginzburg, and Gordon Oppenheimer described
a disease of unknown etiology in the terminal ileum of young adults [90]. The disease was
characterized as being similar to UC (fever, diarrhea and weight loss) and having ulcerations
of the mucosa that would eventually lead to stenosis of the lumen and formation of multiple
fistulas. Eventually, surgical intervention was used to resect the affected portion of the
intestinal tract and patients recovered with little signs of the disease persisting. In their 1932
report, Crohn and colleagues discuss observations from other physicians regarding observa‐
tions of granulomas in the small and large intestine of unknown etiology being classified under
the umbrella term “benign granulomas”. Still today Crohn’s disease (CD) and UC are both
included under the umbrella term “inflammatory bowel disease.” Crohn and colleagues
described the disease as beginning at the ileocecal junction with lesions separated by normal
mucosa [90]. They described inflammation of the submucosa and the muscularis resulting in
a markedly thickened bowel wall. The presence of “giant cells” was also noted, which they
attributed to vegetable matter becoming entrapped in the ulcers and become encapsulated
during healing. The authors concluded that the presence of these giant cells in the granulom‐
atous lesion led others to believe that the inflammation was due to an unusual form of
tuberculosis. However, the authors could not find any evidence of tuberculosis in their 14
patients.
Clinically, the patients with IBD were characterized as young adults with fever, diarrhea, dull
abdominal pain, and vomiting; they were also weak, anemic and had poor appetite. Upon
physical examination, the author noted five commonalties: 1) a mass in the right iliac region,
2) evidence of fistula formation, 3) emaciation and anemia, 4) approximately half of the subjects
had undergone an appendectomy, and 5) evidence of intestinal obstruction. Treatment was
supportive and surgical resection of the affected portion of the intestinal tract was recom‐
mended; 13 of their 14 patients had no symptoms post-operatively. For the one patient that
developed recurrent symptoms, it was later determined that not all of the affected intestinal
tissue had been resected during the first surgery.
Eighty years after the first published article of what would become known as “Crohn’s
disease,” there is still no cure for this disease nor do we fully understand its etiology. Un‐
fortunately, the number of people being diagnosed with IBD is increasing yearly [91]. There
is not one specific, causative agent of IBD; instead the etiology is thought to be multifactorial
in nature, with host genetics, environmental factors, the induction of aberrant immune
responses, and the gastrointestinal microbiota all contributing to disease pathogenesis.
2.1. Genetic factors affecting IBD
As of 2011, genome-wide meta-analyses had identified 71 susceptibility loci associated with
CD, 47 with UC and 28 associated with both, some of which are shown in Figure 5 [92-95].
Here, we focus on genetic variants within specific genes involved in mediating host responses
to microbial components.
Inflammatory Bowel Disease84
Figure 5. Inflammatory bowel disease susceptibility loci. The loci (depicted by lead gene name) attaining genome
wide significance (p < 5x10-8) are shown for Crohn’s disease (CD, red), ulcerative colitis (UC, blue) and IBD (black where
p < 5x10-8 in CD and UC; red were p < 5x10-8 in CD and p < 5x10-4 in UC; blue where p < 5x10-8 in UC and p < 5x10-4 in
CD. Reprinted with permission from the publisher license number: 2977121069437
2.1.1. Nod2
One of the first candidate genes linked to IBD susceptibility was Nod2. Located on chromosome
16, the defective allele affects the activation of the transcription factor NF-κB. NOD2 is
expressed in antigen-presenting cells, macrophages, lymphocytes, ileal Paneth cells, and
intestinal epithelial cells and functions as an intracellular microbial recognition molecule
[96-100]. NOD2 senses muramyl dipeptide (MDP), a minimally bioactive motif of peptido‐
glycan from both Gram-negative and Gram-positive bacteria. Once activated by its ligand,
NOD2 undergoes a conformational change to expose its CARD domains and recruits the kinase
RIP2 to the complex which associates with NOD2 via homophillic CARD-CARD interactions
[97]. This process leads to the activation of IKK and the subsequent degradation of IκB and
ultimately results in the translocation of NF-κB to the nucleus [96, 101].
Petnicki-Ocwieja et al. demonstrated that MDP stimulation of ileal crypts induced bactericidal
secretions capable of killing E. coli [102]. Moreover, the same authors showed that NOD2 was
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required for the bactericidal activity of crypt secretions of the terminal ileum. The composition
of the ileal microbiota of the NOD2-/- mice was significantly altered in comparison to their WT
counterparts. Specifically, NOD2-/- mice had increased numbers of Firmicutes, specifically
Bacillus species and Bacteroides species. Wild-type mice were able to clear an infection of
Helicobacter hepaticus, an opportunistic mouse pathogen, within seven days while NOD2-/- mice
remained colonized with H. hepaticus for at least 14 days post-infection [102]. Also of note, the
presence of a gut microbiota was required for the expression of NOD2. GF mice possessed
decreased levels of NOD2—a phenotype that could be reversed following monoassociation
with either Gram-negative or Gram-positive organisms. Together, these results outline a
reciprocal regulatory relationship between NOD2 expression and the gut microbiota.
2.1.2. ATG16L1
Another gene implicated in the pathogenesis of IBD that regulates cellular autophagy is
ATG16L1  [95,  103].  Autophagy  is  a  process  utilized  by  cells  to  recycle  cellular  compo‐
nents. This process may also be utilized by cells as a non-apoptotic method of program‐
med  cell  death  [104].  ATG16L1  is  expressed  by  CD4+  and  CD8+  T  cells,  CD19+  B  cells,
epithelial cells, and macrophages [105, 106]. Studies by Caldwell et al.  utilizing mice en‐
gineered to express low or hypomorphic levels of ATG16L1 revealed that this gene is in‐
deed  an  autophagy-related  protein.  Elevated  levels  of  cytosolic  proteins  normally
degraded by  a  rapamycin-induced degradation pathway were  found in  the  cells  of  the
ATG16L1 hypomorphic (ATG16L1HM) mice [95]. Additionally, cells from ATG16L1HM mice
possessed fewer autophagosomes following rapamycin treatment or nutrient deprivation.
The  small  intestines  and  colons  of  ATG16L1HM  mice  had  no  morphological  defects  in
crypt  height  or  villus  length  but  did  possess  abnormalities  found in  their  Paneth  cells.
Specifically, lysozyme within Paneth cells was found to be either depleted/absent or dif‐
fuse, which is in contrast to the normal and orderly packaging of lysozyme within gran‐
ules.  Decreased  levels  of  lysozyme  were  also  observed  in  the  ileal  mucus  layer  of
ATG16L1HM  mice.  However,  there were intact granules observed in the crypt lumen, in‐
dicating a potential role of ATG16L1 in the maintenance of the Paneth cell granule exocy‐
tosis  pathway.  The  authors  observed no differences  between WT and ATG16L1HM  mice
in terms of resistance to a challenge with Listeria monocytogenes. However, others have re‐
ported a reduction in intracellular  bacteria targeted to autophagic vacuoles following in
vitro infections of  HeLa or  Caco-2 cells  with S.  typhimurium  in  conjunction with siRNA
to reduce the expression of  ATG16L1  [105,  107].  Additional  work by Caldwell  et  al.  re‐
vealed  that  100  %  of  ileocolic  resection  specimens  obtained  from  humans  with  the
ATG16L1  risk allele had abnormal Paneth cells that looked similar to those found in the
ATG16L1HM mice [95].
Using siRNA to reduce ATG16L1 expression in THP-1 macrophages revealed an increase in
intracellular adherent and invasive E. coli (AIEC) as compared to normal THP-1 infected
macrophages [106]. AIEC promote enhanced production of TNF-α and IL-6 from macrophag‐
es. Silencing of ATG16L1 expression resulted in significant increases in both cytokines. The
authors postulate that bacterial clearance is less efficient in individuals with the risk alleles for
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ATG16L1. When AIEC are present, this reduction in bacterial clearance likely leads to increased
production of pro-inflammatory cytokines, which could tip the immune balance to an
inflammatory state. Thus, it appears that the presence of bacterial provocateurs (e.g., AIEC) in
the microbiota increases the risk of developing IBD in individuals possessing polymorphisms
in genes such as ATG16L or NOD2.
2.2. The immune response and IBD
The mucosal immune system is charged with the monumental task of balancing respon‐
siveness  and  tolerance  to  a  tremendous  number  of  environmental  antigens,  including
those from both food and bacteria. Although the exact cause of IBD remains elusive, sig‐
nificant evidence supports the hypothesis that GIT inflammation is initiated and perpetu‐
ated by a dysregulated immune response directed against the gut microbiota resulting in
deleterious  responses  in  genetically  susceptible  individuals  following  an  environmental
trigger.  The host with a genetic predisposition for IBD may possess defects in epithelial
permeability and/or altered regulation (i.e., NOD2 deficiency) of commensal bacteria. Po‐
tential  environmental  triggers  may include  smoking,  certain  medications,  or  a  gastroin‐
testinal  illness that induces a break in homeostasis.  Regardless of  the specific  genetic or
environmental trigger, what ensues is an exaggerated, inappropriate mucosal immune re‐
sponse characterized by chronic activation of T cells and the production of cytokines and
other inflammatory mediators.
The success of  cytokine-targeted immunotherapies for a subset of  IBD patients supports
the idea that these chemical messengers of the immune system play an important role in
disease  pathogenesis.  However,  the  nature  of  the  immune  phenotypes  observed  in  CD
and UC patients do differ [108]. The immune response of CD is typically associated with
a T helper 1 (Th1) phenotype while UC is characterized by a T helper 2 (Th2) phenotype
[108].  Isolated lamina propria  (LP)  CD4+  T  cells  from CD patients  produce IFN-γ when
stimulated via the CD2/CD28 pathway; in contrast, LP CD4+ T cells from UC patients se‐
creted mostly IL-5 [109]. Another cytokine with a strong link to CD is IL-12 [110]. Messen‐
ger RNA for IL-12p40 in LP mononuclear cells (LPMC) was found in 85 % of CD patients,
a percentage significantly higher than that found in healthy and UC GIT tissue samples.
Similarly,  IL-12p35 mRNA was detectable in the LPMC of 92 % of CD patients;  expres‐
sion was again significantly higher than for healthy and UC patients.  Elevated levels of
IL-12 were also detectable in the serum of CD patients [110], and this potent Th1-promot‐
ing cytokine is able to induce IFN-γ production from LP lymphocytes (LPL) isolated from
CD patients [111]. Additionally, studies employing a murine model of TNBS-induced col‐
itis have revealed that administration of anti-IL-12 antibodies ameliorated disease severi‐
ty, presumably by decreasing IFN-γ secretion from LP CD4+ T cells [112].
In UC, production of the cytokines IL-5 and IL-13 appear to mediate the disease process. Using
LPMC from IBD patients, those with UC had increased production of IL-13 and IL-5 upon in
vitro restimulation as compared to LPMCs recovered from either CD patients or healthy
individuals [113]. Levels of IFN-γ produced by LPMC from UC patients were similar to those
produced by cells from healthy controls. The authors specifically identified that CD4+ CD161+
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crypt  height  or  villus  length  but  did  possess  abnormalities  found in  their  Paneth  cells.
Specifically, lysozyme within Paneth cells was found to be either depleted/absent or dif‐
fuse, which is in contrast to the normal and orderly packaging of lysozyme within gran‐
ules.  Decreased  levels  of  lysozyme  were  also  observed  in  the  ileal  mucus  layer  of
ATG16L1HM  mice.  However,  there were intact granules observed in the crypt lumen, in‐
dicating a potential role of ATG16L1 in the maintenance of the Paneth cell granule exocy‐
tosis  pathway.  The  authors  observed no differences  between WT and ATG16L1HM  mice
in terms of resistance to a challenge with Listeria monocytogenes. However, others have re‐
ported a reduction in intracellular  bacteria targeted to autophagic vacuoles following in
vitro infections of  HeLa or  Caco-2 cells  with S.  typhimurium  in  conjunction with siRNA
to reduce the expression of  ATG16L1  [105,  107].  Additional  work by Caldwell  et  al.  re‐
vealed  that  100  %  of  ileocolic  resection  specimens  obtained  from  humans  with  the
ATG16L1  risk allele had abnormal Paneth cells that looked similar to those found in the
ATG16L1HM mice [95].
Using siRNA to reduce ATG16L1 expression in THP-1 macrophages revealed an increase in
intracellular adherent and invasive E. coli (AIEC) as compared to normal THP-1 infected
macrophages [106]. AIEC promote enhanced production of TNF-α and IL-6 from macrophag‐
es. Silencing of ATG16L1 expression resulted in significant increases in both cytokines. The
authors postulate that bacterial clearance is less efficient in individuals with the risk alleles for
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ATG16L1. When AIEC are present, this reduction in bacterial clearance likely leads to increased
production of pro-inflammatory cytokines, which could tip the immune balance to an
inflammatory state. Thus, it appears that the presence of bacterial provocateurs (e.g., AIEC) in
the microbiota increases the risk of developing IBD in individuals possessing polymorphisms
in genes such as ATG16L or NOD2.
2.2. The immune response and IBD
The mucosal immune system is charged with the monumental task of balancing respon‐
siveness  and  tolerance  to  a  tremendous  number  of  environmental  antigens,  including
those from both food and bacteria. Although the exact cause of IBD remains elusive, sig‐
nificant evidence supports the hypothesis that GIT inflammation is initiated and perpetu‐
ated by a dysregulated immune response directed against the gut microbiota resulting in
deleterious  responses  in  genetically  susceptible  individuals  following  an  environmental
trigger.  The host with a genetic predisposition for IBD may possess defects in epithelial
permeability and/or altered regulation (i.e., NOD2 deficiency) of commensal bacteria. Po‐
tential  environmental  triggers  may include  smoking,  certain  medications,  or  a  gastroin‐
testinal  illness that induces a break in homeostasis.  Regardless of  the specific  genetic or
environmental trigger, what ensues is an exaggerated, inappropriate mucosal immune re‐
sponse characterized by chronic activation of T cells and the production of cytokines and
other inflammatory mediators.
The success of  cytokine-targeted immunotherapies for a subset of  IBD patients supports
the idea that these chemical messengers of the immune system play an important role in
disease  pathogenesis.  However,  the  nature  of  the  immune  phenotypes  observed  in  CD
and UC patients do differ [108]. The immune response of CD is typically associated with
a T helper 1 (Th1) phenotype while UC is characterized by a T helper 2 (Th2) phenotype
[108].  Isolated lamina propria  (LP)  CD4+  T  cells  from CD patients  produce IFN-γ when
stimulated via the CD2/CD28 pathway; in contrast, LP CD4+ T cells from UC patients se‐
creted mostly IL-5 [109]. Another cytokine with a strong link to CD is IL-12 [110]. Messen‐
ger RNA for IL-12p40 in LP mononuclear cells (LPMC) was found in 85 % of CD patients,
a percentage significantly higher than that found in healthy and UC GIT tissue samples.
Similarly,  IL-12p35 mRNA was detectable in the LPMC of 92 % of CD patients;  expres‐
sion was again significantly higher than for healthy and UC patients.  Elevated levels of
IL-12 were also detectable in the serum of CD patients [110], and this potent Th1-promot‐
ing cytokine is able to induce IFN-γ production from LP lymphocytes (LPL) isolated from
CD patients [111]. Additionally, studies employing a murine model of TNBS-induced col‐
itis have revealed that administration of anti-IL-12 antibodies ameliorated disease severi‐
ty, presumably by decreasing IFN-γ secretion from LP CD4+ T cells [112].
In UC, production of the cytokines IL-5 and IL-13 appear to mediate the disease process. Using
LPMC from IBD patients, those with UC had increased production of IL-13 and IL-5 upon in
vitro restimulation as compared to LPMCs recovered from either CD patients or healthy
individuals [113]. Levels of IFN-γ produced by LPMC from UC patients were similar to those
produced by cells from healthy controls. The authors specifically identified that CD4+ CD161+
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NK T cells were the primary source of IL-13 in UC patients, as these cells produced 30-fold
more IL-13 than NK T cells from CD patients following in vitro restimulation.
More recent work has implicated the T helper 17 (Th17) lineage of CD4+ T cells in the chronic
inflammation observed in IBD [114, 115]. The development of Th17 T cells is dependent upon
the presence of both IL-6 and TGF-β [115]. Colonic biopsies from UC and CD patients expressed
higher levels of IL-17A mRNA as compared to those from healthy controls [115-117]. Immu‐
nohistochemical analysis of these tissues identified increased numbers of IL-17A+ cells in both
the LP and the epithelium of UC and CD patients as compared to controls [116]. Additional
work also noted the presence of IL-17+ cells in patients with active IBD [114]. However, the
IL-17+ cells were found predominantly in the LP of UC patients but in the submucosa and
muscularis propria of CD patients [114]. These different locations of IL-17+ cells complements
prior observations that CD lesions often present as transmural while those in UC are superfi‐
cial. Also of note, a comparison of biopsies from patients with active versus inactive disease
revealed that IL-17+ cells were only increased in numbers during active disease. The authors
also determined that both T cells and monocytes/macrophages are a source of IL-17, and that
IBD patients have elevated levels of IL-17 in their sera as compared to undetectable levels of
this cytokine in the sera of healthy individuals.
The maintenance of Th17 T cells requires the presence of IL-23 [115]. Of interest, a gene variant
significantly associated with CD encodes for the IL-23R, which, along with IL-12Rβ1, com‐
prises the IL-23 receptor complex [118, 119]. This receptor complex interacts with IL-23 (a
heterodimer of IL-12p40 and IL-23p19) to direct the production of a TH17 immune response
[120-122]. Anti-IL-23 antibodies have been shown to both prevent and ameliorate established
disease in a T-cell transfer model of murine colitis [123]. Studies of human tissues demonstrate
that IL-23R expression is upregulated not only on IL-17 producing CD4+ T cells, but also on
IFN-γ+ T cells in both UC and CD patients [115]. Stimulation of LP CD4+ T cells from UC patients
with IL-23 significantly increased IL-17 production; in contrast, IL-23 stimulation of LP CD4+
T cells from CD patients resulted in enhanced IFN-γ secretion [115]. In addition to promoting
the production of TH17 cells, IL-23 also inhibits the production of Foxp3+ Treg cells [124] and
suppresses production of IL-10, a key regulatory cytokine [125].
Another important hallmark of the immune response observed in IBD is the production of IgG
antibodies against the normal commensal microbiota [126]. Increased intestinal permeability,
be it through genetic predisposition or environmental trigger, promotes enhanced immunor‐
eactivity to bacterial antigens. The mucosal immunoglobulin profile of healthy adults consists
predominantly of IgA with only a small amount of IgG. In contrast, patients with active IBD
presented with significantly higher amounts of IgG in their mucosal secretions with no
difference in amounts of IgA as compared to controls. The IgG antibodies present in IBD
patients were identified as binding to non-pathogenic bacterial commensals, including E. coli,
B. fragilis, C. perfringens, Klebsiella aerogenes, and Enterobacter faecalis. Patients with CD had
significantly higher titers than UC patients, while antibody titers to these commensal bacteria
were at or below the limit of detection in serum samples from healthy controls. Notable
differences were also observed in the isotypes of IgG present in UC versus CD patients.
Specifically, UC patients produced predominantly IgG1 and IgG3 antibodies to bacterial
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antigens, while IgG1, IgG2, IgG3 were the predominant isotypes reacting with the bacterial
antigens in serum samples from CD patients [126]. Conversely, other reports have described
an increase in IgG1 antibodies in UC patients and an increased in IgG2 antibodies in CD patients
[127-130]. Additional analyses have determined that IgG antibodies in CD patients are
primarily directed towards bacterial cytoplasmic proteins rather than membrane associated
proteins [126]. Despite the presence of many types of antibodies in both the mucosal secretions
and serum of IBD patients, no direct evidence for their involvement in IBD immunopatho‐
genesis has been reported, indicating that they may simply be a marker for immune respon‐
siveness and/or dysregulation [131].
2.3. Environmental factors affecting IBD
Although  there  are  allelic  differences  in  many  people  with  IBD,  genetics  alone  cannot
completely account for the development of IBD nor the increase in the incidence of IBD
worldwide. Studies of monozygotic twins best highlight this concept, as there are disease
concordance rates  of  only 50 % for  CD and only 20 % for  UC [132,  133].  Of  interest,  a
British study assessing discordant twins with CD found an association with mumps in‐
fection, smoking, and oral contraceptive usage with the development of CD [134]. Addi‐
tionally,  the  twin(s)  with  CD  had  suffered  both  a  medical  illness,  more  episodes  of
gastroenteritis, and spent more time with animals. Smoking is one confounding environ‐
mental factor that is of special interest,  because it  appears to have a protective effect on
UC, but increases the risk of CD [132, 135-137]. Another factor that appears to be protec‐
tive for UC is an appendectomy; its effect on CD is not as evident [138-140]. The equiva‐
lent  procedure  performed  in  mice  has  been  shown  to  ameliorate  colitis  in  both
chemically-induced and genetically-engineered  murine  colitis  models  [141,  142].  Modest
associations between oral  contraceptive use and IBD have been documented,  while  oth‐
ers  have  found  breast-feeding  to  be  protective  against  both  UC  and  CD  [143,  144].  A
meta-analysis performed by investigators in New Zealand identified other potential envi‐
ronmental  factors,  including  being  an  only  child,  using  antibiotics  prior  to  and  during
adolescence (four or more courses in year),  and having a pet in the house during child‐
hood [145]. IBD also tends to occur in extended families as first and second degree rela‐
tives  of  IBD  patients  reported  the  occurrence  of  disease  with  a  significantly  higher
frequency  than  the  general  population  [146].  These  finding  strengthen  the  interconnec‐
tion between genetics, environmental factors, and the incidence of IBD.
2.3.1. Antibiotic usage
Antibiotics  are  used  in  the  treatment  of  IBD to  reduce  microbial  load  and dampen in‐
flammatory immune responses. However, their use prior to disease diagnosis is now be‐
ing  identified  as  a  risk  factor  for  developing  IBD.  A  Danish  study  of  IBD  patients
revealed that antibiotic users were 1.84 times more likely to develop IBD, which correlat‐
ed to  a  12  % increase  in  disease  risk  for  each course  of  antibiotics  taken [147].  Further
analysis  revealed  that  antibiotic  users  were  3.41  times  more  likely  to  develop  CD than
UC, which correlated to an increased risk of 18 % per course of antibiotics used. Specifi‐
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NK T cells were the primary source of IL-13 in UC patients, as these cells produced 30-fold
more IL-13 than NK T cells from CD patients following in vitro restimulation.
More recent work has implicated the T helper 17 (Th17) lineage of CD4+ T cells in the chronic
inflammation observed in IBD [114, 115]. The development of Th17 T cells is dependent upon
the presence of both IL-6 and TGF-β [115]. Colonic biopsies from UC and CD patients expressed
higher levels of IL-17A mRNA as compared to those from healthy controls [115-117]. Immu‐
nohistochemical analysis of these tissues identified increased numbers of IL-17A+ cells in both
the LP and the epithelium of UC and CD patients as compared to controls [116]. Additional
work also noted the presence of IL-17+ cells in patients with active IBD [114]. However, the
IL-17+ cells were found predominantly in the LP of UC patients but in the submucosa and
muscularis propria of CD patients [114]. These different locations of IL-17+ cells complements
prior observations that CD lesions often present as transmural while those in UC are superfi‐
cial. Also of note, a comparison of biopsies from patients with active versus inactive disease
revealed that IL-17+ cells were only increased in numbers during active disease. The authors
also determined that both T cells and monocytes/macrophages are a source of IL-17, and that
IBD patients have elevated levels of IL-17 in their sera as compared to undetectable levels of
this cytokine in the sera of healthy individuals.
The maintenance of Th17 T cells requires the presence of IL-23 [115]. Of interest, a gene variant
significantly associated with CD encodes for the IL-23R, which, along with IL-12Rβ1, com‐
prises the IL-23 receptor complex [118, 119]. This receptor complex interacts with IL-23 (a
heterodimer of IL-12p40 and IL-23p19) to direct the production of a TH17 immune response
[120-122]. Anti-IL-23 antibodies have been shown to both prevent and ameliorate established
disease in a T-cell transfer model of murine colitis [123]. Studies of human tissues demonstrate
that IL-23R expression is upregulated not only on IL-17 producing CD4+ T cells, but also on
IFN-γ+ T cells in both UC and CD patients [115]. Stimulation of LP CD4+ T cells from UC patients
with IL-23 significantly increased IL-17 production; in contrast, IL-23 stimulation of LP CD4+
T cells from CD patients resulted in enhanced IFN-γ secretion [115]. In addition to promoting
the production of TH17 cells, IL-23 also inhibits the production of Foxp3+ Treg cells [124] and
suppresses production of IL-10, a key regulatory cytokine [125].
Another important hallmark of the immune response observed in IBD is the production of IgG
antibodies against the normal commensal microbiota [126]. Increased intestinal permeability,
be it through genetic predisposition or environmental trigger, promotes enhanced immunor‐
eactivity to bacterial antigens. The mucosal immunoglobulin profile of healthy adults consists
predominantly of IgA with only a small amount of IgG. In contrast, patients with active IBD
presented with significantly higher amounts of IgG in their mucosal secretions with no
difference in amounts of IgA as compared to controls. The IgG antibodies present in IBD
patients were identified as binding to non-pathogenic bacterial commensals, including E. coli,
B. fragilis, C. perfringens, Klebsiella aerogenes, and Enterobacter faecalis. Patients with CD had
significantly higher titers than UC patients, while antibody titers to these commensal bacteria
were at or below the limit of detection in serum samples from healthy controls. Notable
differences were also observed in the isotypes of IgG present in UC versus CD patients.
Specifically, UC patients produced predominantly IgG1 and IgG3 antibodies to bacterial
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antigens, while IgG1, IgG2, IgG3 were the predominant isotypes reacting with the bacterial
antigens in serum samples from CD patients [126]. Conversely, other reports have described
an increase in IgG1 antibodies in UC patients and an increased in IgG2 antibodies in CD patients
[127-130]. Additional analyses have determined that IgG antibodies in CD patients are
primarily directed towards bacterial cytoplasmic proteins rather than membrane associated
proteins [126]. Despite the presence of many types of antibodies in both the mucosal secretions
and serum of IBD patients, no direct evidence for their involvement in IBD immunopatho‐
genesis has been reported, indicating that they may simply be a marker for immune respon‐
siveness and/or dysregulation [131].
2.3. Environmental factors affecting IBD
Although  there  are  allelic  differences  in  many  people  with  IBD,  genetics  alone  cannot
completely account for the development of IBD nor the increase in the incidence of IBD
worldwide. Studies of monozygotic twins best highlight this concept, as there are disease
concordance rates  of  only 50 % for  CD and only 20 % for  UC [132,  133].  Of  interest,  a
British study assessing discordant twins with CD found an association with mumps in‐
fection, smoking, and oral contraceptive usage with the development of CD [134]. Addi‐
tionally,  the  twin(s)  with  CD  had  suffered  both  a  medical  illness,  more  episodes  of
gastroenteritis, and spent more time with animals. Smoking is one confounding environ‐
mental factor that is of special interest,  because it  appears to have a protective effect on
UC, but increases the risk of CD [132, 135-137]. Another factor that appears to be protec‐
tive for UC is an appendectomy; its effect on CD is not as evident [138-140]. The equiva‐
lent  procedure  performed  in  mice  has  been  shown  to  ameliorate  colitis  in  both
chemically-induced and genetically-engineered  murine  colitis  models  [141,  142].  Modest
associations between oral  contraceptive use and IBD have been documented,  while  oth‐
ers  have  found  breast-feeding  to  be  protective  against  both  UC  and  CD  [143,  144].  A
meta-analysis performed by investigators in New Zealand identified other potential envi‐
ronmental  factors,  including  being  an  only  child,  using  antibiotics  prior  to  and  during
adolescence (four or more courses in year),  and having a pet in the house during child‐
hood [145]. IBD also tends to occur in extended families as first and second degree rela‐
tives  of  IBD  patients  reported  the  occurrence  of  disease  with  a  significantly  higher
frequency  than  the  general  population  [146].  These  finding  strengthen  the  interconnec‐
tion between genetics, environmental factors, and the incidence of IBD.
2.3.1. Antibiotic usage
Antibiotics  are  used  in  the  treatment  of  IBD to  reduce  microbial  load  and dampen in‐
flammatory immune responses. However, their use prior to disease diagnosis is now be‐
ing  identified  as  a  risk  factor  for  developing  IBD.  A  Danish  study  of  IBD  patients
revealed that antibiotic users were 1.84 times more likely to develop IBD, which correlat‐
ed to  a  12  % increase  in  disease  risk  for  each course  of  antibiotics  taken [147].  Further
analysis  revealed  that  antibiotic  users  were  3.41  times  more  likely  to  develop  CD than
UC, which correlated to an increased risk of 18 % per course of antibiotics used. Specifi‐
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cally,  usage of  penicillin  V and extended spectrum penicillins  were  associated with  the
greatest  disease  risks.  A Swedish  study focused on  the  use  of  antibiotics  from birth  to
age 5, a time when the microbiota and immune response are still developing and/or ma‐
turing,  as  a  risk  factor  for  IBD.  They  reported  an  association  between  a  diagnosis  of
pneumonia,  subsequent  antibiotic  treatment  and  the  onset  of  both  pediatric  and  adult
CD [148].  Another study by Card et al.  revealed a statistically significant association be‐
tween antibiotic usage 2 to 5 years prior to diagnosis of CD in patients from the United
Kingdom  [149].  This  finding  was  confirmed  in  a  Canadian  study,  which  reported  that
the more antibiotics taken within 2 to 5 years of diagnosis, the greater the risk of devel‐
oping  IBD  [150].  That  same  study  found  that  disease  risk  was  weakly  associated  with
penicillin use and greatly associated with metronidazole use,  which was prescribed pri‐
marily for “non-infectious gastroenteritis.” This association with antibiotic usage may be
explained by the failure of the gut microbiota to reestablish its normal community struc‐
ture and function following a course of antibiotics [151].  This alteration in the microbio‐
ta  or  dysbiosis  may  be  a  predisposing  factor  to  the  onset  of  IBD  in  a  susceptible
individual.
2.3.2. MAP
Another  potential  environmental  risk  factor  for  the  development  of  IBD  is  a  chronic
pathogenic infection in the GIT.  To date,  no one particular organism has been found to
be the causative agent of IBD. Although many microbial pathogens have been implicated
as causative,  only two have been significantly investigated.  The first  organism hypothe‐
sized to  be  associated  with  IBD was  Mycobacterium avium  subsp.  paratuberculosis,  which
causes Johne’s disease in cattle [152,  153].  The granulomatous inflammation observed in
CD patients led many early researchers to investigate various types of Mycobacterial  spp.
in  CD pathogenesis  but  confirmation  was  never  achieved (reviewed in  [154]).  The  first
report  of  M. paratuberculosis-like  organisms isolated from patients  with CD in was pub‐
lished 1984. Now known as M. avium  subsp. paratuberculosis  (MAP), there is still no con‐
sensus as to whether or not it plays a role in the onset of IBD in a subset of genetically
susceptible patients [155]. Using PCR to amplify the DNA insertion element IS900, which
is  specific  to MAP, in biopsy sections,  Sanderson et  al.  reported that  65 % of  adult  CD
patients examined were PCR positive [156]. Dell’Isola et al.  reported that 72 % of pedia‐
tric CD patients examined were PCR positive for the presence of MAP [156, 157]. While
many  studies  have  reported  the  presence  of  MAP  DNA  in  CD  patients,  just  as  many
have found MAP DNA in samples from healthy individuals  and UC patients  [156-162].
Moreover,  multiple  studies  have  failed  to  detect  MAP-specific  DNA in  any CD patient
sample  examined [163-169].  The  ability  to  detect  MAP in  some tissue  samples  and not
others  may  be  due,  in  part,  to  the  organism’s  fastidiousness,  slow  growth,  and/or  the
presence of PCR inhibitors in fecal/tissue samples that inhibit  the detection of IS900. Se‐
rological evidence also fails to provide definitive answers for the involvement of MAP in
the  pathogenesis  of  IBD.  Some  studies  assessing  the  presence  of  serum  antibody  titers
against MAP-derived antigens find an association with IBD [170-176] while others do not
[177-182].  More recent  work has identified a possible link between variants in the Nod2
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gene and the  presence  of  MAP [183].  In  this  study,  68  % of  CD patients  were  positive
for MAP DNA based on PCR analysis  as compared to 21 % of  the healthy individuals.
Fifty-one percent of the CD patients were carriers of NOD2 polymorphisms as compared
to 21 % of healthy individuals, and 74 % of the CD patients possessing one of the mutat‐
ed NOD2 alleles were positive for MAP DNA. Even with of all of the data collected, the
debate continues as to whether or not MAP plays an important role in the pathogenesis
of CD [184, 185].
2.3.3. Adherent-invasive Escherichia coli
Another organism implicated in IBD pathogenesis is adherent-invasive Escherichia coli (AIEC).
First described in 1998, AIEC isolates were recovered from the ileal mucosa of CD patients
[186]. These organisms are found in higher numbers in CD patients (22 %) as compared to
healthy controls (6 %) [187]. These isolates were able to adhere to Caco-2 cells and did not
posses any of the virulence genes associated with known E. coli pathotypes (e.g., ETEC, EHEC)
[186]. A characterization of expressed adhesions in AIEC strains revealed the Pap and Sfa
adhesion or colonization factors, both of which are found in uropathogenic E. coli strains;
however many of the AIEC strains did not possess any of the known adhesions associated
with pathogenic E. coli (e.g., intimin). Some of the cytotoxic strains were found to express the
hly operon, and it was subsequently demonstrated that these organisms express a type 1 pili
similar in sequence to an E. coli strain associated with avian colisepticemia and meningitis
[188]. Type 1 pili are involved in both the adherence and internalization of E. coli into host cells.
They specifically bind to the CEACAM6 receptor on ileal enterocytes, which is expressed at
significantly higher levels in the inflamed small intestinal epithelium of CD patients as
compared to healthy controls [189].
Further research involving the prototypic AIEC strain, LF82, has shown that this pathogenic
group of E. coli invades epithelial cells via engagement of actin microtubules and microfila‐
ments and replicates intracellularly even without possessing any of the known invasive
determinants found in other invasive E. coli strains [190]. AIEC strains are also able to survive
and replicate within macrophages without causing apoptosis; they also induce production of
the pro-inflammatory cytokine TNF-α [191]. LF82 is also able to induce in vitro aggregation of
peripheral blood mononuclear cells (PBMCs), an observation reminiscent of the granulomas
observed in the colonic tissue of CD patients [192].
In addition to being detected with increased frequency in human IBD patients, AIEC strains
have also been isolated from Boxer dogs with granulomatous colitis. These E. coli isolates were
found to have the same adherent-invasive phenotype as human AIEC strains. The Boxer dog
isolates were also of the same phylotype (B2 and D) and possessed similar virulence gene
profiles as LF82. In contrast to the human AIEC strains, however, the canine AIEC strains were
only isolated from diseased dogs and not healthy controls. Simpson and colleagues also
demonstrated that remission of colitis in Boxer dogs could be achieved by treatment with
enrofloxacin, the use of which resulted in the eradication of AIEC E. coli [193].
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cally,  usage of  penicillin  V and extended spectrum penicillins  were  associated with  the
greatest  disease  risks.  A Swedish  study focused on  the  use  of  antibiotics  from birth  to
age 5, a time when the microbiota and immune response are still developing and/or ma‐
turing,  as  a  risk  factor  for  IBD.  They  reported  an  association  between  a  diagnosis  of
pneumonia,  subsequent  antibiotic  treatment  and  the  onset  of  both  pediatric  and  adult
CD [148].  Another study by Card et al.  revealed a statistically significant association be‐
tween antibiotic usage 2 to 5 years prior to diagnosis of CD in patients from the United
Kingdom  [149].  This  finding  was  confirmed  in  a  Canadian  study,  which  reported  that
the more antibiotics taken within 2 to 5 years of diagnosis, the greater the risk of devel‐
oping  IBD  [150].  That  same  study  found  that  disease  risk  was  weakly  associated  with
penicillin use and greatly associated with metronidazole use,  which was prescribed pri‐
marily for “non-infectious gastroenteritis.” This association with antibiotic usage may be
explained by the failure of the gut microbiota to reestablish its normal community struc‐
ture and function following a course of antibiotics [151].  This alteration in the microbio‐
ta  or  dysbiosis  may  be  a  predisposing  factor  to  the  onset  of  IBD  in  a  susceptible
individual.
2.3.2. MAP
Another  potential  environmental  risk  factor  for  the  development  of  IBD  is  a  chronic
pathogenic infection in the GIT.  To date,  no one particular organism has been found to
be the causative agent of IBD. Although many microbial pathogens have been implicated
as causative,  only two have been significantly investigated.  The first  organism hypothe‐
sized to  be  associated  with  IBD was  Mycobacterium avium  subsp.  paratuberculosis,  which
causes Johne’s disease in cattle [152,  153].  The granulomatous inflammation observed in
CD patients led many early researchers to investigate various types of Mycobacterial  spp.
in  CD pathogenesis  but  confirmation  was  never  achieved (reviewed in  [154]).  The  first
report  of  M. paratuberculosis-like  organisms isolated from patients  with CD in was pub‐
lished 1984. Now known as M. avium  subsp. paratuberculosis  (MAP), there is still no con‐
sensus as to whether or not it plays a role in the onset of IBD in a subset of genetically
susceptible patients [155]. Using PCR to amplify the DNA insertion element IS900, which
is  specific  to MAP, in biopsy sections,  Sanderson et  al.  reported that  65 % of  adult  CD
patients examined were PCR positive [156]. Dell’Isola et al.  reported that 72 % of pedia‐
tric CD patients examined were PCR positive for the presence of MAP [156, 157]. While
many  studies  have  reported  the  presence  of  MAP  DNA  in  CD  patients,  just  as  many
have found MAP DNA in samples from healthy individuals  and UC patients  [156-162].
Moreover,  multiple  studies  have  failed  to  detect  MAP-specific  DNA in  any CD patient
sample  examined [163-169].  The  ability  to  detect  MAP in  some tissue  samples  and not
others  may  be  due,  in  part,  to  the  organism’s  fastidiousness,  slow  growth,  and/or  the
presence of PCR inhibitors in fecal/tissue samples that inhibit  the detection of IS900. Se‐
rological evidence also fails to provide definitive answers for the involvement of MAP in
the  pathogenesis  of  IBD.  Some  studies  assessing  the  presence  of  serum  antibody  titers
against MAP-derived antigens find an association with IBD [170-176] while others do not
[177-182].  More recent  work has identified a possible link between variants in the Nod2
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gene and the  presence  of  MAP [183].  In  this  study,  68  % of  CD patients  were  positive
for MAP DNA based on PCR analysis  as compared to 21 % of  the healthy individuals.
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First described in 1998, AIEC isolates were recovered from the ileal mucosa of CD patients
[186]. These organisms are found in higher numbers in CD patients (22 %) as compared to
healthy controls (6 %) [187]. These isolates were able to adhere to Caco-2 cells and did not
posses any of the virulence genes associated with known E. coli pathotypes (e.g., ETEC, EHEC)
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significantly higher levels in the inflamed small intestinal epithelium of CD patients as
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isolates were also of the same phylotype (B2 and D) and possessed similar virulence gene
profiles as LF82. In contrast to the human AIEC strains, however, the canine AIEC strains were
only isolated from diseased dogs and not healthy controls. Simpson and colleagues also
demonstrated that remission of colitis in Boxer dogs could be achieved by treatment with
enrofloxacin, the use of which resulted in the eradication of AIEC E. coli [193].
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2.4. The microbiota and IBD
Although no single organism has been implicated in the induction of IBD, a preponderance of
studies indicates that the GI microbial community of IBD patients is different from that of
healthy individuals. This imbalance is known as “dysbiosis”. Characteristics of a dysbiotic
community in IBD include a reduction in members of the C. leptum and C. cocciodes clusters
(members of the Firmicutes phyla and major butyrate producers) and an increase in Entero‐
bacteriaceae and members of the Bacteroidetes, thereby leading to a reduction in the microbial
diversity of the gut. Another notable difference is the greater concentration of mucosally-
associated bacteria in IBD patients as compared to healthy individuals [194-197]. Using
fluorescence in situ hybridization (FISH), patients with CD were found to have predominantly
Enterobacteriaceae, γ-Proteobacteria, or Bacteroides/Prevotella adherent to their mucosa and
present in their submucosa [195]. Another FISH-based analysis revealed that Bacteroides spp.
were the dominant gut bacteria, representing up to 80 % of the total mucosally-adherent
bacterial population in some samples. Of interest was the authors’ additional finding that
treatment of IBD patients with mesalamine (an anti-inflammatory therapeutic drug) signifi‐
cantly reduced the numbers of mucosally-adherent bacteria [198].
Sample origin is an important factor to consider when interpreting data for microbial analyses.
Although stool samples are easy to obtain, it may not accurately reflect the microbial com‐
munity in the cecum and proximal colon of patients [14]. In a comparative study of the
microbial populations detected in cecal versus fecal samples, more anaerobes and Bifidobacte‐
rium spp. were detected in fecal samples using culture-based methods [199]. Molecular probe
hybridization revealed that facultative anaerobes represented by Lactobacillus, Enterococcus,
and E. coli were higher in numbers in cecal contents, yet the number of strict anaerobes
represented by the Bacteroides, C. leptum, and C. coccoides groups were significantly lower in
the cecal contents. Differences in microbial composition have also been observed when
comparing colonic biopsies versus feces [200]. Analysis of feces from Japanese IBD patients
showed that Faecalibacterium spp. were significantly decreased in CD patients, while Bacter‐
oides spp. were significantly increased only in patients with active IBD [201]. Based on the
Shannon diversity index, this study demonstrated that microbial diversity was significantly
reduced in CD patients both during active disease and remission as compared to healthy
individuals.
Several studies have noted a specific decrease in the numbers of C. leptum and C. coccoides
clusters present in colonic contents or feces in IBD patients [18, 197, 202-206]. A reduction in
the C. coccoides group in UC patients and C. leptum in CD patients has been shown using FISH
probes on patient feces [202]. Another study employing a combination of PCR and FISH
analysis of fecal samples found a reduced presence of both C. leptum and C. coccoides clusters
in IBD patients [197]. Additional analyses revealed significant decreases in the concentrations
of the SCFAs (e.g., butyric and propionic acid) in the feces of IBD patients [197]. In other work,
high throughput sequencing demonstrated reduced numbers of Faecalibacterium, Ruminococ‐
caceae, Alistipes, Collinsella, and Roseburia and increased numbers of Enterobacteriaceae in a twin
with ileal CD as compared to the healthy twin [204]. This latter study again emphasizes the
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involvement of the microbiota in the development of IBD in a genetically susceptible host, as
only one of the twins developed disease.
One  specific  member  of  the  C.  leptum  cluster,  Faecalibacterium  prausnitzii,  has  recently
been the subject of many published studies. This organism is a major butyrate producer
that  also possesses some anti-inflammatory properties [59,  207].  A study by Sokol  et  al.
described a reduction of  both C. leptum  and C. coccoides  clusters  in the stool  of  patients
with  active  IBD  along  with  a  skewed  Firmicutes/Bacteroidetes  ratio  [203].  The  authors
specifically identified a reduction in F. prausnitzii  in IBD patients,  confirming results ob‐
tained using biopsy samples from twins analyzed via qPCR [205].  In other work,  dena‐
turing gradient gel electrophoresis (DGGE) analysis of biopsy samples also demonstrated
a  significant  decrease  in  Faecalibacterium  spp.  along  with  increased  levels  of  E.  coli  and
Clostridium spp. in CD patients as compared to healthy individuals [208]. Using fecal cyl‐
inders and 11 different FISH probes to analyze sections GIT tissue specimens, Swidsinski
and colleagues found the presence of F. prausnitzii  to be significantly reduced in CD pa‐
tients [209]. Of special note, analysis of samples from IBD patients given high-dose corti‐
sol  or  infliximab to  reduce  inflammation revealed a  dramatic  increase  (>14  x109)  in  the
levels  of  F.  prausnitzii  within days of  initiating treatment.  This  increase was short-lived,
however, as levels of F. prausnitzii  decreased when the cortisol dose was reduced or the
time  between  infliximab  infusions  was  increased.  Together,  these  data  indicate  that  in‐
flammation plays a major role in shaping the intestinal microbiota.
Work in murine models of colitis also demonstrates that inflammation in the gut, be it
chemically or bacterially induced, causes an increase in Enterobacteriaceae [210]. Colonization
of mice with Citrobacter rodentium resulted in a reduction of the total number of bacteria in the
colon at 7 and 14 days post-infection; this decrease coincided with the highest levels of both
C. rodentium and intestinal inflammation [211]. Further analysis specifically determined that
members of the Cytophaga-Flavobacter-Bacteroides phylum were decreased. Infection with
C. rodentium infection is self-limiting, and the total bacterial levels returned to normal following
pathogen clearance. These changes in the bacterial load were not simply associated with
colonization of a new organism to the microbial community, such as Campylobacter jejuni, an
organism that does not cause intestinal inflammation in immunocompetent CONVR mice
[212], induced no detectable changes in microbial load.
The induction of GIT inflammation in mice via administration of dextran sulfate sodium (DSS)
in the drinking water for seven days was associated with increased numbers of aerobic bacteria,
specifically Entercococcus faecalis [210]. Bacteroidetes were eliminated from the community and
the total number of bacteria was also decreased. A dramatic increase in the numbers of a non-
pathogenic E. coli following DSS treatment was also observed. The authors subsequently
colonized IL-10-/- mice, which spontaneously develop colitis [213], with this non-pathogenic
E. coli. Upon the development of GIT inflammation, the E. coli was able to proliferate to the
same level observed in DSS treated mice, but displacing the Firmicutes phylum instead of the
Bacteroidetes. These results indicate that regardless of the source, GIT inflammation creates a
niche that favors the colonization and expansion of Enterobacteriaceae. Collectively, these data
suggest that the induction of inflammation following the colonization of the GIT by a bacterial
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provocateur along with perturbations of the microbiota together have a deleterious impact on
the microbiota and mucosal homeostasis.
2.5. Canine IBD
In addition to affecting humans, IBD can also occur in dogs as well [214]. As in human IBD,
the interactions between genetics, the mucosal immune system, inflammation, and environ‐
mental factors (ie, diet and imbalances in the intestinal microbiome) all contribute to the
pathogenesis of canine IBD (Figure 6) [215-217].
Figure 6. The etiology for canine IBD involves complex interactions between host genetics, mucosal immunity, and
the enteric microbiota. Therapeutic intervention with diet, antibiotics and immunosuppressive drugs is aimed at re‐
ducing inflammation and dysbiosis.
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Mutations in innate immune receptors in German shepherd dogs (TLR5, NOD2) have been
linked to IBD susceptibility which in the presence of an inappropriate enteric microbiota may
lead to upregulated pro-inflammatory cytokine production (e.g., IL-17, IL-22, TNF-α) and
reduced bacterial clearance, thereby promoting chronic intestinal inflammation [218, 219].
Commensal bacterial antigens are likely to be important in disease pathogenesis because it has
been observed that boxer dogs with granulomatous colitis (GC) show clinical remission
following the eradication of mucosally associated AIEC that share a novel adherent and
invasive pathotype which bears phylogenetic similarity with AIEC strains recovered from
patients with ileal Crohn’s disease [193, 220, 221]. Moreover, genome-wide analysis in affected
boxer dogs has identified disease-associated single nucleotide polymorphisms (SNPs) in a
gene (NCF2) involved with killing intracellular bacteria [222]. Still others have shown that
CD11c+ cells are significantly decreased in the intestines of dogs with IBD suggesting that
chronic mucosal inflammation may involve an imbalance in the intestinal dendritic cell
population leading to aberrant immune activation [223]. Molecular analysis of the intestinal
microbiome in different breeds of dogs with IBD have consistently shown that diseased tissues
are enriched with members of the families Enterobacteriaceae and Clostridiaceae [224, 225]. These
bacteria are believed to contribute to the pathogenesis of GIT inflammatory disease in dogs as
in humans [187, 226]. A recent trial using high throughput 16S rDNA sequencing methods (ie,
454 pyrosequencing) on intestinal biopsies of IBD dogs revealed a dysbiosis in the mucosally-
adherent microbiota with an increase in sequences belonging to Proteobacteria and a decrease
in Bacteroidetes, Fusobacteria, and the Clostridiales [227]. Taken together, these studies
suggest that chronic intestinal inflammation of canine IBD may be due to overly aggressive
adaptive immune responses to enteric bacteria (or fungi) [225] in hosts with genetic defects
that fail to properly regulate microbial killing, mucosal barrier function, or immune responses.
As in human IBD, environmental factors (diet, microbiota imbalances) likely govern the onset
of inflammation or reactivation and modulate genetic susceptibility to disease.
2.5.1. Clinical and diagnostic features
The clinical manifestations of IBD are diverse and are influenced by the organ(s) involved,
presence of active versus inactive disease, and physiologic complications seen with enteric
plasma protein loss and/or micronutrient (cobalamin) deficiency [215, 216, 228, 229]. Canine
IBD is a disease that predominantly affects middle-aged animals. Vomiting and diarrhea are
most commonly observed and are often accompanied by decreased appetite and weight loss.
Gastric and duodenal inflammation is associated with vomiting and small bowel diarrhea
while colonic involvement causes large bowel diarrhea with blood, mucus, and straining. The
clinical course of IBD is generally cyclical and is characterized by spontaneous exacerbations
and remissions. Importantly, the clinical signs of IBD are not disease specific and share
numerous over-lapping features with other canine disorders. A diagnosis of IBD is one of
exclusion and requires careful elimination of IBD mimics [230]. The possible causes for chronic
intestinal inflammation may be excluded through the integration of history, physical findings,
clinicopathological testing, diagnostic imaging, and histopathology of intestinal biopsies. A
baseline CBC, biochemistry profile, urinalysis, and diagnostic imaging are useful in eliminat‐
ing the most common systemic and metabolic disorders (e.g., renal disease, hepatopathy,
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hypoadrenocorticism) causing chronic GI signs in dogs. The measure of clinical disease activity
by means of quantifiable indices is well established in human IBD [231-233].
A canine IBD activity index (CIBDAI) used for assessment of inflammatory activity in dogs
has been recently designed [234]. Similar to other indices, the magnitude of the numerical score
is proportional to the degree of inflammatory activity. This index serves as the principal
measure of response to a therapeutic regimen and may be used to tailor medical therapy for
an individual patient’s needs [235]. Intestinal biopsies are required to confirm histopatholog‐
ical inflammation and to determine the extent of mucosal disease. Diagnostic endoscopy is
preferred since this technique allows for direct assessment of mucosal abnormalities and the
acquisition of targeted biopsy specimens. The microscopic findings in canine IBD consist of
minimal to pronounced inflammatory cell (lymphoplasmacytic) infiltration of the intestinal
lamina propria accompanied by varying degrees of mucosal architectural disruption similar
to that observed in tissue from human IBD patients (Figure 7).
Figure 7. Histopathological lesions of (A) crypt distortion with abscessation, (B) diffuse villous atrophy, and (C) mucos‐
al ulceration seen in duodenal biopsies of dogs with IBD.
Unfortunately, biopsy interpretation is notoriously subjective and suffers from extensive intra-
observer variability and the technical constraints of procurement/processing artifacts inherent
in evaluation of endoscopic specimens [236]. Although several histopathological scoring
schemes have been proposed there are no uniform grading criteria that pathologists can
universally agree on. One small study has resulted in development of a ‘simplified model
system’ for defining intestinal inflammation of IBD that is presently being tested in a separate
clinical trial.
2.5.2. Therapeutic approach
Treatment principles for canine IBD are empirical and consist of combination therapy us‐
ing both dietary and pharmacologic interventions. As compared to clinical trials evaluat‐
ing the  efficacy of  therapy for  CD and UC,  only one randomized,  controlled drug trial
for canine IBD has been reported [235]. There are, however, abundant evidence-based ob‐
servations  that  feeding elimination diets  and administering corticosteroids,  immunosup‐
pressive drugs,  and/or select  antibiotics  are useful  in the clinical  management of  canine
IBD.  Some  clinicians  prefer  a  sequential  approach  to  nutritional  and  drug  therapy  for
IBD.  The optimal  drug or  drug combinations  as  well  as  duration of  therapy for  induc‐
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tion and maintenance of  remission of  clinical  signs  have not  been determined for  most
protocols  [216,  230].  In  general,  the  administration  of  corticosteroids  (i.e.,  prednisone,
prednisolone or budesonide), antimicrobials (i.e., metronidazole or tylosin), and immuno‐
suppressive  drugs  (i.e.,  cyclosporine,  chlorambucil,  azathioprine)  used alone or  in  some
combination are effective in inducing clinical remission in most animals. Some dogs will
require intermittent or life-long drug therapy.
The rationale for nutritional therapy of IBD is that restricting exposure to antigens (i.e., dietary
proteins) known to evoke sensitivity will reduce exaggerated host responses and attenuate
intestinal inflammation. Other indications for specialized nutrition include the presence of
decreased appetite, impaired nutrient absorption, or enteric plasma protein loss seen with
moderate-to-severe mucosal inflammation. While evidence-based observations indicate that
most dogs respond favorably to dietary intervention, the superiority of one novel protein
source versus another or the advantage in feeding an intact protein elimination diet versus a
hydrolyzed protein elimination diet has not been shown to date. Modifying the dietary n3:n6
fatty-acid ratio may also modulate inflammatory responses by reducing production of pro-
inflammatory metabolites [237]. There is relatively sparse clinical data investigating prebiotic
or probiotic therapy for canine IBD (see subsequent section on probiotics).
2.5.3. Future directions in canine IBD
Canine IBD represents a common and frustrating GI disorder in veterinary medicine. More
research is needed to unravel the mechanisms responsible for disease development and to
translate these findings directly to human IBD. The primary features of IBD in humans and
animals are remarkably similar (Table 1).
Feature Human IBD Canine IBD
Genetic basis Yes Likely
Etiology Unknown but multifactorial Unknown but multifactorial
Involves the microbiota Yes Yes
Hematochezia Yes Yes
Diarrhea Yes Yes
Definitive Diagnosis GI biopsy GI biopsy
Disease activity assessment Clinical indices, biomarkers (ASCA,
pANCA, CRP, calprotectin)
Clinical indices, biomarkers (pANCA,
CRP, calprotectin ?)
Responsive to anti-inflammatory drugs Yes Yes
Responsive to antibiotics Yes Yes
Spontaneous GI flares Yes Yes
Table 1. Comparative features of IBD in humans and dogs.
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IBD.  The optimal  drug or  drug combinations  as  well  as  duration of  therapy for  induc‐
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tion and maintenance of  remission of  clinical  signs  have not  been determined for  most
protocols  [216,  230].  In  general,  the  administration  of  corticosteroids  (i.e.,  prednisone,
prednisolone or budesonide), antimicrobials (i.e., metronidazole or tylosin), and immuno‐
suppressive  drugs  (i.e.,  cyclosporine,  chlorambucil,  azathioprine)  used alone or  in  some
combination are effective in inducing clinical remission in most animals. Some dogs will
require intermittent or life-long drug therapy.
The rationale for nutritional therapy of IBD is that restricting exposure to antigens (i.e., dietary
proteins) known to evoke sensitivity will reduce exaggerated host responses and attenuate
intestinal inflammation. Other indications for specialized nutrition include the presence of
decreased appetite, impaired nutrient absorption, or enteric plasma protein loss seen with
moderate-to-severe mucosal inflammation. While evidence-based observations indicate that
most dogs respond favorably to dietary intervention, the superiority of one novel protein
source versus another or the advantage in feeding an intact protein elimination diet versus a
hydrolyzed protein elimination diet has not been shown to date. Modifying the dietary n3:n6
fatty-acid ratio may also modulate inflammatory responses by reducing production of pro-
inflammatory metabolites [237]. There is relatively sparse clinical data investigating prebiotic
or probiotic therapy for canine IBD (see subsequent section on probiotics).
2.5.3. Future directions in canine IBD
Canine IBD represents a common and frustrating GI disorder in veterinary medicine. More
research is needed to unravel the mechanisms responsible for disease development and to
translate these findings directly to human IBD. The primary features of IBD in humans and
animals are remarkably similar (Table 1).
Feature Human IBD Canine IBD
Genetic basis Yes Likely
Etiology Unknown but multifactorial Unknown but multifactorial
Involves the microbiota Yes Yes
Hematochezia Yes Yes
Diarrhea Yes Yes
Definitive Diagnosis GI biopsy GI biopsy
Disease activity assessment Clinical indices, biomarkers (ASCA,
pANCA, CRP, calprotectin)
Clinical indices, biomarkers (pANCA,
CRP, calprotectin ?)
Responsive to anti-inflammatory drugs Yes Yes
Responsive to antibiotics Yes Yes
Spontaneous GI flares Yes Yes
Table 1. Comparative features of IBD in humans and dogs.
The Role of the Microbiota in Gastrointestinal Health and Disease
http://dx.doi.org/10.5772/53920
97
Recent advances in clinical indices, histopathological standards, and the development of
species-specific immunologic reagents and innovative molecular tools have made the dog an
excellent ‘spontaneous’ animal model to study chronic immunologically-mediated intestinal
inflammation. In addition, the dog has higher genomic sequence similarity to that of humans
than do mice, a species traditionally used for comparative disease genetics [238]. However,
clinical manifestations of complex disease in the mouse do not compare to the human form as
closely as they do in the dog. Furthermore, the lifespan of the dog is much shorter than that
of a human; thus, clinical trials aimed at treatment of IBD can be carried out much quicker and
yield results that should have relevant application to human trials [230, 235, 239].
2.6. Treatment for human IBD
Treatments for human IBD patients typically involve the use of anti-inflammatory drugs,
antibiotics, and there is a growing trend of probiotics and prebiotics being studied to determine
their effects on disease activity. When patients fail to respond to treatment, the last and most
drastic treatment option is surgery to resect sections of the inflamed bowel [240]. Most
treatment options are primarily focused on reducing the inflammation associated with IBD.
Some of these drugs also impact the microbiota and those will be discussed below.
2.6.1. Antibiotics
Given the importance of the microbiota in the pathogenesis of IBD, antibiotic therapy may
seem an obvious treatment option. A meta-analysis by Khan et al. in 2011 reviewed random‐
ized controlled trials utilizing antibiotics in the treatment of IBD [241]. Rifamycin derivatives,
ciprofloxacin, and clofazamine all induced remission in CD patients. Rifaximin (a rifamycin
derivative) is effective against both Gram-negative and Gram-positive anaerobes and aerobes;
it is also poorly absorbed after oral administration, resulting in little to no systemic side effects
[242, 243]. Analysis of the effect of the drug using an in vitro continuous culture method with
fecal samples from CD patients revealed increases in beneficial bacteria post-rifaximin
administration [244]. Significant increases in Bifidobacterium spp., the Atopobium cluster, and
F. prausnitzii were noted, as were increases in levels of lactate, acetate, and propionate as
determined by 1H-NMR spectroscopy [244].
Ciprofloxacin is a fluoroquinolone with broad-spectrum antibiotic activity [245]. In addition
to having anti-bacterial properties, this drug has also been shown to have immunomodulatory
properties as well [246]. In a TNBS mouse model of colitis, administration of ciprofloxacin
ameliorated disease as compared to mice given ceftazidime (an antibacterial with a similar
spectrum of activity compared to ciprofloxacin) [245]. Clinically, mice treated with ciproflox‐
acin did not lose weight and had reduced histopathological inflammatory scores associated
with their colons. Ciprofloxacin treated mice also had reduced expression of IL-1β, IL-8, and
TNF-α as measured from colonic homogenates as well as reduced expression of NF-κB. Since
ceftazidime was less effective in ameliorating GIT inflammation, there appears to be additional
benefits (i.e., anti-inflammatory) to the use of ciprofloxacin in addition to its spectrum of
antimicrobial activity.
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Clofazamine has also been documented to significantly affect the rate of remission in CD
patients [241]. This drug, used to treat leprosy, is similar to ciprofloxacin, in that it has both
anti-bacterial and anti-inflammatory properties [247-249]. It is only effective against Gram-
positive organisms, and its effectiveness increases in anaerobic environments [250]. Its effects
on the immune system include increasing the presence of lysosomal enzymes in macrophages
[251] and increasing phagocytosis by macrophages resulting in enhanced uptake and digestion
of immune complexes [252]. Clofazamine has also been shown to inhibit TCR-mediated IL-2
production by T cells, thereby limiting T cell activation, a component of the pathogenesis of
IBD [253].
2.6.2. Corticosteroids
The most commonly used corticosteroids used are prednisolone, methylprednisolone, and
budesonide [254]. These drugs are very effective at inducing remission, however, they are not
without side effects. In a study comparing prednisolone and budesonide, both were found to
be effective at inducing remission [255]. However, patients on budesonide had reduced
evidence of adrenal axis suppression and peripheral leucocyte counts compared to those
treated with prednisolone. These results indicate that budesonide is a safer choice yet it is still
as effective as prednisolone. Corticosteroids are able to prevent NFκB activation [256] as well
as block infiltration of neutrophils, prevent vasodilation and enhanced vascular permeability
and downregulate the production of pro-inflammatory cytokines [254]. Although it is well
established that these corticosteroids have an anti-inflammatory effect, little research has been
conducted on the effects they have on the gut microbiota. A study by Swidsinski et al.,
mentioned previously, indicated that administration of cortisol increased the population of F.
prausnitzii in a dose dependent manner [209].
2.6.3. Immunosuppressive therapy
Drugs such as methotrexate, 6-mercaptopurine (6-MP) and azathioprine (the prodrug of 6-MP)
work by inhibiting the proliferation and activation of lymphocytes and decreasing the
production of pro-inflammatory cytokines [254]. 6-mercaptopurine (6-MP) and azathioprine
are purine antagonists and inhibit cellular metabolism by interfering with DNA replication
[257, 258]. Methotrexate is a folic acid analog that inhibits DNA synthesis and, therefore, has
an anti-proliferative effect [259]. Antibacterial effects, including growth inhibition of MAP,
have also been demonstrated for methotrexate and 6-MP [258].
2.6.4. 5-aminosalicyclic acid (5-ASA)
Sulfasalazine was the first 5-ASA-type drug developed and is a combination of sulfapyridine
(an antimicrobial) and salicyclic acid (an anti-inflammatory) to form a pro-drug. Upon entering
the colon, this pro-drug is cleaved by colonic bacteria into the two separate molecules [260,
261]. Unfortunately, the frequency of gastrointestinal side effects was quite high due to the
sulfapyridine moiety [262, 263]. It was later determined that the active moiety is 5-aminosali‐
cyclic acid (5-ASA, mesalazine) [264]. More recently formulations of this pro-drug have
eliminated the sulfapyridine moiety and replaced it with either a second salicyclic acid moiety
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their effects on disease activity. When patients fail to respond to treatment, the last and most
drastic treatment option is surgery to resect sections of the inflamed bowel [240]. Most
treatment options are primarily focused on reducing the inflammation associated with IBD.
Some of these drugs also impact the microbiota and those will be discussed below.
2.6.1. Antibiotics
Given the importance of the microbiota in the pathogenesis of IBD, antibiotic therapy may
seem an obvious treatment option. A meta-analysis by Khan et al. in 2011 reviewed random‐
ized controlled trials utilizing antibiotics in the treatment of IBD [241]. Rifamycin derivatives,
ciprofloxacin, and clofazamine all induced remission in CD patients. Rifaximin (a rifamycin
derivative) is effective against both Gram-negative and Gram-positive anaerobes and aerobes;
it is also poorly absorbed after oral administration, resulting in little to no systemic side effects
[242, 243]. Analysis of the effect of the drug using an in vitro continuous culture method with
fecal samples from CD patients revealed increases in beneficial bacteria post-rifaximin
administration [244]. Significant increases in Bifidobacterium spp., the Atopobium cluster, and
F. prausnitzii were noted, as were increases in levels of lactate, acetate, and propionate as
determined by 1H-NMR spectroscopy [244].
Ciprofloxacin is a fluoroquinolone with broad-spectrum antibiotic activity [245]. In addition
to having anti-bacterial properties, this drug has also been shown to have immunomodulatory
properties as well [246]. In a TNBS mouse model of colitis, administration of ciprofloxacin
ameliorated disease as compared to mice given ceftazidime (an antibacterial with a similar
spectrum of activity compared to ciprofloxacin) [245]. Clinically, mice treated with ciproflox‐
acin did not lose weight and had reduced histopathological inflammatory scores associated
with their colons. Ciprofloxacin treated mice also had reduced expression of IL-1β, IL-8, and
TNF-α as measured from colonic homogenates as well as reduced expression of NF-κB. Since
ceftazidime was less effective in ameliorating GIT inflammation, there appears to be additional
benefits (i.e., anti-inflammatory) to the use of ciprofloxacin in addition to its spectrum of
antimicrobial activity.
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Clofazamine has also been documented to significantly affect the rate of remission in CD
patients [241]. This drug, used to treat leprosy, is similar to ciprofloxacin, in that it has both
anti-bacterial and anti-inflammatory properties [247-249]. It is only effective against Gram-
positive organisms, and its effectiveness increases in anaerobic environments [250]. Its effects
on the immune system include increasing the presence of lysosomal enzymes in macrophages
[251] and increasing phagocytosis by macrophages resulting in enhanced uptake and digestion
of immune complexes [252]. Clofazamine has also been shown to inhibit TCR-mediated IL-2
production by T cells, thereby limiting T cell activation, a component of the pathogenesis of
IBD [253].
2.6.2. Corticosteroids
The most commonly used corticosteroids used are prednisolone, methylprednisolone, and
budesonide [254]. These drugs are very effective at inducing remission, however, they are not
without side effects. In a study comparing prednisolone and budesonide, both were found to
be effective at inducing remission [255]. However, patients on budesonide had reduced
evidence of adrenal axis suppression and peripheral leucocyte counts compared to those
treated with prednisolone. These results indicate that budesonide is a safer choice yet it is still
as effective as prednisolone. Corticosteroids are able to prevent NFκB activation [256] as well
as block infiltration of neutrophils, prevent vasodilation and enhanced vascular permeability
and downregulate the production of pro-inflammatory cytokines [254]. Although it is well
established that these corticosteroids have an anti-inflammatory effect, little research has been
conducted on the effects they have on the gut microbiota. A study by Swidsinski et al.,
mentioned previously, indicated that administration of cortisol increased the population of F.
prausnitzii in a dose dependent manner [209].
2.6.3. Immunosuppressive therapy
Drugs such as methotrexate, 6-mercaptopurine (6-MP) and azathioprine (the prodrug of 6-MP)
work by inhibiting the proliferation and activation of lymphocytes and decreasing the
production of pro-inflammatory cytokines [254]. 6-mercaptopurine (6-MP) and azathioprine
are purine antagonists and inhibit cellular metabolism by interfering with DNA replication
[257, 258]. Methotrexate is a folic acid analog that inhibits DNA synthesis and, therefore, has
an anti-proliferative effect [259]. Antibacterial effects, including growth inhibition of MAP,
have also been demonstrated for methotrexate and 6-MP [258].
2.6.4. 5-aminosalicyclic acid (5-ASA)
Sulfasalazine was the first 5-ASA-type drug developed and is a combination of sulfapyridine
(an antimicrobial) and salicyclic acid (an anti-inflammatory) to form a pro-drug. Upon entering
the colon, this pro-drug is cleaved by colonic bacteria into the two separate molecules [260,
261]. Unfortunately, the frequency of gastrointestinal side effects was quite high due to the
sulfapyridine moiety [262, 263]. It was later determined that the active moiety is 5-aminosali‐
cyclic acid (5-ASA, mesalazine) [264]. More recently formulations of this pro-drug have
eliminated the sulfapyridine moiety and replaced it with either a second salicyclic acid moiety
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(disodium azodisalicylate [265]) or an inert carrier (balsalazide [266]) thereby reducing the side
effects.
In addition to being an anti-inflammatory agent [267-270], 5-ASA also affects the gut micro‐
biota. As mentioned previously, patients taking mesalamine had a reduction in mucosa-
adherent bacteria [198, 271]. 5-ASA has also been shown to inhibit the growth of MAP [272]
and Bacteroides spp. [273] and moderately inhibit the growth of C. difficile and C. perfringens in
culture [273]. This drug also effects bacterial gene expression, as Salmonella enterica serovar
Typhimurium incubated with 5-ASA had no change in growth but differentially expressed
110 genes [274]. Those genes characterized were found to be involved in invasion, metabolism,
and antibiotic and stress resistance. In vitro assays revealed attenuation in the invasiveness of
S. enterica serovar Typhimurium towards HeLa cells when pretreated with 5-ASA. These
results indicate that in addition to inhibiting host-mediated inflammation, 5-ASA also has the
potential to affect the intestinal microbiota.
2.6.5. Anti-TNF monoclonal antibodies
The induction of TNF-α is most often a downstream event following the interaction of
phlogistic microbial components with toll-like receptors (TLRs) on host cells. The interest in
TNF-α as a therapeutic target for IBD treatment began when the expression and secretion of
this cytokine was found to be increased in IBD patients [275, 276]. For example, pediatric
patients with either active UC or CD present with elevated levels of TNF-α in their stool [275].
Additionally, the incubation of GIT tissue sections in culture medium has demonstrated that
significantly elevated levels of TNF-α are spontaneously secreted from inflamed tissue of both
UC and CD patients when compared to the amounts produced by non-inflamed tissue and
tissue from otherwise healthy individuals [276]. The predominant cell type producing the TNF-
α has been shown to be the macrophage [276]. Based on the central role TNF-α appears to play
in the pathogenesis of IBD, there was interest in developing a therapeutic approach to control
the harmful effects of this cytokine.
Clinically, the use of monoclonal antibodies to treat IBD patients began with Infliximab, an
IgG1 murine-human chimeric monoclonal antibody specific for TNF-α, which was approved
for human use in 1998 for CD [277, 278]. This monoclonal antibody consists of human constant
regions and murine antigen binding regions [277]. These chimeric antibodies reduce the risk
of immunoreactivity that occurs when murine antibodies are used. In addition to being less
immunoreactive, this chimeric antibody had improved binding and neutralization character‐
istics for TNF-α than that of the original murine antibody [277]. Another monoclonal anti-TNF
antibody, Adalimumab, is a fully humanized IgG1 antibody that avoids the induction of anti-
species IgG that neutralize the effectiveness of the anti-TNF-α reagent [278, 279]. Lastly,
Certolizumab is a monoclonal antibody fragment with a polyethylene glycol moiety (PEGy‐
lated) [278]. Certolizumab lacks the crystallizable fragment (Fc) portion of the immunoglobulin
molecule and is an IgG4 isotype unlike Infliximab and Adalimumab, which are IgG1 antibodies
[278, 280, 281]. In addition, the PEGylation increases the half-life of the antibody thereby
reducing the frequency of administration.
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Anti-TNF-α therapy works via multi-factorial mechanisms. First, it neutralizes TNF-α by
blocking its ability to bind to TNF receptors, thus, inhibiting the pro-inflammatory response.
Second, Anti-TNF-α binds to cell surface bound TNF-α on CD4+ T cells and macrophages,
resulting in both complement- and antibody-dependent cell-mediated cytotoxicity [282]. All
three monoclonal antibodies bind to and neutralize both soluble and membrane forms of TNF-
α [281]. Infliximab and Adalimumab both mediate complement- and antibody-dependent cell-
mediated cytotoxicity; however, Certolizumab only mediates complement-dependent cellular
cytotoxicity as it lacks of an Fc region. Furthermore, Infliximab and Adalimumab induce
apoptosis in peripheral blood lymphocytes and monocytes, as well as cause degranulation and
loss of membrane integrity of PMNs. These activities were not induced with Certolizumab.
Lastly, all three monoclonal antibodies inhibit the production of IL-1β after LPS stimulation
in vitro, suggesting that there is a sequential production of pro-inflammatory cytokines
induced by microbial components. Infliximab and Adalimumab both inhibit T cell prolifera‐
tion in mixed lymphocyte reactions in vitro, again suggesting that anti-TNF-α monoclonal
antibodies ameliorate the inflammation associated with IBD via more than one mode of action
[283]. The impact of these therapies on the microbiota, however, is not well studied. As
previously mentioned, treatment with Infliximab resulted in increased levels of F. prausnitzii
after administration [209]. As mentioned above, it is clear that the host inflammatory response
often negatively impacts (i.e., shapes) the composition of the GIT microbiota, and that
controlling mucosal inflammation benefits the health of the microbiota as well. Otherwise,
there have been no specific studies performed to directly evaluate the role of anti-TNF-α
therapies on the gut microbiota.
2.6.6. Complementary and alternative therapies
An estimated 70 % of IBD patients have reported using complementary and alternative
medicine (CAM) products at some time to treat their symptoms In a Canadian study of IBD
patients, some of the most commonly used CAM treatments included massage therapy,
chiropractic visits, probiotics, herbs, and fish oils [284]. A systematic review of the literature
on the use of herbal medicines reveals some anti-inflammatory benefits associated with the
administration of these herbs to both animals and humans [285]. It should be stressed that
prior to utilizing any herbal remedy, which are potentially biologically active, patients need
to consult their physician. This is especially important because the number two reason patients
using CAM gave as to why they sought these products was that “natural therapy is safe”[286].
Some of the biological properties associated with CAM products include the reduction of pro-
inflammatory cytokines, increased antioxidant production, inhibition of leukotriene B4,
decreased NF-κB activation, and inhibition of platelet activation [285].
Increasing evidence supports a potential therapeutic role for prebiotic and probiotic therapy
in human IBD [287, 288]. If IBD in dogs is indeed driven by loss of tolerance to components of
the intestinal microbiota as it is in humans, then prebiotics and probiotics may also prove
beneficial as primary or adjunct therapies with diet and drugs. Probiotics are living microor‐
ganisms that, upon ingestion in sufficient numbers, impart health benefits beyond those of
inherent basic nutrition [289]. Lactobacilli and Bifidobacterium have been the most commonly
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adherent bacteria [198, 271]. 5-ASA has also been shown to inhibit the growth of MAP [272]
and Bacteroides spp. [273] and moderately inhibit the growth of C. difficile and C. perfringens in
culture [273]. This drug also effects bacterial gene expression, as Salmonella enterica serovar
Typhimurium incubated with 5-ASA had no change in growth but differentially expressed
110 genes [274]. Those genes characterized were found to be involved in invasion, metabolism,
and antibiotic and stress resistance. In vitro assays revealed attenuation in the invasiveness of
S. enterica serovar Typhimurium towards HeLa cells when pretreated with 5-ASA. These
results indicate that in addition to inhibiting host-mediated inflammation, 5-ASA also has the
potential to affect the intestinal microbiota.
2.6.5. Anti-TNF monoclonal antibodies
The induction of TNF-α is most often a downstream event following the interaction of
phlogistic microbial components with toll-like receptors (TLRs) on host cells. The interest in
TNF-α as a therapeutic target for IBD treatment began when the expression and secretion of
this cytokine was found to be increased in IBD patients [275, 276]. For example, pediatric
patients with either active UC or CD present with elevated levels of TNF-α in their stool [275].
Additionally, the incubation of GIT tissue sections in culture medium has demonstrated that
significantly elevated levels of TNF-α are spontaneously secreted from inflamed tissue of both
UC and CD patients when compared to the amounts produced by non-inflamed tissue and
tissue from otherwise healthy individuals [276]. The predominant cell type producing the TNF-
α has been shown to be the macrophage [276]. Based on the central role TNF-α appears to play
in the pathogenesis of IBD, there was interest in developing a therapeutic approach to control
the harmful effects of this cytokine.
Clinically, the use of monoclonal antibodies to treat IBD patients began with Infliximab, an
IgG1 murine-human chimeric monoclonal antibody specific for TNF-α, which was approved
for human use in 1998 for CD [277, 278]. This monoclonal antibody consists of human constant
regions and murine antigen binding regions [277]. These chimeric antibodies reduce the risk
of immunoreactivity that occurs when murine antibodies are used. In addition to being less
immunoreactive, this chimeric antibody had improved binding and neutralization character‐
istics for TNF-α than that of the original murine antibody [277]. Another monoclonal anti-TNF
antibody, Adalimumab, is a fully humanized IgG1 antibody that avoids the induction of anti-
species IgG that neutralize the effectiveness of the anti-TNF-α reagent [278, 279]. Lastly,
Certolizumab is a monoclonal antibody fragment with a polyethylene glycol moiety (PEGy‐
lated) [278]. Certolizumab lacks the crystallizable fragment (Fc) portion of the immunoglobulin
molecule and is an IgG4 isotype unlike Infliximab and Adalimumab, which are IgG1 antibodies
[278, 280, 281]. In addition, the PEGylation increases the half-life of the antibody thereby
reducing the frequency of administration.
Inflammatory Bowel Disease100
Anti-TNF-α therapy works via multi-factorial mechanisms. First, it neutralizes TNF-α by
blocking its ability to bind to TNF receptors, thus, inhibiting the pro-inflammatory response.
Second, Anti-TNF-α binds to cell surface bound TNF-α on CD4+ T cells and macrophages,
resulting in both complement- and antibody-dependent cell-mediated cytotoxicity [282]. All
three monoclonal antibodies bind to and neutralize both soluble and membrane forms of TNF-
α [281]. Infliximab and Adalimumab both mediate complement- and antibody-dependent cell-
mediated cytotoxicity; however, Certolizumab only mediates complement-dependent cellular
cytotoxicity as it lacks of an Fc region. Furthermore, Infliximab and Adalimumab induce
apoptosis in peripheral blood lymphocytes and monocytes, as well as cause degranulation and
loss of membrane integrity of PMNs. These activities were not induced with Certolizumab.
Lastly, all three monoclonal antibodies inhibit the production of IL-1β after LPS stimulation
in vitro, suggesting that there is a sequential production of pro-inflammatory cytokines
induced by microbial components. Infliximab and Adalimumab both inhibit T cell prolifera‐
tion in mixed lymphocyte reactions in vitro, again suggesting that anti-TNF-α monoclonal
antibodies ameliorate the inflammation associated with IBD via more than one mode of action
[283]. The impact of these therapies on the microbiota, however, is not well studied. As
previously mentioned, treatment with Infliximab resulted in increased levels of F. prausnitzii
after administration [209]. As mentioned above, it is clear that the host inflammatory response
often negatively impacts (i.e., shapes) the composition of the GIT microbiota, and that
controlling mucosal inflammation benefits the health of the microbiota as well. Otherwise,
there have been no specific studies performed to directly evaluate the role of anti-TNF-α
therapies on the gut microbiota.
2.6.6. Complementary and alternative therapies
An estimated 70 % of IBD patients have reported using complementary and alternative
medicine (CAM) products at some time to treat their symptoms In a Canadian study of IBD
patients, some of the most commonly used CAM treatments included massage therapy,
chiropractic visits, probiotics, herbs, and fish oils [284]. A systematic review of the literature
on the use of herbal medicines reveals some anti-inflammatory benefits associated with the
administration of these herbs to both animals and humans [285]. It should be stressed that
prior to utilizing any herbal remedy, which are potentially biologically active, patients need
to consult their physician. This is especially important because the number two reason patients
using CAM gave as to why they sought these products was that “natural therapy is safe”[286].
Some of the biological properties associated with CAM products include the reduction of pro-
inflammatory cytokines, increased antioxidant production, inhibition of leukotriene B4,
decreased NF-κB activation, and inhibition of platelet activation [285].
Increasing evidence supports a potential therapeutic role for prebiotic and probiotic therapy
in human IBD [287, 288]. If IBD in dogs is indeed driven by loss of tolerance to components of
the intestinal microbiota as it is in humans, then prebiotics and probiotics may also prove
beneficial as primary or adjunct therapies with diet and drugs. Probiotics are living microor‐
ganisms that, upon ingestion in sufficient numbers, impart health benefits beyond those of
inherent basic nutrition [289]. Lactobacilli and Bifidobacterium have been the most commonly
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used human probiotics, but multi-strain cocktails (e.g., VSL#3), E. coli Nissle 1917, and
nonbacterial Saccharomyces boulardii have also been used as probiotics [226]. Probiotic bacteria
have measurable host benefits, including the ability to improve epithelial barrier function,
modulate the mucosal immune system, and alter the intestinal flora [290]. Prebiotics are non-
digestible dietary carbohydrates, such as lactosucrose, fructo-oligosaccharides (FOS), psylli‐
um, bran, which beneficially stimulate the growth and metabolism of endogenous enteric
bacteria upon consumption [291]. Beneficial effects of prebiotics are also associated with the
production of short chain fatty acids (SCFA) due to fermentation by colonic bacteria. Synbiot‐
ics are combinations of probiotics and prebiotics that are an emerging therapeutic modality.
Increasing evidence supports a therapeutic role for probiotics, prebiotics, and synbiotics in
treating gastrointestinal diseases of humans, including infectious diarrhea, H. pylori infection,
irritable bowel syndrome, lactase deficiency, and IBD [84]. A comparison of prebiotic and
probiotic preparations is outlined in Table 2.
2.6.7. Probiotics
VSL#3 is one of the most commonly used probiotic cocktails and contains a very high bacterial
concentration per gram of product characterized by greater number of different bacterial
species as compared to traditional probiotic preparations [292]. This commercially prepared
formulation consists of 450 billion bacteria/g of viable lyophilized bacteria comprised of eight
bacterial strains (Lactobacillus casei, L plantarum, L. bulgaricus, L. acidolphilus, Bifidobacterium
longum, B. breve, B. infantis and Streptococcus thermophiles). While the exact mechanism of action
of VSL#3 is unknown, several studies have demonstrated the effects of VSL#3 on epithelial
barrier function and down regulation of cytokine secretion from immune cells. For example,
Madsen [293] has shown in in vitro studies that epithelial barrier function could be enhanced
by exposure to a soluble factor secreted by VSL#3 bacteria. Moreover, this same study
demonstrated that VSL#3 did not alter the ability of the epithelial cell to activate a mucosal
inflammatory response to a bacterial invasion. Studies with VSL#3 formulations have also been
conducted in several animal models of colitis, inflammatory liver disease, sepsis, and irritable
bowel syndrome (IBS). In models of experimentally-induced colitis, these studies demonstrat‐
ed that VSL#3 normalized gut permeability and barrier function, and that VSL#3 modulated
inflammatory and immune responses [226, 294]. Animal models of sepsis have also demon‐
strated that VSL#3 administration reduced bacterial translocation and significantly attenuated
damage to the liver and intestinal mucosa [295]. The use of VSL#3 as an innovative probiotic
preparation, developed specifically to balance the intestinal microbiota, is supported by
studies in humans with IBD (ulcerative colitis [296], pouchitis) and in other patients with
diverse gastrointestinal disorders, such as IBS [297, 298].
Studies have shown VSL#3 to induce remission of inflammation in 77 % of adult UC patients
with no adverse effects [298] and 56 % of pediatric UC patients [299]. These same pediatric UC
patients had a reduction in disease activity index and sigmoidoscopy scores following VSL#3
treatment. They also had reduced levels of the pro-inflammatory cytokines TNF-α and IFN-
γ following therapy [299]. In vitro analysis of the effects of VSL#3 on Mode-K epithelial cells
revealed that only one of the eight organisms, L. casei, inhibited TNF-induced secretion of the
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pro-inflammatory chemokine IP-10 [300]. The most recent studies with VSL#3 treatment of UC
show increased fecal concentrations of beneficial bacterial species, improved clinical, endo‐
scopic and histopathological scores in most patients, and higher rates of remission compared
to placebo [298]. The most recent studies with VSL#3 treatment of UC show increased fecal
concentrations of beneficial bacterial species, improved clinical, endoscopic and histopatho‐
logical scores in most patients, and higher rates of remission compared to placebo [298]. VSL#3
is available without prescription and can be ordered via the internet or obtained locally at the
pharmacy in the U.S. [301].
Probiotics Prebiotics
Definition Live microorganisms which, given in
adequate amounts confer health benefits to
the host
Non-digestible carbohydrate which stimulate
replication of protective enteric bacteria
when consumed
















Protective Mechanisms Alters microbiota to suppress pathogens
Improved intestinal barrier function
Increased production of antimicrobial peptides
Decreased expression of proinflammatory cytokines
Stimulates replication of beneficial
bacteria (Bifidobacterium)
Enhances production of SCFA
(butyrate)
Improved intestinal barrier function
Decreases proinflammatory cytokines
Table 2. Basic Features of Probiotics and Prebiotics
Recent studies have also shown that dogs with IBD have distinctly different duodenal
microbial communities compared to healthy dogs. Current treatments for IBD include the
administration of nonspecific anti-inflammatory drugs which may confer serious side effects
and do not address the underlying basis for disease, namely, altered microbial composition.
The use of probiotics offers an attractive, physiologic, and non-toxic alternative to shift the
balance to protective species and treat canine IBD. The authors (AEJ) have initiated a clinical
trial to investigate the clinical, microbiologic, and anti-inflammatory effects of probiotic VSL#3
in the treatment of canine IBD. We hypothesize that VSL#3 used as an adjunct to standard
therapy (i.e., elimination diet and prednisone) will induce a beneficial alteration of enteric
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used human probiotics, but multi-strain cocktails (e.g., VSL#3), E. coli Nissle 1917, and
nonbacterial Saccharomyces boulardii have also been used as probiotics [226]. Probiotic bacteria
have measurable host benefits, including the ability to improve epithelial barrier function,
modulate the mucosal immune system, and alter the intestinal flora [290]. Prebiotics are non-
digestible dietary carbohydrates, such as lactosucrose, fructo-oligosaccharides (FOS), psylli‐
um, bran, which beneficially stimulate the growth and metabolism of endogenous enteric
bacteria upon consumption [291]. Beneficial effects of prebiotics are also associated with the
production of short chain fatty acids (SCFA) due to fermentation by colonic bacteria. Synbiot‐
ics are combinations of probiotics and prebiotics that are an emerging therapeutic modality.
Increasing evidence supports a therapeutic role for probiotics, prebiotics, and synbiotics in
treating gastrointestinal diseases of humans, including infectious diarrhea, H. pylori infection,
irritable bowel syndrome, lactase deficiency, and IBD [84]. A comparison of prebiotic and
probiotic preparations is outlined in Table 2.
2.6.7. Probiotics
VSL#3 is one of the most commonly used probiotic cocktails and contains a very high bacterial
concentration per gram of product characterized by greater number of different bacterial
species as compared to traditional probiotic preparations [292]. This commercially prepared
formulation consists of 450 billion bacteria/g of viable lyophilized bacteria comprised of eight
bacterial strains (Lactobacillus casei, L plantarum, L. bulgaricus, L. acidolphilus, Bifidobacterium
longum, B. breve, B. infantis and Streptococcus thermophiles). While the exact mechanism of action
of VSL#3 is unknown, several studies have demonstrated the effects of VSL#3 on epithelial
barrier function and down regulation of cytokine secretion from immune cells. For example,
Madsen [293] has shown in in vitro studies that epithelial barrier function could be enhanced
by exposure to a soluble factor secreted by VSL#3 bacteria. Moreover, this same study
demonstrated that VSL#3 did not alter the ability of the epithelial cell to activate a mucosal
inflammatory response to a bacterial invasion. Studies with VSL#3 formulations have also been
conducted in several animal models of colitis, inflammatory liver disease, sepsis, and irritable
bowel syndrome (IBS). In models of experimentally-induced colitis, these studies demonstrat‐
ed that VSL#3 normalized gut permeability and barrier function, and that VSL#3 modulated
inflammatory and immune responses [226, 294]. Animal models of sepsis have also demon‐
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preparation, developed specifically to balance the intestinal microbiota, is supported by
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diverse gastrointestinal disorders, such as IBS [297, 298].
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patients had a reduction in disease activity index and sigmoidoscopy scores following VSL#3
treatment. They also had reduced levels of the pro-inflammatory cytokines TNF-α and IFN-
γ following therapy [299]. In vitro analysis of the effects of VSL#3 on Mode-K epithelial cells
revealed that only one of the eight organisms, L. casei, inhibited TNF-induced secretion of the
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pro-inflammatory chemokine IP-10 [300]. The most recent studies with VSL#3 treatment of UC
show increased fecal concentrations of beneficial bacterial species, improved clinical, endo‐
scopic and histopathological scores in most patients, and higher rates of remission compared
to placebo [298]. The most recent studies with VSL#3 treatment of UC show increased fecal
concentrations of beneficial bacterial species, improved clinical, endoscopic and histopatho‐
logical scores in most patients, and higher rates of remission compared to placebo [298]. VSL#3
is available without prescription and can be ordered via the internet or obtained locally at the
pharmacy in the U.S. [301].
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bacteria leading to induction and maintenance of remission in dogs with IBD. A randomized,
controlled clinical trial of eight weeks duration will assess the efficacy of standard therapy in
conjunction with VSL#3 versus standard therapy alone in the management of canine IBD.
There is a need for additional data to be generated to provide proof of efficacy in probiotic
therapy before these agents can be applied to widespread clinical use. These studies will also
provide highly relevant insight into the anti-inflammatory effects of probiotics for treatment
of human and canine IBD.
Another popular probiotic is E. coli Nissle 1917 also known as Mutaflor®. This probiotic has
been shown to be just as effective as mesalazine in achieving and maintaining remission of
inflammation in UC patients [302-304]. It has recently been shown that when E. coli Nissle 1917
is genetically modified to produce the quorum-sensing molecule AI-2, it affected the beneficial
probiotic properties of this organism [305]. Colonization of healthy newborn infants with E.
coli Nissle 1917 has shown that the presence of pathogenic bacteria in the gut was significantly
reduced compared to non-colonized infants [306]. In vitro studies have shown E. coli Nissle
1917 is able to reduce the invasive ability of multiple pathogenic organisms [307], and also to
reduce the adherent and invasive ability of AIEC [308]. E. coli Nissle 1917 was also shown to
either inhibit the growth (49 %) or overgrowth (30 %) of 79 % of uropathogenic organisms
recovered from children with urinary tract infections [309]. Unlike VSL#3, Mutaflor® cannot
be purchased in the U.S. due to its reclassification by the F.D.A. from a “medical food” (which
is what VSL#3 is classified as) to a “biologic” [301, 310].
There are few reports on the use of probiotic bacteria in dogs and cats. Recent in vitro studies
have confirmed the capacity of a lyophilized probiotic cocktail (e.g., three different Lactobacil‐
lus spp strains) to modulate the expression of regulatory versus pro-inflammatory cytokines
in dogs with chronic enteropathies [311]. However, a clinical trial using this same probiotic
cocktail fed to dogs with food-responsive diarrhea failed to induce consistent patterns of
regulatory (e.g., beneficial) cytokine expression in spite of obvious clinical improvement [312].
One commercially-manufactured probiotic (FortiFlora™–Enterococcus faecium SF68, Nestle
Purina) is reported to potentially control diarrhea and enhance immune responses in dogs and
cats. Several recent trials attest to the short-term efficacy of probiotics in treating acute diarrhea
in dogs and cats [313]. The link between the intestinal microbiota and gastrointestinal health
in companion animals is now obvious. Future developments in the pharmabiotic field must
include performance of randomized clinical trials to determine the role of probiotics and
prebiotics in the management of canine chronic enteropathy. One large multicenter trial
investigating the efficacy of VSL#3 in reducing inflammatory activity of canine IBD is presently
underway
2.6.8. Prebiotics
Prebiotics are substances that can be used to promote specific changes in the microbiota.
Administration has been shown to shift the microbiota in healthy adults; for example, in‐
dividuals  who  consume  either  soluble  corn  fiber  or  polydextrose  had  increases  in  F.
prausnitzii and those who consumed the soluble corn fiber had increases in Roseburia spp.
[314].  As mentioned previously,  both of these organisms metabolically produce butyrate
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and F. prausnitzii  also has other anti-inflammatory properties. In animal models, prebiot‐
ics  have been shown to be effective as  well.  The severity of  DSS-induced colitis  in  rats
was attenuated by administering inulin orally as evidenced by a reduction in histopatho‐
logical  scores  and  myeloperioxidase  accumulation  in  the  colons  [315].  In  addition,  the
acidity of the colonic contents increased in rats fed inulin as well as an increase in Lacto‐
bacillus  spp.  in  the  feces.  In  a  multicenter  trial  feeding  UC  patients  germinated  barley
foodstuff  (GBF),  patients  consuming  GBF  had  improved  clinical  activity  index  scores
[316]. GBF has also been shown to be effective in maintaining remission [317] and reduc‐
ing pro-inflammatory cytokine  levels  in  UC patients  [318].  In  CD patients,  dietary sup‐
plementation  with  fructo-oligosaccharide  (FOS)  reduced  their  disease  activity  index,
increased fecal Bifidobacterium spp. levels as well as increased production of IL-10 and ex‐
pression of TLR-2 and TLR-4 from lamina propria dendritic cells [319].
Scientific studies have also investigated the effects of dietary supplementation with prebiotics
on the intestinal microbiota of healthy dogs and cats. In one study, FOS supplemented at 0.75
% dry matter produced qualitative and quantitative changes in the fecal flora of healthy cats
[320]. Compared with samples from cats fed a basal diet, increased numbers of lactobacilli and
Bacteroides spp. and decreased numbers of E. coli were associated with cats fed the FOS
supplemented diet. However, bacteriologic examination of the duodenal juice in these same
cats showed wide variation in the composition of the duodenal microbiota, across sampling
periods, which was not affected by FOS supplementation [321]. Moreover, healthy Beagle dogs
fed a 1 % FOS diet over a three-month trial showed inconsistent fecal excretion of Lactobacil‐
lus spp. and Bifidobacterium spp. [322]. While FOS supplementation has been shown to have
health benefits, these studies demonstrate that FOS does not have an adverse affect on the
microbiota and suggest that it may have positive physiological benefits as seen in humans.
This observation and the lack of significant side effects associated with FOS supplementation
provide evidence that FOS should be considered as an attractive alternative or adjunct therapy
for IBD in dogs and cats.
3. Mouse models of IBD
Many different mouse models have been utilized in IBD research to elucidate the roles that
bacteria, genetics, the immune response, and environment play in the induction and mainte‐
nance of IBD [323]. They fall into two main categories: chemically-induced and genetically-
engineered models. The composition of the microbiota in the various mouse models is also
discussed. Regardless of the strain of mouse employed in chemically-induced or genetically-
engineered models, there are only five options for its microbiota—conventional, specific
pathogen free, restricted, gnotobiotic, or germ-free. Note that the word gnotobiotic (gnostos–
“known” bios –“life”) indicates that all the organisms present, regardless of the numbers of
species, are known and does not apply only to mice that are completely devoid of microbes
(i.e., germfree).
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health benefits, these studies demonstrate that FOS does not have an adverse affect on the
microbiota and suggest that it may have positive physiological benefits as seen in humans.
This observation and the lack of significant side effects associated with FOS supplementation
provide evidence that FOS should be considered as an attractive alternative or adjunct therapy
for IBD in dogs and cats.
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Many different mouse models have been utilized in IBD research to elucidate the roles that
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nance of IBD [323]. They fall into two main categories: chemically-induced and genetically-
engineered models. The composition of the microbiota in the various mouse models is also
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Dextran sulfate sodium (DSS) is formed by the esterification of dextran with chlorosulphonic
acid [324]. Administered ad libtum in the drinking water, this compound causes enterocolitis
in mice with disease severity being dependent on mouse strain, DSS molecular mass, and
sulfur content [325-328]. Within three to seven days after the addition of DSS (1 to 10 % w/v)
to the drinking water, mice exhibit loose stools, weight loss, and occult blood. Upon necropsy
of mice treated with DSS, cecal atrophy and colonic shortening are noted, and histopathological
examination reveals mucosal ulceration, inflammatory infiltrate, and hyperplastic epithelium
in the colonic mucosa. It has also been reported that glandular dropout occurs prior to signs
of inflammation. Although the exact mechanism of action for DSS-induced colitis is currently
not known, it is thought to manifest epithelial toxicity [329, 330]. Other reports indicate that
DSS increases mucosal permeability within three days of administration (before the appear‐
ance of inflammatory infiltrate) [331]. Studies have also shown that DSS is taken up by
macrophages in the colon and mesenteric lymph node and by Kupffer cells in the liver [326,
330]. When macrophages become laden with DSS, they have a reduced ability to perform
normal homeostatic functions such as tissue repair and phagocytosis of bacteria [332]. DSS
was demonstrated to be cytotoxic to Caco-2 cells, binding to their nucleus, causing cell cycle
arrest and reduced production of reactive oxygen species [333].
Microbial populations of the GIT are altered after DSS administration, with the microbiota of
the treated mice having increased numbers of Bacteroidaceae and Clostridium spp. [326]. This
result indicates that the changes to the microbiota may play a contributory role (e.g., reduction
of butyrate production) in the induction of DSS-induced disease. However, DSS induces more
severe colitis and increased mortality in GF mice as compared to their conventional counter‐
parts [334, 335]. GF mice given either 5% or 1% DSS died at days three or 14, respectively, after
the start of DSS administration [335]. Collectively, these studies indicate that the composition
of the microbiota may influence the sensitivity of mice to DSS-induced colitis as well as support
the idea that the resident microbiota affords cytoprotective benefits for the host.
3.1.2. TNBS (2,4,6,-trinitrobenzne sulfonic acid)
TNBS is a haptenating agent that causes a disease similar to CD when mixed with etha‐
nol and administered rectally as an enema. Mice treated with TNBS develop a pan-colitis
with  the  peak  of  clinical  signs,  such  as  diarrhea  and  rectal  prolapse,  occurring  two  to
four weeks post-administration [112].  Microscopically,  transmural  inflammation is  noted
along  with  neutrophil  infiltration,  loss  of  goblet  cells,  edema,  and  granulomas.  T  cells
isolated  from  the  lamina  propria  secrete  elevated  levels  of  IFN-γ  and  IL-2  following
stimulation with anti-CD3 and anti-CD28. However, administration of anti-IL-12 antibod‐
ies after induction of TNBS-induced colitis reduced the disease severity, and treated mice
also showed reduced production of IFN-γ [112]. Further studies have shown that CD4+ T
cells  recovered  from  mice  with  TNBS-induced  colitis  could  induce  mild  colitis  when
adoptively  transferred  into  naive  control  mice;  the  colitic  lesions  were  characterized by
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inflammatory  cell  infiltrate  that  produced  IFN-γ  [336].  In  that  same  study,  researchers
found that feeding mice TNBS-haptenized colonic protein caused the mice to develop or‐
al tolerance. These mice subsequently failed to develop colitis after TNBS administration
or the transfer  of  CD4+  T cells  from mice with TNBS-induced colitis.  T cells  from these
tolerant mice secreted elevated amounts of TGF-β, IL-4, and IL-10 [336].
3.1.3. Oxazolone
Oxazolone is a haptenating agent that causes a disease in mice similar to UC when mixed
with ethanol and administered rectally [337, 338]. SJL/J mice rapidly develop diarrhea and
weight loss that peaks at day two post-administration with a 50 % mortality rate by day
four.  At day two, the distal  half  of  the colon becomes hemorrhagic and edematous and
histologically shows signs of superficial inflammation. There is epithelial cell erosion, gob‐
let cell depletion, edema, and inflammatory cell infiltrate composed of neutrophils and eo‐
sinophils.  This  is  similar  to  what  is  observed  microscopically  in  the  colonic  tissues  of
human UC patients. These mice also develop elevated levels of IL-4 and IL-5, but no IFN-
γ,  indicating  that  oxazolone  induces  a  Th2  response.  Elevated  levels  of  TGF-β  are  also
noted and may play in a role in the induction of disease in only part of the colon. The
model  has  also  been  examined  for  its  role  in  determining  efficacy  of  IBD  treatments.
BALB/c  mice  given  either  5-aminosalicylic  acid  (5-ASA)  or  sodium  prednisolone  phos‐
phate intra-rectally prior to and during induction of oxazolone colitis  had decreased se‐
verity of disease [337]. The disease is self-limiting, and the mice that survive beyond day
four show increased weight gain and are healthy by days 10-12 post-administration.
3.2. Genetically engineered models
3.2.1. IL-10-/-
In 1993, Kuhn et al. discovered that mice deficient in the anti-inflammatory cytokine IL-10
spontaneously develop enterocolitis  [213].  This model has been popular in IBD research
and this genetic deficiency has been crossed onto many different genetic backgrounds of
mouse [339-345]. The availability of different strains has highlighted the role that genetics
plays in enterocolitis, as the severity of disease is strain dependent. The order of severity
from most severe to least severe is as follows: C3Bir > 129 > BALB/c or NOD/Lt > C57BL/
6  or  C57BL/10.  In  addition  to  strain  differences,  development  of  entercolitis  is  also  de‐
pendent on the microbiota, as GF IL-10-/- do not develop enterocolitis and disease is atte‐
nuated  after  administration  of  antibiotics  to  IL-10-/-  mice  harboring  a  conventional
microbiota [346,  347].  The lack of IL-10 does not affect the development of B or T cells,
but  its  absence  does  result  in  a  lack  of  regulatory  T  cells  [213,  348].  Studies  to  under‐
stand the development of disease in these mice have shown that B cells (while present in
high numbers in the lamina propria) are not needed for the initiation of disease, but that
disease is mediated by CD4+ T cells [342, 349]. Transfer studies using RAG2-/- mice as re‐
cipients  have specifically  shown that  naive CD4+  T  cells  are  capable  of  inducing colitis,
and CD45RBlow CD4+  T cells  from IL-10-/-  mice can induce disease in these RAG2-/-  mice
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microbiota [346,  347].  The lack of IL-10 does not affect the development of B or T cells,
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[348,  349].  This  latter  observation implicates  IL-10 as  a  central  mediator  of  regulatory T
cells (CD25+ Foxp3+ CD4+ T cells). It has also been shown that IL-12 and IFN-γ are need‐
ed for initiation but not the continuation of colitis [342, 350]. The increase in the produc‐
tion  of  IL-12  and  IFN-γ  along  with  undetectable  levels  of  IL-4  indicates  that  the
enterocolitis  in  these  mice  is  mediated  by  a  Th1  immune  response,  similar  to  that  ob‐
served in humans with IBD [342, 346].
3.2.2. Mdr1a-/-
In 1994, mice lacking the gene mdr1a were generated. This gene encodes a P-glycoprotein,
which is a drug efflux pump, thus protecting host cells from the build-up of toxic compounds.
It was noted later that these mice spontaneously develop a colitis similar to human IBD and
that disease can be exacerbated by colonization with Helicobacter bilis [351, 352]. These mdr1a-/-
mice have reduced growth rates compared to their WT counterparts and their histological
lesions begin in the proximal colon and proceed distally as disease severity progresses. Mdr1a-/-
males are more susceptible to the onset of severe disease than females [353, 354]. Mdr1a-/- mice
also have increased epithelial permeability and reduced phosphorylation of both occludin and
ZO-1, tight junction proteins, compared to WT counterparts [354]. They exhibit increased
bacterial translocation with bacteria detected in both the spleen and lymph nodes that
correlates with disease severity. Therefore, the induction of disease is associated with a defect
in the epithelial barrier function of the GI tract. In addition to the similar disease progression
found in IBD patients, studying these mice are of interest because the human MDR1 gene has
been mapped on a loci that that is associated with susceptibility of IBD, although this rela‐
tionship is under debate [355-358].
3.2.3. TRUC
TRUC mice are both T-bet-/- and RAG-/- and spontaneously develop colitis by four weeks of
age [359, 360]. T-bet (T-box expressed in T cells) is a transcription factor that aids in the
development of a Th1 response [359]. These mice have increased permeability of their colonic
epithelium that increases with age and increased rate of epithelial cell death. Microscopically,
there is inflammatory cell infiltrate, goblet cell dropout, crypt loss, and the presences of ulcers.
The only cytokine elevated in these mice is TNF-α and disease can be ameliorated using an
anti-TNF-α antibody. The microbiota also contributes to disease in this model, as treatment
with antibiotics was able to “cure” the mice of their colitis. Additionally, the TRUC colitic
microbiota can be horizontally transferred to both WT and RAG-/- mice, and 16S rRNA analysis
of feces from TRUC mice revealed that the presence of Klebsiella pneumoniae and Proteus
mirabilis correlate with colitis. Interestingly, GF TRUC mice colonized with these two organ‐
isms alone do not develop colitis unless a more complete microbiota is present [361].
3.3. CD45RBhi CD4+ T-cell transfer model
C.B.-17 scid mice administered CD45RBhi CD4+ T cells develop a wasting disease which is
not  seen if  CD45RBlo  CD4+  T  cells  or  CD45RBhi  CD8+  T  cells  are  adoptively  transferred
[362-364].  Disease  occurs  three  to  five  weeks  post-administration  and  is  limited  to  the
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large intestine. The mucosa, submucosa, and muscularis all presented with inflammatory
cell  infiltrates (macrophages and CD4+ T cells predominately),  and there was also a loss
of goblet cells, epithelial cell hyperplasia, and deep fissure ulcers. Elevated levels of IFN-
γ were present in these mice, and treatment with anti-IFN-γ or anti-TNF (α and β) anti‐
bodies ameliorated disease in these mice. However, the protection garnered by using the
antibodies was not as great as when CD45RBlo CD4+ T cells were transferred along with
CD45RBhi CD4+ T cells [362]. This disease type mimics CD with respect to the type of in‐
flammatory  response  generated  (Th1)  and  the  type  of  intestinal  inflammation  present
(transmural infiltrate of CD4+ T cells) [365]. There is also a definite microbial component
in  this  model  of  disease,  as  restricted microbiota mice have less  severe disease as  com‐
pared to their SPF counterparts [364].
3.4. Bacterial-induced models
3.4.1. Helicobacter spp.
Although not considered a microbial cause of IBD, the presence of Helicobacter spp. does
adjuvant or predispose mice to the onset of colitis in some models. In our lab, we utilize a dual
hit model of colitis consisting of both Helicobacter bilis colonization and low-dose (1.5%) DSS
to elicit colitis, as shown in Figure 8 [366].
Figure 8. To increase sensitivity to a colitic insult, ASF-bearing C3H/HeN:Tac mice were colonized with a bacterial pro‐
vocateur, Helicobater bilis. An otherwise non-colitic low dose of DSS is then administered resulting in colitis.
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Figure 9. Mice colonized with Helicobacter bilis and subsequently administered a low dose of DSS exhibit colitis that is
not seen with H. bilis or DSS alone. Disease is characterized grossly by colonic shortening, edema, cecal atrophy, en‐
larged lymphoid aggregates, and blood present in the contents. Microscopically, the disease presents with inflamma‐
tory cell infiltrate, crypt hyperplasia, glandular dropout, and cellular erosion
It has been noted that colonization of mice with H. bilis alone can change mucosal gene
expression and alter the immune response in C3H/HeN mice bearing the altered Schaedler’s
flora (ASF) [366, 369]. Genes involved in T cell receptor signaling, the survival and activation
of peripheral B cells, and chemotaxis are a few examples of the host genes that were upregu‐
lated by H. bilis colonization. Genes that were down regulated were involved in fatty acid
metabolism and detoxification. After H. bilis colonization, serum antibodies directed at
antigens derived from members of the ASF are induced [366, 369]. H. hepaticus colonization of
A/JCr mice also induced changes in gene expression in the cecum, with female mice being
more susceptible to the onset of disease [370, 371].
It appears that an over zealous host response to the introduction of the novel organism (i.e.,
provocateur) predisposes certain strains of mice for the onset of typholocoltiis following a
secondary colitic insult. In a study comparing A/JCr mice (that develop mild inflammation) to
C57BL/6 (who do not develop inflammation) mice, cecal gene expression profiles revealed that
A/JCr mice had more genes differentially regulated (176) compared to C57BL/6 (80). Differ‐
entially expressed genes were predominantly those associated with immune response,
chemotaxis, signal transduction, and antigen processing in the A/JCr mice while the genes
upregulated in the C57BL/6 mice were predominately associated with immunoglobulin
production.
In the mdr1a-/- mouse, it is not simply the presence of Helicobacter that results in the induction
of colitis but the specific species of Helicobacter influences the induction of a differential
immune response. In mdr1a-/- mice, H. bilis colonization causes colitis as early as three weeks
post-infection, whereas H. hepaticus colonization ameliorated the severity of colitis in these
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mice compared to the uninfected control mdr1a-/- mice [352]. The disease phenotypes between
spontaneous versus Helicobacter-induced colitis in mdr1a-/- mice were different, with epithelial
ulceration not present in the Helicobacter-induced colitis. When mdr1a-/- mice were co-colonized
with both Helicobacter species, the morbidity and mortality rate was between that of mice
colonized by either H. bilis or H. hepaticus and the colitis that developed was characterized by
dysplasia [372]. H. bilis was also able to out compete H. hepaticus in vivo as evidenced by
recovery of higher numbers of H. bilis, suggesting that these two species may compete for
similar niches in the GIT.
Additionally, colonization of IL-10-/- C57BL/6 mice with Helicobacter species results in the
induction of colitis in otherwise disease-free mice [373]. It was also shown that the onset and
severity of colitis was species specific in relation to colonization by H. bilis or H. hepaticus [374].
With respect to C3Bir.129 IL-10-/- mice, the presence of Helicobacter spp. is required for the
spontaneous onset of disease [339]. Further studies show that colonization of RAG1-/- mice
with Helicobacter species fails to elicit clinical signs of disease after nine months of colonization
and only very mild colonic inflammation was detected at necropsy [374]. Taken together, these
observations indicate that disease induction can be mediated by an aberrant adaptive immune
response initiated by bacterial provocateurs entering an otherwise stable host-microbe
environment.
3.4.2. Brachyspira hyodysenteriae
Similar to the need for the a resident microbiota in the TRUC model of colitis, mice colonized
with Brachyspira hyodysenteriae also require the presence of a microbiota for the induction of
typhlocolitis. B. hyodysenteriae is an anaerobic spirochete that is the causative agent of swine
dysentery [375]. While the pathogenesis of B. hyodysenteriae is associated with the production
of a ß-hemolysin [376], disease does not develop in the absence of a resident microbiota as was
demonstrated by the inoculation of germfree pigs [377-379]. The importance of the microbiota
was further demonstrated when the microbiota of C3H/HeSnJ or BALB/c mice was depleted
by adding a cocktail of antibiotics (rifampicin, colistin, spectinomycin, spiramycin, and
vancomycin) to their drinking water. As can be seen in Figure 10, the antibiotic cocktail
depleted the numbers of Gram-positive, Gram-negative, and strict anaerobes by as much as 5
to 7 log10 (Nibbelink and Wannemuehler, unpublished observations). On day seven, antibiotic
treated and sham treated mice were inoculated with 1 x 108 B. hyodysenteirae strain B204 and
severity of disease was evaluated at 5, 10, and 15 days post-infection (DPI). As can be seen in
Figure 11, the sham-treated mice developed severe typhlocolitis while the antibiotic treated
mice had no lesions. At 15 DPI, the antibiotics were withdrawn from the drinking water of the
remaining B. hyodysenteriae-infected mice to allow the microbiota to recover. On day 30 PI, the
mice that had been treated with antibiotics through 15 DPI now presented with severe
typhlocolitis. The presence and severity of typhlocolitis in these mice correlated with the
presence of TNF-specific mRNA in the cecal tissue of the B. hyodysenteriae-infected mice (data
not shown). Lastly, B. hyodysenteriae-induced typhlocolitis could also be prevented when the
host’s inflammatory response was inhibited [380, 381]. Collectively, these observations
indicate that certain bacterial provocateurs (K. pneumoniae, P. mirabilis, and B. hyodysenteriae)
The Role of the Microbiota in Gastrointestinal Health and Disease
http://dx.doi.org/10.5772/53920
111
Figure 9. Mice colonized with Helicobacter bilis and subsequently administered a low dose of DSS exhibit colitis that is
not seen with H. bilis or DSS alone. Disease is characterized grossly by colonic shortening, edema, cecal atrophy, en‐
larged lymphoid aggregates, and blood present in the contents. Microscopically, the disease presents with inflamma‐
tory cell infiltrate, crypt hyperplasia, glandular dropout, and cellular erosion
It has been noted that colonization of mice with H. bilis alone can change mucosal gene
expression and alter the immune response in C3H/HeN mice bearing the altered Schaedler’s
flora (ASF) [366, 369]. Genes involved in T cell receptor signaling, the survival and activation
of peripheral B cells, and chemotaxis are a few examples of the host genes that were upregu‐
lated by H. bilis colonization. Genes that were down regulated were involved in fatty acid
metabolism and detoxification. After H. bilis colonization, serum antibodies directed at
antigens derived from members of the ASF are induced [366, 369]. H. hepaticus colonization of
A/JCr mice also induced changes in gene expression in the cecum, with female mice being
more susceptible to the onset of disease [370, 371].
It appears that an over zealous host response to the introduction of the novel organism (i.e.,
provocateur) predisposes certain strains of mice for the onset of typholocoltiis following a
secondary colitic insult. In a study comparing A/JCr mice (that develop mild inflammation) to
C57BL/6 (who do not develop inflammation) mice, cecal gene expression profiles revealed that
A/JCr mice had more genes differentially regulated (176) compared to C57BL/6 (80). Differ‐
entially expressed genes were predominantly those associated with immune response,
chemotaxis, signal transduction, and antigen processing in the A/JCr mice while the genes
upregulated in the C57BL/6 mice were predominately associated with immunoglobulin
production.
In the mdr1a-/- mouse, it is not simply the presence of Helicobacter that results in the induction
of colitis but the specific species of Helicobacter influences the induction of a differential
immune response. In mdr1a-/- mice, H. bilis colonization causes colitis as early as three weeks
post-infection, whereas H. hepaticus colonization ameliorated the severity of colitis in these
Inflammatory Bowel Disease110
mice compared to the uninfected control mdr1a-/- mice [352]. The disease phenotypes between
spontaneous versus Helicobacter-induced colitis in mdr1a-/- mice were different, with epithelial
ulceration not present in the Helicobacter-induced colitis. When mdr1a-/- mice were co-colonized
with both Helicobacter species, the morbidity and mortality rate was between that of mice
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may fail to induce disease in the absence of an appropriate resident microbiota. As depicted
in Figure 12, the etiology of colitis is complex and may require the presence of a microbial
provocateur, the resident microbiota, and a host inflammatory response.
Figure 10. To assess the role of the microbiota in Brachyspira hyodysenteriae-induced typhlocolitis, C3H/HeSnJ mice
were treated with an antibiotic cocktail to deplete the resident microbiota. Six days later, mice were infected with B.
hyodysenteriae. The data indicate that there was a five to seven log10 reduction in the resident microbiota.
3.5. Conventional mice
The majority of commercially available mice harbor a “conventional” microbiota. This simply
means that the composition of the community is unknown. There are different types of
conventionally-reared mice. For example, Taconic Farms maintain two types of conventional
microbiota mice, restricted flora™ (RF) and murine pathogen free™ (PF). RF mice are not
colonized by β-hemolytic Streptococcus species, K. pneumoniae, K. oxytoca, Pseudomonas aerugi‐
nosa, or Staphylococcus aureus. Mice that are PF are Helicobacter free but can contain organisms
not found in RF mice [382]. Additionally, mice on the same background purchased from
different vendors can harbor different microbiota, as highlighted in work by Ivanov and
colleagues demonstrating the presence of SFB in C57BL/6 mice from Taconic but not Jackson
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Laboratories [54]. This lack of consistency in microbiota from mice of the same strain has even
been identified at different facilities from the same vendor (Overstreet and Wannemuehler
unpublished observation). Therefore, comparison of studies evaluating the microbiota of mice
are difficult because there are hundreds of unknown bacterial species present in the murine
microbiota and there is no standardized microbiota used by investigators. The advent of next-
gen sequencing has helped to alleviate some of this challenge as all of the organisms in the gut
can be identified based on 16S rRNA sequences. However, it still does not resolve the issue
related to the use of disparate strains of mice with varying microbiota from different suppliers.
Figure 11. Assessment of Brachyspira hyodysenteriae-induced typhlocolitis in C3H/HeSnJ mice treated with an antibi‐
otic cocktail. While B. hyodysenteriae colonized the antibiotic-treated mice to the same extent as it did the sham-treat‐
ed mice, there was no evidence of typhlocolitis in the antibiotic treated mice through 15 days post-infection (DPI).
However, 15 days after the antibiotics were withdrawn (30 DPI), the mice that had been treated with the antibiotics
had developed severe disease once the microbiota recovered.
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Figure 12. The pathogenesis of inflammatory bowel disease is complex. Studies from animal models indicate that the
etiology of disease involves the presence of a bacterial provocateur, the resident microbiota, and the host response.
3.6. Germfree mice
GF  mice  are  completely  devoid  of  microbial  life.  As  mentioned  previously,  this  does
grossly affect  the anatomy of  these mice,  which is  most  evident by the enlarged cecum
being the most  prominent  feature  [34].  The discovery that  many GF mouse strains  that
carry genetic deficiencies associated with IBD (notably the IL-10-/-)  do not develop colitis
has led to the popularity of GF models to study the role of bacteria in the pathogenesis
of  IBD  [346].  To  determine  if  an  organism  is  capable  of  initiating  colitis,  GF  mice  are
monoassociated  with  a  single  bacterial  species  and then  monitored  for  clinical  signs  of
disease. Some of the bacterial strains used to date to evaluate their ability to induce dis‐
ease in IL-10-/- mice are shown in Table 3.
Organism Colitis Severity Time of Disease Onset Reference
Enterococcus faecalis Severe 10-12 weeks p.i. [383, 384]
Escherichia coli (from WT SPF mouse) Moderate 3 weeks p.i. [383]
Pseudomonas flourescens No disease - [383]
Helicobacter hepaticus No disease - [385]
Lactococcus lactis No disease - [384]
Viridans group Streptococcus No disease - [386]
Clostridium sordellii No disease - [386]
Bacteroides vulgatus No disease - [386]
Bifidobacterium animalis Mild 23 weeks p.i. [387]
Bifidobacterium infantis No disease - [387]
Table 3. Bacterial strains used to monoassociate GF mice to examine the ability of the strain to induce colitis
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Although the information gathered from these studies  has been useful  in  analyzing the
immune response to specific organisms, trying to relate the resultant disease to that char‐
acteristic of IBD is marginal at best because of the differences in the complexities of the
microbiota.  IBD itself  is  a  multi-factorial  disease  and it  has  been  fairly  well-established
that  the  role  of  bacteria  in  IBD is  associated  with  a  shift  in  community  dynamics  (i.e.,
dysbiosis)  and not  the  presence/absence of  one particular  species.  A perfect  example of
this  complexity is  the fact  that  K. pneumonia  and P.  mirabilis  fail  to  induce colitis  in GF
TRUC mice (Figure 12) [361].
3.7. Defined microbiota mice
Also referred to as gnotobiotic, defined microbiota (DM) mice have a microbiota in which all
members are known and are housed in flexible film isolators to maintain this status [388]. One
of the most established DM mouse models harbors the “Altered Schaedler Flora” (ASF).
Developed by Dr. Rodger Orcutt and colleagues as a request from the National Cancer
Institute, these eight microbial species were originally used to standardized the microbiota of
the rodents used as founders in their breeding colonies [389]. He chose to modify his mentor’s
(Dr. Russ Schaedler) cocktail of organisms by eliminating facultative anaerobes (Escherichia
coli var. mutabilis and Streptococcus fecalis) and the anaerobic Streptococcus and Clostridia spp.
that formed the original “Schaedler Flora”. Dr. Orcutt added four additional species (see Table
4 below). This resulted in an anaerobic community devoid of any cocci or spore-forming blunt
ended rods, which comprise the main isolator contaminants, making it easier to monitor for
contamination of the gnotobiotic isolator. This new community was dubbed the “Altered
Schaedler Flora” and was utilized in the breeding stock by major commercial mouse vendors
in the US in that era. The ASF consists of members with different morphologies so that
identification using fecal smears for microscopic evaluation was possible. The members, whose
full genomes have yet to be sequenced, have had 16S rRNA sequencing performed to assist
with the identification of the organisms [390].
Multiple studies have demonstrated the stability of this community both when maintained
under gnotobiotic housing conditions or when part of a conventionalized microbiota [391-394].
In our own lab, all eight ASF members have been stably maintained in our breeding colony
for over 12 years, indicating the remarkable stability of this model microbial community over
time. PCR primers have been developed for each of the eight ASF members as well as group-
specific FISH probes [391, 394]. Therefore, the effects of any perturbation of the ASF, such as
with antibiotics, inflammation, or CAM treatments can be monitored by bacterial abundance
as well as spatial redistribution using qPCR and FISH, respectively. All of the organisms can
be cultured and whole cell sonicates produced to measure the immune response to each
organism individually (something that is impossible to do with a conventional microbiota).
Additionally, this community, although limited in scope, is able to synthesize all the metabo‐
lites needed by the mouse and maintains near normal cecal shape and size, something not
possible in GF mice. It is important to note, however, that some of the characteristics of ASF
mice are more similar to GF than conventional mice. Both ASF and GF mice have high fecal
tryptic activity and possess the ability to degrade mucin and β-aspartylglycine. They also
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Figure 12. The pathogenesis of inflammatory bowel disease is complex. Studies from animal models indicate that the
etiology of disease involves the presence of a bacterial provocateur, the resident microbiota, and the host response.
3.6. Germfree mice
GF  mice  are  completely  devoid  of  microbial  life.  As  mentioned  previously,  this  does
grossly affect  the anatomy of  these mice,  which is  most  evident by the enlarged cecum
being the most  prominent  feature  [34].  The discovery that  many GF mouse strains  that
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Bifidobacterium infantis No disease - [387]
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cannot convert bilirubin to urobilinogens or cholesterol to coprostanol [395]. Interestingly, this
same research team compared these parameters in CD patients versus healthy subjects and
the characteristics of the microbial metabolism associated with the microbiota of CD patients
were very similar to those of the ASF [396]. This study suggests that there is benefit to the use
of the ASF in mouse models of IBD.
Other defined microbiota mouse studies have been published [397-400]. A study using ten
bacterial species specifically chosen for their metabolic function were used to colonize GF mice
[397]. Using microbial RNA-seq, the authors were able to build a model relating perturbation
of the microbial community to changes in diet. By modeling the functional capacity of a
gnotobiotic community under different conditions, this model and similar approaches can be
used to unravel the operational dynamics of the gut microbiome with respect to nutrient
utilization such that the microbiota might be manipulated to improve human and animal
health [397]. Another study colonized mice with E. rectale and B. thetaiotamicron, and the
authors then assessed changes in bacterial gene expression using Affymetrix GeneChips to
show that the cross-talk between these two organisms affected up- and down-regulated genes
in response to one another.
Strain Identity
ASF356 Most closely related to Clostridium propionicum (92% max identity) [390]
Member of Clostridium cluster XIV
ASF360 Lactobacillus intestinalis (99% max identity) [401]
ASF361 Lactobacillus murinus [390]
ASF457 Mucispirillum schaedleri [402]
ASF492 Eubacterium plexicaudatum [403]
Member of Clostridium cluster XIV
ASF500 Clostridium sp. with no known related organism in GenBank Database [390]
ASF502 Most closely related to Ruminococcus gnavus (92% max identity) [390]
Member of Clostridium cluster XIV
ASF519 Parabacteroides goldsteinii (99% max identity) [404, 405]
Table 4. Members of the altered Schaedler flora
Three human commensals, E. coli, B. longum, and L. johnsonii, have also been used to colonize
GF mice to create a gnotobiotic community [398]. This community was used to identify the
effects that the introduction of novel organisms has on the community dynamic. When
colonized with a second Lactobacillus, L. paracasei, it was noted that both Lactobacillus spp. were
able to co-habitate reaching similar fecal titers. However, that was not the same when a fifth
organism was added, a second B. longum strain. This new strain was only maintained in the
mouse at detectable levels for three days. Lastly, a second E. coli strain was added to the original
community of three. This new E. coli reached the highest titer of any organism in the com‐
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munity. This addition caused the reduction of the original E. coli to drop to undetectable levels
at day two post-addition. Later L. johnsonii also reached undetectable levels. B. longum
decreased initially but them returned to normal titer levels. Lastly, when the original tri-
associated mice were exposed to conventional mouse feces, the numbers of the original three
organisms decreased.
In this chapter, we have discussed the three most common types of microbiota available for
use in IBD research. Because it is clear that IBD is associated with an imbalance in the microbial
community, the use of GF mice (which cannot mimic a “community” dynamic) may be less
useful in unraveling the complexities of a multifactorial disease in place of defined microbiota
and conventional microbiota mice. Ideally, one would want to use a simplified community
(such as the ASF) where the actions of all organisms can be assessed. To understand the
dynamic interactions that occur between microbes and between the microbes and the host, it
will be important to start with what is known in order to begin the unraveling the enigmatic
nature of gut health and disease.
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1. Introduction
The objectives of this chapter are to review clinical and pathophysiologic aspects of fibrosis
in inflammatory bowel disease, particularly in Crohn’s disease. Potential therapeutic strat‐
egies and the current status of preclinical animal models to evaluate these therapeutic strat‐
egies will also be discussed.
2. Clinical considerations
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, relapsing inflammatory gastro‐
intestinal diseases which often onset in young adulthood. Unlike in UC, where inflamma‐
tion is limited to the mucosa, CD patients frequently develop transmural disease which can
extend to involve the muscularis and serosa. While inflammatory disease accounts for much
of the symptomatology associated with CD, significant morbidity results from fibrotic le‐
sions and their resulting complications.
CD can be broadly categorized as having three major clinical subtypes: stricturing, penetrat‐
ing or inflammatory (nonstricturing nonpenetrating) disease [1]. This categorization is re‐
flected by the inclusion of disease behavior ( stricturing, penetrating or inflammatory) as
one of three variables elected for inclusion in the Vienna classification in 1998 [2]. Review of
natural history data from shows that the majority of patients undergo progression from in‐
flammatory disease to development of complications including stricture [3]. Even though
most patients present with inflammatory disease only and later progress to a more compli‐
cated disease phenotype, a subset of patients will present with stricturing or penetrating dis‐
ease. In population-based studies, 19-36% of patients newly diagnosed with CD present
with disease complications such as strictures, fistulas or abscesses [4-6].
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Intestinal stricture is a common and serious complication of long term CD. Critical intestinal
stricture formation will occur in at least one-third of CD patients within 10 years of onset
[7-9]. By contrast, fibrosis associated with UC is generally limited to the mucosa and stric‐
ture formation is rare although rectal strictures, when they occur, can be problematic to
manage [10]. Advances in CD treatment have yet to make significant impact on the inci‐
dence of strictures and the associated morbidity [11].
While surgical resection is a highly effective short term treatment, remission after surgical
resection in CD is only temporary. The disease course in CD patients postsurgery is relative‐
ly consistent and has allowed development of a postoperative recurrence model [12, 13]. In
this model, a focal inflammatory infiltrate forms in the ileum above the anastomosis fol‐
lowed by aphthous ulcers which are endoscopically visible in two-thirds of patients within 3
months after surgery. These patients go on to develop extensive superficial and deep ulcers
that precede the development of a new stricture. Postoperative reoccurrence is very com‐
mon with fewer than 5% of patients having normal endoscopy results 10 years after surgery.
Symptoms occur on average 2-3 years after lesions are observed.
In patients with a fibrostenotic disease behavior, symptomatic strictures tend to return de‐
spite medical therapy and this leads to repeated bowel resections and eventually to short
bowel syndrome [14-16]. Endoscopic balloon dilation can provide a treatment option for pa‐
tients with fibrostenotic strictures 7 cm or less in length although there is some risk of perfo‐
ration [17, 18]. Strictureplasty can be a useful bowel-preserving surgical option for stenosing
small bowel CD in patients with multiple obstructions and in those vulnerable to short bow‐
el syndrome [19]. The incidence of postoperative recurrence is very similar between strictur‐
eplasty and resection [11].
Strictures can arise due to either inflammatory or fibrotic processes. There is evidence that
direct steroid injection can provide symptom relief in some CD patients with anastomotic
strictures, presumably in patients with active inflammation and relatively little fibromuscu‐
lar proliferation at the anastomotic site [18]. Given the risk of multiple bowel resection sur‐
geries and the possibility of short bowel syndrome, the ability to differentiate between
inflammatory or fibrotic strictures could be used to drive treatment decisions. Endoscopy-
based techniques such as colonoscopy, small intestinal endoscopy, and capsule endoscopy
have high clinical utility but only visualize the mucosal surface. Cross-sectional imaging
techniques can be used to visualize deep layers of the intestinal wall and assess for stric‐
tures. Computed tomography enterography (CTE) has become the most widely used cross-
sectional imaging technology for CD although concern about cumulative radiation
exposure, particularly in young patients, has led to interest in alternative imaging modali‐
ties [20, 21].
Imaging methods such as magnetic resonance (MR) enterography or ultrasonography are ef‐
fective in determining the anatomic location and length of affected intestinal segments and
these techniques, as well as CTE, have shown a good correlation with endoscopy [22-24].
However, distinguishing stricture composition remains a challenge. In 2006, the European
Crohn’s and Colitis Organization (ECCO) stated in their consensus report on treatment of
CD that current techniques are insufficiently accurate to differentiate between inflammatory
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and fibrostenotic strictures [25]. A recent study confirms that, while the combination of MR-
enterography and ultrasound as well as the combination of 18FDG-PET/CT and ultrasound
are highly efficient in detecting CD strictures, no current imaging techniques shows suffi‐
cient sensitivity or specificity to reliably differentiate inflamed from fibrotic strictures [26].
The clinical need for this for such differentiation remains high and may require both techno‐
logic advancement and establishment of criteria for grading or distinguishing strictures
which contain both fibrotic and inflammatory components [27]. [25]. In clinical practice, a
variety of diagnostic tools including imaging techniques and inflammatory biomarkers are
often applied in an effort to obtain sufficient evidence to inform treatment decisions [28].
Therapeutic strategies have evolved over the past decade and having the ability to predict
disease outcomes could guide the clinician’s choice of therapy. The goals of CD treatment
should include 1.) steroid-free sustained clinical remission; 2.) mucosal healing; 3.) potential
induction and maintenance of radiological healing; 4.) prevention of surgery; 5.) mainte‐
nance of normal gastrointestinal function; and 6.) prevention of disability [6]. There are a
number of therapeutic options available for the treatment of inflammation in CD patients,
however none of these have been demonstrated to be effective in preventing preventing or
treating fibrostenosis thereby failing to achieve at least 2 of the 6 major treatment goals in
patients with fibrostenotic disease. There have been some reports of regression of strictures
and of overall benefit following infliximab treatment in a subset of patients with small bow‐
el stricturing disease [18, 29, 30]. This data is largely anecdotal and remains controversial as
large controlled trials have not yet been performed.
In CD, disease location (ileal vs. colonic) remains relatively stable but clinical behavior can
alter significantly over time [8, 31, 32]. During the first few years of disease, inflammatory
forms predominate, whereas, after 40 years, most patients have experienced complications
and are classified as having penetrating or stricturing disease[33]. However, the rate at
which disease behavior evolves can vary widely between CD patients and those differences
would determine therapeutic strategies if rapidly progressing patients could be identified.
For example, initiation of more aggressive treatment early in the course of disease has the
potential to result in better outcomes, however, these therapies can also lead to greater risk
of toxicity and adverse effects [34, 35]. Decisions on whether to use a conservative or an ag‐
gressive treatment strategy in newly diagnosed patients could be informed by the ability to
identify patients at higher risk for developing disabling or complicated disease.
3. Fibrosis risk factors
A number of retrospective studies have identified specific disease characteristics that may
be of use in predicting risk for individual CD patients. These include an initial CD diagnosis
under age 40, need for steroid therapy at diagnosis, and perianal fistulizing disease [31, 36].
Localization of inflammation to the small bowel has also been identified as predictive of
progression to more complicated disease and higher rate of surgery [37]. However, all of
these clinical features tend to correlate with the presence of small intestinal disease and do
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not necessarily identify which patients with small bowel disease are at greatest risk of devel‐
oping fibrostenosing disease.
Genetic polymorphisms play an important role in susceptibility to CD so the use of genetic
markers to provide risk stratification and drive clinical decisions is very attractive. The ob‐
servation that some CD patients are susceptible to stricture development early and often in
their clinical course while others never develop a stenosing phenotype argues for the exis‐
tence of a genetic background which predisposes to stricturing behavior in CD.
One of the genes linked with susceptibility to CD is the CARD15/NOD2 gene which encodes
a protein involved in bacterial recognition and activation of nuclear factor kB. Carriers of
two mutant alleles have 17 to 42 times the risk while carriers of one mutation have 1.5 to 3
times the risk of developing CD [38, 39]. There is a significant body of evidence suggesting
that the main NOD2/CARD15 variants (Arg702Trp, Gly908Arg, and Leu1007insC) are asso‐
ciated with risk for developing stenotic disease and increased need for surgery [40-44].
However, this finding is not reproducible in every CD cohort evaluated [45, 46]. One large
meta-analysis of the NOD2/CARD15 literature indicated that carrying at least one NOD2/
CARD15 variant increased the risk of both small intestinal disease and of the stenosing phe‐
notype [47]. The discrepancy between studies may be due to differences in definitions of dis‐
ease behavior between studies and, perhaps, to the particular genetic epidemiological
analyses used. At present, understanding whether the relationship between the NOD2/
CARD15 variants and a stenosing phenotype is a true association or whether it instead re‐
flects aspects of disease duration and ileal localization remains a matter of controversy.
Other gene polymorphisms have been described as associated with a fibrostenotic pheno‐
type although the existing data is much less extensive than that available for NOD2/
CARD15. The ATG16L1 gene encodes for a protein involved in autophagy and mutations in
this gene have been associated with stricturing disease as well as perianal involvement in
CD [48]. CX3CR1, the receptor of CX3CL1 (fractalkine), is involved in regulation of inflam‐
matory response and the V249I polymorphism has been reported to be associated with in‐
testinal strictures [49]. A recent study linked the receptor for advanced glycation
endproducts (RAGE) -374T/A polymorphism to protection from stricturing phenotype in
CD. The polymorphism increases RAGE gene transcription which may provide protection
by increasing levels of soluble RAGE leading to neutralization of proinflammatory media‐
tors [50]. Some fibrostenosis-related polymorphisms have been observed in combination
with NOD2/CARD15. CXCL16 is a chemokine involved in bacterial defense mechanisms.
CD patients with at least one CXCL16 p.Ala181Val allele and one CARD15/NOD2 variant
had a higher incidence of stricturing and penetrating phenotype as well as stenosis as pa‐
tients with the NOD2 variant alone [51].
Despite their potential, genetic markers may never fully be able to predict the clinical course
of CD. The low frequency, incomplete penetrance, and interplay with other genetic poly‐
morphisms greatly complicate interpretation of genetic markers. In addition, environmental
factors can modulate disease history and impact phenotypic features. It is probable that ge‐
netic markers will need to be integrated with other clinical and serologic information in or‐
der to be useful predictors of disease course and to inform treatment decisions.
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4. Serologic biomarkers
Serologic markers may identify CD patients at higher risk of developing disease-related
complications. Some of the best characterized serologic markers associated with CD are di‐
rected against microbial peptides. Most of the available data is from cross sectional studies
in which the patient samples analyzed have been collected at various times in the disease
course allowing for comparison of serum from before, concomitant with, and after diagnosis
or treatment of bowel stricture.
Disease progression from non-complicated CD to stricturing and/or penetrating phenotypes
has been significantly associated with the presence and magnitude of serologic response to
microbial antigens. This concept was initially triggered by the observation that high anti-
Saccharomyces cerevisiae antibody (ASCA) levels were found to be associated with fibroste‐
nosing and penetrating disease and with the need for surgery [52]. This observation was
repeated in another cross sectional study where ASCA positive patients were more likely to
undergo surgery within 3 years of diagnosis than ASCA negative patients [53]. Time to first
complication was shown to be shorter in ASCA positive pediatric CD patients than in ASCA
negative patients [54]. In addition, anti-I2 (an antibody directed against Pseudomonas fluores‐
cens), anti-OmpC (the outer membrane porin protein of Escherichia coli) and anti-CBir1 (an‐
ti-flagellin) levels have also been shown to associated with fibrostenotic disease [55-60]. A
multi-center study evaluated the association of ASCA, anti-I2, anti-OmpC, and anti-CBir1
reactivity with disease course in a large cohort of pediatric CD patients and found that the
frequency of fibrostenotic or penetrating disease increased in parallel with the number of
antigens recognized [61]. Combining anti-microbial antibody titers and evaluation of NOD2
variants or other gene polymorphisms may improve detection of patients at higher risk of
developing fibrostenotic disease [62].
The predictive value of other serologic markers for fibrostenotic disease has been evaluated
on a much more limited basis than the anti-microbial antibodies. C-reactive protein (CRP) is
widely used to monitor inflammatory disease activity and one prospective study found a
significant association between CRP levels and subsequent risk of intestinal resection in pa‐
tients with ileal disease [63]. Despite the prominent place of extracellular matrix proteins in
composition of fibrostenotic lesions, little association has been found with levels of these
molecules in the circulation [64]. However, one study did find that higher levels of plasma
fibronectin were associated with stricture formation in CD patients [65]. Growth factors
have also been evaluated in a limited fashion. Serum levels of YKL-40, a mammalian glyco‐
protein member of the chitinase family, has been reported as increased in CD patients with
stricturing disease compared to those without strictures [66]. Another study found serum
levels of basic fibroblast growth factor, a cytokine promoting fibroblast activation and prolif‐
eration, were higher in CD patients with intestinal strictures compared to patients with fis‐
tulizing or inflammatory phenotypes [67]. Prospective studies will be required to determine
which, if any, of these serologic tests may have potential as a clinically useful biomarker of
fibrostenotic disease.
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not necessarily identify which patients with small bowel disease are at greatest risk of devel‐
oping fibrostenosing disease.
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tence of a genetic background which predisposes to stricturing behavior in CD.
One of the genes linked with susceptibility to CD is the CARD15/NOD2 gene which encodes
a protein involved in bacterial recognition and activation of nuclear factor kB. Carriers of
two mutant alleles have 17 to 42 times the risk while carriers of one mutation have 1.5 to 3
times the risk of developing CD [38, 39]. There is a significant body of evidence suggesting
that the main NOD2/CARD15 variants (Arg702Trp, Gly908Arg, and Leu1007insC) are asso‐
ciated with risk for developing stenotic disease and increased need for surgery [40-44].
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ease behavior between studies and, perhaps, to the particular genetic epidemiological
analyses used. At present, understanding whether the relationship between the NOD2/
CARD15 variants and a stenosing phenotype is a true association or whether it instead re‐
flects aspects of disease duration and ileal localization remains a matter of controversy.
Other gene polymorphisms have been described as associated with a fibrostenotic pheno‐
type although the existing data is much less extensive than that available for NOD2/
CARD15. The ATG16L1 gene encodes for a protein involved in autophagy and mutations in
this gene have been associated with stricturing disease as well as perianal involvement in
CD [48]. CX3CR1, the receptor of CX3CL1 (fractalkine), is involved in regulation of inflam‐
matory response and the V249I polymorphism has been reported to be associated with in‐
testinal strictures [49]. A recent study linked the receptor for advanced glycation
endproducts (RAGE) -374T/A polymorphism to protection from stricturing phenotype in
CD. The polymorphism increases RAGE gene transcription which may provide protection
by increasing levels of soluble RAGE leading to neutralization of proinflammatory media‐
tors [50]. Some fibrostenosis-related polymorphisms have been observed in combination
with NOD2/CARD15. CXCL16 is a chemokine involved in bacterial defense mechanisms.
CD patients with at least one CXCL16 p.Ala181Val allele and one CARD15/NOD2 variant
had a higher incidence of stricturing and penetrating phenotype as well as stenosis as pa‐
tients with the NOD2 variant alone [51].
Despite their potential, genetic markers may never fully be able to predict the clinical course
of CD. The low frequency, incomplete penetrance, and interplay with other genetic poly‐
morphisms greatly complicate interpretation of genetic markers. In addition, environmental
factors can modulate disease history and impact phenotypic features. It is probable that ge‐
netic markers will need to be integrated with other clinical and serologic information in or‐
der to be useful predictors of disease course and to inform treatment decisions.
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4. Serologic biomarkers
Serologic markers may identify CD patients at higher risk of developing disease-related
complications. Some of the best characterized serologic markers associated with CD are di‐
rected against microbial peptides. Most of the available data is from cross sectional studies
in which the patient samples analyzed have been collected at various times in the disease
course allowing for comparison of serum from before, concomitant with, and after diagnosis
or treatment of bowel stricture.
Disease progression from non-complicated CD to stricturing and/or penetrating phenotypes
has been significantly associated with the presence and magnitude of serologic response to
microbial antigens. This concept was initially triggered by the observation that high anti-
Saccharomyces cerevisiae antibody (ASCA) levels were found to be associated with fibroste‐
nosing and penetrating disease and with the need for surgery [52]. This observation was
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complication was shown to be shorter in ASCA positive pediatric CD patients than in ASCA
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multi-center study evaluated the association of ASCA, anti-I2, anti-OmpC, and anti-CBir1
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have also been evaluated in a limited fashion. Serum levels of YKL-40, a mammalian glyco‐
protein member of the chitinase family, has been reported as increased in CD patients with
stricturing disease compared to those without strictures [66]. Another study found serum
levels of basic fibroblast growth factor, a cytokine promoting fibroblast activation and prolif‐
eration, were higher in CD patients with intestinal strictures compared to patients with fis‐
tulizing or inflammatory phenotypes [67]. Prospective studies will be required to determine
which, if any, of these serologic tests may have potential as a clinically useful biomarker of
fibrostenotic disease.




Stricture due to fibrostenotic change resulting in chronic obstruction is a major pathologic
event in chronic CD. Histologically, CD strictures are characterized by hyperplasia of the in‐
testinal muscle layers which is typically manifest as islands of smooth muscle cells in the
submucosa surrounded by dense collagen deposits. These regions of smooth muscle prolif‐
eration may become so extensive that they obliterate the submucosa [68]. Transmission elec‐
tron microscopy studies show alteration of muscle cells of the muscularis propria, especially
the inner muscle layer, including hypertrophy, synthesis and deposition of collagen, and fo‐
cal cellular necrosis [69].
Despite the general categorization of strictures as inflammatory, fibrostenotic or both, fibro‐
sis is often well correlated with inflammation and the majority of strictures contain some de‐
gree of both processes [70]. When histologic tissue inflammation and fibrosis were
compared in a relatively small cohort of patients undergoing surgical resection, the authors
found that all specimens which were significantly fibrotic were also significantly inflamed
[71]. This may accurately reflect the reality of stricturing disease in many patients, however,
this has not yet been confirmed in studies of larger patient cohorts and the results may be
skewed because histologic evaluation is only possible in patients undergoing surgical resec‐
tion. This excludes stricture patients who either respond to aggressive medical therapy or
who undergo bowel-sparing procedures which may inadvertently exclude many patients
who fall on either end of the inflammation/fibrosis spectrum.
Further  consideration  of  the  relationship  between  histologic  categorization  and  disease
behavior is needed and new histologic scoring systems may be required which consider
cellular  composition  or  other  features  in  order  to  more  effectively  categorize  strictures.
One retrospective study has been published where biopsies were evaluated to determine
if  certain  histologic  characteristics  correspond  to  eventual  development  of  complicated
CD [72]. The authors report that severe lymphoid infiltration of the lamina propria with
crypt atrophy and absence of intraepithelial lymphocytes correlates with non-stricturing/
non-penetrating  disease  while  these  features  were  absent  in  80%  of  CD  patients  with
stricturing  disease.  Once  again,  these  findings  were  based  on  a  small  cohort  size  and
need further evaluation but do accord with the larger concept of inflammatory vs. fibros‐
tenotic stricture processes.
Other studies comparing histologic features with biologic behavior are limited. At least two
studies have noted an association of mast cells in the submucosa and especially in the mus‐
cularis propria with stricture formation in CD patients [73, 74]. When compared to normal
bowel or non-strictured CD bowel, mast cell numbers were significantly higher in the thick‐
ened muscularis propria of CD strictures. No increase in mast cells was associated with ul‐
cerative colitis or other intestinal inflammatory conditions. Also, epitheliold granulomas
have been implicated as a risk factor for progression to complicated disease behavior. Epi‐
theliod granulomas are one of the most characteristic histologic features in biopsies or re‐
sected tissue from patients with CD although only about 15-25% of patients present with
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this lesion. Several studies have shown an association between the occurrence of epitheliod
granulomas, especially at presentation, and a more aggressive disease course [75].
6. Pathophysiology of fibrosis
Tissue injury or inflammation triggers a cascade of wound healing activities in the sur‐
rounding cell populations. Normal wound healing is a tightly regulated and coordinated
series of events triggered by secretion of mediators from activated immune and mesenchy‐
mal cells which induce cell proliferation, migration, and extracelluar matrix (ECM) produc‐
tion. Wound healing activity is followed by resolution of inflammation and tissue
remodeling. A balance must be achieved between processes involved in ECM production
and degradation and those involved in cellular hyperplasia (proliferation and cell death). In
the intestinal tract, tissue repair and regeneration are of great importance in mucosal ho‐
meostasis and intestinal barrier function. Rapid wound healing and restitution of an intact
mucosal barrier is crucial for controlling mucosal inflammation. However, excessive wound
healing response can result in fibrosis and stricture formation while insufficient tissue repair
can result in fistula formation.
The classic model of wound healing has 4 phases: hemostasis, inflammation, proliferation,
and remodeling [76, 77]. In the hemostasis phase, platelet degranulation and fibrin forma‐
tion provide both hemostasis and a provisional matrix for subsequent healing events to take
place. Cytokine and chemokine expression, initially by the innate immune system and later
including the adaptive immune system, drives the inflammatory phase. During the prolifer‐
ative phase, activated fibroblasts and myofibroblasts secrete collagen and other matrix mole‐
cules which provide a granulation tissue scaffold on which tissue structure repair can
commence. During the proliferative phase, cytokines and growth factors regulate reconstitu‐
tion of the mucosal epithelium allowing closing of the epithelial defect. Angiogenesis and
lymphangiogenesis also take place during this phase and there is expansion of the fibro‐
blast/myofibroblast population with concomitant ECM production. Finally, in the remodel‐
ing phase, myofibroblasts produce matrix-modifying molecules which assist in the restoring
anatomic structural integrity and completing the transition from wound to normal or near
normal intestine architecture.
When severe mucosal tissue damage occurs, myofibroblasts migrate to the edges of the tis‐
sue defect. The ability of myofibroblasts to migrate to the wound area and synthesize ECM
proteins is critical in proliferative phase of intestinal wound healing [78]. Migration of sube‐
pithelial myofibroblasts can be mediated by a variety of soluble factors such as transforming
growth factor –β (TGFβ), insulin-like growth factor (IGF-1), platelet-derived growth factor-
AB (PDGF-AB), and epidermal growth factor (EGF) [79]. Fibronectin, synthesized by myofi‐
broblasts, is essential and is largely responsible for autocrine induction of intestinal
myfibroblast migration [80].
Wound healing and myofibroblast migration can be affected by chronic inflammation [79].
Subepithelial myofibroblasts isolated from CD patients show a significant reduction in mi‐
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gration response when compared to cells from control patients [81]. Similar reduction in fi‐
broblast migration can be induced by treatment with tumor necrosis factor (TNF) or gamma
interferon (IFN-g) suggesting that an inflammatory environment can induce changes in my‐
ofibroblast function [82]. However, environmental impact on fibroblast migration is com‐
plex. For example, fibroblasts from lung tissue with dense fibrosis show higher PDGF-
driven migratory potential than do fibroblasts from tissues at an early stage of fibrosis [83].
A recent paper compared migratory potential in colonic fibroblasts isolated from CD pa‐
tients with either fistulizing (penetrating) or fibrotic (stricturing) disease [81]. These authors
showed that, while migratory potential is reduced in CD patients with fistulizing disease,
there is in an increase in fibroblast migratory potential in patients with fibrotic disease.
Fibrosis in CD is thought to result from an excessive wound healing response. For reasons
that are not wholly understood, the wound repair process in a subset of CD patients contin‐
ues to progress rather than reaching a termination and allowing for tissue remodeling. Ulti‐
mately, the fibrotic process leads to thickening of the intestinal wall and luminal narrowing
which can result in bowel obstruction. There are three hallmark pathological features which
characterize intestinal stricutres in CD: proliferation of mesenchymal cells including myofi‐
broblasts, smooth muscle cells and fibroblasts; hypertrophy of smooth muscle cells and my‐
ofibroblasts ; and accumulation of excess extracellular matrix proteins [84].
Mesenchymal cells in the intestine can be broadly classed as fibroblasts, smooth muscle cells
or myofibroblasts on the basis of immunostaining properties with antibodies to vimentin (V)
and smooth muscle actin (A) [85, 86]. Fibroblasts are typically V+/A- and are present in the
intestinal submucosal and serosa. Subepithelial myofibroblasts (SEMF) are found adjacent to
intestinal epithelial cells and are V+/A+. Intestinal smooth muscle cells of the muscularis
mucosa and muscularis propria are normally V-/A+. All of these mesenchymal cell types
have been implicated in collagen production in CD patients [69, 87, 88].
Activated fibroblasts or myofibroblasts in tissues undergoing a fibrotic process may be de‐
rived from a variety of sources. There are three general mechanisms which allow for tissue
accumulation of these cells: proliferation of existing tissue fibroblasts, recruitment of fibro‐
blast precursor cells from bone marrow, and transformation either of epithelial cells via epi‐
thelial to mesenchymal transistion (EMT), or of endothelial cells by endothelial to
mesenchymal transition (EndoMT) [89, 90]. Proliferation and activation of tissue fibroblasts
occurs in response to profibrotic signals from infiltrating inflammatory cells or from colonic
epithelial cells exposed to proinflammatory cytokines [91]. Soluble inflammatory mediators
also drive recruitment of fibroblast precursor cells (fibrocytes) from bone marrow. These fi‐
brocytes migrate from the bloodstream into tissues undergoing pathologic fibrosis in re‐
sponse to specific chemokine gradients [89]. EMT and EndoMT are induced by TGFβ [92].
The relative significance of each of mechanisms discussed above to activated fibroblast/
myofibroblast accumulation at the site of injury in CD is not yet fully understood
Smooth muscle hyperplasia surrounded by collagen deposits is the major histologic feature
of fibrostenotic CD. This smooth muscle proliferation expands and disrupts the muscularis
mucosa. Thickening of the muscular layer is associated with an increase in the number of
vimentin-positive cells [93, 94]. In severely affected tissue, even histologically normal mus‐
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cularis mucosa is populated largely by V+/A- and V+/A+ cells rather than the V-/A+ smooth
muscle cells seen in normal muscularis mucosa from non-CD patients. This suggests a tran‐
sition from an enteric smooth muscle cell phenotype toward a fibroblast or myofibroblast
phenotype.
Mesenchymal cells including myofibroblasts as well as smooth muscle cells of the muscula‐
ris mucosa and muscularis propria are the main producers of ECM proteins in the intestine.
These ECM proteins include structural proteins such as collagen, matricellular proteins such
as osteopontin and thrombospondin, and other specialized proteins such as vitronectin and
fibronectin. Collagen is the major ECM component associated with intestinal fibrosis. The
most common collagen subtypes in normal intestine are type I, type III, and type V in order
of abundance. In intestinal fibrosis, there is an increase in total collagen as well as specific
and relative increases in collagen types III and V [95-97].
Fibronectin and vitronectin are ligands for the αVβ3 integrin and, in the presence of fibro‐
nectin, smooth muscle IGF-1-stimulated IGF-1 receptor activation is augmented [98]. This
suggests that increased production of these proteins by smooth muscle cells at sites of intes‐
tinal stricture could activate αVβ3 integrin and further increase secretion of collagen as well
as promote cellular proliferation creating a positive feedback loop which could further sub‐
vert the normal healing process. Fibronectin is also an important mediator in focal adhesion
kinase (FAK) signaling pathways involved in cell migration [99]. Myofibroblasts synthesize
abundant fibronectin which is largely responsible for the autocrine induction of intestinal
myofibroblast migration [100].
The balance between formation and breakdown of ECM proteins determines the net dep‐
osition  in  tissues.  In  intestinal  fibrosis,  mechanisms  to  degrade  ECM  fail  to  keep  pace
with  deposition.  Matrix  metalloproteinases  (MMPs),  a  large  family  of  proteolytic  en‐
zymes,  are  responsible  for  the  breakdown of  ECM components.  The proteolytic  activity
of  MMPs is  controlled by tissue inhibitors  of  metalloproteinases  (TIMPs)  and an imbal‐
ance  between  MMP and  TIMP activity  can  result  in  excessive  deposition  of  ECM pro‐
teins with subsequent fibrosis [101]. Higher levels of constitutive TIMP-1 expression have
been  shown  in  intestinal  myofibroblast  culture  derived  from  fibrotic  CD  patients  than
those from normal individuals [102].
Transforming growth factor –β (TGFβ) is a pleotrophic cytokine and one of the most influ‐
ential factors in fibrotic processes. It is a component of Th17 as well as regulatory T cell type
immune responses as well as a profibrotic mediator. TGFβ exerts profibrotic effects through
its ability to regulate collagen expression and extracellular matrix dynamics. There are three
isoforms of TGFβ: TGFβ1, TGFβ2, and TGFβ3. TGFβ1 activates the canonical Smad signal‐
ing cascade leading to translocation of the Smad receptor complex into the nucleus and reg‐
ulation of gene transcription including ECM genes such as collagen I, collagen III, and
fibronectin [103]. TGFβ also induces EMT in organ-fibrosis inducing diseases [104] and can
to induce EndoMT in vitro via a “noncanonical” signaling pathway [105]. In CD patients,
TGFβ1 and TGFβ3 are increased in in smooth muscle, fibroblasts and myofibroblasts from
the strictured region when compared to normal intestine [102, 106].
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TGFβ family proteins are important in regulating the synthesis and breakdown of ECM pro‐
teins [107]. TGFβ1 downregulates MMP expression and enhances the expression of TIMP-1
[101]. Characterization of the role of TGFβ expression in disease has been done using myofi‐
broblast cultures. Myofibroblasts from normal intestine predominantly express TGFβ3 while
those patients with fibrotic CD had significantly lower expression of TGFβ3 and higher lev‐
els of TGFβ1 and TGFβ2 [102, 108].
Insulin-like growth factor has also been implicated in the pathogenesis of stricture forma‐
tion [109].  Intestinal smooth muscle cells  express IGF-1 which activates the IGF-1 recep‐
tor  thereby  regulating  smooth  muscle  cell  hyperplasia  by  simultaneously  stimulating
proliferation  and  inhibiting  apoptosis  [110,  111].  Studies  using  CD tissue  from patients
undergoing intestinal resection show increased expression of both IGF-1 as well as syner‐
gistic IGF binding protein 5 (IGFBP-5) in lesional tissue [112].  Localization studies show
IGF-1 is upregulated in smooth muscle cells in regions of stricture when compared to tis‐
sue from surgical margins.
7. Preclinical models
A major challenge facing scientists interested in developing treatments for CD-associated fi‐
brotic disease is the need for a robust animal model which develops morphologic features
and utilizes pathogenic processes similar to those characterized for the human disease. Pre‐
clinical models should provide a consistent environment for testing intervention strategies
and quantifying outcomes. At present, no animal model exists which reproduces the unique
histologic features associated with CD intestinal strictures. There are several models which
address some aspects of CD stricture pathogenesis and those are reviewed below.
Intestinal inflammation and fibrosis can be induced in rats by injection of peptidoglycan-
polysaccharide (PG-PS) into the intestinal wall or by repeated rounds of trinitrobenzene sul‐
fonic acid (TNBS) treatment [113, 114]. PG-PS injection causes acute inflammation which
peaks by 2 days followed by remission. Spontaneous reactivation of inflammation occurs in
genetically susceptible rat strains by 12-17 days and is characterized by progressive trans‐
mural granulomatous enterocolitis [115]. Multiple cycles of intrarectal injection of TNBS in
ethanol also induces a granulomatous transmural inflammatory response which becomes
dominated by chronic inflammation and fibrosis after cycle 4[113, 116]. This model features
transmural collagen deposition which is most prominent in the submucosa. Smooth muscle
proliferation and expansion into the submucosal space is not a feature of these models.
Given that no existing preclinical model completely mimics changes found in human CD fi‐
brostenosis, assessment of the value of models should be based on the presence of pathways
of interest as well as tractability in testing potential therapeutic entities. These rat models
show transmural inflammation associated with transmural fibrosis as well as overexpres‐
sion of TGFβ and/or IGF-1 in a manner consistent with human disease [116-119]. However,
given the availability of reagents and other research tools, mouse models of intestinal fibro‐
sis are more desirable to the research community.
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While many murine models of inflammatory colitis or enteritis exist, these models are gen‐
erally not suitable for study the pathogenesis of stricture formation or for testing interven‐
tion strategies because they generate very little intestinal fibrosis. Fibrotic models have been
challenging to develop given the inherent resistance of mice when compared to other spe‐
cies in development of fibrotic disease [94]. However, progress is being made in this area.
Ileocecal resection is a common surgical intervention in CD and is associated with high rates
of disease recurrence[120]. After surgery, recurrence of inflammation and/or fibrosis typical‐
ly occurs at the anastomosis and in the small intestine immediately upstream of the anasto‐
mosis. A model of ileocecal resection in IL-10 gene knockout mice has been described which
develops inflammation and fibrosis both at the anastomosis site and in other regions of the
small intestine [121]. This approach is attractive because it models a major clinical feature of
CD fibrostenotic disease and is highly relevant to future clinical trials where therapeutics
targeting CD fibrosis will likely be evaluated for prevention of postsurgical recurrence.
However, IL-10 null mice do not spontaneously develop small intestinal inflammation and
this surgical approach may need to be combined with one of the existing murine ileitis mod‐
els to achieve the most relevant preclinical model.
Chronic  TNBS treatment  has  been used to  induce colitis  in  mice as  well  as  rats.  In  the
mouse, TNBS with concomitant administration of ethanol as an epithelial barrier disrupt‐
er induces intestinal  ulceration and inflammation.  This model is  widely used to investi‐
gate acute inflammation in the gut. Chronic TNBS treatment has been tested in an effort
to develop a more robust intestinal fibrosis model in mouse [122].  This model has been
reported  to  have  some  common  features  with  CD  including  transmural  inflammation
and stricturing with proximal  dilation and fibrosis.  Affected animals  have increased ex‐
pression of MMP-1 and collagen type 1. Fibrosis in this model can be enhanced by treat‐
ment  with  indomethacin,  a  cyclooxygenase  (COX)  inhibitor  which  can  block  the  anti-
fibrotic effects of COX-2 [123].
Dextran sulfate sodium added to drinking water is frequently used to induce epithelial in‐
jury and acute colitis in mice. Fibrosis with associated increase in collagen, TGFβ, and ma‐
trix metalloproteinase expression has been described in C57BL6 mice following a single 5
day cycle of DSS exposure [124]. The authors were also able to show an increase in fibro‐
blasts (V+/A-) and myofibroblasts (V+/A+ ) cells in the mucosa and submucosa. While this
likely reflects a primary intestinal wound healing response rather than the chronic fibrotic
process suggested by the authors, it is worth considering if this could be a useful pathway
model which might allow rapid testing the effect of therapeutic candidates on specific ele‐
ments of the wound healing/fibrotic response. Other groups have investigated the effect of
multiple cycles of DSS exposure on fibrotic response in FVB-N and C57BL6 mice [125]. A
single cycle of DSS exposure in C57BL6 mice does result in ECM deposition followed by
mucosal repair and normalized mucosal architecture. Multiple cycles of DSS exposure did
not result in enhanced fibrosis in FVB-N mice, however, it did result in prolongation of a
fibrotic response in C57BL6 mice as measured by procollagen α1(I) promoter-GFP reporter
transgene reporter activity. Further characterization will be needed to determine the utility
of this model.
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Salmonella species are facultative intracellular gram negative bacteria which cause a range of
illnesses including, but not limited to, enterocolitis [126]. Salmonella enterica serovar Typhi‐
murium is an enteric bacterial pathogen which normally causes little intestinal pathology in
mice but instead mimics human typhoid. However, a model which utilizes oral streptomy‐
cin pretreatment has been developed which allows study of S. Typhimurium-induced cecal
inflammation [127]. This work has been extended by utilizing attenuated S. Typhimurium
strains or by infecting resistant mouse strains which carry a functional nramp1 gene to in‐
duce chronic infection which results in intestinal fibrosis characterized by transmural colla‐
gen deposition and accumulation of fibroblasts in the intestinal submucosa [128]. While
increase in collagen deposition is observed throughout the colon, the most intense lesions
are present in the cecum. The Salmonella model of intestinal fibrosis is unique in that it is
induced by bacterial colitis. It results in a relatively long term fibrotic process where fibrosis
can be observed in the cecal submucosa at least to day 40 post infection. Similar to human
CD, increased TGFβ and IGF-1 are associated with fibrosis in this model.
8. Prevention or treatment of CD fibrosis
While considerable progress has been made, the pathophysiology of fibrostenotic disease in
CD patients is incompletely understood. The drug development challenges this creates are
greatly compounded by the absence of a well defined and widely accepted preclinical ani‐
mal model of intestinal fibrosis. Recognition of the unmet need for medical interventions
which can effectively prevent or treat CD fibrostenotic disease drives ongoing research in
both areas. Despite the challenges, a number of potential therapeutic agents or pathways
have undergone preliminary testing. A few of these results are summarized below. The data
available for all of these agents is quite limited.
Prostaglandins (PGE1 and 2) are known to inhibit smooth muscle proliferation as well as fi‐
broblast proliferation induced by proinflammatory cytokines [129, 130]. Reduced PGE2 lev‐
els are associated with development of fibrosis in idiopathic pulmonary fibrosis (IPF) [131]
and indomethacin treatment, which inhibits PGE2, increases fibrosis in the chronic murine
TNBS model of colon fibrosis. However, mice deficient in prostaglandin endoperoxide syn‐
thase (Ptgs) 2, an enzyme involved in prostaglandin production, showed deficient wound
healing following full-thickness colonic biopsy so the effects of prostaglandins may be com‐
plex and, perhaps, dependent on the stage of wound healing [132]. Phosphatidyl choline, a
polyunsaturated fatty acid which is a precursor to PGE2, has been shown to decrease stric‐
ture formation in the rat TNBS intestinal fibrosis model [133]. These data suggest a role for
PGE2 in intestinal wound healing and fibrosis but the potential for a therapeutic role re‐
quires further investigation.
The steroid hormone retinoic acid (RA) is another potential agent for modification of fibrosis
in CD. RA has been shown to have effects on human fibroblast proliferation in cells isolated
from IPF lungs [134] and to protect against bleomycin-induced pulmonary fibrosis in mice
[135]. More recently, RA has been shown to reduce intestinal fibrosis in the chronic TNBS
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mouse model of intestinal fibrosis [123]. Much more research will be needed to determine if
RA has promise as a fibrosis modifying agent in CD.
Resveratrol (trans-3,5,4’-trihydroxystilbene) is a phytoalexin found in a variety of plant
products including berries, peanuts, grapes and red wine. It has been shown to reduce in‐
flammation in rat colitis [136]. Resveratrol has also been shown to reduce activation of NF-
kB in TNBS colitis [137]. A recent paper reports that resveratrol exposure results in
decreased collagen synthesis as well as apoptosis in rat intestinal smooth muscle cells [138].
While the data on resveratrol is quite preliminary, the data is of interest because it targets
smooth muscle rather than the fibroblasts or myofibroblasts.
Anti-inflammatory and anti-fibrotic effects of the cholesterol lowering 3-hydroxy-3-methyl‐
glutaryl-CoA reductase inhibitors (statins) have been reported. Statins may play an anti-fi‐
brotic role through inhibition of the activation and proliferation of fibroblasts and by
inducing apoptosis of activated fibroblasts [139]. Angiotensin type 1 receptor blockers [140]
and the angiotensin-converting enzyme inhibitor captopril [141] have also been proposed as
fibrosis inhibitors.
Fibrosis has traditionally been considered an irreversible process. Further testing of these
and other agents which have potential to block initiation or inhibit progression of fibrosis
may also reveal if medical treatment has the potential to reverse existing fibrotic lesions. Re‐
search to further characterize the underlying pathophysiologic processes involved in fibros‐
tenotic disease and to test potential therapeutic approaches remains important to the goal of
fully meeting CD therapeutic needs.
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1. Introduction
Radiologic techniques play an integral role in the diagnosis and management of patients
with inflammatory bowel disease (IBD). Imaging has long been utilized to evaluate seg‐
ments of the digestive tract that are inaccessible to conventional endoscopy. While endos‐
copy offers unparalleled visualization of the large bowel lumen and biopsy capabilities, the
small bowel remains essentially wholly inaccessible by conventional endoscopic techniques
[1]. Thus, one important role that imaging plays in the care of patients with IBD is the evalu‐
ation of the small bowel.
With the advancement of cross-sectional imaging techniques such as computed tomography
(CT) and magnetic resonance imaging (MRI), the role of imaging in IBD has greatly expanded
to include the mucosal, transmural, extraluminal, and extra-intestinal manifestations of these
diseases. Imaging now not only assists in making the diagnosis of IBD, including helping to
discriminate between ulcerative colitis and Crohn’s disease, but also is a critical component in
the determination of active versus indolent disease. Imaging assessment of IBD activity is in‐
creasingly being utilized by surgeons and gastroenterologists for treatment planning and as a
biomarker of treatment response/resistance. Urgent and emergent complications of IBD in‐
cluding abscesses, fistulae, perforations, obstructing strictures, and toxic megacolon are also
best detected by cross-sectional imaging techniques over endoscopic methods [2]. Imaging is
pivotal in the identification of extra-intestinal involvement of IBD, processes that both pro‐
vide important adjunctive data in the diagnosis of IBD as well as contribute significantly to the
morbidity and mortality of IBD. Techniques such as MRI that provide superior soft tissue con‐
trast  allow for both the improved visualization of the perianal disease manifestations of
Crohn’s disease such as fistulae and abscesses, as well as the precise anatomic localization for
treatment planning [3]. Moreover, as our understanding of the pathophysiologic underpin‐
nings of IBD continually expands, novel molecular imaging approaches have been applied to
© 2012 A. Sheth and S. Gee; licensee InTech. This is an open access article distributed under the terms of the
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copy offers unparalleled visualization of the large bowel lumen and biopsy capabilities, the
small bowel remains essentially wholly inaccessible by conventional endoscopic techniques
[1]. Thus, one important role that imaging plays in the care of patients with IBD is the evalu‐
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cluding abscesses, fistulae, perforations, obstructing strictures, and toxic megacolon are also
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pivotal in the identification of extra-intestinal involvement of IBD, processes that both pro‐
vide important adjunctive data in the diagnosis of IBD as well as contribute significantly to the
morbidity and mortality of IBD. Techniques such as MRI that provide superior soft tissue con‐
trast  allow for both the improved visualization of the perianal disease manifestations of
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highlight the specific intra-cellular perturbations occurring within the bowel and thus identify
areas of pathology with unparalleled resolution and specificity.
Multiple radiologic modalities, including fluoroscopy, CT, MRI, ultrasound, and nuclear
medicine/molecular imaging techniques, have been applied towards imaging IBD. In this
chapter, we will discuss technical considerations, appropriate indications, and key imaging
findings for the most common imaging modalities currently applied in the care of patients
with IBD. We will also discuss the risks attendant to the use of ionizing radiation, imaging
findings of the extra-intestinal manifestations of IBD, and the potential role that molecular
imaging may play in the future for patients with IBD.
2. Fluoroscopic imaging
2.1. Indications
Fluoroscopic imaging historically has been considered as the “gold standard” approach to
imaging the small bowel. Despite the promotion of newer endoscopic technologies such as
video capsule endoscopy and double balloon endoscopy, as well as the development of
cross-sectional methods such as CT and MR enterography, fluoroscopy remains a staple tool
for the identification of small bowel pathology, particularly pathology involving the termi‐
nal ileum. The benefits of fluoroscopic imaging include the ability to visualize peristaltic
loops of small bowel in real time, a feature that allows for the discrimination between true
abnormalities and transient changes in configuration related to motion. Additionally, with
optimal contrast opacification, inspection of the mucosal surface of the entire length of the
small bowel in relief is feasible. The examination may be performed as either a small bowel
follow through, in which oral contrast is administered, or as a small bowel enteroclysis, in
which the patient undergoes nasojejunal intubation followed by catheter instillation of both
positive and negative contrast agents at a controlled rate. Advantages of the latter include
more uniform distention and opacification of the entire small bowel leading to enhanced de‐
tection of segmental strictures and mucosal disease from double contrast opacification. En‐
teroclysis is particularly useful in patients with intermittent symptoms of IBD, as the
complete distention of the small bowel can provoke correlative imaging findings which may
otherwise go undetected with a standard oral contrast preparation in a small bowel follow
through. Significant disadvantages of enteroclysis are invasiveness and patient discomfort.
Though fluoroscopic examination of the small bowel is still widely used, trans- and extra‐
mural disease are poorly detected with this technique. Moreover, the exposure of patients to
ionizing radiation with this modality should be taken into consideration, particularly in pa‐
tients who are likely to undergo frequent imaging examinations.
2.2. Technical considerations
In fluoroscopic imaging, conventional two-dimensional radiographs are obtained with the
patient lying on an examination table. The patient is kept nil per os (NPO) for several hours
prior to the examination; a bowel cleansing regimen is rarely employed. Bowel visualization
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is achieved following the administration of radio-opaque contrast agents, a large class of sol‐
utions that generally contain varying concentrations of barium. The benefits of fluoroscopic
imaging include the ability to visualize peristaltic loops of small bowel in real time, a feature
that allows for the discrimination between true abnormalities and transient changes in con‐
figuration related to motion. Additionally, with optimal contrast opacification, inspection of
the mucosal surface along the entire length of the small bowel in relief is feasible. The pa‐
tient’s position can be adjusted by the fluoroscopist to any desirable obliquity with respect
to the X-ray source so that the outline of every loop of small bowel is visualized. The fluoro‐
scopist also employs compressive maneuvers using paddles, balloons, and gloves to spread
out the loops of bowel so that they are individually visible.
In a small bowel follow through, the patient is asked to drink approximately 500cc of a bari‐
um containing oral contrast solution. Serial spot radiographs are obtained until the bolus
has passed the terminal ileum into the cecum; this takes approximately 45-60 minutes,
though pro-peristaltic agents such as metoclopramide may be administered to accelerate the
process. Fluoroscopy with compression is then performed to identify areas of pathology.
In enteroclysis, a naso-jejunal catheter is placed such that the tip of the catheter terminates in
the proximal jejunum, distal to the ligament of Treitz. A barium-containing solution is then
infused at a uniform rate through the catheter. One variation is to infuse methylcellulose af‐
ter a small amount of barium; this “double contrast” technique offers an improved inspec‐
tion of the mucosal surface pattern [4]. Advantages of naso-jejunal intubation include
bypassing the regulatory mechanisms of the pylorus and a more uniform distention and
opacification of the entire small bowel, particularly in patients who are unable to drink an
adequate volume of contrast by their own volition. Enteroclysis is particularly effective in
provoking radiographic evidence of low-grade partial obstructions in patients with intermit‐
tent symptoms, findings that may have been undetectable by small bowel follow through.
The process of naso-jejunal intubation and infusion of contrast, however, can be very un‐
comfortable, and in some cases intolerable, for patients; some institutions provide conscious
sedation for that reason.
2.3. Interpretation of imaging findings
Much of the fluoroscopic imaging of UC, which predominantly involves the large bowel,
has been replaced by colonoscopy. However, approximately 20% of patients with severe UC
have associated “backwash” ileitis. Fluoroscopy demonstrates a patulous, incompetent ileo‐
cecal valve with a granulated mucosal relief pattern of the terminal ileum. This finding is in
contrast to Crohn’s disease, which is characterized by a stenotic ileocecal valve with luminal
narrowing and ulceration of the terminal ileum. Backwash ileitis usually resolves following
total colectomy [5].
Crohn’s disease can affect the digestive tract anywhere from the mouth to the anus; approxi‐
mately 80% of these patients have small bowel involvement (Figure 1). Unlike UC, “skip
areas” of uninvolved bowel may be interspersed between segments of affected bowel. How‐
ever, Crohn’s disease has a predilection for affecting the terminal ileum. The earliest radio‐
graphic sign of Crohn’s disease is aphthous ulcers, which appear as shallow collections of
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highlight the specific intra-cellular perturbations occurring within the bowel and thus identify
areas of pathology with unparalleled resolution and specificity.
Multiple radiologic modalities, including fluoroscopy, CT, MRI, ultrasound, and nuclear
medicine/molecular imaging techniques, have been applied towards imaging IBD. In this
chapter, we will discuss technical considerations, appropriate indications, and key imaging
findings for the most common imaging modalities currently applied in the care of patients
with IBD. We will also discuss the risks attendant to the use of ionizing radiation, imaging
findings of the extra-intestinal manifestations of IBD, and the potential role that molecular
imaging may play in the future for patients with IBD.
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through. Significant disadvantages of enteroclysis are invasiveness and patient discomfort.
Though fluoroscopic examination of the small bowel is still widely used, trans- and extra‐
mural disease are poorly detected with this technique. Moreover, the exposure of patients to
ionizing radiation with this modality should be taken into consideration, particularly in pa‐
tients who are likely to undergo frequent imaging examinations.
2.2. Technical considerations
In fluoroscopic imaging, conventional two-dimensional radiographs are obtained with the
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contrast with surrounding radiolucent haloes due to adjacent mucosal edema. Aphthous ul‐
cers are not specific to Crohn’s disease and may be seen in a number of diseases. However,
as Crohn’s disease progresses, the ulcers coalesce to form linear, curvilinear, or spiculated
areas of ulceration along the mesenteric border of the small bowel. There is resultant retrac‐
tion of the bowel wall, leading to pseudodiverticula and pseudosacculation of the anti-mes‐
enteric bowel wall. These active inflammatory changes can lead to intermittent small bowel
obstruction, which is best diagnosed by enteroclysis technique. Severe disease produces a
classic “cobblestone” appearance, with deep transverse and longitudinal ulcerations bor‐
dered by areas of edema creating a checkered mucosal relief pattern. Chronic Crohn’s dis‐
ease leads to circumferential bowel wall thickening and irreversible stricture formation.
Figure 1. Fluoroscopic imaging findings in Crohn’s disease. A, Aphthous ulcers, which appear as focal collections of
contrast with surrounding haloes of mucosal edema, are present in early Crohn’s disease (red arrow). B, Progressive
disease results in longitudinal ulcerations on the mesenteric bowel surface with pseudosacculation formation on the
anti-mesenteric surface. C, Severe disease can have a “cobblestone” mucosal relief pattern due to intersecting trans‐
verse and longitudinal ulcers.
Though fluoroscopic examination of the small bowel is still widely used, trans- and extra‐
mural disease are poorly detected with this technique. Moreover, the exposure of patients to
ionizing radiation with this modality should be taken into consideration, particularly in pa‐
tients who are likely to undergo frequent imaging examinations.
3. Computed tomographic imaging
3.1. Indications
Computed tomography remains the work-horse imaging modality for IBD and its complica‐
tions in the United States. As a high-resolution cross-sectional technique, CT can visualize
not only the bowel lumen, but also the bowel wall, visceral fat, intra-abdominal lymph no‐
des, and mesenteric vasculature supplying the bowel. Extraintestinal disease manifestations
such as nephrolithiasis, sacroiliitis, and primary sclerosing cholangitis can readily be evalu‐
ated. Computed tomography can additionally be performed rapidly, and CT scanners are
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present in most emergency rooms, rendering it an ideal choice in the urgent or emergent set‐
ting. As such, CT is an appropriate imaging examination for the diagnosis of IBD, the evalu‐
ation of response to intervention including post-surgical changes, and the detection of
urgent and emergent complications such as abscess formation and acute bowel obstruction.
However, since subtle mucosal ulcerations are not well visualized by CT, this modality
should not be used as a first line approach for the detection of suspected mild disease.
3.2. Technical considerations
The past two decades have witnessed a revolution in the technology of CT scanners. The in‐
troduction of the helical CT scanner has permitted the acquisition of volumetric data sets in
a continuous, uninterrupted manner. The source data are obtained with sub-millimeter slice
thickness, so that images may be be reconstructed from the source axial plane into standard
coronal or sagittal planes, or any other plane desired by the radiologist. Also, the advent of
multidetector row scanners, initially with 4-slice devices in 1998, followed by 8-, 16-, 64-,
and most recently 320-slice devices, has had a dramatic effect on reducing scanning time.
This, in turn, has shortened the requisite breath hold for the patient, making the examina‐
tion more comfortable and less often degraded by respiratory motion artifact [6].
There exist a variety of CT protocols for abdominal indications. With regards to IBD, a com‐
mon reason to pursue imaging is for the assessment of small bowel pathology. CT enterog‐
raphy is usually the imaging protocol of choice, which combines large volume enteral
contrast distention of small bowel with intravenous contrast administration. For this imag‐
ing examination, patients are kept NPO for several hours prior; similar to fluoroscopy, a
bowel cleansing regimen is not routinely required. Intravenous contrast is always used
when possible. Enteral contrast is an indispensible component of the technique. Initial CT
enterography relied on “positive” enteral contrast agents, usually barium containing solu‐
tions whose higher attenuation characteristics opacify the bowel lumen. However, differen‐
tiating the thin line of mucosal enhancement due to intravenous contrast from the opaque
enteral contrast in the bowel lumen can be challenging. Therefore, a more popular approach
is to use “neutral” enteral contrast agents that distend but do not opacify the bowel lumen.
In this manner, mucosal enhancement patterns are better seen, as are areas of non-distensi‐
bility such as strictures. Water is a commonly used neutral enteral agent, but since this has
the disadvantage of being absorbed by the body, commercially available preparations that
are isodense to water on CT imaging but are non-absorbable are also prevalent [7]. Essential‐
ly all current CT enterography protocols utilize neutral enteral contrast.
The volume of enteral contrast administered to the patient and the duration over which they
are asked to ingest contrast vary by institution. However, the overall goal is to maximize
uniform distention of the small bowel, which typically requires 1000-1500 mL of contrast.
Patients are first instructed to drink the enteral contrast, generally over approximately 45 to
60 minutes. They then lie down on the CT scanner; intravenous contrast is administered;
originally CT enterography studies were scanned at 55-60 seconds post-contrast (entero‐
graphic phase) coinciding with peak superior mesenteric artery enhancement. However,
The Imaging of Inflammatory Bowel Disease: Current Concepts and Future Directions
http://dx.doi.org/10.5772/53025
181
contrast with surrounding radiolucent haloes due to adjacent mucosal edema. Aphthous ul‐
cers are not specific to Crohn’s disease and may be seen in a number of diseases. However,
as Crohn’s disease progresses, the ulcers coalesce to form linear, curvilinear, or spiculated
areas of ulceration along the mesenteric border of the small bowel. There is resultant retrac‐
tion of the bowel wall, leading to pseudodiverticula and pseudosacculation of the anti-mes‐
enteric bowel wall. These active inflammatory changes can lead to intermittent small bowel
obstruction, which is best diagnosed by enteroclysis technique. Severe disease produces a
classic “cobblestone” appearance, with deep transverse and longitudinal ulcerations bor‐
dered by areas of edema creating a checkered mucosal relief pattern. Chronic Crohn’s dis‐
ease leads to circumferential bowel wall thickening and irreversible stricture formation.
Figure 1. Fluoroscopic imaging findings in Crohn’s disease. A, Aphthous ulcers, which appear as focal collections of
contrast with surrounding haloes of mucosal edema, are present in early Crohn’s disease (red arrow). B, Progressive
disease results in longitudinal ulcerations on the mesenteric bowel surface with pseudosacculation formation on the
anti-mesenteric surface. C, Severe disease can have a “cobblestone” mucosal relief pattern due to intersecting trans‐
verse and longitudinal ulcers.
Though fluoroscopic examination of the small bowel is still widely used, trans- and extra‐
mural disease are poorly detected with this technique. Moreover, the exposure of patients to
ionizing radiation with this modality should be taken into consideration, particularly in pa‐
tients who are likely to undergo frequent imaging examinations.
3. Computed tomographic imaging
3.1. Indications
Computed tomography remains the work-horse imaging modality for IBD and its complica‐
tions in the United States. As a high-resolution cross-sectional technique, CT can visualize
not only the bowel lumen, but also the bowel wall, visceral fat, intra-abdominal lymph no‐
des, and mesenteric vasculature supplying the bowel. Extraintestinal disease manifestations
such as nephrolithiasis, sacroiliitis, and primary sclerosing cholangitis can readily be evalu‐
ated. Computed tomography can additionally be performed rapidly, and CT scanners are
Inflammatory Bowel Disease180
present in most emergency rooms, rendering it an ideal choice in the urgent or emergent set‐
ting. As such, CT is an appropriate imaging examination for the diagnosis of IBD, the evalu‐
ation of response to intervention including post-surgical changes, and the detection of
urgent and emergent complications such as abscess formation and acute bowel obstruction.
However, since subtle mucosal ulcerations are not well visualized by CT, this modality
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This, in turn, has shortened the requisite breath hold for the patient, making the examina‐
tion more comfortable and less often degraded by respiratory motion artifact [6].
There exist a variety of CT protocols for abdominal indications. With regards to IBD, a com‐
mon reason to pursue imaging is for the assessment of small bowel pathology. CT enterog‐
raphy is usually the imaging protocol of choice, which combines large volume enteral
contrast distention of small bowel with intravenous contrast administration. For this imag‐
ing examination, patients are kept NPO for several hours prior; similar to fluoroscopy, a
bowel cleansing regimen is not routinely required. Intravenous contrast is always used
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Patients are first instructed to drink the enteral contrast, generally over approximately 45 to
60 minutes. They then lie down on the CT scanner; intravenous contrast is administered;
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many institutions now perform scanning during portal venous phase (~70 seconds) for opti‐
mal visceral organ evaluation.
The CT analog to fluoroscopic enteroclysis, known at CT enteroclysis, is also used as a meth‐
od to achieve optimal luminal filling. A naso-jejunal tube is required and is usually inserted
in a fluoroscopy suite. Contrast is administered under fluoroscopic guidance, after which
the patient is transported to the CT scanner. Unlike fluoroscopy, though, a real-time assess‐
ment of bowel distensibility cannot be made by CT, as the patients are usually only imaged
after the contrast has been fully administered. The disadvantage of patient discomfort
caused by naso-jejunal intubation is no different.
For patients suspected of bowel obstruction or perforation, oral contrast is frequently contra‐
indicated and traditional CT imaging with IV contrast only is recommended.
An important concern with CT is the use of ionizing radiation. Recent studies suggest that
CT exams account for the vast majority of ionizing radiation exposure to IBD patients from
imaging, especially among patients diagnosed at an early age. An informed analysis of the
associated risks, especially for the pediatric patient, should be performed prior to each ex‐
amination.
3.3. Interpretation of imaging findings – Crohn’s disease
A principal clinical question for which CT is utilized in IBD is the determination of active
versus inactive disease in the small bowel. This distinction is of high clinical significance: pa‐
tients with active inflammation are treated medically with immuno-modulatory therapy,
while symptomatic patients with inactive, fibrosed strictures often require surgical interven‐
tion. Areas of actively inflamed bowel on CT most commonly demonstrate pathologic bowel
thickening, which is defined as bowel wall greater than 3mm in thickness. A 3mm cutoff
was selected by consensus as the best compromise between sensitivity and specificity and is
for the most part used universally for all cross-sectional modalities including MRI and ultra‐
sound. Another differentiating characteristic of active disease is mucosal hyperenhance‐
ment, which appears as a pencil-thin line outlining the luminal surface of the bowel wall
and reflects the hyperemia of inflammation (Figure 2A). This finding is considered the most
sensitive for active disease, and the degree of hyperenhancement may correlate with the de‐
gree of underlying inflammation. Active inflammation also results in submucosal edema,
which manifests on CT examination as a lower attenuation submucosal layer interposed be‐
tween mucosal and serosal layers. This mural stratification is also referred to as the “target
sign” due to its characteristic appearance (Figure 2C). The most specific feature for active
Crohn’s disease is engorgement of the vasa recta adjacent to an inflamed loop of bowel, a
finding known as the “comb sign” (Figure 2B). Secondary signs for active inflammation in‐
clude mesenteric fat stranding, focal ascites adjacent to bowel, and lymphadenopathy. Of
note, while mucosal hyperenhancement and abnormal bowel thickening are frequent fea‐
tures of active Crohn’s disease, they are not specific and may be seen in infectious enteritis
or mesenteric ischemia. Similarly, mural stratification can be seen in UC as well as bowel
ischemia. On the other hand, the “comb sign” is considered fairly specific for Crohn’s dis‐
ease [2, 7].
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Figure 2. CT findings in acute Crohn’s disease. A, Active inflammation causes mucosal hyperenhancement and bowel
wall thickening greater than 3mm. B, Engorgement of the vasa recta adjacent to an inflamed loop of bowel is a specif‐
ic finding in active Crohn’s disease and has been coined the “comb sign.” C, Submucosal edema yields a characteristic
“target sign.”
The presence of mucosal hyperenhancement, abnormal bowel wall thickening, mural strati‐
fication, and prominent adjacent vasa recta in an area of poorly distensible bowel suggests
that the stricture is due to active inflammation and is thus potentially reversible by medical
interventions. The strictures of chronic Crohn’s disease, in contrast, are fibrotic, irreversible,
and do not demonstrate the features of active disease described above. The presence of lu‐
minal narrowing with proximal bowel dilation is suggestive of fibrosis. Long-standing in‐
flammation leads to fat deposition within the submucosa of the bowel wall; this apparent
mural stratification should not be confused with the “target sign” of active disease and can
be differentiated based on the Hounsfield attenuation characteristics of fat, which is less
than 0 Housfield units (Figure 3A). Secondly, the fibrotic retraction preferentially affects the
mesenteric bowel wall, leading to the pseudosacculation appearance on the anti-mesenteric
side that can also be seen by fluoroscopy. Finally, chronic transmural Crohn’s disease, possi‐
bly due to chronic inflammatory stimulation, produces a fibrofatty proliferation of the mes‐
enteric fat, also known on CT examinations as the “creeping fat sign” (Figure 3B).
The Imaging of Inflammatory Bowel Disease: Current Concepts and Future Directions
http://dx.doi.org/10.5772/53025
183
many institutions now perform scanning during portal venous phase (~70 seconds) for opti‐
mal visceral organ evaluation.
The CT analog to fluoroscopic enteroclysis, known at CT enteroclysis, is also used as a meth‐
od to achieve optimal luminal filling. A naso-jejunal tube is required and is usually inserted
in a fluoroscopy suite. Contrast is administered under fluoroscopic guidance, after which
the patient is transported to the CT scanner. Unlike fluoroscopy, though, a real-time assess‐
ment of bowel distensibility cannot be made by CT, as the patients are usually only imaged
after the contrast has been fully administered. The disadvantage of patient discomfort
caused by naso-jejunal intubation is no different.
For patients suspected of bowel obstruction or perforation, oral contrast is frequently contra‐
indicated and traditional CT imaging with IV contrast only is recommended.
An important concern with CT is the use of ionizing radiation. Recent studies suggest that
CT exams account for the vast majority of ionizing radiation exposure to IBD patients from
imaging, especially among patients diagnosed at an early age. An informed analysis of the
associated risks, especially for the pediatric patient, should be performed prior to each ex‐
amination.
3.3. Interpretation of imaging findings – Crohn’s disease
A principal clinical question for which CT is utilized in IBD is the determination of active
versus inactive disease in the small bowel. This distinction is of high clinical significance: pa‐
tients with active inflammation are treated medically with immuno-modulatory therapy,
while symptomatic patients with inactive, fibrosed strictures often require surgical interven‐
tion. Areas of actively inflamed bowel on CT most commonly demonstrate pathologic bowel
thickening, which is defined as bowel wall greater than 3mm in thickness. A 3mm cutoff
was selected by consensus as the best compromise between sensitivity and specificity and is
for the most part used universally for all cross-sectional modalities including MRI and ultra‐
sound. Another differentiating characteristic of active disease is mucosal hyperenhance‐
ment, which appears as a pencil-thin line outlining the luminal surface of the bowel wall
and reflects the hyperemia of inflammation (Figure 2A). This finding is considered the most
sensitive for active disease, and the degree of hyperenhancement may correlate with the de‐
gree of underlying inflammation. Active inflammation also results in submucosal edema,
which manifests on CT examination as a lower attenuation submucosal layer interposed be‐
tween mucosal and serosal layers. This mural stratification is also referred to as the “target
sign” due to its characteristic appearance (Figure 2C). The most specific feature for active
Crohn’s disease is engorgement of the vasa recta adjacent to an inflamed loop of bowel, a
finding known as the “comb sign” (Figure 2B). Secondary signs for active inflammation in‐
clude mesenteric fat stranding, focal ascites adjacent to bowel, and lymphadenopathy. Of
note, while mucosal hyperenhancement and abnormal bowel thickening are frequent fea‐
tures of active Crohn’s disease, they are not specific and may be seen in infectious enteritis
or mesenteric ischemia. Similarly, mural stratification can be seen in UC as well as bowel
ischemia. On the other hand, the “comb sign” is considered fairly specific for Crohn’s dis‐
ease [2, 7].
Inflammatory Bowel Disease182
Figure 2. CT findings in acute Crohn’s disease. A, Active inflammation causes mucosal hyperenhancement and bowel
wall thickening greater than 3mm. B, Engorgement of the vasa recta adjacent to an inflamed loop of bowel is a specif‐
ic finding in active Crohn’s disease and has been coined the “comb sign.” C, Submucosal edema yields a characteristic
“target sign.”
The presence of mucosal hyperenhancement, abnormal bowel wall thickening, mural strati‐
fication, and prominent adjacent vasa recta in an area of poorly distensible bowel suggests
that the stricture is due to active inflammation and is thus potentially reversible by medical
interventions. The strictures of chronic Crohn’s disease, in contrast, are fibrotic, irreversible,
and do not demonstrate the features of active disease described above. The presence of lu‐
minal narrowing with proximal bowel dilation is suggestive of fibrosis. Long-standing in‐
flammation leads to fat deposition within the submucosa of the bowel wall; this apparent
mural stratification should not be confused with the “target sign” of active disease and can
be differentiated based on the Hounsfield attenuation characteristics of fat, which is less
than 0 Housfield units (Figure 3A). Secondly, the fibrotic retraction preferentially affects the
mesenteric bowel wall, leading to the pseudosacculation appearance on the anti-mesenteric
side that can also be seen by fluoroscopy. Finally, chronic transmural Crohn’s disease, possi‐
bly due to chronic inflammatory stimulation, produces a fibrofatty proliferation of the mes‐
enteric fat, also known on CT examinations as the “creeping fat sign” (Figure 3B).
The Imaging of Inflammatory Bowel Disease: Current Concepts and Future Directions
http://dx.doi.org/10.5772/53025
183
Figure 3. CT findings in chronic Crohn’s disease. A, Fatty depositions in the submucosal layer may mimic the “target
sign” of active disease (red arrow). B, Fibrofatty proliferation of the mesenteric fat, or “creeping fat,” (red arrow) is
seen in chronic, transmural disease.
The extra-mural complications of Crohn’s disease are excellently depicted by CT. Penetrat‐
ing disease is present in approximately 20% with Crohn’s disease, with fistulas representing
the most common pathology in this category [3]. Fistulous tracts may form between any two
epithelially lined viscera in the abdomen, such as other loops of bowel (entero-enteric), the
bladder (entero-vesicular), and the skin (entero-cutaneous). A communicating tract that fills
with enteral contrast is diagnostic (Figure 4A). Evaluation with CT is highly sensitive for the
detection of fistulae, though certain anatomic locations such as the perianal region are better
imaged by MRI, as discussed below.
Figure 4. Complications of Crohn’s disease on CT. A, A fistula between two loops of small bowel is well depicted by CT
as a thin tract of oral contrast connecting the lumens of the two loops. B, An intra-abdominal abscess posterior to the
distal large bowel, likely due to a microperforation, was identified in this patient.
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Intra-abdominal abscesses are extra-luminal fluid collections that do not communicate with
the bowel (Figure 4B). The discontinuity of the abscess collection with the bowel lumen is
important to verify but can occasionally be challenging, as neural enteral contrast within the
bowel mimics the attenuation characteristics of the infected fluid within the abscess cavity.
For this reason, positive enteral contrast is often preferred to neutral contrast in patients
with suspected abscess.
3.4. Interpretation of imaging findings – Ulcerative colitis
As discussed previously, colonoscopy remains the primary approach for diagnosing and de‐
termining extent of disease in UC. However, severe complications of UC such as toxic mega‐
colon are an important indication for imaging, with CT representing the mainstay modality
in these unstable patients. CT findings include thinning of the colonic wall, luminal disten‐
sion, and pneumatosis; severe cases can lead to perforation and free intraperitoneal gas.
4. Magnetic resonance imaging
4.1. Indications
Magnetic resonance imaging enjoys many inherent advantages over other cross-sectional
imaging modalities. These include the ability to acquire images in any imaging plane, the
lack of ionizing radiation, and excellent soft tissue resolution. Because of the lack of ionizing
radiation, imaging may be performed at multiple time points during an examination, for ex‐
ample at different phases of contrast enhancement, providing a multiparametric assessment
of any particular pathology. Additionally, “cine” images can be obtained sequentially over
time, in an MRI analog to fluoroscopy.
The strengths of MRI when applied towards IBD are best suited for investigating the small
bowel and the perianal region, anatomic locations towards which Crohn’s disease demon‐
strates a tropism. Magnetic resonance imaging of the large bowel, an examination that
would have increased relevance in UC, is not routinely performed. The intrinsic spatial reso‐
lution of MRI is inferior to that of CT. An MRI examination also takes longer to complete
than a CT exam. However, the widespread adoption of new, faster MRI pulse sequences, de‐
scribed in the subsequent section, has significantly reduced scanning time and opened the
door for small bowel imaging. For specific clinical scenarios, such as perianal disease, MRI is
the recognized gold standard non-invasive technique.
4.2. Technical considerations
As with CT, multiple different MRI protocols exist for examining the abdomen. In the realm
of IBD, one very useful MR examination is magnetic resonance enterography (MRE). Al‐
though an in-depth discussion of the various pulse sequences used in abdominal MRI imag‐
ing is beyond the scope of this text, a familiarity with the commonly used sequences is
valuable in understanding the applicability of MRE. Sequences with T2 weighting are the
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Figure 3. CT findings in chronic Crohn’s disease. A, Fatty depositions in the submucosal layer may mimic the “target
sign” of active disease (red arrow). B, Fibrofatty proliferation of the mesenteric fat, or “creeping fat,” (red arrow) is
seen in chronic, transmural disease.
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imaged by MRI, as discussed below.
Figure 4. Complications of Crohn’s disease on CT. A, A fistula between two loops of small bowel is well depicted by CT
as a thin tract of oral contrast connecting the lumens of the two loops. B, An intra-abdominal abscess posterior to the
distal large bowel, likely due to a microperforation, was identified in this patient.
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Intra-abdominal abscesses are extra-luminal fluid collections that do not communicate with
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bowel mimics the attenuation characteristics of the infected fluid within the abscess cavity.
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with suspected abscess.
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ample at different phases of contrast enhancement, providing a multiparametric assessment
of any particular pathology. Additionally, “cine” images can be obtained sequentially over
time, in an MRI analog to fluoroscopy.
The strengths of MRI when applied towards IBD are best suited for investigating the small
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would have increased relevance in UC, is not routinely performed. The intrinsic spatial reso‐
lution of MRI is inferior to that of CT. An MRI examination also takes longer to complete
than a CT exam. However, the widespread adoption of new, faster MRI pulse sequences, de‐
scribed in the subsequent section, has significantly reduced scanning time and opened the
door for small bowel imaging. For specific clinical scenarios, such as perianal disease, MRI is
the recognized gold standard non-invasive technique.
4.2. Technical considerations
As with CT, multiple different MRI protocols exist for examining the abdomen. In the realm
of IBD, one very useful MR examination is magnetic resonance enterography (MRE). Al‐
though an in-depth discussion of the various pulse sequences used in abdominal MRI imag‐
ing is beyond the scope of this text, a familiarity with the commonly used sequences is
valuable in understanding the applicability of MRE. Sequences with T2 weighting are the
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best for evaluating the bowel wall. Intravenous contrast enhancement appears bright on T1
weighted sequences; however, as feces can occasionally be bright on T1 imaging too, pre-
contrast T1 image sets are obtained to help identify true enhancement. Conventional spin
echo pulse sequences do not afford the requisite temporal resolution to image the abdomen
during a single breath hold; as such, the resulting images are often degraded by respiratory
motion artifact. Beyond that, high temporal resolution is made all the more critical when in‐
vestigating a moving target as the bowel. For these reasons, MRE capitalizes on customized
MR pulse sequences that offer improved temporal resolution and are able to image the en‐
tire abdomen during a single breath hold. For example, single-shot turbo spin echo (e.g.
SSFSE or HASTE) sequences produce high quality, motion-free T2 weighted images of the
entire bowel [8]. Balanced steady state free precession sequences (e.g. FIESTA or TrueFISP)
are T1 and T2 intermediate-weighted sequences that that are rapid and demonstrate in‐
creased conspicuity of the mesentery for detection of inflammatory changes or fistula forma‐
tion [9]. These sequences, due to their rapidity, can be performed as thick slab cinematic
acquisitions to evaluate bowel peristalsis, known as MR fluoroscopy. Fat suppression is rou‐
tinely employed during both T2-weighted and T1-weighted post-contrast sequences, to
highlight areas of bowel wall edema and enhancement. The post-contrast T1 fat-suppressed
sequences are performed using 3-D techniques to accelerate image acquisition and enable
dynamic evaluation of bowel enhancement at multiple timepoints post-contrast. An average
imaging time for MRE, exclusive of the time required for enteral contrast administration, is
approximately 30-45 minutes.
Diffusion weighted imaging (DWI) is an MRI technique that has been used with tremendous
success in neurological imaging and has shown promise in gastrointestinal imaging. Diffu‐
sion imaging provides quantitative maps of the ability of water molecules in tissue to ran‐
domly move in a process known as Brownian motion. In areas of inflammation,
hypercellularity, or ischemia, the free movement of water molecules is restricted; this char‐
acteristic manifests as a low apparent diffusion coefficient (ADC) value when MRI sequen‐
ces sensitive to diffusion are obtained. Diffusion weighted imaging is at present an
experimental technique in IBD imaging (Figure 5), but initial reports have suggested that
this method may not only improve disease detection but also provide a quantitative metric
for assessing interval changes in bowel wall inflammation [10].
There is no specific bowel preparation prior to MRE, but patients generally are kept NPO for
several hours prior to the exam. Anti-peristaltic agents such as glucagon may help improve
image quality and are often administered just prior to imaging. Intravenous contrast with a
gadolinium-chelate containing agent is standardly administered. There are several options
in enteral contrast, which can be categorized by their MRI signal characteristics. “Negative”
agents are intrinsically T1 and T2 dark compounds that usually contain superparamagnetic
iron oxide particles. Their principal advantage is that they emphasize mucosal enhancement
and bowel wall edema. “Positive” agents are intrinsically T1 and T2 bright compounds;
these, similar to positive CT contrast agents, may obscure mucosal enhancement findings
and thus are infrequently used. The most commonly used class of MR enteral contrast
agents is the “biphasic” type, which are T1 dark and T2 bright (e.g. dilute barium with sorbi‐
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tol, polyethylene glycol). With these agents, one can readily assess the pattern of bowel wall
folds on T2 weighted images without losing mucosal enhancement data on T1 weighted im‐
ages [11]. Contrast agents are often hyperosmolar to maximize luminal distention; an impor‐
tant side effect for patients to be aware of is diarrhea. It is critically important that patients
ingest adequate enteric contrast for MR enterography. Unlike CT in which underdistended
bowel loops can still be evaluated, the relative diminished spatial resolution of MRI renders
collapsed bowel difficult to assess for disease. In addition, enteric contrast is needed to dis‐
place intraluminal air that can produce significant susceptibility artifact on dynamic post-
contrast MRI sequences.
Figure 5. Representative T2 (left) and diffusion weighted (right) images from an MR enterography of a child with
Crohn’s disease. Images demonstrate two colonic loops (red arrows) exhibiting bowel edema and restricted water dif‐
fusion, consistent with active inflammation.
Enteral contrast is primarily administered orally, though MR enteroclysis is also an option.
The attendant patient discomfort and added radiation from the fluoroscopy-guided place‐
ment of the naso-jejunal tube are identical to the CT analog. However, one benefit of MR
enteroclysis is the ability to perform MR fluoroscopy during the instillation of enteral con‐
trast, a technique that provides dynamic information regarding bowel distensibility.
Patients may be imaged in the supine or prone position; the latter orientation is preferred at
some institutions as the patient’s own weight is used to spread out loops of small bowel; the
compression in the anterior-posterior dimension also reduces imaging volume.
4.3. Interpretation of imaging findings – Crohn’s disease
Magnetic resonance imaging is an excellent tool for the detection of active Crohn’s disease,
with a sensitivity of > 90% [12]. Many of the imaging characteristics of active Crohn’s dis‐
ease on MRI, as one may expect, are morphologically identical to those appreciated on CT.
For example, bowel wall thickening greater than 3mm is considered abnormal and evidence
of active inflammation. Active disease with intramural edema manifests as T2 hyperintensi‐
ty between the mucosa and muscularis propria (Figure 6A) [13]. Mucosal hyperenhance‐
ment is also an important marker of active disease. Diffuse, avid, homogeneous mucosal
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sequences are performed using 3-D techniques to accelerate image acquisition and enable
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imaging time for MRE, exclusive of the time required for enteral contrast administration, is
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acteristic manifests as a low apparent diffusion coefficient (ADC) value when MRI sequen‐
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this method may not only improve disease detection but also provide a quantitative metric
for assessing interval changes in bowel wall inflammation [10].
There is no specific bowel preparation prior to MRE, but patients generally are kept NPO for
several hours prior to the exam. Anti-peristaltic agents such as glucagon may help improve
image quality and are often administered just prior to imaging. Intravenous contrast with a
gadolinium-chelate containing agent is standardly administered. There are several options
in enteral contrast, which can be categorized by their MRI signal characteristics. “Negative”
agents are intrinsically T1 and T2 dark compounds that usually contain superparamagnetic
iron oxide particles. Their principal advantage is that they emphasize mucosal enhancement
and bowel wall edema. “Positive” agents are intrinsically T1 and T2 bright compounds;
these, similar to positive CT contrast agents, may obscure mucosal enhancement findings
and thus are infrequently used. The most commonly used class of MR enteral contrast
agents is the “biphasic” type, which are T1 dark and T2 bright (e.g. dilute barium with sorbi‐
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tol, polyethylene glycol). With these agents, one can readily assess the pattern of bowel wall
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ages [11]. Contrast agents are often hyperosmolar to maximize luminal distention; an impor‐
tant side effect for patients to be aware of is diarrhea. It is critically important that patients
ingest adequate enteric contrast for MR enterography. Unlike CT in which underdistended
bowel loops can still be evaluated, the relative diminished spatial resolution of MRI renders
collapsed bowel difficult to assess for disease. In addition, enteric contrast is needed to dis‐
place intraluminal air that can produce significant susceptibility artifact on dynamic post-
contrast MRI sequences.
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Crohn’s disease. Images demonstrate two colonic loops (red arrows) exhibiting bowel edema and restricted water dif‐
fusion, consistent with active inflammation.
Enteral contrast is primarily administered orally, though MR enteroclysis is also an option.
The attendant patient discomfort and added radiation from the fluoroscopy-guided place‐
ment of the naso-jejunal tube are identical to the CT analog. However, one benefit of MR
enteroclysis is the ability to perform MR fluoroscopy during the instillation of enteral con‐
trast, a technique that provides dynamic information regarding bowel distensibility.
Patients may be imaged in the supine or prone position; the latter orientation is preferred at
some institutions as the patient’s own weight is used to spread out loops of small bowel; the
compression in the anterior-posterior dimension also reduces imaging volume.
4.3. Interpretation of imaging findings – Crohn’s disease
Magnetic resonance imaging is an excellent tool for the detection of active Crohn’s disease,
with a sensitivity of > 90% [12]. Many of the imaging characteristics of active Crohn’s dis‐
ease on MRI, as one may expect, are morphologically identical to those appreciated on CT.
For example, bowel wall thickening greater than 3mm is considered abnormal and evidence
of active inflammation. Active disease with intramural edema manifests as T2 hyperintensi‐
ty between the mucosa and muscularis propria (Figure 6A) [13]. Mucosal hyperenhance‐
ment is also an important marker of active disease. Diffuse, avid, homogeneous mucosal
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enhancement is suggestive of active disease (Figure 6B). Alternatively, low-level, heteroge‐
neous mural enhancement without a mucosal component with upstream dilatation favors
the diagnosis of mural fibrosis due to irreversible collagen deposition in the bowel wall (Fig‐
ure 6C). Ulceration may be difficult to identify without proper bowel distention; ulcers ap‐
pear as thin lines of high signal intensity within thickening loops of bowel. Both MRI and
CT are insensitive for early aphthous ulcers, for which fluoroscopy or endoscopy should be
considered as more sensitive.
Figure 6. Findings of Crohn’s disease by MR enterography. A) Submucosal edema appears as T2 hyperintensity inter‐
posed between the mucosa and muscularis propria (red arrow). B) Homogeneous, avid mucosal enhancement on T1-
weighted imaging is suggestive of active disease (red arrow). C) Conversely, fixed lumimal narrowing on a T2
weighted image (red arrow, C-1) that demonstrates delayed mural enhancement on a post contrast T1 weighted im‐
age (red arrow, C-2) without a mucosal component is seen in chronic fibrosis.
Additional evidence of active disease such as the “comb sign,” in which there is engorge‐
ment of the mesenteric vessels adjacent to an inflamed loop of bowel, are well identified by
MRI. Strictures appear as a focal narrowing in the bowel lumen and are considered signifi‐
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cant if there is a pre-stenotic dilation of the proximal bowel. The so-called “creeping fat
sign” occurs in chronic, transmural inflammation, in which hypertrophy of the mesenteric
fat produces mass effect and surrounds viscera; this sign is specific for Crohn’s disease. An‐
other sign of chronic fibrosis is T2 hypointensity of the bowel wall relative to muscle.
Figure 7. MRI findings of anorectal fistulae. A, T2 hyperintensity that extends between the external and internal
sphincter complexes is diagnostic of an intersphincteric fistula (red arrow). B, Two sequential T2 weighted images
demonstrate a linear hyperintense focus traversing through the internal and external sphincter complexes consist
with a transsphincteric fistula (red arrow, B-1). The subsequent image demonstrates an associated fluid collection ex‐
tending into the left ischioanal fossa (white arrow, B-2).
Extramural disease is as conspicuous, if not more so, on MRI as it is on CT. Fistulae appear
as T2 hyperintense tracts that avidly enhance and extend from bowel to a second epithelial
lined organ such as another segment of bowel, the skin, or the bladder. Sinuses are blind-
ending tracts that extend from bowel and typically terminate within the mesentery. Both fis‐
tulae and sinuses cause translocation of gut flora out of the bowel and can be associated
with abscess formation.
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In addition to evaluating the small bowel with enterography, MRI is a powerful tool in the
investigation of perianal Crohn’s disease because of its superior soft tissue contrast for de‐
lineation of the anal sphincter complex. The lifetime risk of developing fistulous disease in
Crohn’s disease is approximately 20-40%. Anorectal fistulae are common and are classified
based on their location relative to the anal sphincter complex and pelvic floor musculature,
as anatomic location impacts upon treatment options. The most common type of anorectal
fistula is the intersphincteric fistula (Figure 7A), followed by the transphincteric fistula (Fig‐
ure 7B). The accuracy of MRI for diagnosing and classifying anorectal fistulae is comparable
to exam under anesthesia [3].
5. Ultrasound
5.1. Indications
Ultrasound is a cross-sectional imaging technique that has been used extensively in the
imaging of IBD. As with other technologies, ultrasound has its own unique set of advantag‐
es, such as low relative cost, lack of ionizing radiation, and real-time imaging capability.
Disadvantages include the inability to visualize portions of small bowel, rectum, and sig‐
moid, difficulty tracing long bowel segments, as well as operator dependence, with the qual‐
ity of the examination contingent on the technical skill of the ultrasonographer. Ultrasound
has been shown to possibly be as accurate in the diagnosis of IBD as CT and MRI based on
detection of wall thickening and hypervascularity by Doppler. However, a high sensitivity
is likely achievable only in the hands of an expert ultrasonographer, a resource that is not
widely available or easy to standardize. Ultrasound is particularly relevant in pediatric
imaging: the smaller body habitus in this patient population allows for a more complete ex‐
amination, and the lack of ionizing radiation is likely safer compared to CT. The most com‐
mon indication for ultrasound is evaluation for active inflammation in a symptomatic IBD
patient whose anatomic distribution of bowel inflammation is known.
5.2. Technical considerations
Similar to the previously described modalities, minimal patient preparation is required in
ultrasound. Since luminal gas can cause acoustic shadowing artifacts that obscure underly‐
ing structures, non-effervescent liquid may be administered to displace bowel gas distally
and provide some luminal distension. The choice of ultrasound transducer is predicated by
the patient’s body size. Higher frequency transducers produce higher resolution images but
have poorer tissue penetration compared to lower frequency transducers. Practically, an ul‐
trasonographer will begin the examination with the highest frequency transducer available,
which is usually a 15 megahertz transducer; if there are structures that are not well seen, the
ultrasonographer change to a lower frequency one.
The approach to handling the ultrasound transducer and physically tracing it across the ab‐
domen is of paramount importance. A key technique in imaging the bowel is known as
“graded compression.” Increasing pressure is applied with the transducer head as it is
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swept across the surface of the abdomen. This has the effect of displacing bowel gas and
overlying bowel loops so that the area of interest can be inspected with the greatest possible
clarity [14].
5.3. Interpretation of imaging findings
A normal segment of bowel on ultrasound exhibits five discrete layers. The inner-most layer
is a thin hyperechoic line that demarcates the interface between the lumen and the mucosa.
The next layer is a hypoechoic line at the interface between the mucosa and submucosa. The
third layer is a hyperechoic line between submucosa and the muscularis propria; this is the
most commonly involved layer in IBD. The fourth layer is the muscularis propria itself and
is hypoechoic. The fifth and final layer is hyperechoic and represents the serosa [15].
Inflammatory bowel disease is manifested on ultrasound as abnormal bowel wall thicken‐
ing, defined as greater than 3mm, and loss of definition of the discrete bowel wall layers.
Both UC and Crohn’s disease result in bowel wall thickening. However, in UC the bowel
wall layers are preserved, as opposed to Crohn’s disease; this distinction though may not be
sufficiently accurate to differentiate the two diseases by US alone. Intra-mural edema ap‐
pears as generalized hypoechogenicity within the bowel wall. Conversely, fibrostenoic dis‐
ease exhibits hyperechogenicity of the submucosal layer. Superficial ulcers may be detected
as hypoechoic interruptions within the innermost bowel wall layer.
Doppler ultrasound can provide useful adjunct data to the structural information from con‐
ventional ultrasound. Normal bowel wall, as well as fibrostenotic bowel wall, does not usu‐
ally demonstrate detectable Doppler blood flow. Therefore, the presence of intramural blood
flow is suggestive of the hyperemia of active disease.
6. Nuclear medicine/Molecular imaging
As molecule-targeted therapies become increasingly prevalent in the treatment of IBD, it is
likely that imaging their downstream effects directly via molecular imaging techniques will
play a pivotal role in the management of patients with IBD. Molecular imaging with radio‐
nuclides in IBD has been thoroughly investigated. Analogous to conventional fluoroscopy,
planar scintigraphic imaging was the predominant method of nuclear imaging for IBD in
the past, but recently tomographic techniques such as single photon emission computed to‐
mography (SPECT) and positron emission tomography (PET) have supplanted this two-di‐
mensional modality. As novel, targeted imaging agents become clinically available, it is
reasonable to expect that molecular imaging will be critical in directly tracking the efficacy
of therapies in patients with IBD in a manner that far precedes anatomic changes detectable
by conventional imaging methods.
The pathophysiology of IBD involves infiltration of gut mucosa with activated lymphocytes
and macrophages. By radiolabeling autologous white blood cells (WBCs) and re-injecting
the cells into the patient, non-invasive imaging of WBC migration into areas of inflamma‐
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mensional modality. As novel, targeted imaging agents become clinically available, it is
reasonable to expect that molecular imaging will be critical in directly tracking the efficacy
of therapies in patients with IBD in a manner that far precedes anatomic changes detectable
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The pathophysiology of IBD involves infiltration of gut mucosa with activated lymphocytes
and macrophages. By radiolabeling autologous white blood cells (WBCs) and re-injecting
the cells into the patient, non-invasive imaging of WBC migration into areas of inflamma‐
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tion can be achieved. The radionuclide Tc-99m has been used in such a paradigm to label
WBCs, and Tc-99m-labeled WBCs have been thoroughly investigated as a highly sensitive
and specific instrument for diagnosing IBD. Radiolabeled WBCs may also be helpful to
prognosticate response to therapy within only a few days of its initiation [16, 17].
Beyond WBCs, multiple radio-labeled probes targeting inflammation have been studied, in‐
cluding interleukins such as IL-2 and IL-8. Additionally, Annexin V, a molecular probe spe‐
cific for apoptosis, has been shown to function as an early marker of response to therapy in
patients with IBD being treated with infliximab.
The advent of positron-emitting radionuclides has paved the way for the introduction of
PET imaging into clinical practice, a modality that enjoys far greater spatial resolution than
single photon techniques. The most widely used PET imaging agent is 2-deoxy-2[18F]fluoro-
d-glucose (FDG), a radiolabeled glucose molecule that accumulates in areas of increased gly‐
colysis. Imaging with FDG-PET has a reported sensitivity and specificity for colonic mucosal
inflammation on par with endoscopy.
With the recent introduction of whole-body PET-MRI scanners, combined PET imaging with
MR enterography offers the benefits of MRI morphological assessment of diseased areas
with PET quantitation of inflammatory activity. The exquisite soft tissue differentiation of
MRI coupled with the molecular sensitivity of PET has the potential to provide unparalleled
structure-function correlation. The simultaneous acquisition of the two data sets that can be
performed with new hybrid PET-MRI systems allows for true co-registration of PET and MR
images (Figure 8); this feature is particularly relevant for abdominal imaging, as peristalsis
can result in significant changes in bowel positioning.
Figure 8. PET-MRI of patient with cecal inflammation. Fused imaging demonstrates small area of active inflammatory
changes in the cecum that would be difficult to diagnose on either FDG-PET or MR imaging independently. Images
generously provided by Drs. Alex Guimaraes, Ciprian Catana, Bruce Rosen, and David Berger (Massachusetts General
Hospital, Boston, MA).
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7. Special considerations in the pediatric population
Performing diagnostic imaging examinations on pediatric patients requires consideration of
several important factors. For example, pediatric patients may not be able to tolerate pro‐
longed examinations such as MR enterography, necessitating the use of sedation to obtain
satisfactory images. Moreover, not only are pediatric patients with IBD committed to a life‐
time of imaging studies, but also their increased percentage of actively dividing tissue and
relatively smaller body habitus render them inherently more sensitive to radiation injury
and mutagenesis compared an adult. When these risks are coupled with their baseline in‐
creased risk of malignancy due to IBD, the importance of radiation dose reduction becomes
apparent.
The association between diagnostic radiation and cancer risk is controversial. Directly
studying the effects of ionizing radiation on malignancy risk is extremely challenging. Fre‐
quently cited epidemiologic data are based on atomic bomb survivors and nuclear power
plant workers who were exposed to radiation levels that exceed those in diagnostic imaging.
Moreover, the deleterious effects of radiation likely have a prolonged incubation time, per‐
haps on the order of decades, before they are clinically apparent. A recent large retrospec‐
tive study of CT scans performed on pediatric patients suggests a measurable but small
increase in the risk of malignancy [18]. It should be noted that the radiation doses associated
with CT scans included in that study are significantly higher than current CT technique.
Nonetheless, there is little doubt that every effort should be made to reduce the radiation
exposure in pediatric patients to minimize any potential risk.
Estimating the magnitude of absorbed radiation during a CT examination can be made
through the use of phantoms. Though no patient, and especially no pediatric patient, is
identical to the standard, adult-sized body phantom, this approach remains the most quanti‐
tative means of estimating radiation levels within the body during a CT exam. However, ex‐
trapolating malignancy risk from these data is difficult, as different organs exhibit unique
susceptibilities to radiation exposure. For example, the gonads are far more radio-sensitive
than muscle tissue. For this reason, the concept of “effective dose” was introduced. This
term, measured in millisieverts (mSv), reflects an attempt to create a standard metric that
quantifies the impact of the absorbed radiation [19]. Effective dose is calculated by multiply‐
ing the absorbed radiation dose by a conversion factor for the body segment that was im‐
aged; this conversion factor varies based upon the radiosensitivity of the exposed organs.
The choice of imaging modality for IBD over the past two decades has trended towards an
increase in the use of CT. Pediatric patients may undergo multiple CT examinations over
their lifetime, and the cumulative effective dose they receive may exceed 75 mSv, a level be‐
yond which radiation-induced malignancy is felt to become an increasing concern. Patients
with Crohn’s disease are imaged far more frequently than those with UC. Also, patients
who require immunosuppressive therapy or surgery are also at a higher risk of frequent
imaging. Additional risk factors include stricturing or penetrating disease [20].
The most important avenue for reducing radiation dose is the eradication of unnecessary ex‐
aminations. Minimizing exposure time during fluoroscopy should be standard practice.
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Multiple techniques for reducing radiation dose in CT examinations have been developed
and should be implemented when imaging pediatric patients. Finally, substituting non-ion‐
izing radiation imaging modalities such as MRI and ultrasound should be considered when
appropriate.
8. Conclusions and recommendations
The modalities described in this chapter each demonstrate their own unique set of advanta‐
geous and disadvantageous features. While fluoroscopy may show superficial mucosal dis‐
ease better than any cross-sectional technique, extra-luminal disease is poorly visualized.
The high spatial and temporal resolution of CT has driven its rise in popularity over the past
two decades; however, this examination requires the use of ionizing radiation, and an ap‐
preciation of the possible associated risks is paramount prior to selecting this modality.
While MRI is more costly and time consuming, it may be the best choice in a clinical situa‐
tion where minimizing radiation dose is important or when soft tissue characterization is re‐
quired.
For imaging symptomatic patients with suspected IBD, we recommend fluoroscopic upper
GI and small bowel series because of its high sensitivity for early IBD as well as its accuracy
for diagnosing other disease entities (e.g. sprue, infectious enteritides) that can mimic IBD.
For initial imaging evaluation of newly diagnosed Crohn’s disease, as well as evaluation of
symptomatic exacerbation of known Crohn’s disease in adult patients, CT enterography is
recommended because of its superior ability to detect active bowel inflammation as well as
extraluminal and extraintestinal disease manifestations. Urgent and emergent complications
such as abscess formation and acute bowel obstruction are best imaged with traditional CT
using intravenous and no enteric contrast. Crohn’s disease patients with perianal symptoms
should be investigated with pelvic MRI. MR enteroraphy is becoming the preferred primary
imaging modality for pediatric patients, as well as adult patients who previously have un‐
dergone multiple prior CT exams, because of its lack of ionizing radiation. In patients with
longstanding IBD with persistent obstructive symptoms, MR enterography is the best imag‐
ing modality for distinguishing inflammatory from fibrotic stricture [21], which has impor‐
tant therapeutic implications. Enteroclysis techniques should generally be reserved for those
patients with remitting-relapsing obstructive symptoms despite normal enterography stud‐
ies, as a provocative examination to detect short strictures. There is likely to be an increasing
role for ultrasound in surveillance imaging in the future given its low cost and lack of re‐
quirement of sedation or oral contrast preparation.
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An Update to Surgical Management of Inflammatory
Bowel Diseases
V. Surlin, C. Copaescu and A. Saftoiu
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1. Introduction
Surgery still has its place in the treatment of inflammatory bowel diseases (IBD) but it is re‐
served generally to cases in which medical treatment is unsuccessful in relieving symptoms,
preventing disease progression and complications. As the medical treatment has added new
drugs (especially newly targeted therapy) and surgical advance in technology has gain in
more complex procedures with less morbidity and mortality and minimal invasivity there is
a need for periodic update.
2. Perioperative care of patients with IBD
Good perioperative care always ensures better surgical results. Patients undergoing surgery
for IBD must be prepared psychologically and medically.
Psychological preparation should start by explaining the patient the need for surgery. In this
approach the surgeon must be aided by the gastroenterologist that has managed the patient
for a long time in most of the cases. After acceptance of surgery, the patient must be ex‐
plained the objectives, the advantages and disadvantages of each surgical intervention and
the decision must be taken in common. People that will be submitted to stomas should also
get a consultation from stomatherapist.
Medical preparation of the patients includes correction of hemoglobin, volemia, electrolytes
and acid-base levels, coagulopathy, liver function. Total parenteral nutrition may be neces‐
sary in patients with nutritional deficits. Coexisting diseases should also be addressed. Any
corticosteroid and immunosuppressive therapy should be discontinued before surgery, but
corticosteroids need to be tapered immediately after surgery.
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2.1. Prevention of infection
Adequate antibiotic prophylaxis or antibiotic therapy should be given, especially in cases
with prolonged corticosteroid or infliximab therapy. Anyway, antibiotic prophylaxis pre
and intraoperative is mandatory in colon surgery, but we think that may be continued sev‐
eral days after surgery especially in patient treated by corticosteroids and immunosupres‐
sive and immunomodulator therapy because of higher risk of infection on a reduced
immune host defense.
The mechanical bowel preparation in elective cases is no longer mandatory in colon surgery
and is contraindicated in patients with an acute abdomen or obstruction [1]
2.2. Prophylaxis for venous thrombosis
Patients with IBD are at increased risk for thromboembolic venous and arterial complica‐
tions [2, 3]. Thus, intermittent pneumatic compression and/or low dose heparin should be
used prophylactically.
3. Indications for surgery in ulceative colitis (UC)
Approximately 30–40% of patients with ulcerative colitis will require surgical treatment.
Indications for surgery are:
• intractable chronic disease,
• lack of response to high-dose corticosteroid therapy
• recurrence of symptoms upon stop of corticosteroid therapy,
• disease progression under maximal medical therapy,
• significant treatment-related complications such as severe steroid or infliximab side ef‐
fects,
• dysplasia or cancer in patients with long-standing colitis during endoscopic surveillance,
• colonic strictures,
• acute exacerbation of the disease not responsive to rescue therapy such as intravenous
steroids, cyclosporine, or infliximab,




The development of restorative procedures such as the ileal pouch anal-canal anastomosis
has made surgery a more attractive option in patients in whom medical therapy has been
unsuccessful or undesirable.
3.2. Refractory colitis
The treatment of choice for acute severe steroid refractory ulcerative colitis is controversial
[4]. Gastroenterologists sustain infliximab [5], while surgeons plead for colectomy [6].
3.3. Intractable chronic disease
The most common indication for elective surgery is disease activity that has been intractable
to medical therapy. However, "intractable" is kind of blurry. Some authors have suggested
that disease should be considered intractable when it or its treatment is associated with se‐
vere and persistent impairment in the quality of life [7]. However, these parameters are dif‐
ficult to measure and are variable among individual patients.
3.4. Refractory Acute Severe Ulcerative Colitis (RASUC)
Refractory acute severe ulcerative colitis (RASUC), is defined by greater than six bloody
stools per day and one of the following: heart rate more that 90 beat/min, erythrocyte sedi‐
mentation rate more than 30mm/h, temperature more than 37.8°C, and hemoglobin less than
10.5 g/dl. The appropriate time to initiate surgical intervention during the treatment of RA‐
SUC has been a topic of investigation, because patients are usually severely malnourished,
immunocompromised, and weakened by side-effects of immunomodulating drugs. [8].
3.5. Emergency surgery
Advances in medical therapy (including use of infliximab) have reduced the need for emer‐
gency surgery due to catastrophic complications such as massive hemorrhage, perforation,
fulminant colitis, and acute colonic obstruction [9].
A longer duration of in-hospital ineffective medical therapy (8 versus 5 days) that delays
surgical therapy in patients with acute severe ulcerative colitis is associated with an in‐
creased risk of postoperative complications [10].
Biologic agents were introduced with the intent to help avoid operative intervention in pa‐
tients with moderately to severely active IBD who have demonstrated an inadequate re‐
sponse to conventional therapies. Ananthakrishnan et al. analyzing a large number of cases
hospitalized for IBD found that the use of biologic agents decreases the incidence of emer‐
gency surgery in patients with mild disease, but not in those with severe forms. [11]
For Ousslan et al, failure to respond to infliximab determined the decision for colectomy in
19% of the patients. Predicting factors for colectomy were C-reactive protein > 10mg/l before
treatment with infliximab, hemoglobin less than 9.4 g/dl, episodic use of infliximab, and pre‐
vious treatment with cyclosporin. [12]
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In the study of Gustavsson et al, with 3-year follow-up, infliximab significantly reduced the
need for surgery at 3 month compared to placebo (29% vs 67%), for patients with corticoste‐
roid refractory UC. At 3 years, 50% of patients in the infliximab group and 76% of patients
in placebo group needed colectomy. [13]
In a spanish multicenter experience, patients in whom corticosteroids and ciclosporin failed
to control the disease, were submitted to infliximab. A 40 years patient, operated because of
infliximab failure died after surgery from nosocomial pneumonia. Authors stated that sal‐
vage therapy with infliximab after failed corticosteroids and ciclosporin may be associated
with risk for morbidity and mortality and therefore should be used in selected patients. [14]
Adalimumab emerged as an indication in the cases in which there is partial or no response
to infliximab. In a study from Taxonera et al at 48 weeks of follow-up only 20% of the pa‐
tients needed surgery. Therefore, application of this new therapy may diminish the indica‐
tions for surgery in the group of patient non-responders to infliximab therapy.
3.6. Suspicion of cancer
The risk of malignancy is directly proportional to the duration of disease. The risk during
the first decade of disease is low, but increases substantially after that. After 30 years of dis‐
ease the risk is about 50 %. [8] Patients with more than 10 years of disease should undergo a
colonoscopy each year. Most of the gastroenterologists consider discovery of moderate to se‐
vere dysplasia an indication for surgery.
3.7. Extraintestinal manifestations
Surgical indication is seldom for extracolonic manifestations of IBD. Benefits from surgery
will be in the rare cases of massive hemolytic anemia unresponsive to treatment. In those
cases splenectomy should be associated to colectomy [7]. Another extracolonic indication for
colectomy is thromboembolic complications. Erythema nodosum and arthralgia of the small
and large joints appear to benefit the most from proctocolectomy [15]. In cases of pyoderma
gangrenosum, ankylosing spondylitis and arthritis, sclerosing cholangitis surgery may not
be so profitable.
Surgical options for ulcerative colitis are:
• Proctocolectomy with permanent ileostomy (Brooke ileostomy)
• Proctocolectomy with continent ileostomy (Kock pouch)
• Abdominal colectomy with ileorectal anastomosis
• Colectomy, mucosal proctectomy, and ileal pouch-anal canal anastomosis (IPAA)
• Colectomy and stapled ileal pouch distal rectal anastomosis (IPDRA)
3.8. Elective procedures
• Curative procedure - Proctocolectomy with permanent ileostomy.
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• Avoiding of ileostomy - IPAA. Patients under infliximab - three stages IPAA
In the elective surgical population, the standard operation performed is a total proctocolec‐
tomy with ileal pouch anal anastomosis. Described by Parks and Nichols in 1978, the proce‐
dure involves excision of the abdominal colon, pelvic dissection to remove the rectum,
creation of an ileal reservoir, and anastomosis of the pouch to the anus. A variety of pouch
designs can be used. The most commonlyof thrm is the J-pouch. Preference for the J-pouch
lies in its limited use of bowel, reliable emptying, and ease of construction. [8]
Mortality is low - 0.2–0.4%; however, the risk of pelvic sepsis can be as high as 23% from
leaks from the ileoanal anastomosis. To prevent this complication, the operation could be
performed in multiple stage (two or three), to allow anastomoses to heal without important
consequences [16,17].
3.9. In emergency situations
Toxic megacolon – the procedure of choice is open colectomy with ileostomy and closure of
the rectum or distal colostomy. The rectum may be resected afterwards with ileal pouch-
anal anastomosis. IPAA from the beginning should not be performed because of risk of
complications.
Hemmorhage – Proctocolectomy, suture of a bleeding ulcer or Hartmann-type colectomy
leaving a small stump of distal rectum.
3.10. Other options for restorative proctocolectomy
Ileal pouch distal rectum anastomosis (IPDRA) – anastomosis between ileal pouch and dis‐
tal rectum – easier to perform, better anal sensation and continence especially at night.
Main disadvantage – leaving rectal mucosa behind, that should be avoided in patients with
cancer or severe dysplasia in colorectal mucosa, severe extraintestinal manifestations.
Advantage – older patients, lack of adequate mobilisation for tension-free anastomosis –
ileorectal anastomosis (IRA)
Indications
• Patients not suitable for IPAA
• Refusal of ileostomy
• Medical conditions in which a stoma is relatively contraindicated (eg, portal hypertension
or ascites),
• Women of childbearing age because of the risk of infertility,
• Patients in whom Crohn's disease cannot be excluded,
• Patients with colitis complicated by advanced colonic malignancy,
Functional results after IRA
An Update to Surgical Management of Inflammatory Bowel Diseases
http://dx.doi.org/10.5772/53057
201
In the study of Gustavsson et al, with 3-year follow-up, infliximab significantly reduced the
need for surgery at 3 month compared to placebo (29% vs 67%), for patients with corticoste‐
roid refractory UC. At 3 years, 50% of patients in the infliximab group and 76% of patients
in placebo group needed colectomy. [13]
In a spanish multicenter experience, patients in whom corticosteroids and ciclosporin failed
to control the disease, were submitted to infliximab. A 40 years patient, operated because of
infliximab failure died after surgery from nosocomial pneumonia. Authors stated that sal‐
vage therapy with infliximab after failed corticosteroids and ciclosporin may be associated
with risk for morbidity and mortality and therefore should be used in selected patients. [14]
Adalimumab emerged as an indication in the cases in which there is partial or no response
to infliximab. In a study from Taxonera et al at 48 weeks of follow-up only 20% of the pa‐
tients needed surgery. Therefore, application of this new therapy may diminish the indica‐
tions for surgery in the group of patient non-responders to infliximab therapy.
3.6. Suspicion of cancer
The risk of malignancy is directly proportional to the duration of disease. The risk during
the first decade of disease is low, but increases substantially after that. After 30 years of dis‐
ease the risk is about 50 %. [8] Patients with more than 10 years of disease should undergo a
colonoscopy each year. Most of the gastroenterologists consider discovery of moderate to se‐
vere dysplasia an indication for surgery.
3.7. Extraintestinal manifestations
Surgical indication is seldom for extracolonic manifestations of IBD. Benefits from surgery
will be in the rare cases of massive hemolytic anemia unresponsive to treatment. In those
cases splenectomy should be associated to colectomy [7]. Another extracolonic indication for
colectomy is thromboembolic complications. Erythema nodosum and arthralgia of the small
and large joints appear to benefit the most from proctocolectomy [15]. In cases of pyoderma
gangrenosum, ankylosing spondylitis and arthritis, sclerosing cholangitis surgery may not
be so profitable.
Surgical options for ulcerative colitis are:
• Proctocolectomy with permanent ileostomy (Brooke ileostomy)
• Proctocolectomy with continent ileostomy (Kock pouch)
• Abdominal colectomy with ileorectal anastomosis
• Colectomy, mucosal proctectomy, and ileal pouch-anal canal anastomosis (IPAA)
• Colectomy and stapled ileal pouch distal rectal anastomosis (IPDRA)
3.8. Elective procedures
• Curative procedure - Proctocolectomy with permanent ileostomy.
Inflammatory Bowel Disease200
• Avoiding of ileostomy - IPAA. Patients under infliximab - three stages IPAA
In the elective surgical population, the standard operation performed is a total proctocolec‐
tomy with ileal pouch anal anastomosis. Described by Parks and Nichols in 1978, the proce‐
dure involves excision of the abdominal colon, pelvic dissection to remove the rectum,
creation of an ileal reservoir, and anastomosis of the pouch to the anus. A variety of pouch
designs can be used. The most commonlyof thrm is the J-pouch. Preference for the J-pouch
lies in its limited use of bowel, reliable emptying, and ease of construction. [8]
Mortality is low - 0.2–0.4%; however, the risk of pelvic sepsis can be as high as 23% from
leaks from the ileoanal anastomosis. To prevent this complication, the operation could be
performed in multiple stage (two or three), to allow anastomoses to heal without important
consequences [16,17].
3.9. In emergency situations
Toxic megacolon – the procedure of choice is open colectomy with ileostomy and closure of
the rectum or distal colostomy. The rectum may be resected afterwards with ileal pouch-
anal anastomosis. IPAA from the beginning should not be performed because of risk of
complications.
Hemmorhage – Proctocolectomy, suture of a bleeding ulcer or Hartmann-type colectomy
leaving a small stump of distal rectum.
3.10. Other options for restorative proctocolectomy
Ileal pouch distal rectum anastomosis (IPDRA) – anastomosis between ileal pouch and dis‐
tal rectum – easier to perform, better anal sensation and continence especially at night.
Main disadvantage – leaving rectal mucosa behind, that should be avoided in patients with
cancer or severe dysplasia in colorectal mucosa, severe extraintestinal manifestations.
Advantage – older patients, lack of adequate mobilisation for tension-free anastomosis –
ileorectal anastomosis (IRA)
Indications
• Patients not suitable for IPAA
• Refusal of ileostomy
• Medical conditions in which a stoma is relatively contraindicated (eg, portal hypertension
or ascites),
• Women of childbearing age because of the risk of infertility,
• Patients in whom Crohn's disease cannot be excluded,
• Patients with colitis complicated by advanced colonic malignancy,
Functional results after IRA
An Update to Surgical Management of Inflammatory Bowel Diseases
http://dx.doi.org/10.5772/53057
201
A retrospective analysis of the functional results after IRA for ulcerative colitis or indetermi‐
nant colitis in 86 patients found that the rectum was eventually resected in 17% of cases, rec‐
tal dysplasia occurred in 17%, rectal cancer 8% and refractory proctitis 28%. The cumulative
probability of developing rectal dysplasia at 5, 10, 15, and 20 years was 7, 9, 20, and 25 per‐
cent, respectively. The cumulative probability of developing rectal cancer at 5, 10, 15, and 20
years was 0, 2, 5, and 14 percent, respectively. The cumulative probability of having a func‐
tioning IRA at 10 and 20 years was 74 and 46 percent, respectively. [18]
Satisfactory rectal function varies greatly depending upon the selections of patients and
length of follow-up. The risk of cancer in the residual rectum has been reported to be 6 % at
20 years and 15 % at 30 years. The risk is significant considering that most patients are
young and have many years to live.
Farouk et al noted that in 1386 patients with restorative proctocolectomy and over 8-year
follow-up, 80% reported complete diurnal continence, with 50% requiring medications to
slow intestinal transit. [19]
4. Surgical options for Crohn's disease
Crohn's disease is not curable by surgery. Therefore, this is actualy reserved for complica‐
tions or to symptoms refractory to medical therapy [20].
Surgical decision making in Crohn's disease is driven by anatomic distribution and inflam‐
matory subtype of disease. Forty percent of patients have ileal disease with segments of co‐
lonic involvement, with 20–25% of patients exhibiting isolated colonic disease and 5–10%
with isolated anorectal disease [21]. Surgical intervention is primarily performed for the
complications of Crohn's disease: stricture and obstruction, fistula, or medically refractory
disease. Approximately 70% of Crohn's disease patients ultimately require surgery, often
multiple, making minimally invasive options appealing
Indications for surgery are:
• obstruction,
• perforation in small intestinal Crohn's disease,
• failure to respond to medical therapy in patients with colonic involvement,
• strictures,
• fistula
Surgery should to adress only to segments causing obstruction, bleeding, or perforation. Re‐
section is performed when there is an abscess or fistula to an adjacent organ. The disease-
free margins are established by gross inspection, microscopic disease at the margins will not
be associated with recurrence. Therefore we should avoid large margins, in the idea of pre‐
serving as much as possible of small bowel capital because the patients may need another
resection in the future and thus preventing the short bowel syndrome.
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Ileocolic resections should be followed by a side-to-side anastomosis. A meta-analysis of
eight comparative studies found that a side-to-side anastomosis was associated with fewer
anastomotic leaks and postoperative complications, a shorter hospital stay and a lower peri‐
anastomotic recurrence rates compared to end-to-end anastomosis [22]. However, the au‐
thors suggested that further randomized controlled trials are needed to confirm these
associations.
4.1. Duodenal disease
Duodenal Crohn's disease very rarely requires surgery. The major indications for surgery
are obstruction and less often perforation or fistula formation. Gastrojejunostomy rather
than resection is typically performed. Strictureplasty, duodenojejunostomy, and endoscopic
balloon dilation have also been described [23].
4.2. Intra-abdominal abscess, peritonitis
• Intraperitoneal abscesses were classically drain by open surgery and were followed by
surgical resection of the diseased segment of the bowel.
• Progress of interventional radiology, new biologic agents and progress of laparoscopy
changed this classic approach [24,25].
• Percutaneous drainage guided by CT or abdominal ultrasound has a low rate of compli‐
cations and a high rate of success - approximately 70% of attempted cases. Complete
drainage of the abscess may necessitate repeated punctures. This attitude allows the pa‐
tient to be prepared for an elective resection of the bowel after the sepsis resides, after im‐
proving nutritional status and decreasing corticosteroids. Controversy exists regarding
the need for subsequent operation after adequate abscess drainage as intractable disease
or recurrent abscess occurs in at least 30% of these patients within a year.
• If percutaneous drainage is unsuccessful, surgical drainage should be performed. The
timing of surgery following percutaneous abscess drainage, when clinically indicated, oc‐
curs after clinical resolution of sepsis.
• Peritonitis is rare in Crohn's disease. Exploratory laparotomy with peritoneal lavage, with
construction of a stoma is most commonly required. The decision whether to resect or not
the bowel depends upon the operative findings and the patient's condition [26].
• Abdominal wall abscesses (psoas and rectus sheath) are less common and more difficult to
control locally than intra-abdominal abscesses. In a retrospective review of 13 patients with
an abdominal wall abscess treated by percutaneous and/or open operative drainage, all 13
required resection of the diseased segment even after successful drainage of the abscess [25].
4.3. Fistulas
Fistulas to adjacent organs (stomach, duodenum, bladder, vagina, and sigmoid colon) are
treated by resection and anastomosis of the diseased segment of the bowel and closure of
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the fistula. Resection of the adjacent segment is necessary only when it is primarily involved
with Crohn's disease. Bypasses should be avoided because persistent disease in the by‐
passed segment can lead to abscess formation, bleeding, perforation, bacterial overgrowth,
and malignancy.
4.4. Strictures
Intestinal strictures can be relieved by resection; synchronous small bowel resection in pa‐
tients with multiple strictures is common [27]. Strictureplasty or balloon dilation may be a
suitable alternative for selected patients.
4.4.1. Strictureplasty
Strictureplasty is performed by longitudinal incision across the stricture and a transversal
closure that enlarges the lumen. Indication is represented by the patients that have isolated
areas of short stricture and are at risk for short bowel syndrome due to previous surgery or
extension of enterectomy. Strictureplasty can relieve obstruction, and is often performed in
association with a small bowel resection [27, 28]. It can also be performed without excision
of bowel [29, 30]. It should not be performed in acutely inflamed bowel.
To avoid large enterectomy for extensive and/or multiple strictures occurring over long in‐
testinal segments, a side-to-side isoperistaltic or other type of nonconventional strictureplas‐
ty is safe and effective [31, 32].
Strictureplasty has been associated with excellent results, including relief of obstruction, the
ability to withdraw steroids, and improvement in symptoms [31, 33] the risk of fistula or re‐
current stricture formation is low and comparable to resection. Whether preservation of dis‐
eased bowel increases the long-term risk of malignancy is unknown, although case reports
have documented adenocarcinoma arising from sites of previous strictureplasty [34].
The following examples illustrate the range of findings in two of the largest series
In a series of 1124 procedures of strictureplasty on 314 patients there was a synchronous
bowel resection in 66% of cases, overall morbidity was 18%, septic complications in 5%,
morbidity was higher in patients with preoperative weight loss and older age, recurrence af‐
ter surgery was met in 34% during a median follow-up of 7.5 years, recurrence was higher
in younger patients [30]:
Another study included 479 procedures of strictureplasty performed in 100 patients with a
follow-up of 7 years in average [35]. Overall morbidity was 22% and included sepsis – 11%,
obstruction 4%, hemorrhage - 4% percent, and mortality – 3%. After a first strictureplasty
the reoperation rate were 52% at 40 months, 56% at 26 months after a second, 86% at 27
months after a third, 63% at 26 months after a fourth. The major risk factor for reoperation
was young age. The early relaparotomy rate was 8 percent. One patient developed cancer
after many years of disease. The authors biopsied suspicious lesions, rather than going for
routine biopsy of all lesions.
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4.4.2. Balloon dilation
Another method to dilate intestinal strictures is with a hydrostatic balloon Experience is rel‐
atively limited compared with strictureplasty or resection, and the long-term efficacy and
safety is therefore less well-established. A meta-analysis of 13 studies (with a total of 347 pa‐
tients) reported overall technical success in 86 % of cases and long-term efficacy in 58 per‐
cent, with up to 33 months of follow-up [36]. On multivariate analysis, a stricture length of
≤4 cm was associated with better surgery-free outcomes. The outcome of balloon dilatation
to relieve obstruction from intestinal strictures in Crohn’s disease is not influenced by the
type of concomitant medical therapy [37].
Couckuyte et al performed 78 dilatation procedures for 59 ileocolonic strictures in 55 pa‐
tients, all procedures were carried out endoscopically under general anesthesia. Succes was
registered in 90% with 11% perforations from which 30% needed surgery and 60% were
solved only with medical treatment. Mean period of time to recurrence of obstruction was
up to 11 months for 62% of patients. [38]
In pediatric patients injections of corticosteroids into strictures after balloon dilatations were
followed by fewer redilatations than in placebo group. [39]. For adults it didn’t work the
same [40]
4.4.3. Stenting
Placement of an expandable metal stent within colonic strictures has been described, but ex‐
perience is limited, and the safety of this approach is uncertain [41].
4.5. Colorectal disease
Options for surgery range from temporary diverting ileostomy to resection of segments of
diseased colon or even the entire colon and rectum. Same conservative principles applied to
disease involving the small intestine should also be applied to the surgical management of
Crohn's colitis
The optimal procedure depends in part upon the extent of the disease and the clinical setting:
• Segmental colectomy may be adequate for isolated areas of colonic involvement. An Ileor‐
ectal anastomosis can be carried out if the rectum is spared. A proctectomy will be re‐
quired in half of the patients [42]. While no prospective randomized study has been
undertaken to compare segmental colectomy and total colectomy with ileorectal anasto‐
mosis, both procedures appear to be equally effective as treatment options for colonic
Crohn's disease. However, patients undergoing segmental resection may have earlier re‐
currence [43]. The choice of operation depends upon the extent of colonic disease; there
may be better outcomes with ileorectal anastomosis in those who have two or more in‐
volved colonic segments.
• Total proctocolectomy is indicated for patients with extensive, diffuse colorectal disease.
• Subtotal colectomy with ileostomy is usually performed in emergency situations.
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obstruction 4%, hemorrhage - 4% percent, and mortality – 3%. After a first strictureplasty
the reoperation rate were 52% at 40 months, 56% at 26 months after a second, 86% at 27
months after a third, 63% at 26 months after a fourth. The major risk factor for reoperation
was young age. The early relaparotomy rate was 8 percent. One patient developed cancer
after many years of disease. The authors biopsied suspicious lesions, rather than going for
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4.4.2. Balloon dilation
Another method to dilate intestinal strictures is with a hydrostatic balloon Experience is rel‐
atively limited compared with strictureplasty or resection, and the long-term efficacy and
safety is therefore less well-established. A meta-analysis of 13 studies (with a total of 347 pa‐
tients) reported overall technical success in 86 % of cases and long-term efficacy in 58 per‐
cent, with up to 33 months of follow-up [36]. On multivariate analysis, a stricture length of
≤4 cm was associated with better surgery-free outcomes. The outcome of balloon dilatation
to relieve obstruction from intestinal strictures in Crohn’s disease is not influenced by the
type of concomitant medical therapy [37].
Couckuyte et al performed 78 dilatation procedures for 59 ileocolonic strictures in 55 pa‐
tients, all procedures were carried out endoscopically under general anesthesia. Succes was
registered in 90% with 11% perforations from which 30% needed surgery and 60% were
solved only with medical treatment. Mean period of time to recurrence of obstruction was
up to 11 months for 62% of patients. [38]
In pediatric patients injections of corticosteroids into strictures after balloon dilatations were
followed by fewer redilatations than in placebo group. [39]. For adults it didn’t work the
same [40]
4.4.3. Stenting
Placement of an expandable metal stent within colonic strictures has been described, but ex‐
perience is limited, and the safety of this approach is uncertain [41].
4.5. Colorectal disease
Options for surgery range from temporary diverting ileostomy to resection of segments of
diseased colon or even the entire colon and rectum. Same conservative principles applied to
disease involving the small intestine should also be applied to the surgical management of
Crohn's colitis
The optimal procedure depends in part upon the extent of the disease and the clinical setting:
• Segmental colectomy may be adequate for isolated areas of colonic involvement. An Ileor‐
ectal anastomosis can be carried out if the rectum is spared. A proctectomy will be re‐
quired in half of the patients [42]. While no prospective randomized study has been
undertaken to compare segmental colectomy and total colectomy with ileorectal anasto‐
mosis, both procedures appear to be equally effective as treatment options for colonic
Crohn's disease. However, patients undergoing segmental resection may have earlier re‐
currence [43]. The choice of operation depends upon the extent of colonic disease; there
may be better outcomes with ileorectal anastomosis in those who have two or more in‐
volved colonic segments.
• Total proctocolectomy is indicated for patients with extensive, diffuse colorectal disease.
• Subtotal colectomy with ileostomy is usually performed in emergency situations.
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• An abdominoperineal resection with a permanent end-colostomy is indicated in patients
with severe Crohn's disease limited to the anorectum. An intersphincteric proctectomy
will minimize the risk of a nonhealing wound and sexual or urinary dysfunction, by
avoiding dissection near the hipogastric plexuses. In the presence of anorectal disease and
sepsis a Hartmann procedure can be carried out in the first place leaving a small stump of
distal rectum, followed by a perineal proctectomy. [44].
4.6. Anorectal disease
The management of anorectal disease, present in 14–38% of patients, remains difficult de‐
spite advances in medical therapy. Perianal fistula or abscess is the initial presentation of
Crohn's disease in approximately 30% of cases and has been associated with increased extra‐
intestinal symptoms and steroid resistance, resulting in significant disability [8].
The number of Crohn's patients who require surgery has, however, decreased with the ad‐
vances in medical management.
Most of the abscesses are small, difficult to drain and can disappear with antibiotics alone.
The antibiotic therapy should associate ciprofloxacin to metronidazole. Greater abscesses
can be drained by placement of a seton or by ultrasound or CT guided large bore needle as‐
piration or drain placement.
Treatment of the perianal fistula depends on the type of fistula (simple vs. complex) and un‐
derlying rectal inflammation.
Simple fistulas are intersphincteric or transsphincteric below the dentate line in origin with a
single opening and no associated stricture or abscess. Such fistulas have an excellent response
to antibiotic and surgical therapy and heal 80–100% of the time with simple fistulotomy [8]
Complex fistulas on the contrary, involve the superficial, transsphincteric, or intersphincter‐
ic region below the dentate line, have multiple openings, and can be associated with rectal
stricture or rectovaginal fistula.
Pelvic MRI provides the most accurate information (90% accuracy) about fistulous burden
and underlying rectal inflammation and is instrumental in surgical planning and monitor‐
ing response to therapy. Accuracy approaches 100% when MRI is combined with examina‐
tion under anesthesia. [45, 46]
Complex fistulas represent a challenge and require aggressive immunomodulating therapy
in combination with surgical therapy. Many patients feel improvement in symptoms with
antibiotic therapy (ciprofloxacin and metronidazole); however, symptom relief is transient
with recurrence on withdrawal of antibiotics. Infliximab has proven to be the immunosup‐
pressive drug of choice in treatment of complex perianal fistulas with two randomized trials
showing decreased number of fistulas, increased disease-free period, and fewer required
hospitalizations and surgeries.[47]
Surgical therapy has evolved for complex fistulas as well with the development of less inva‐
sive techniques for closure of high fistulas to prevent incontinence associated with damage
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to the anal sphincters. Some of the newest approaches use fibrin glue and collagen plugs to
occlude fistulous tracts without requiring incision.
A study from Chung et al comparing collagen fistula plug to fibrin glue, rectal advancement
flap, and seton placement for treatment of 51 patients with complex perianal fistulas showed
a 75% resolution rate with use of the plug compared with less than 30% for each of the other
modalities. [48]
The systematic review by Soltani and Kaiserof evaluating the efficacy of endorectal flap ad‐
vancement for complex perianal Crohn's disease found a 46% resolution [49].
The review by Lewis and Maron on anorectal Crohn's disease provides an algorithm for
management of complex perianal fistulas, stressing that surgical therapy in excess of seton
placement should not be attempted during active proctitis due to inflammation [50].
Postoperative medical treatment for prevention of Crohn's disease recurrence is controver‐
sial in light of data supporting increased incidence of complications with preoperative im‐
munosuppressive therapy. However, a randomized, placebo-controlled clinical trial showed
no difference in incidence of adverse events (anastomotic leak, wound complications, infec‐
tion, obstruction, bleeding, death) between postoperative patients treated with infliximab
within 4 weeks of surgery and those untreated. [51]
Bordeianou et al studied the effect of immediate vs. tailored medical prophylaxis on endo‐
scopic and/or symptomatic recurrence in 199 patients who underwent ileocecectomy for
Crohn's disease. The group found that there was no difference in recurrence rates between
patients treated with medication immediately after surgery and those treated based on en‐
doscopic finding, adding to the debate on whether perioperative and postoperative medical
suppression is advantageous. [52]
5. Minimally invasive surgery for inflammatory bowel disease
The laparoscopic approach was already proven feasible both for UC and CD.
5.1. Minimally invasive surgery for chronic ulcerative colitis
A way to use laparoscopy is only for the mobilization of the colon (cecum, ascendent, de‐
scendent, sigmoid) and to perform the rest of the operation in open but with a smaller inci‐
sion [53]
Laparoscopic subtotal colectomy performed in emergency conditions was followed by ac‐
ceptable outcomes and shorter hospital stay, although in such cases is not usually recom‐
mended [54].
Another possibility is to perform colon and rectal mobilisation, section of the mesocolon and
even the rectum with liniar ENDO-GIA. Some authors do that by hand assisted technique.
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5.1.1. To divert or not after laparoscopic surgery
This is a question still under debate. Ky et al had a series of 32 laparoscopic IPAA (29 for
UC) in which they didn’t divert and had a morbidity of 34% and 3% leak rate [55]. Hasega‐
wa et al performed 18 cases all with diversions and had 33% morbidity and 0% leak rate
[56]. Others like Marcello et al from 20 cases (13 for UC) divert only in 60% of cases and had
5% leak rate.[57]
Is laparoscopy superior to open approach? In short term yes – as already proven by compar‐
ison between them, with faster recovery (including faster ambulation, less postoperative
pain, faster return of bowel movement and time to first passage of flatus and feces).
Brown et al compared laparoscopic-assisted restorative proctocolectomy to open approach
and found shorter operative time in open group, and similar functional outcome and recov‐
ery, only better cosmesis by shorter abdominal scar. The hand-assisted method seems to re‐
duce the operative time with more than 30 minutes [58].
Postoperative morbidity is still relatively high duet o extensive procedure (25-34%) [55, 56, 57]
5.2. Minimally invasive surgery for Crohn’s disease
Laparoscopic approach have the potential of decreasing morbidity, speeding recovery, and
reducing costs, while decreasing the incidence of small bowel obstruction and ventral (ab‐
dominal wall) hernias [59,60].
A randomized comparative trial between open and laparoscopic ileo-colic resection found a
conversion rate of 6% and no significant difference in immediate postoperative recovery
(passage of flatus and length of hospital stay). The only benefice was a faster recovery of
forced expiratory volume and forced expiratory vital capacity. [61]
Maartense et al performed a comparative randomized controlled trial between laparoscopic-
assisted ileocolonic resection performed by experienced surgeons in laparoscopy with open
resections in Crohn's disease [62]. Morbidity, hospital stay, and costs were lower in the lapa‐
roscopic group, although there were no significant differences in quality-of-life at three
months follow-up.
Alves et al found that the need for conversion to an open procedure was predicted by the
severity of disease; independent predictors of conversion including a history of recurrent
medical episodes of Crohn's disease and the presence of intra-abdominal abscess or fistula at
the time of laparoscopy [63].
Recurrences after laparoscopic surgery were similar after conventional surgery. Laparoscop‐
ic colectomy was found to be safe and effective in the hands of experienced surgeons for se‐
lected patients with Crohn’s colitis [64].
In the review by Fichera et al on Crohn's disease, the author highlights three meta-analyses
that compared laparoscopic with open ileocolic surgery that demonstrated earlier return of
bowel function leading to shorter hospital stay, fewer late small bowel obstructions, and de‐
Inflammatory Bowel Disease208
creased early complications such as wound infections and bleeding with laparoscopic sur‐
gery. [20]
Two large studies on laparoscopic surgery for isolated colonic disease found similarly good
outcomes with fewer complications. Holubar et al reported their outcomes for 92 patients
who underwent laparoscopic colectomy, showing a total complication rate of 34%, reinter‐
vention rate of 7.6%, and anastomotic leak rate of 3.8%, all consistent with reported out‐
comes for open colectomy. Fifteen percent of laparoscopic cases were converted to open and
presence of small bowel disease was the only predictive factor identified, independent of
presence of phlegmonous or fistulous disease. [65]
Umanskiy et al compared outcomes of 125 patients who underwent laparoscopic vs. open co‐
lectomy and/or proctectomy for Crohn's disease. The most common procedure in both groups
was total proctocolectomy with end ileostomy and the only statistically significant difference
in procedures performed applied to completion proctectomies, which were more likely to be
open. Patients in the laparoscopic group had earlier return of bowel function, reduced length
of hospital stay, and decreased intraoperative blood loss. Interestingly, the reduced blood loss
did not result in fewer transfusions, which were similar in both groups [66].
5.2.1. Recurrence after laparoscopic surgery
There was also no clinical recurrence at 20 months [60]. In a study by Tabet et al with 39
months follow up, there were similar rates of recurrence 48% vs 45%. [67]
Watanabe et al and Bemelman et al performed laparoscopic-assisted resection for Crohn’s
disease, including patients with enteric fistulas. Postoperative outcome was better in laparo‐
scopic group [68, 69]. Same results were noted by Duepree et al., Tabet et al, and Young Fa‐
dok et al. (all comparative studies) who found short term outcome benefits associated with
the minimally invasive approach [60, 67, 70].
5.2.2. Costs
For Duepree et al costs per case were higher for laparoscopic group.[70]. Young-Fadok et al
reported an overall cost for laparoscopic cases significantly less than for the open ones [60].
There is a broad range of conversion rates (1.4-24 %), morbidity (10-29 %), length of stay
(3.3-8.8 days), and leak rates (0-5%). Most of the series involve relatively small numbers of
patients. [59, 69, 70]
5.2.3. Long term benefits of laparoscopic approach
Laparoscopic surgery is considered to generate less postoperative adhesions and less inci‐
sional hernias.
Bergamaschi et al reported the results of a comparative study with long term follow up be‐
tween laparoscopic and open ileocecal resections. At 5 years, they found a rate of 11.1 %
small bowel obstructions for laparoscopic group and 35.4 percent for the open group, and
the result was statistically significant.[59]
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Generally, laparoscopic colectomy is followed by lower incidence of incisional hernia and
small bowel obstruction, with significant differences, as reported by Duepree et al [70].
Functional outcome [71], quality of life [71] are similar but cosmetic results [71] especially
for women [72] are higher after laparoscopy.
6. Complications
6.1. Early complications
Are usual after restorative proctocolectomy.
The most frequent are bowel obstruction, pouch bleeding, pelvic and wound sepsis, transi‐
ent urinary dysfunction, and dehydration from temporary loop ileostomy with high output.
Surgery is not mandatory in many of those cases. Incidence of pelvic abscess after IPAA is
estimated to 5% [73]. Pelvic abscesses lead to transabdominal or local surgery in most of the
cases, failure of pouch in quarter of cases, incontinence, need for constipating or bulking
medications was in the patients in whom the reservoir was preserved. There was also a de‐
crease in the quality of life of those patients.
Portal vein thrombosis can occur after IPAA. Clinical manifestations may include pain, fe‐
ver, vomiting, leukocytosis, and unexplained postoperative ileus. Diagnose is made with
CT-scanner. Treatment with anticoagulation will lead to full resolution.
6.2. Late complications
• stricture of the anastomosis,
• poor postoperative anorectal function,
• anal fistula and abscess,
• reduced fertility [74],
• pouchitis - this is the most frequent. In one series, the cumulative probability of suffering at
least one episode of clinical pouchitis was 18 and 48 % at 1 and 10 years, respectively [75],
• irritable pouch syndrome and anismus (anorectal dysfunction)[76].
Majority of the pouch related complication can be solved by medical treatment consisting main‐
ly in local measures, surgery being required in a minority. In one series of almost 1000 patients
who had undergone IPAA, reoperation for complications was necessary in only 12 % [77].
As an example, ileal pouch fistulas and strictures refractory to dilatation are difficult to treat
and may require revision of the pouch if Crohn's disease can be excluded. A transvaginal
repair is favored for a pouch-vaginal fistula [78]. A combined abdominal perineal repair
may offer better results compared with a local procedure [79]. A controlled septic condition
does not preclude salvage surgery. Although pouch failure occurs more often than with pri‐
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mary IPAA, high patient satisfaction and quality of life can be achieved [80]. Furthermore,
excision of the pouch is associated with a high risk of complications, especially delayed peri‐
neal wound healing [81, 82].
A number of unusual late complications have been described including [83, 84, 85]:
• Solitary ileal ulcer
• Traumatic ileal ulcer perforation
• Superior mesenteric artery syndrome






6.3. Long-term results of surgery
The long-term success of surgery depends upon the type of operation, the clinical setting,
and surgical expertise. Several studies have suggested that functional results are poor dur‐
ing the long-term follow-up in patients who had adverse personality factors before surgery
(such as problems with sexual satisfaction, difficulty expressing emotions, perfectionist
body ideals, and poor frustration tolerance) [79]. The following results were described in
some of the largest series.
One series included 1885 patients who underwent an ileal pouch-anal anastomosis for ulcer‐
ative colitis and were followed for an average of 11 years. The mean number of stools was
5.7 per day at one year and 6.4 at 20 years, and also increased at night from 1.5 to 2.0. The
incidence of frequent fecal incontinence increased from 5 to 11 percent during the day and
from 12 to 21 percent at night. The overall rate of pouch success at 5, 10, 15, and 20 years
was 96, 93, 92, and 92 percent, respectively. Quality of life remained unchanged and 92 per‐
cent remained in the same employment. [86]
In another report that included 486 patients who had undergone proctocolectomy and ileoa‐
nal anastomosis for ulcerative colitis or familial adenomatous polyposis, the cumulative
probabilities of pouch failure were 1, 5, and 7 percent at 1, 5, and 10 years, respectively [87]
The most common cause of pouch failure was fistula formation.
Tulchinsky et al reported 634 patients who underwent restorative proctocolectomy for IBD.
Patients were followed for a mean of 85 months. Failure (defined as removal of the pouch or
the need for an ileostomy) was divided into early (occurring within one-year) or late (occur‐
ring more than one-year postoperatively). Three patients died postoperatively while an ad‐
ditional 23 died (of a variety of causes) during follow-up. Of the remaining patients, there
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was 96, 93, 92, and 92 percent, respectively. Quality of life remained unchanged and 92 per‐
cent remained in the same employment. [86]
In another report that included 486 patients who had undergone proctocolectomy and ileoa‐
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were a total of 61 failures (10 %) of which 24.6% were early and 75.4% late. Failures were
due to pelvic sepsis (52 %), poor function (30 %), pouchitis (11 %), and miscellaneous causes
(four patients, all early failures). Predictors of failure included a final diagnosis of Crohn's
disease, a type J or S reservoir, female gender, postoperative pelvic sepsis, and a one-stage
procedure. Failure rates increased with time from 9% at five years to 13% at 10 years. [88]
Another series showed that results in older patients (>65) are not as good; however, appro‐
priate case selection was followed by acceptable function and quality of life to patients of all
ages [89].
Anal canal strictures were described in up to 11 percent of 213 patients [82]. Strictures that
were not fibrotic responded well after anal dilation while fibrotic strictures were more com‐
monly associated with intra- or postoperative complications and frequently required surgi‐
cal therapy.
A systematic review of 43 observational studies (with a total of 9317 patients) found a pouch
failure rate of 6.8%, increasing to 8.5% in those with more than five-year follow-up [90]. Pel‐
vic sepsis occurred in 9.5%. Severe, mild, and urge fecal incontinence was reported in 3.7, 17,
and 7.3 percent, respectively. These results suggest that current techniques are associated
with non-negligible complication rates and leave room for improvement and continued de‐
velopment of alternative procedures.
IPAA may have long-term effects:
• on female reproductive health [91],
• some women experience increased dyspareunia [92], although the ability to experience
orgasm and coital frequency remain unchanged,
• female fertility is significantly decreased [93], possibly due to pelvic adhesions, although
successful pregnancies occur regularly [94], patients may experience a transient increase
in stool frequency (including incontinence) during pregnancy, which resolves after deliv‐
ery, pregnancy and delivery are safe in patients with IPAA. Patients should not be dis‐
couraged from childbearing because of the pouch. Whether vaginal or cesarean delivery
is better for women with a pelvic pouch remains controversial.
Satisfactory long-term functional outcome and excellent quality of life have also been descri‐
bed after stapled restorative proctocolectomy. In a series of 977 patients, quality of life in‐
creased for two years after surgery, with no deterioration thereafter [95]. The prevalence of
perfect continence increased from 76 percent before surgery to 82 percent after surgery and,
although continence deteriorated somewhat more than two years after surgery, it was no
worse than preoperative values. Ninety-eight percent of patients would have recommended
the surgery to others. In another prospective, observational study, patients who had a sta‐
pled anastomosis had higher rates of daytime, nighttime, and complete continence com‐
pared with patients who underwent a hand-sewn anastomosis [32].
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6.4. Morbidity of operation due to use of biologic agents
Preoperative use of infliximab. The efficacy of the biologic agents must be balanced against the
morbidity associated with their usage, and surgeons have been worried about the safety as‐
sociated with the preoperative use of these medications in patients requiring elective or non‐
elective operations for their IBD.
Beddy et al believed the evidence showed that recent biologic agent administration in a pa‐
tient with Crohn's disease should not cause the surgeon to delay surgery or employ fecal di‐
version proximal to an anastomosis. However, they felt that patients with ulcerative colitis
preoperatively managed with infliximab and immunosuppressant medications should un‐
dergo a three-stage rather than two-stage restorative proctocolectomy and ileal pouch-anal
anastomosis (IPAA); the first operation would be a total or subtotal colectomy and creation
of ileostomy that allows patients to be withdrawn from medications prior to performing the
IPAA procedure. They proposed this approach in hopes of improving long-term ileal pouch
function by decreasing the risk of short-term infectious complications attributed to combina‐
tion therapy.[83]
Gainsbury et al, remarked that there is an increased risk of septic complications associated
with preoperative infliximab and elective surgery for ulcerative colitis, growing evidence
appears to refute that notion. [99]
Whether immunosuppressive therapy increases the risk of postoperative complications is
still controversy. For some authors [98, 99, 100, 101] it may not be responsible but for others
[102, 103, 104] it is, increasing risk for sepsis, intraabdominal abscesses [102,104], and espe‐
cially when associated with other immunomodulators (ciclosporin) [103]. In this conceptual
area there is need for more controlled trials.
Ellis et al found that unlike surgical mortality for most disorders, the operative mortality as‐
sociated with colectomy for ulcerative colitis has increased in recent years despite centraliza‐
tion of care. This finding raises considerable concern that patients potentially are not
receiving prompt or appropriate surgical care because of alterations in medical therapy.
[105]
6.5. Pouchitis
Outside of the perioperative period, the most common late complication of ileal pouch anal
anastomosis is pouchitis, occurring in up to 60% of patients.[106] Pouchitis is thought to be
the result of immunologic reaction to altered bowel flora. Symptoms range from mild diar‐
rhea to severe abdominal pain and fistulization with neighboring organs. In a recent review
from the Cleveland Clinic, multivariate analysis identified pulmonary co-morbidities, S-
pouch reconstruction, disease proximal to the splenic flexure, and extraintestinal disease are
the factors predictive of subsequent pouchitis. Patients who developed pouchitis had higher
incidence of obstruction, fistula, and stricture and reported lower quality of life than con‐
trols [94]. Once identified, the treatment of pouchitis is primarily medical, with most pa‐
tients showing excellent response to antibiotics and/or probiotics and immunomodulators.
A Cochrane database review of trials through 2010 found that ciprofloxacin was more effec‐
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tive than metronidazole and budesonide enemas were equally effective to metronidazole in
the treatment of acute pouchitis. The probiotic VSL#3 was more effective than placebo for
prevention and treatment of chronic pouchitis[108]. Haveranet al reported complete resolu‐
tion of symptoms in stricturing and antibiotic resistant pouchitis with azathioprine and 6-
mercaptorpurine. However, fistulizing disease required the addition of infliximab, with 46%
of such patients ultimately requiring diverting ileostomy for relief. Alternatives to ileostomy
for pouch failure include pouch salvage techniques such as transanal mobilization or ab‐
dominoperineal revision of the pouch, with success rates ranging from 48 to 93%.[18] A
small percentage of patients will ultimately be identified as having Crohn's disease as the
cause of their fistulae and pouch complications.[109]
In a review of almost 1800 IPAA attempts from the Mayo Clinic, abandonment was required
in 4.1 % [97].
7. Postoperative monitoring
Risk of dysplasia and cancer
All patients who undergo surgical procedures for ulcerative colitis should be monitored reg‐
ularly for the development of long-term complications.
In addition to functional problems, complications can occur at any stage, including the de‐
velopment of dysplasia and possibly cancer.
However, in a study of potentially high-risk patients (eg, Kock pouch for ≥14 years, a pelvic
pouch for ≥12 years, a history of dysplasia or cancer in the proctocolectomy specimen or
troublesome pouchitis), the development of dysplasia was rare [98].
7.1. Dysplasia
The presence of inflammatory changes in a retained rectal stump, anal transitional zone, and
ileal reservoir after stapled pouch-anal anastomosis is a cause of concern because of the
long-term risk of dysplasia.
A systematic review of 23 observational and case control studies estimated that the preva‐
lence of confirmed dysplasia in the pouch, anal transitional zone, or rectal cuff was 1.13 %
(0-19%) The prevalence of high-grade, low-grade, or indefinite dysplasia was 0.15, 0.98, and
1.23 %, respectively. Dysplasia was equally frequent in the pouch and rectal cuff or anal
transitional zone [112].
If dysplasia and cancer are identified before or at operation the risk for postoperative dys‐
plasia is higher. The risk of neoplasia is not completely eliminated by colectomy and muco‐
sectomy. A retrospective review of 3203 patients with a preoperative diagnosis of IBD who
underwent restorative proctocolectomy found that the cumulative incidence for pouch neo‐
plasia at 5, 10, 15, 20 and 25 years were 0.9, 1.3, 1.9, 4.2, and 5.1 %, respectively 11 patients
developed adenocarcinoma of the pouch or at the anal transitional zone, one developed
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lymphoma in the pouch, three developed squamous cell carcinoma at the anal transitional
zone, and 23 developed pouch dysplasia. The prognosis of pouch adenocarcinoma appeared
to be poor [100].
If the rectal cuff becomes symptomatic or develops dysplasia, the retained rectal mucosa
from the restorative proctocolectomy can be removed by a transanal completion mucosecto‐
my and reconstructing the ileal pouch-anal anastomosis as an alternative to a complete anal
rectal resection and permanent ileostomy. The mucosectomy removes all rectal mucosa, con‐
fers a highest likelihood of a surgical cure, and reduces the risk of future dysplasia. Short
term results in a series of 27 patients included reduced pouchitis symptoms and 90 % of pa‐
tients were moderately to very satisfy with the procedure. Incontinence was reduced by 70
percent at 12 months of observation [101].
The optimal frequency of pouch endoscopy and biopsy is not well established. It is recom‐
mended to perform an initial screening five years after creation of an ileal pouch in children
or when the total disease duration exceeds seven years [102].
In patients that had severe villous atrophy or dysplasia in the resected colon or rectum the
aforementioned interval may be reduced. In patients with pouch or anal high-grade dyspla‐
sia detected during surveillance, resection of the ileal pouch and anal canal should be con‐
sidered.
In a retrospective review of 222 patients who required operative intervention for Crohn's
colitis, there were 2.3% dysplasia and 2.7% adenocarcinoma. In this small cohort, the risk
factors for the development of dysplasia or adenocarcinoma included longer disease dura‐
tion (over 17 years), extensive disease, and older age at diagnosis (38 years of age or older).
These findings support colonoscopic screening and surveillance of patients with Crohn's
colitis. [116]
7.2. Recurrence
The postoperative recurrence rate for patients undergoing a resection and anastomosis is
high in Crohn’s disease. In most series up to 20 percent of patients will not have a clinical
recurrence even at 15 years after surgery Those with severe endoscopic or radiologic find‐
ings are at increased risk to have or develop symptoms (72 versus 42%). An increased risk
for reoperation has been associated with perforating disease and smoking [117].
A laparoscopic approach does not appear to decrease the risk of recurrence. A retrospective
review of 89 patients undergoing laparoscopically resected primary ileocolonic Crohn’s coli‐
tis found recurrent disease in 61 percent [118]. The median time to recurrence was 13
months (range 1.3 months to 8.7 years). Only the presence of granulomas in the resected
specimen was identified as a risk factor for time to recurrence, and these patients were al‐
most three times more likely to develop a recurrence.
The recurrence rate is lower in patients with Crohn's colitis who undergo a total colectomy
and ileostomy compared to those with disease involving other segments of the digestive
tract. We already know, from a study in 1985 by Goligher et al Such patients have only a 10
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percent recurrence rate in the small intestine at 10 years [106]. A number of medical options
are available that may reduce the risk of recurrence. A relatively aggressive approach
should be considered in patients with diffuse and distal Crohn's colitis. Total proctocolecto‐
my in properly selected patients is associated with low morbidity, a decreased risk of recur‐
rence, and a longer time to recurrence [20]
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1. Introduction
Inflammatory Bowel Disease (IBD) classified with Ulcerative Colitis (UC) and Crohn Dis‐
ease (CD) is an idiopathic, life-long, destructive chronic inflammatory disease in gastrointes‐
tinal tract [1] and probably multi-factorial disease caused by interplay of the external and
internal environment. Little is known about the mechanism of pathogenesis of the disease
but it has been reported that immunological mechanisms are involved in etiology. Under
normal situations, the intestinal mucosa is in a state of controlled inflammation regulated by
a delicate balance of pro-inflammatory (tumor necrosis factor [TNF]-alpha, interferon [IFN]-
gamma, interleukin [IL]-1, IL-6, IL-12 and anti-inflammatory cytokines (IL-4, IL-10, IL-11),
where particularly, IL-6 stimulates T-cell and B-cell proliferation and differentiation.
Therefore, the mucosal immune system is the central effect or of intestinal inflammation and
injury, with cytokines playing a central role in modulating inflammation [2,3].
During last a couple of decade, the therapeutic agents for IBD have been changed rapidly
and anti-inflammatory agents such as corticosteroid and salicylates or its metabolite were
used but recently biological agents are introduced. Emerging changes in IBD medications or
their use for an instance, balsalazid, budesonide, 5-aminosalicylate (5-ASA) and purine ana‐
logues such as azathioprine are improvements in conventional application, additionally,
mycophenolate mofetil (MMF), thalidomide and heparin are newly introduced into IBDther‐
apy [4-6].
On the contrary, advances in molecular technology have enabled the development of novel
and potentially effective targeted therapies with anti-TNF particularly infliximab, interfer‐
on-gamma and interleukin [7, 8]. Nevertheless, biologically active agents have some prob‐
lems in terms of long termstorage conditions and immune-toxicity, additionally
biocompatibility against major histological complex (MHC) of immunoglobulin G, which
may cause in inconvenience of patient compliance and more expenditure. Thus, the great in‐
© 2012 Kim; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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terest has been focused to the interplay between the adaptive and innate natural sources not
only to achieve a better understanding of the immune-pathogeneses of inflammatory bowel
disease but to identify targets for even more potent intervention [9-11].
Furthermore, colonic drug delivery has gained increased importance not just for the treat‐
ment of local diseases associated with the colon but also for its potential improvement relat‐
ed with adverse events such as ileocecal junction (ICJ) barrier and small volume capacity.
The various strategies for targeting orally administered drugs to the colon are consisted of
pH dependent polymers, azo-polymers, covalent linkage of a drug with a carrier, formula‐
tion of timed released systems, drug carriers that are degraded specially by colonic bacteria
and, bio-adhesive.
2. Natural products with anti-inflammatory and anti-tumor activity
In the field of pharmaceutics, the synthetic chemistry is gradually made more efficient and
precise, but also gradually changing into bio-technological applications and a return to the
infinitely more variable and complex chemistry of Nature.
Organisms in Nature produce secondary metabolites with the specific purpose to gain evo‐
lutionary advantages in the competition for example living space and in the search for nu‐
trients. With an estimated numbers of more than 300 thousands species of plants and
probably close to two million species of various organisms, the biodiversity of Nature re‐
mains an unparalleled reservoir of biological and chemical diversity. However, most of the
biodiversity is as yet unexplored.
Most important thing is the development of strategies for selection, isolation and characteri‐
zation with the objective to discover unique bioactive chemical structures with drug poten‐
tial, and to reveal unknown targets, by studying the evolutionary structure–activity
optimization in Nature.
In addition to the possibility to discover new drug candidates for drug development, bioac‐
tive natural projects have potential as pharmacological tools, intermediates, or templates for
synthesis of drugs.
The increased uses of herbal remedies, which contain complex mixtures of natural products,
need intensified scientific studies to establish efficacy and safety of these types of products
as well as clinical studies.
With the increasing interest for environmental aspects, green chemistry, and a sustainable
use of natural products, this renewal could have a strategic position in bridging chemistry
and biology.
The correlation between the chemical structures responsible for the shown bioactivity needs
to be studied to understand the observation on a molecular level using both in vivo, in vitro
and in silico methods [12].Explanatory model the interdisciplinary nature of pharmacogn‐
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ocy interpreted in an explanatory model presented by Larsson and co-workers [13]. In this
model a clearly defined role is presented for aspects of informatics, includingbio- and che‐
mo-informatics. The studies of pure natural products against colon cancer are now in focus.
Another project is focused on bioengineering of circular proteins, so called cyclotides, to cre‐
ate new structure–activity relationships. Novel strategies are developed for efficient predic‐
tion and selection of organisms and molecules and bioinformatics tools to predict novel
targets based on lateral gene transfer.
A scientific platform has been built in our long-term research on anti-inflammatory natural
products as demonstrated in a number of publications and doctoral theses. Many differ‐
entchemical structures have been discovered, and chemically and pharmacologically charac‐
terized using bioassay-guided isolation procedures. In vivo methods such as rat paw and
mouse ear edema was used and later followed by in vitro enzyme and cell based methods.
Two systems have been established to enable investigations of the effects of natural com‐
pounds on COX-2. The first method developed was an in vitro method suitable for measur‐
ing inhibition of COX-2 catalyzed prostaglandin E2 biosynthesis, based on scintillation
proximity assay technology [14]. The second system comprises acell model, suitable for
studying the effects of compounds on COX-2 and inducible nitric oxide synthase (iNOS) at
different cellular levels, including the effects on mRNA, protein, prostaglandin E2, and ni‐
tric oxide levels [15].
In later years the project has developed towards enzyme inhibitors related to anti-tumor ac‐
tivity, especially in colon cancer. It has been shown that the process of inflammation and ex‐
pression of cyclooxygenase-2 is important in colon carcinogenesis.Another important factor
is diet. Many food python-chemicals have been shown to exert anti-inflammatory activity in
vitro, and may act as cancer chemo-preventive agents [16, 17]. A vegetarian diet rich in py‐
thon-chemicals may prevent colon carcinogenesis by affecting biochemical processes in the
colonic mucosa. It has been shown that intact fecal water (water phase) samples from hu‐
man volunteers significantly decreased prostaglandin production and COX-2 expression in
colonic cells. NMR spectroscopy and multivariate data analysis were later used for further
analysis of the composition of the fecal waters and to trace the COX-2 inhibiting activity [18,
19]. The wealth of different natural products with experimentally demonstratedCOX inhibi‐
tory effects and an urge to understand and characterize their structural diversity was the
starting point for the application of chirography in our natural products research.
The identification from chemo graphic  analyses  of  some specific  groups of  compounds,
including a set of cardiac glycosides, as being of prime importance was further establish‐
ed  in  a  screening  of  a  large  number  of  natural  products  for  activity  against  colorectal
cancer where several cardiac glycosides showed significant activity. This activity was fur‐
ther confirmed in primary cells from colon cancer patients. Cardiac glycosides have been
reported  to  exhibit  cytotoxic  activity  against  several  different  cancer  types,  but  studies
against colorectal cancer are lacking. Drugs for clinical treatment of colon cancer are usu‐
ally used in combination to overcome the problem with drug resistance and to increase
the activity.  Therefore,  selected cardiac glycosides were tested in combination with four
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clinically relevant standard cyto-toxic  drugs (5-fluorouracil,  oxaliplatin,  cisplatin,  irinote‐
can) to screen for synergistic effects.
The combination of digoxin and oxaliplatin exhibited synergism including the otherwise
highly drug resistant HT29 cell line [20]. In depth studies are now in progress necessary to
understand these effects on a molecular level.
A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and
Wnt/EGFR/NF-kappaB-signaling pathways, which provide evidence that the plant flavo‐
noid fisetin can induce apoptosis and suppress the growth of colon cancer cells by inhibition
of COX2- and Wnt/EGFR/NF-kappaB-signaling pathways and suggest that fisetin could be a
useful agent for prevention and treatment of colon cancer [21].The contribution of plukene‐
tione A to the antitumor activity of Cuban propolis was assumed that plukenetione A con‐
tributes to the antitumor effect of Cuban propolis mainly by targeting to poisomerase I as
well as DNA polymerase[22].Aberrant Wnt/beta-catenin signaling has recently been impli‐
cated in tumor genesis. On the basis of screening program targeting inhibition of TCF/beta-
catenin transcriptional activity, a plant extract of Eleutherine palmfolia was selected as a hit
sample. Activity-guided fractionations led to the isolation of 15 naphthalene derivatives
(1-15), including 4 new glycosides, eleutherinosides B-E (1-4), and 10 of the 15 compounds
showed strong activities with high viability among 293T cells, whose data showed that 2
and 9 inhibited the transcription of TCF/beta-catenin in SW480 colon cancer cells in a dose-
dependent manner and selective cytotoxicity against three colorectal cancer cell lines. In ad‐
dition, treatment with 9 led to a significant decrease in the level of nuclear beta-catenin
protein, suggesting this reduction to have resulted in the inhibitory effect of 9 on the tran‐
scription of TCF/beta-catenin [23].
Penta-cyclic triterpene acids are known mainly for their anti-antigenic effects as well as their
differentiation inducing effects. In particular, lupane-type triterpenes, such as botulin, bo‐
tulnic acid and lupeol, display anti-inflammatory activities which often accompany immune
modulation. Tri-terpene acids as well as triterpene mono-alcohols and diols also show an
anti-oxidative potential. The pharmacological potential of triterpenes of the lupane, olea‐
nane or urbane type for cancer treatment seems high; although up to now no clinical trial
has been published using these tri-terpenes in cancer therapy. They provide a multi-target
potential for coping with new cancer strategies. Whether this is an effective approach for
cancer treatment has to be proven. Because various triterpenes are an increasingly promis‐
ing group of plant metabolites, the utilization of different plants as their sources is of inter‐
est. Parts of plants, for example birch bark, rosemary leaves, apple peel and mistletoe shoots
are rich in triterpenes and provide different triterpene compositions [24].
Advanced cancer is a multi-factorial disease that demands treatments targeting multiple cel‐
lular pathways. Chinese herbal cocktail which contains various phytochemicals may target
multiple dys-regulated pathways in cancer cells and thus may provide an alternative/
complementary way to treat cancers. Previously reported that the Chinese herbal cocktail
Tien-Hsien Liguid (THL) can specifically induce apoptosis in various cancer cells and have
immuno-modulating activity.Further, evaluated the anti-metastatic, anti-angiogenic and an‐
ti-tumor activities of THL [25]. Dietary grape seed extract (GSE) effectiveness in preventing
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azoxymethane (AOM)-induced aberrant crypt foci (ACF) formation. GSE-feeding inhibited
AOM-induced cell proliferation but enhanced apoptosis in colon including ACF, together
with a strong decrease in cyclin D1, COX-2, iNOS, and survivin levels and showed that GSE-
feeding also decreased AOM-caused increase in beta-catenin and NF-kappaB levels in colon
tissues[26].Grifolin, a secondary metabolite isolated from the fresh fruiting bodies of the
mushroom Albatrellus confluens, has been shown to inhibit the growth of some cancer cell
lines in vitro by induction of apoptosis An apoptosis-related gene expression profiling anal‐
ysis provided a clue that death-associated protein kinase 1 (dapk1) gene was up-regulated at
least twofold in response to grifolin treatment in nasopharyngeal carcinoma cell CNE1. Fur‐
ther,investigated the role of DAPK1 in apoptotic effect induced by grifolin and observed
that protein as well as mRNA level of DAPK1 was induced by grifolin in a dose-dependent
manner in nasopharyngeal carcinoma cell CNE1. It was found that grifolin increased both
Ser392 and Ser20 phosphorylation levels of transcription factor p53 protein, which could
promote its transcriptional activity. Moreover, induced by grifolin, the recruitment of p53 to
dapk1 gene promoter was confirmed to enhance markedly using EMSA and ChIP assays
analysis. The involvement of DAPK1 in grifolin-induced apoptosis was supported by the
studies that introducing siRNA targeting DAPK1 to CNE1 cells remarkably interfered grifo‐
lin-caused apoptotic effect as well as the activation of caspase-3. Grifolin induced up-regula‐
tion of DAPK1 via p53 was also observed in tumor cells derived from human breast cancer
and human colon cancer. Up-regulation of DAPK1 via p53-DAPK1 pathway is an important
mechanism of grifolin contributing to its ability to induce apoptotic effect. Since growing
evidence found a significant loss of DAPK1 expression in a large variety of tumor types, gri‐
folin may represent a promising candidate in the intervention of cancer via targeting
DAPK1[27]. Five derivatives of the natural product sansalvamide A that are potent against
multiple drug-resistant colon cancer cell lines were identified. These analogs share no struc‐
tural homology to current colon cancer drugs, are cytotoxic at levels on par with existing
drugs treating other cancers, and demonstrate selectivity for drug-resistant colon cancer cell
lines over noncancerous cell lines. Thus, we have established sansalvamide A as a privileged
structure for treating multiple drug-resistant colon cancers [28]. Anti-cancer activities of the
ethanol extract of Ka-mi-kae-kyuk-tang (KMKKT) targeting angiogenesis, apoptosis and
metastasis without any adverse effect on the body weight. This formula merits serious con‐
sideration for further evaluation for the chemoprevention and treatment of cancers of multi‐
ple organ sites[29].The effect of aged garlic extract (AGE) on the growth of colorectal cancer
cells and their angiogenesis, which are important microenvironmental factors in carcinogen‐
esis. AGE (aged garlic extract) could prevent tumor formation by inhibiting angiogenesis
through the suppression of endothelial cell motility, proliferation, and tube formation. AGE
would be a good chemo-preventive agent for colorectal cancer because of its anti-prolifera‐
tive action on colorectal carcinoma cells and inhibitory activity on angiogenesis. Aged garlic
extract (AGE) has manifold biological activities including immune-modulated and anti-oxi‐
dative effects. It is used as a major component of nonprescription tonics and cold-prevention
medicines or dietary supplements [30, 31].
Transcription factor NF-kappaB is constitutively active in many human chronic inflammato‐
ry diseases and cancers. Epoxy quinone A monomer (EqM), a synthetic derivative of the nat‐
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clinically relevant standard cyto-toxic  drugs (5-fluorouracil,  oxaliplatin,  cisplatin,  irinote‐
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understand these effects on a molecular level.
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Wnt/EGFR/NF-kappaB-signaling pathways, which provide evidence that the plant flavo‐
noid fisetin can induce apoptosis and suppress the growth of colon cancer cells by inhibition
of COX2- and Wnt/EGFR/NF-kappaB-signaling pathways and suggest that fisetin could be a
useful agent for prevention and treatment of colon cancer [21].The contribution of plukene‐
tione A to the antitumor activity of Cuban propolis was assumed that plukenetione A con‐
tributes to the antitumor effect of Cuban propolis mainly by targeting to poisomerase I as
well as DNA polymerase[22].Aberrant Wnt/beta-catenin signaling has recently been impli‐
cated in tumor genesis. On the basis of screening program targeting inhibition of TCF/beta-
catenin transcriptional activity, a plant extract of Eleutherine palmfolia was selected as a hit
sample. Activity-guided fractionations led to the isolation of 15 naphthalene derivatives
(1-15), including 4 new glycosides, eleutherinosides B-E (1-4), and 10 of the 15 compounds
showed strong activities with high viability among 293T cells, whose data showed that 2
and 9 inhibited the transcription of TCF/beta-catenin in SW480 colon cancer cells in a dose-
dependent manner and selective cytotoxicity against three colorectal cancer cell lines. In ad‐
dition, treatment with 9 led to a significant decrease in the level of nuclear beta-catenin
protein, suggesting this reduction to have resulted in the inhibitory effect of 9 on the tran‐
scription of TCF/beta-catenin [23].
Penta-cyclic triterpene acids are known mainly for their anti-antigenic effects as well as their
differentiation inducing effects. In particular, lupane-type triterpenes, such as botulin, bo‐
tulnic acid and lupeol, display anti-inflammatory activities which often accompany immune
modulation. Tri-terpene acids as well as triterpene mono-alcohols and diols also show an
anti-oxidative potential. The pharmacological potential of triterpenes of the lupane, olea‐
nane or urbane type for cancer treatment seems high; although up to now no clinical trial
has been published using these tri-terpenes in cancer therapy. They provide a multi-target
potential for coping with new cancer strategies. Whether this is an effective approach for
cancer treatment has to be proven. Because various triterpenes are an increasingly promis‐
ing group of plant metabolites, the utilization of different plants as their sources is of inter‐
est. Parts of plants, for example birch bark, rosemary leaves, apple peel and mistletoe shoots
are rich in triterpenes and provide different triterpene compositions [24].
Advanced cancer is a multi-factorial disease that demands treatments targeting multiple cel‐
lular pathways. Chinese herbal cocktail which contains various phytochemicals may target
multiple dys-regulated pathways in cancer cells and thus may provide an alternative/
complementary way to treat cancers. Previously reported that the Chinese herbal cocktail
Tien-Hsien Liguid (THL) can specifically induce apoptosis in various cancer cells and have
immuno-modulating activity.Further, evaluated the anti-metastatic, anti-angiogenic and an‐
ti-tumor activities of THL [25]. Dietary grape seed extract (GSE) effectiveness in preventing
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azoxymethane (AOM)-induced aberrant crypt foci (ACF) formation. GSE-feeding inhibited
AOM-induced cell proliferation but enhanced apoptosis in colon including ACF, together
with a strong decrease in cyclin D1, COX-2, iNOS, and survivin levels and showed that GSE-
feeding also decreased AOM-caused increase in beta-catenin and NF-kappaB levels in colon
tissues[26].Grifolin, a secondary metabolite isolated from the fresh fruiting bodies of the
mushroom Albatrellus confluens, has been shown to inhibit the growth of some cancer cell
lines in vitro by induction of apoptosis An apoptosis-related gene expression profiling anal‐
ysis provided a clue that death-associated protein kinase 1 (dapk1) gene was up-regulated at
least twofold in response to grifolin treatment in nasopharyngeal carcinoma cell CNE1. Fur‐
ther,investigated the role of DAPK1 in apoptotic effect induced by grifolin and observed
that protein as well as mRNA level of DAPK1 was induced by grifolin in a dose-dependent
manner in nasopharyngeal carcinoma cell CNE1. It was found that grifolin increased both
Ser392 and Ser20 phosphorylation levels of transcription factor p53 protein, which could
promote its transcriptional activity. Moreover, induced by grifolin, the recruitment of p53 to
dapk1 gene promoter was confirmed to enhance markedly using EMSA and ChIP assays
analysis. The involvement of DAPK1 in grifolin-induced apoptosis was supported by the
studies that introducing siRNA targeting DAPK1 to CNE1 cells remarkably interfered grifo‐
lin-caused apoptotic effect as well as the activation of caspase-3. Grifolin induced up-regula‐
tion of DAPK1 via p53 was also observed in tumor cells derived from human breast cancer
and human colon cancer. Up-regulation of DAPK1 via p53-DAPK1 pathway is an important
mechanism of grifolin contributing to its ability to induce apoptotic effect. Since growing
evidence found a significant loss of DAPK1 expression in a large variety of tumor types, gri‐
folin may represent a promising candidate in the intervention of cancer via targeting
DAPK1[27]. Five derivatives of the natural product sansalvamide A that are potent against
multiple drug-resistant colon cancer cell lines were identified. These analogs share no struc‐
tural homology to current colon cancer drugs, are cytotoxic at levels on par with existing
drugs treating other cancers, and demonstrate selectivity for drug-resistant colon cancer cell
lines over noncancerous cell lines. Thus, we have established sansalvamide A as a privileged
structure for treating multiple drug-resistant colon cancers [28]. Anti-cancer activities of the
ethanol extract of Ka-mi-kae-kyuk-tang (KMKKT) targeting angiogenesis, apoptosis and
metastasis without any adverse effect on the body weight. This formula merits serious con‐
sideration for further evaluation for the chemoprevention and treatment of cancers of multi‐
ple organ sites[29].The effect of aged garlic extract (AGE) on the growth of colorectal cancer
cells and their angiogenesis, which are important microenvironmental factors in carcinogen‐
esis. AGE (aged garlic extract) could prevent tumor formation by inhibiting angiogenesis
through the suppression of endothelial cell motility, proliferation, and tube formation. AGE
would be a good chemo-preventive agent for colorectal cancer because of its anti-prolifera‐
tive action on colorectal carcinoma cells and inhibitory activity on angiogenesis. Aged garlic
extract (AGE) has manifold biological activities including immune-modulated and anti-oxi‐
dative effects. It is used as a major component of nonprescription tonics and cold-prevention
medicines or dietary supplements [30, 31].
Transcription factor NF-kappaB is constitutively active in many human chronic inflammato‐
ry diseases and cancers. Epoxy quinone A monomer (EqM), a synthetic derivative of the nat‐
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ural product epoxyquinol A, has previously been shown to be a potent inhibitor of tumor
necrosis factor-alpha (TNF-alpha)-induced activation of NF-kappaB [32]. EqM also effective‐
ly inhibits the growth of human leukemia, kidney, and colon cancer cell lines in the NCI's
tumor cell panel. Among six colon cancer cell lines, those with low amounts of constitutive
NF-kappaB DNA-binding activity are generally more sensitive to growth inhibition by EqM.
Therefore, EqM inhibits growth and induces cell death in tumor cells through a mechanism
that involves inhibition of NF-kappaB activity at multiple steps in the signaling pathway.
Colorectal cancer, the second most frequent diagnosed cancer in the US, causes significant
morbidity and mortality in humans. Over the past several years, the molecular and bio‐
chemical pathways that influence the development of colon cancer have been extensively
characterized. Since the development of colon cancer involves multi-step events, the availa‐
ble drug therapies for colorectal cancer are largely ineffective. The radiotherapy, photody‐
namic therapy, and chemotherapy are associated with severe side effects and offer no firm
expectation for a cure. Thus, there is a constant need for the investigation of other potential‐
ly useful options. One of the widely sought approaches is cancer chemoprevention that uses
natural agents to reverse or inhibit the malignant transformation of colon cancer cells and to
prevent invasion and metastasis [33]. Curcumin (diferuloylmethane), a natural plant prod‐
uct, possesses such chemopreventive activity that targets multiple signaling pathways in the
prevention of colon cancer development [34].Colon-targeting delivery of rhubarb extract, as
a purgative, may prevent absorption of free anthraquinones in the upper gastrointestinal
tract, thus improving clinical effects and lowering dosage [35, 36].Chemopreventive effects
of arctiin, a lignin isolated from Arctium lappa (burdock) seeds, on the initiation or post ini‐
tiation period of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) induced mam‐
mary carcinogenesis in female rats and on 2-amino-3, 8-dimethylimidazo[4,5-f]quinoxaline
(MeIQx)-associated hepatocarcinogenesis [37].
3. Plant peptides and proteins
Plant peptides and proteins may be considered an overlooked source for new chemical enti‐
ties and novel bioactivities compared to low molecular natural products. The reason for this
seems to be based on tradition and biased by the most commonly used techniques for natu‐
ral products. However, during the last decades, the number of reported plant peptides has
grown substantially, and the field is about to mushroom. In the form of Professor Gunnar
Samuelsson’s’ pioneering studies of mistletoe toxins was reported [38]. In the mid 1990san
attempt to assess plant peptides more broadly, with the design of an isolation protocol di‐
rectly designed for their isolation [39]. One of the results of this effort was the discovery of a
set of macrocyclic peptides in the plant family Violaceae [40]. Strikingly, the peptides we
characterized in Violaceae were found to be nearly identical with one of the most intriguing
examples of pharmacognostic research in general, and plant peptides in particular, namely
the peptide Kalata B1. The discovery of Kalata B1 was based on the ethno-pharmacological
use of the plant Oldenlandia affinis. It was experienced a high frequency of complicated de‐
liveries due to the use of this plant, which was locally known as ‘‘Kalata-Kalata’’ [41]. Na‐
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tive women secretly used a decoction of this plant to facilitate childbirth, which they sipped
as a tea but also applied directly at the birth canal [42]. It induced extremely strong uterine
contractions, which sometimes developed into cervical spasms necessitating acute caesarean
section.
The complete sequence and the cyclic structure was however not determined for more than
20 years later [43].At the time of our report of the first cocktail of ‘‘palate-like’’ peptides in
Violaceae, four similar peptides had been reported in the literature as the serendipitous dis‐
coveries of three independent groups. When including those peptides in a sequence compar‐
ison, i.e. the anti-HIV circulins A and B, the neurotensin binding inhibitor cyclo-psychotride
A and the partially characterized violapeptide I, it was clear that they fell in two subgroups
based on sequencesimilarity. Today, around 150 cyclotides have been reported from species
of three plant families, Violaceae, Rubiaceae and Cucurbitaceae. The family Violaceae seems
to be particularly rich in these proteins [44-47] and a single Violaceae species may contain
more than 60 different cyclotides. It has been suggested that there might be 9,000 cyclotides
in the Violaceae alone[48].
In addition to the amide bond that cyclizes the backbone, cyclotides contain three stabilizing
disulfide bonds in a knotted arrangement, i.e. two disulfides form a ring together with their
connecting protein backbone, which is threaded by the third disulfide [49-51].
CCK motif, and make cyclotides extraordinary stable protein structures [52]. Besides being
uterotonic,anti-HIV, hemolytic and neurotensin binding inhibitory, the list now includes an‐
timicrobial [53], antifouling [54], antihelmintic, molluscicidal, cytotoxic [55, 56]) and insecti‐
cidal activities. The latter effects are some of the most well studied and interesting effects:
the cytotoxic effect together with the haemolytic effect have been the focus for detailed
structure activity studies [57, 58], and the discovery of their insecticidal effect likely revealed
cyclotides’ role in planta. Cyclotides’ mechanism of action is however yet unknown, but evi‐
dence is accumulating showing that membrane interactions followed by membrane pore or
fissure formation are involved [59-61], which could provide an explanation to several of the
reported effects.
Combined with the extraordinary CCK motif—with its conserved scaffold that can be
dressed with variable loop sequences—the demonstrated biological activity of the cyclotides
make them a first class target for protein engineering. To this end, inherent activities of na‐
tive cyclotides can be reinforced or abolished, or new biologically active peptide epitopes
can begrafted into the scaffold. For example, reinforcing the cytotoxic effect could potential‐
ly provide us with leads for anticancer drugs, or to completely remove that effect could pro‐
vide us with an inert scaffold ideal for grafting. The first successful grafting of a
biologicallyactive epitope was reported just recently, showing proof of concept [62].
The success of these strategies relies on the ability of efficient methods for production of cy‐
clotides and cyclotide mutants. Being gene products, cell based production systems seem
promising, but although cyclotide producing plant cell cultures have been established [63],
solid phase peptide synthesis is still the method of choice [64, 65].Our knowledge about
their biosynthesis is yet scarce. We know the structural arrangement of the cyclotide precur‐
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ural product epoxyquinol A, has previously been shown to be a potent inhibitor of tumor
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tumor cell panel. Among six colon cancer cell lines, those with low amounts of constitutive
NF-kappaB DNA-binding activity are generally more sensitive to growth inhibition by EqM.
Therefore, EqM inhibits growth and induces cell death in tumor cells through a mechanism
that involves inhibition of NF-kappaB activity at multiple steps in the signaling pathway.
Colorectal cancer, the second most frequent diagnosed cancer in the US, causes significant
morbidity and mortality in humans. Over the past several years, the molecular and bio‐
chemical pathways that influence the development of colon cancer have been extensively
characterized. Since the development of colon cancer involves multi-step events, the availa‐
ble drug therapies for colorectal cancer are largely ineffective. The radiotherapy, photody‐
namic therapy, and chemotherapy are associated with severe side effects and offer no firm
expectation for a cure. Thus, there is a constant need for the investigation of other potential‐
ly useful options. One of the widely sought approaches is cancer chemoprevention that uses
natural agents to reverse or inhibit the malignant transformation of colon cancer cells and to
prevent invasion and metastasis [33]. Curcumin (diferuloylmethane), a natural plant prod‐
uct, possesses such chemopreventive activity that targets multiple signaling pathways in the
prevention of colon cancer development [34].Colon-targeting delivery of rhubarb extract, as
a purgative, may prevent absorption of free anthraquinones in the upper gastrointestinal
tract, thus improving clinical effects and lowering dosage [35, 36].Chemopreventive effects
of arctiin, a lignin isolated from Arctium lappa (burdock) seeds, on the initiation or post ini‐
tiation period of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) induced mam‐
mary carcinogenesis in female rats and on 2-amino-3, 8-dimethylimidazo[4,5-f]quinoxaline
(MeIQx)-associated hepatocarcinogenesis [37].
3. Plant peptides and proteins
Plant peptides and proteins may be considered an overlooked source for new chemical enti‐
ties and novel bioactivities compared to low molecular natural products. The reason for this
seems to be based on tradition and biased by the most commonly used techniques for natu‐
ral products. However, during the last decades, the number of reported plant peptides has
grown substantially, and the field is about to mushroom. In the form of Professor Gunnar
Samuelsson’s’ pioneering studies of mistletoe toxins was reported [38]. In the mid 1990san
attempt to assess plant peptides more broadly, with the design of an isolation protocol di‐
rectly designed for their isolation [39]. One of the results of this effort was the discovery of a
set of macrocyclic peptides in the plant family Violaceae [40]. Strikingly, the peptides we
characterized in Violaceae were found to be nearly identical with one of the most intriguing
examples of pharmacognostic research in general, and plant peptides in particular, namely
the peptide Kalata B1. The discovery of Kalata B1 was based on the ethno-pharmacological
use of the plant Oldenlandia affinis. It was experienced a high frequency of complicated de‐
liveries due to the use of this plant, which was locally known as ‘‘Kalata-Kalata’’ [41]. Na‐
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contractions, which sometimes developed into cervical spasms necessitating acute caesarean
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The complete sequence and the cyclic structure was however not determined for more than
20 years later [43].At the time of our report of the first cocktail of ‘‘palate-like’’ peptides in
Violaceae, four similar peptides had been reported in the literature as the serendipitous dis‐
coveries of three independent groups. When including those peptides in a sequence compar‐
ison, i.e. the anti-HIV circulins A and B, the neurotensin binding inhibitor cyclo-psychotride
A and the partially characterized violapeptide I, it was clear that they fell in two subgroups
based on sequencesimilarity. Today, around 150 cyclotides have been reported from species
of three plant families, Violaceae, Rubiaceae and Cucurbitaceae. The family Violaceae seems
to be particularly rich in these proteins [44-47] and a single Violaceae species may contain
more than 60 different cyclotides. It has been suggested that there might be 9,000 cyclotides
in the Violaceae alone[48].
In addition to the amide bond that cyclizes the backbone, cyclotides contain three stabilizing
disulfide bonds in a knotted arrangement, i.e. two disulfides form a ring together with their
connecting protein backbone, which is threaded by the third disulfide [49-51].
CCK motif, and make cyclotides extraordinary stable protein structures [52]. Besides being
uterotonic,anti-HIV, hemolytic and neurotensin binding inhibitory, the list now includes an‐
timicrobial [53], antifouling [54], antihelmintic, molluscicidal, cytotoxic [55, 56]) and insecti‐
cidal activities. The latter effects are some of the most well studied and interesting effects:
the cytotoxic effect together with the haemolytic effect have been the focus for detailed
structure activity studies [57, 58], and the discovery of their insecticidal effect likely revealed
cyclotides’ role in planta. Cyclotides’ mechanism of action is however yet unknown, but evi‐
dence is accumulating showing that membrane interactions followed by membrane pore or
fissure formation are involved [59-61], which could provide an explanation to several of the
reported effects.
Combined with the extraordinary CCK motif—with its conserved scaffold that can be
dressed with variable loop sequences—the demonstrated biological activity of the cyclotides
make them a first class target for protein engineering. To this end, inherent activities of na‐
tive cyclotides can be reinforced or abolished, or new biologically active peptide epitopes
can begrafted into the scaffold. For example, reinforcing the cytotoxic effect could potential‐
ly provide us with leads for anticancer drugs, or to completely remove that effect could pro‐
vide us with an inert scaffold ideal for grafting. The first successful grafting of a
biologicallyactive epitope was reported just recently, showing proof of concept [62].
The success of these strategies relies on the ability of efficient methods for production of cy‐
clotides and cyclotide mutants. Being gene products, cell based production systems seem
promising, but although cyclotide producing plant cell cultures have been established [63],
solid phase peptide synthesis is still the method of choice [64, 65].Our knowledge about
their biosynthesis is yet scarce. We know the structural arrangement of the cyclotide precur‐
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sor from cDNA, and that an asparaginyl endo-peptidase has a likely role for cleaving at the
N terminal side of the mature peptide and that protein disulfide isomerases seem to play a
role for their successful folding. However, the order of the events to produce mature cycloti‐
des is not yet known, i.e. if disulfide bonds are formed before or after excision and ligation,
and nothing is known about how these processes are controlled. In the perspective of ex‐
ploiting the cyclotide scaffold for engineering of bioactive peptides, the possibility of farm‐
ing designed molecules in plantar promises to be the optimal solution; the way there is still
long though.
Matrix metalloproteinase (MMP) are zinc-dependent endopeptidases that mediate numer‐
ous physiologic and pathologic processes, including matrix degradation, tissue remodeling,
inflammation, and tumor metastasis. To develop a vaccine targeting stromal antigens ex‐
pressed by cancer-associated fibroblasts, it was focused on MMP11 (or stromelysin 3).
MMP11 expression correlates with aggressive profile and invasiveness of different types of
carcinoma [66]. Overexpression of IL-12 and IL-23, which share the p40 subunit, has been
implicated in the pathogenesis of Crohn's disease. Targeting these cytokines with monoclo‐
nal antibodies has emerged as a new and effective therapy, but one with adverse reactions
[67]. Intestinal fibrosis and stricture formation are major complications of inflammatory
bowel disease (IBD), for which there are currently few effective treatments. It was investigat‐
ed whether targeting transforming growth factor-beta1 (TGF-beta1), a key profibrotic medi‐
ator, with a peptide-based virus-like particle vaccine would be effective in suppressing
intestinal fibrosis by using a mouse model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-in‐
duced chronic colitis [68]. Neutralization of macrophage migration inhibitory factor (MIF)
by anti-MIF antibody reduces intestinal inflammation in mice. Anti-MIF autoantibody in‐
duced by DNA vaccine targeting MIF protects mice against experimental colitis [69].
Overexpression of the proto-oncogene c-Myb occurs in more than 80% of colorectal cancer
(CRC) and is associated with aggressive disease and poor prognosis. To test c-Myb as a ther‐
apeutic target in CRC, which devised a DNA fusion vaccine to generate an anti-CRC im‐
mune response. c-Myb, like many tumor antigens, is weakly immunogenic as it is a "self"
antigen and subject to tolerance [70].Four novel oral DNA vaccines provide protection
against melanoma, colon, breast, and lung carcinoma in mouse models. Vaccines are deliv‐
ered by attenuated Salmonella typhimurium to secondary lymphoid organs and respective‐
ly target vascular endothelial growth factor receptor-2, transcription factor Fos-related
antigen-1, anti-apoptosis protein survivin and Legumain, an asparaginyl endopeptidase
specifically overexpressed on tumor-associated macrophages (TAMs) in the tumor microen‐
vironment (TME). These vaccines are all capable of inducing potent cell-mediated protective
immunity against self-antigens, resulting in marked suppression of tumor growth and dis‐
semination. Key mechanisms induced by these DNA vaccines include efficient suppression
of angiogenesis in the tumor vasculature and marked activation of cytotoxic T cells, natural
killer cells, and antigen-presenting dendritic cells [71]. Shigellosis is a major form of bacil‐
lary dysentery caused by Shigella infection. Shigella ribosome-based vaccines (SRV), consid‐
ered among the potent vaccine candidates, are composed of O-antigen and ribosome
isolated from S. flexneri 2a. The immunogenicity and protective efficacy of SRV was investi‐
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gated and mice were vaccinated with SRV via the intranasal route. Interestingly, robust lev‐
els of Shigella-derived LPS-specific IgG and IgA Abs and antibody-forming cells were
elicited in systemic and mucosal compartments following two intranasal administrations of
SRV. Groups of mice receiving intranasal SRV developed milder pulmonary pneumonia
upon challenge with virulent S. flexneri 2a than did those receiving parenteral SRV [72].
Over the past several years it has become apparent that the tumor stroma represents a sig‐
nificant target for anti-cancer therapies. Therefore we evaluated the strategy of targeting the
tumor stroma with a novel DNA vaccine encoding murine platelet derived growth factor re‐
ceptor-beta (mPDGFRbeta). Immunization with this vaccine induced cytotoxic lysis of
mPDGFRbeta-expressing target cells and protected mice from the growth and dissemination
of murine colon, breast and lung carcinoma. Furthermore, this novel vaccine suppresses an‐
giogenesis in vivo and reduces the numbers of tumor-associated, mPDGFRbeta-expressing
pericytes as suggested by a decrease in intra-tumor expression of mPDGFRbeta and NG2
[73].Viral vectors are under development for anticancer therapy. As they can infect tumors
and activate the immune system, viral vectors may directly destroy cancers (oncolysis), de‐
liver genes with antitumor activity directly to the cancer cells, or act as cancer vaccines. Bet‐
ter insights into the biology of the various vectors in use (e.g., poxvectors, adenovirus,
adeno-associated virus, retrovirus, Newcastle disease virus) are making it possible to engi‐
neer viruses that are more tumor-specific, efficient at tumor infection, and which have en‐
hanced safety due to incorporation of safeguards should dissemination occur [74].
Colorectal carcinoma is a leading cause of cancer-related mortality. Despite the introduc‐
tion of  new cytotoxic drugs,  improved surgical  and radiotherapeutic techniques,  a  large
proportion  of  colorectal  carcinomas  remain  incurable.  New  targeted  therapeutic  strat‐
egies,  including  immunotherapy,  are  being  explored  as  complementary  treatments.  Re‐
cent advances in immunology and molecular biology have opened new avenues for the
clinical testing of rationally designed vaccination strategies against cancer [75].The use of
retrogen plasmid-based vaccine technology to  break tolerance and to  generate  a  robust,
dose-dependent  antibody  response  against  the  self  cancer  antigen,  survivin.  This  phe‐
nomenon  is  due  to  the  incorporation  of  the  survivin  antigen  into  the  retrogen  system
rather than to some peculiarity unique to survivin. In contrast to other genetic immuni‐
zation methods designed to produce antibody responses, the retrogen system results in a
broad range of  antibody isotypes,  indicative of  both a  Th-1 and a Th-2 CD4+ response.
Additional evidence of a Th-1 response is demonstrated by tumor growth inhibition in a
mouse model of colon cancer metastasis [76].
An efficient strategy based on a fully synthetic dendrimeric carbohydrate display (multiple
antigenic glycolpeptide; MAG) to induce anti carbohydrate antibody responses for thera‐
peutic vaccination against cancer was developed. The superior efficacy of the MAG strategy
over the traditional keyhole limpet hemocyanin glycolconjugate to elicit an anticarbohy‐
drate IgG response against the tumor-associated Tn antigen was shown. The influence of the
glycolic carrier elements of such a tumor antigen for their recognition by the immune sys‐
tem was influenced. Finally, we additionally developed the MAG system by introducing
promiscuous HLA-restricted T-helper epitopes and performed its immunological evaluation
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sor from cDNA, and that an asparaginyl endo-peptidase has a likely role for cleaving at the
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isolated from S. flexneri 2a. The immunogenicity and protective efficacy of SRV was investi‐
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gated and mice were vaccinated with SRV via the intranasal route. Interestingly, robust lev‐
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neer viruses that are more tumor-specific, efficient at tumor infection, and which have en‐
hanced safety due to incorporation of safeguards should dissemination occur [74].
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nomenon  is  due  to  the  incorporation  of  the  survivin  antigen  into  the  retrogen  system
rather than to some peculiarity unique to survivin. In contrast to other genetic immuni‐
zation methods designed to produce antibody responses, the retrogen system results in a
broad range of  antibody isotypes,  indicative of  both a  Th-1 and a Th-2 CD4+ response.
Additional evidence of a Th-1 response is demonstrated by tumor growth inhibition in a
mouse model of colon cancer metastasis [76].
An efficient strategy based on a fully synthetic dendrimeric carbohydrate display (multiple
antigenic glycolpeptide; MAG) to induce anti carbohydrate antibody responses for thera‐
peutic vaccination against cancer was developed. The superior efficacy of the MAG strategy
over the traditional keyhole limpet hemocyanin glycolconjugate to elicit an anticarbohy‐
drate IgG response against the tumor-associated Tn antigen was shown. The influence of the
glycolic carrier elements of such a tumor antigen for their recognition by the immune sys‐
tem was influenced. Finally, we additionally developed the MAG system by introducing
promiscuous HLA-restricted T-helper epitopes and performed its immunological evaluation
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in nonhuman primates. MAG:Tn vaccines induced in all of the animals strong tumor-specif‐
ic anti-Tn antibodies that can mediate antibody-dependent cell cytotoxicity against human
tumor [77].
Overcoming immune tolerance of tumor angiogenesis should be useful for adjuvant therapy
of cancer, which hypothesized that vaccination with autologous endothelium would induce
an autoimmune response targeting tumor angiogenesis.The effect of autologous with a vac‐
cine of glutaraldehyde-fixed murine hepatic sinusoidal endothelial cells (HSEs) was more
pronounced than that of xenogeneic human umbilical vein endothelial cells (HUVECs),
which were tested in the same experimental setting. Its results suggest that vaccination with
autologous endothelium can overcome peripheral tolerance of self-angiogenic antigens and
therefore should be useful for adjuvant immunotherapy of cancer [78].Tumor cells are elu‐
sive targets for immunotherapy due to their heterogeneity and genetic instability. Here, a
novel, oral DNA vaccine that targets stable, proliferating endothelial cells in the tumor vas‐
culature rather than tumor cells was described. Targeting occurs through upregulated vas‐
cular-endothelial growth factor receptor 2 (FLK-1) of proliferating endothelial cells in the
tumor vasculature. This vaccine effectively protected mice from lethal challenges with mela‐
noma, colon carcinoma and lung carcinoma cells and reduced growth of established meta‐
stases in a therapeutic setting. CTL-mediated killing of endothelial cells indicated breaking
of peripheral immune tolerance against this self antigen, resulting in markedly reduced dis‐
semination of spontaneous and experimental pulmonary metastases. Angiogenesis in the tu‐
mor vasculature was suppressed without impairment of fertility, neuromuscular
performance or hematopoiesis, albeit with a slight delay in wound healing [79]. The
HER-2/neu oncogenic protein is a well-defined tumor antigen. HER-2/neu is a shared anti‐
gen among multiple tumor types. Patients with HER-2/neu protein-overexpressing breast,
ovarian, non-small cell lung, colon, and prostate cancers have been shown to have a pre-ex‐
istent immune response to HER-2/neu. No matter what the tumor type, endogenous im‐
munity to HER-2/neu detected in cancer patients demonstrates two predominant
characteristics. First, HER-2/neu-specific immune responses are found in only a minority of
patients whose tumors overexpress HER-2/neu. Secondly, immunity, if detectable, is of low
magnitude. These observations have led to the development of vaccine strategies designed
to boost HER-2/neu immunity in a majority of patients. HER-2/neu is a non-mutated self-
protein, therefore vaccines must be developed based on immunologic principles focused on
circumventing tolerance, a primary mechanism of tumor immune escape [80].Listeria mono‐
cytogenes is an intracellular organism that has the unusual ability to live in the cytoplasm of
the cell. It is thus a good vector for targeting protein antigens to the cellular arm of the im‐
mune response. Here, a model system, consisting of colon and renal carcinomas that express
the influenza virus nucleoprotein and a recombinant L. monocytogenes that secrets This an‐
tigen, to test the potential of this organism as a cancer immunotherapeutic agent, which
show that this recombinant organism can not only protect mice against lethal challenge with
tumour cells that express the antigen, but can also cause regression of established macro‐
scopic tumours in an antigen-specific T-cell-dependent manner.
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An efficient strategy for the targeting of anti-tumor effector cells were prepared bispecific
antibody (BsAb) containing anti-CD3 and an anti-c-erbB-2 proto-oncogene product.A troph‐
oblast cell surface antigen has been characterized by a monoclonal antibody (mAb) 5T4,
raised following immunization with solubilized wheat germ agglutinin binding glycopro‐
teins from human syncytiotrophoblast plasma membrane (StMPM) [81].
4. Plant peptides and proteins targets and regulation of this important
pathway
Aberrant activation of the canonical Wnt/beta-catenin pathway occurs in almost all colorec‐
tal cancers and contributes to their growth, invasion and survival. Phospholipase D (PLD)
has been implicated in progression of colorectal carcinoma However, an understanding of
the targets and regulation of this important pathway remains incomplete and besides, rela‐
tionship between Wnt signaling and PLD is not known [82].Fibroblast activation protein is a
product overexpressed by tumor-associated fibroblasts (TAF) and is the predominant com‐
ponent of the stoma in most types of cancer. Tumor-associated fibroblasts differ from nor‐
mal adult tissue fibroblasts, and instead resemble transient fetal and wound healing-
associated fibroblasts. Tumor-associated fibroblasts are critical regulators of tumor genesis,
but differ from tumor cells by being more genetically stable [83]. Capability of human adi‐
pose tissue-derived mesenchyme stem cells (AT-MSC) to serve as cellular vehicles for gene-
directed enzyme prodrug molecular chemotherapy. Yeast fusion cytosine deaminize : uracil
phosphorribosyltransferase expressing AT-MSC (CD y-AT-MSC) combined with systemic 5-
fluorocytosine (5FC) significantly inhibited growth of human colon cancer xenografts [84].
Dendritic cells (DCs), pulsed with the respective endothelium lysates significantly inhibited
the growth of subcutaneous tumors as well as pulmonary metastases in mice, and their anti-
tumor effect was superior to that of unparsed DCs. Immunohistopathological analysis
showed significant decrease in the mean vascular density of tumors, correlating well with
the extent of tumor inhibition. In vitro analysis of splenocytes isolated from immunized
mice revealed an induction of cytotoxic T lymphocytes and activation of natural killer cells,
with a lytic activity against activated endothelium but not tumor cells. In addition, antibod‐
ies reacting with activated endothelium [85]. Crohn's disease (CD) is an inflammatory bowel
disease that is associated with several changes in the immune system, including an in‐
creased number of infiltrating macrophages. These macrophages release a variety of pro-in‐
flammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) which are critically
involved in the onset and the development of CD. The present study was performed to ex‐
plore the initial involvement of macrophages in the development of T-cell-mediated chronic
colitis [86].
Tumor-associated fibroblasts are key regulators of tumor genesis. In contrast to tumor cells,
which are genetically unstable and mutate frequently, the presence of genetically more sta‐
ble fibroblasts in the tumor-stromal compartment makes them an optimal target for cancer
immunotherapy. These cells are also the primary source of collagen type I, which contrib‐
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in nonhuman primates. MAG:Tn vaccines induced in all of the animals strong tumor-specif‐
ic anti-Tn antibodies that can mediate antibody-dependent cell cytotoxicity against human
tumor [77].
Overcoming immune tolerance of tumor angiogenesis should be useful for adjuvant therapy
of cancer, which hypothesized that vaccination with autologous endothelium would induce
an autoimmune response targeting tumor angiogenesis.The effect of autologous with a vac‐
cine of glutaraldehyde-fixed murine hepatic sinusoidal endothelial cells (HSEs) was more
pronounced than that of xenogeneic human umbilical vein endothelial cells (HUVECs),
which were tested in the same experimental setting. Its results suggest that vaccination with
autologous endothelium can overcome peripheral tolerance of self-angiogenic antigens and
therefore should be useful for adjuvant immunotherapy of cancer [78].Tumor cells are elu‐
sive targets for immunotherapy due to their heterogeneity and genetic instability. Here, a
novel, oral DNA vaccine that targets stable, proliferating endothelial cells in the tumor vas‐
culature rather than tumor cells was described. Targeting occurs through upregulated vas‐
cular-endothelial growth factor receptor 2 (FLK-1) of proliferating endothelial cells in the
tumor vasculature. This vaccine effectively protected mice from lethal challenges with mela‐
noma, colon carcinoma and lung carcinoma cells and reduced growth of established meta‐
stases in a therapeutic setting. CTL-mediated killing of endothelial cells indicated breaking
of peripheral immune tolerance against this self antigen, resulting in markedly reduced dis‐
semination of spontaneous and experimental pulmonary metastases. Angiogenesis in the tu‐
mor vasculature was suppressed without impairment of fertility, neuromuscular
performance or hematopoiesis, albeit with a slight delay in wound healing [79]. The
HER-2/neu oncogenic protein is a well-defined tumor antigen. HER-2/neu is a shared anti‐
gen among multiple tumor types. Patients with HER-2/neu protein-overexpressing breast,
ovarian, non-small cell lung, colon, and prostate cancers have been shown to have a pre-ex‐
istent immune response to HER-2/neu. No matter what the tumor type, endogenous im‐
munity to HER-2/neu detected in cancer patients demonstrates two predominant
characteristics. First, HER-2/neu-specific immune responses are found in only a minority of
patients whose tumors overexpress HER-2/neu. Secondly, immunity, if detectable, is of low
magnitude. These observations have led to the development of vaccine strategies designed
to boost HER-2/neu immunity in a majority of patients. HER-2/neu is a non-mutated self-
protein, therefore vaccines must be developed based on immunologic principles focused on
circumventing tolerance, a primary mechanism of tumor immune escape [80].Listeria mono‐
cytogenes is an intracellular organism that has the unusual ability to live in the cytoplasm of
the cell. It is thus a good vector for targeting protein antigens to the cellular arm of the im‐
mune response. Here, a model system, consisting of colon and renal carcinomas that express
the influenza virus nucleoprotein and a recombinant L. monocytogenes that secrets This an‐
tigen, to test the potential of this organism as a cancer immunotherapeutic agent, which
show that this recombinant organism can not only protect mice against lethal challenge with
tumour cells that express the antigen, but can also cause regression of established macro‐
scopic tumours in an antigen-specific T-cell-dependent manner.
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oblast cell surface antigen has been characterized by a monoclonal antibody (mAb) 5T4,
raised following immunization with solubilized wheat germ agglutinin binding glycopro‐
teins from human syncytiotrophoblast plasma membrane (StMPM) [81].
4. Plant peptides and proteins targets and regulation of this important
pathway
Aberrant activation of the canonical Wnt/beta-catenin pathway occurs in almost all colorec‐
tal cancers and contributes to their growth, invasion and survival. Phospholipase D (PLD)
has been implicated in progression of colorectal carcinoma However, an understanding of
the targets and regulation of this important pathway remains incomplete and besides, rela‐
tionship between Wnt signaling and PLD is not known [82].Fibroblast activation protein is a
product overexpressed by tumor-associated fibroblasts (TAF) and is the predominant com‐
ponent of the stoma in most types of cancer. Tumor-associated fibroblasts differ from nor‐
mal adult tissue fibroblasts, and instead resemble transient fetal and wound healing-
associated fibroblasts. Tumor-associated fibroblasts are critical regulators of tumor genesis,
but differ from tumor cells by being more genetically stable [83]. Capability of human adi‐
pose tissue-derived mesenchyme stem cells (AT-MSC) to serve as cellular vehicles for gene-
directed enzyme prodrug molecular chemotherapy. Yeast fusion cytosine deaminize : uracil
phosphorribosyltransferase expressing AT-MSC (CD y-AT-MSC) combined with systemic 5-
fluorocytosine (5FC) significantly inhibited growth of human colon cancer xenografts [84].
Dendritic cells (DCs), pulsed with the respective endothelium lysates significantly inhibited
the growth of subcutaneous tumors as well as pulmonary metastases in mice, and their anti-
tumor effect was superior to that of unparsed DCs. Immunohistopathological analysis
showed significant decrease in the mean vascular density of tumors, correlating well with
the extent of tumor inhibition. In vitro analysis of splenocytes isolated from immunized
mice revealed an induction of cytotoxic T lymphocytes and activation of natural killer cells,
with a lytic activity against activated endothelium but not tumor cells. In addition, antibod‐
ies reacting with activated endothelium [85]. Crohn's disease (CD) is an inflammatory bowel
disease that is associated with several changes in the immune system, including an in‐
creased number of infiltrating macrophages. These macrophages release a variety of pro-in‐
flammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) which are critically
involved in the onset and the development of CD. The present study was performed to ex‐
plore the initial involvement of macrophages in the development of T-cell-mediated chronic
colitis [86].
Tumor-associated fibroblasts are key regulators of tumor genesis. In contrast to tumor cells,
which are genetically unstable and mutate frequently, the presence of genetically more sta‐
ble fibroblasts in the tumor-stromal compartment makes them an optimal target for cancer
immunotherapy. These cells are also the primary source of collagen type I, which contrib‐
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utes to decreased chemotherapeutic drug uptake in tumors and plays a significant role in
regulating tumor sensitivity to a variety of chemotherapies [87].
Conventional anticancer therapy using cytotoxic drugs lacks selectivity and is prone to tox‐
icity and drug resistance. Anticancer therapies targeting aberrant growth factor receptor sig‐
naling are gaining interest. The erbB receptor family belongs to the type I, the receptor
tyrosine kinases class, and comprises EGFR, HER-2, HER-3, and HER-4. It has been targeted
for solid tumor therapy, including breast, ovarian, colon, head-and-neck, and non-small-cell
lung cancers. Structural aspects of this class of growth factor receptors, their oncogenic ex‐
pression, and various pharmacological interventions including biological products and
small molecules that inhibit these enzymes [88].
Recent reports of tumor regression following delivery of autologous tumor antigen-pulsed
DCs suggest that defective antigen presentation may play a key role in tumor escape. Here,
it is shown in two different murine tumor models, CT26 (colon adenocarcinoma) and B16
(melanoma), that the number and activation state of intratumor DCs are critical factors in
the host response to tumors [89].Epidermal growth factor receptor (EGFR), a member of a
family of membrane receptors with tyrosine kinase activity, is emerging as a target candi‐
date for anti-cancer therapy, due to its overexpression in many carcinomas and its relation‐
ship with several hallmark properties of malignant behavior such as continuous cell
proliferation, escape from apoptosis, cell migration and angiogenesis. Specially appealing is
the overexpression of EGFR in tumors such as lung, colon, kidney and head and neck carci‐
nomas which are mostly resistant to current chemotherapy [90].
It was identified an organic solute transporter (OST) that is generated when two novel gene
products are co-expressed, namely human OSTalpha and OSTbeta or mouse OSTalpha and
OSTbeta. The results also demonstrate that the mammalian proteins are functionally com‐
plemented by evolutionarily divergent OST alpha-OST beta proteins recently identified in
the little skate, Raja erinaceous, even though the latter exhibit only 25-41% predicted amino
acid identity with the mammalian proteins. Human, mouse, and skate OSTalpha proteins
are predicted to contain seven trans membrane helices, whereas the OSTbeta sequences are
predicted to have a single trans membrane helix. co-expression is not required for proper
membrane targeting. Interestingly, OSTalpha and OSTbeta mRNAs were highly expressed
and widely distributed in human tissues, with the highest levels occurring in the testis, co‐
lon, liver, small intestine, kidney, ovary, and adrenal gland [91].Human mucin 1 (MUC1) is
an epithelial mucin glycoprotein that is overexpressed in 90% of all adenocarcinomas in‐
cluding breast, lung, pancreas, prostate, stomach, colon, and ovary. MUC1 is a target for im‐
mune intervention, because, in patients with solid adenocarcinomas, low-level cellular and
humoral immune responses to MUC1 have been observed, which are not sufficiently strong
to eradicate the growing tumor [92]. Efficient T cell priming by GM-CSF and CD40 ligand
double-transduced C26 murine colon carcinoma is not sufficient to cure metastases in a ther‐
apeutic setting [93].
A new therapy against colon cancer was developed and investigated two kinds of strategy
using a cancer-specific approach. First, employed the Cre/loxP regulation system to enhance
the specific expression by carcinoembryonic antigen (CEA) promoter in CEA-producing tu‐
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mor cells, and examined whether sufficient enhancement to transcriptional activity of CEA
promoter, which maintains its specificity in vitro and in vivo, could be obtained. Next, using
dendritic cells pulsed with HLA-A24 epitope peptides of CEA, we performed a Phase I
study of active immunotherapy in patients with advanced colon cancer. These results sug‐
gest that the newly developed therapy for colon cancer is a promising strategy; however,
minor modification may be necessary [94].Serum gastrin is known to be elevated in patients
with liver-metastasizing colon cancer; thus, cholecystokinin (CCK) B/gastrin receptors may
also be up-regulated. A liver-invasive model of colon cancer was established with the hu‐
man colonic cell line C170HM2, which expresses the CCKB/gastrin receptor at both the gene
and protein level. An antiserum has been derived that is directed against the NH2-terminal
17 amino acids of the human CCKB/gastrin receptor coupled to diphtheria toxoid. The pep‐
tide was denoted gastrin receptor protein (GRP) 1[95].2B1 is a bispecific murine monoclonal
antibody (BsMAb) with specificity for the c-erbB-2 and Fc gamma RIII extracellular do‐
mains. This BsMAb promotes the targeted lysis of malignant cells overexpressing the c-
erbB-2 gene product of the HER2/neu proto-oncogene by human natural killer cells and
mononuclear phagocytes expressing the Fc gamma RIII A isoform [96-98].
5. Methods of targeting colon drug delivery by natural products
The various targeting methods to the colon include coating with pH dependent polymers,
degradation by bacteria, specially azo-cross linked polymers and certain polysaccharides
such as pectin and guar gum are good carriers for formulation, which are presented in Table
1.To achieve successful colonic delivery, a drug needs to be protected from absorption and
the environment of the upper gastrointestinal tract and then be released into the proximal
colon, which is considered the optimum site for colon targeted delivery of natural com‐
pounds. Colon targeting is naturally of value for the treatment of diseases of colon such as
Chron’s disease, ulcerative colitis, and colorectal cancer.
6. Classification of targeting colon drug delivery system
Colon targeting drug delivery system is classified into three categories greatly and the rele‐
vant developed systems are published in many reports.
Firstly, Local Therapy - Higher local drug level can be achieved while minimizing side ef‐
fects that occur due to the release in the upper GIT.The system can treat local disease effec‐
tively such as constipation, irritable bowel disease and colon cancer.
Secondly,DelayedOnset - Maximal plasmalevel can be achieved in the morning hours after
bedtime administration by delayed onset of the system to adjust the circadian variations in
the signs and symptoms of disease such asrheumatoid arthritis, hypertension and etc.
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ship with several hallmark properties of malignant behavior such as continuous cell
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predicted to have a single trans membrane helix. co-expression is not required for proper
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and widely distributed in human tissues, with the highest levels occurring in the testis, co‐
lon, liver, small intestine, kidney, ovary, and adrenal gland [91].Human mucin 1 (MUC1) is
an epithelial mucin glycoprotein that is overexpressed in 90% of all adenocarcinomas in‐
cluding breast, lung, pancreas, prostate, stomach, colon, and ovary. MUC1 is a target for im‐
mune intervention, because, in patients with solid adenocarcinomas, low-level cellular and
humoral immune responses to MUC1 have been observed, which are not sufficiently strong
to eradicate the growing tumor [92]. Efficient T cell priming by GM-CSF and CD40 ligand
double-transduced C26 murine colon carcinoma is not sufficient to cure metastases in a ther‐
apeutic setting [93].
A new therapy against colon cancer was developed and investigated two kinds of strategy
using a cancer-specific approach. First, employed the Cre/loxP regulation system to enhance
the specific expression by carcinoembryonic antigen (CEA) promoter in CEA-producing tu‐
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tide was denoted gastrin receptor protein (GRP) 1[95].2B1 is a bispecific murine monoclonal
antibody (BsMAb) with specificity for the c-erbB-2 and Fc gamma RIII extracellular do‐
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such as pectin and guar gum are good carriers for formulation, which are presented in Table
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the environment of the upper gastrointestinal tract and then be released into the proximal
colon, which is considered the optimum site for colon targeted delivery of natural com‐
pounds. Colon targeting is naturally of value for the treatment of diseases of colon such as
Chron’s disease, ulcerative colitis, and colorectal cancer.
6. Classification of targeting colon drug delivery system
Colon targeting drug delivery system is classified into three categories greatly and the rele‐
vant developed systems are published in many reports.
Firstly, Local Therapy - Higher local drug level can be achieved while minimizing side ef‐
fects that occur due to the release in the upper GIT.The system can treat local disease effec‐
tively such as constipation, irritable bowel disease and colon cancer.
Secondly,DelayedOnset - Maximal plasmalevel can be achieved in the morning hours after
bedtime administration by delayed onset of the system to adjust the circadian variations in
the signs and symptoms of disease such asrheumatoid arthritis, hypertension and etc.
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Thirdly,Protein and Peptide Delivery - The colon is a "friendlier" environment for proteins,
peptides and vaccines compare to the upper GIT. Clinically relevant bioavailability may be
achieved if the drugs can be protected from the upper GIT.
7. Local targeting colon drug delivery
It was evaluated that colon targeting characteristic of Kuikang colon targeted pellets (KCP)
with determination of residual baicalin and baicalein concentration in gastrointestinal tract
(GIT).The major challenges in targeting drug to various parts of the gastrointestinal tract in‐
clude control of drug release with respect to its environment and transit time. These two
variables should be taken into consideration in designing a rational colonic drug delivery
system. To this end, a swelling matrix core containing pectin, hydroxylpropyl methylcellu‐
lose (HPMC), microcrystalline cellulose and 5-aminosalicylic acid was developed. This was
subjected to a dual coating operation: an inner pH-sensitive enteric and an outer semi-per‐
meable membrane coat with a pore former [99-101].
A pectin-hydroxylpropyl methylcellulose coating was compressed onto core tablets labeled
with 4MBq (99m)Tc-DTPA. Prolonged residence at the ICJ is assumed to have increased hy‐
dration of the hydrogel layer surrounding the core tablet. Forces applied as the tablets pro‐
gressed through the ICJ may have disrupted the hydrogel layer sufficiently to initiate
radiolabel release. Inadequate prior hydration of the hydrogel layer preventing access of
pectinolytic enzymes and reduced fluid availability in the TC may have retarded tablet dis‐
integration and radiolabel diffusion.
8. Delayed onset for targeting colon drug delivery
A multiparticulate system having pH-sensitive property and specific enzyme biodegradabil‐
ity for colon-targeted delivery of metronidazole was developed [102]. Pectin microspheres
were prepared using emulsion-dehydration technique. These microspheres were coated
with Eudragit(R) S-100 using oil-in-oil solvent evaporation method. The in vivo studies were
also performed by assessing the drug concentration in various parts of the GIT at different
time intervals which exhibited the potentiality of formulation for colon targeting. Hence, it
can be concluded that Eudragit coated pectin microspheres can be used for the colon specific
delivery of drug.
Designing pH-sensitive, polymeric nanoparticles of curcumin, a natural anti-cancer agent,
for the treatment of colon cancer, which enhance the bioavailability of curcumin, simultane‐
ously reducing the required dose through selective targeting to colon [103]. Eudragit S100
was chosen to aid targeting since the polymer dissolves at colonic pH to result in selective
colonic release of the entrapped drug. Solvent emulsion-evaporation technique was em‐
ployed to formulate the nanoparticles. The combined influence of 3 independent variables in
the compression coated tablet of mesalamine [104] for ulcerative colitis. A 3-factor, 3-level
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Box-Behnken design was used to derive a second order polynomial equation and construct
contour plots to predict responses. The independent variables selected were: percentage of
polymers (pectin and compritol ATO 888) in compression coating (X(1)), coating mass (X(2))
and coating force (X(3)). Fifteen batches were prepared and evaluated for percent of drug
released in 5 h (Y(5)), time required for 50 % mesalamine to dissolve (t(50)) with rat cecal
(RC) content and without rat cecal content (t(50)), percent of drug released in 24 h in the
presence of rat cecal content (Y(24) with RC) [105].
The colon specificity of novel natural polymer kaya gum and compare with guar gum. Re‐
lease profile of tablets was carried out in presence and absence of rat cecal contents. The fast
disintegrating core tablets of budesonide, were initially prepared by direct compression
technique. Later, these tablets were coated with kaya gum or guar gum. After suitable pre
compression and post compression evaluation, these tablets were further coated using Eu‐
dragit L-100 by dip coating technique [106].Enteric-coated calcium pectinase microspheres
(MS) aimed for colon drug delivery have been developed, by using theophylline as a model
drug. The influence of pectin type (animated or non-animated) and MS preparation condi‐
tions (CaCl2) concentration and cross-linking time) was investigated upon the drug entrap‐
ment efficiency and its release behavior. Pectin/ethyl cellulose-film-coated pellets of 5-
fluorouracil (5-FU) [107] for colonic targeting were characterized. The pellet cores were
coated to different film thicknesses with three different pectinethyl cellulose formulations
using a fluidized bed coater [108]. The gastrointestinal (GI) transit of coated pellets was de‐
termined by counting the percentage of coated pellets in the GI lumen by celiotomy at cer‐
tain times after oral administration. 5FU was administered to rats at a dose of 15 mg kg(-1).
The toxicity of 5-FU in the GI tract was evaluated using histological examination. The 1:2 ra‐
tio pectin:ethyl cellulose-coated pelletswith 30% total weight gain (TWG-30%) produced
more satisfactory drug-release profiles in the simulated gastric, intestinal and colonic fluids
[109]. Most of the coated pellets were eliminated from the stomach in 2 h, moved into the
small intestine after 2-4 h, and reached the large intestine after 4 h.A novel colon targeted
tablet formulation was developed using natural polysaccharides such as chitosan and guar
gum as carriers and diltiazem hydrochloride as model drug [110]. The prepared blend of
polymer-drug tablets were coated with two layers, inulin as an inner coat followed by shel‐
lac as outer coat and was evaluated for properties such as average weight, hardness and
coat thickness. In vitro release studies of prepared tablets were carried out for 2 h in pH 1.2
HCl buffers, 3 h in pH 7.4 phosphate buffer and 6 h in simulated colonic fluid (SCF) in order
to mimic the conditions from mouth to colon. Coated micro-pellets of pH-dependent and
enzyme-dependent kangfuxin colon targeting delivery system were prepared; to make them
go to colon, then release, educe partial effect [111].
The ingredients for preparing the micro-pellets are 125% starch +2% CMC-Na, and add 30%
ethanol to be binder, pellets were coated with Eudragit S100 to prepare pH-dependent and
pectin-HPMC to prepare enzyme-dependent colon targeting micro-pellets.
Guar gum/ethyl cellulose mix coated pellets for potential colon-specific drug delivery were
designed [112, 113]. The coated pellets, containing 5-fluorouracil as a model drug, were pre‐
pared in a fluidized bed coater by spraying the aqueous/ethanol dispersion mixture of guar
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Thirdly,Protein and Peptide Delivery - The colon is a "friendlier" environment for proteins,
peptides and vaccines compare to the upper GIT. Clinically relevant bioavailability may be
achieved if the drugs can be protected from the upper GIT.
7. Local targeting colon drug delivery
It was evaluated that colon targeting characteristic of Kuikang colon targeted pellets (KCP)
with determination of residual baicalin and baicalein concentration in gastrointestinal tract
(GIT).The major challenges in targeting drug to various parts of the gastrointestinal tract in‐
clude control of drug release with respect to its environment and transit time. These two
variables should be taken into consideration in designing a rational colonic drug delivery
system. To this end, a swelling matrix core containing pectin, hydroxylpropyl methylcellu‐
lose (HPMC), microcrystalline cellulose and 5-aminosalicylic acid was developed. This was
subjected to a dual coating operation: an inner pH-sensitive enteric and an outer semi-per‐
meable membrane coat with a pore former [99-101].
A pectin-hydroxylpropyl methylcellulose coating was compressed onto core tablets labeled
with 4MBq (99m)Tc-DTPA. Prolonged residence at the ICJ is assumed to have increased hy‐
dration of the hydrogel layer surrounding the core tablet. Forces applied as the tablets pro‐
gressed through the ICJ may have disrupted the hydrogel layer sufficiently to initiate
radiolabel release. Inadequate prior hydration of the hydrogel layer preventing access of
pectinolytic enzymes and reduced fluid availability in the TC may have retarded tablet dis‐
integration and radiolabel diffusion.
8. Delayed onset for targeting colon drug delivery
A multiparticulate system having pH-sensitive property and specific enzyme biodegradabil‐
ity for colon-targeted delivery of metronidazole was developed [102]. Pectin microspheres
were prepared using emulsion-dehydration technique. These microspheres were coated
with Eudragit(R) S-100 using oil-in-oil solvent evaporation method. The in vivo studies were
also performed by assessing the drug concentration in various parts of the GIT at different
time intervals which exhibited the potentiality of formulation for colon targeting. Hence, it
can be concluded that Eudragit coated pectin microspheres can be used for the colon specific
delivery of drug.
Designing pH-sensitive, polymeric nanoparticles of curcumin, a natural anti-cancer agent,
for the treatment of colon cancer, which enhance the bioavailability of curcumin, simultane‐
ously reducing the required dose through selective targeting to colon [103]. Eudragit S100
was chosen to aid targeting since the polymer dissolves at colonic pH to result in selective
colonic release of the entrapped drug. Solvent emulsion-evaporation technique was em‐
ployed to formulate the nanoparticles. The combined influence of 3 independent variables in
the compression coated tablet of mesalamine [104] for ulcerative colitis. A 3-factor, 3-level
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Box-Behnken design was used to derive a second order polynomial equation and construct
contour plots to predict responses. The independent variables selected were: percentage of
polymers (pectin and compritol ATO 888) in compression coating (X(1)), coating mass (X(2))
and coating force (X(3)). Fifteen batches were prepared and evaluated for percent of drug
released in 5 h (Y(5)), time required for 50 % mesalamine to dissolve (t(50)) with rat cecal
(RC) content and without rat cecal content (t(50)), percent of drug released in 24 h in the
presence of rat cecal content (Y(24) with RC) [105].
The colon specificity of novel natural polymer kaya gum and compare with guar gum. Re‐
lease profile of tablets was carried out in presence and absence of rat cecal contents. The fast
disintegrating core tablets of budesonide, were initially prepared by direct compression
technique. Later, these tablets were coated with kaya gum or guar gum. After suitable pre
compression and post compression evaluation, these tablets were further coated using Eu‐
dragit L-100 by dip coating technique [106].Enteric-coated calcium pectinase microspheres
(MS) aimed for colon drug delivery have been developed, by using theophylline as a model
drug. The influence of pectin type (animated or non-animated) and MS preparation condi‐
tions (CaCl2) concentration and cross-linking time) was investigated upon the drug entrap‐
ment efficiency and its release behavior. Pectin/ethyl cellulose-film-coated pellets of 5-
fluorouracil (5-FU) [107] for colonic targeting were characterized. The pellet cores were
coated to different film thicknesses with three different pectinethyl cellulose formulations
using a fluidized bed coater [108]. The gastrointestinal (GI) transit of coated pellets was de‐
termined by counting the percentage of coated pellets in the GI lumen by celiotomy at cer‐
tain times after oral administration. 5FU was administered to rats at a dose of 15 mg kg(-1).
The toxicity of 5-FU in the GI tract was evaluated using histological examination. The 1:2 ra‐
tio pectin:ethyl cellulose-coated pelletswith 30% total weight gain (TWG-30%) produced
more satisfactory drug-release profiles in the simulated gastric, intestinal and colonic fluids
[109]. Most of the coated pellets were eliminated from the stomach in 2 h, moved into the
small intestine after 2-4 h, and reached the large intestine after 4 h.A novel colon targeted
tablet formulation was developed using natural polysaccharides such as chitosan and guar
gum as carriers and diltiazem hydrochloride as model drug [110]. The prepared blend of
polymer-drug tablets were coated with two layers, inulin as an inner coat followed by shel‐
lac as outer coat and was evaluated for properties such as average weight, hardness and
coat thickness. In vitro release studies of prepared tablets were carried out for 2 h in pH 1.2
HCl buffers, 3 h in pH 7.4 phosphate buffer and 6 h in simulated colonic fluid (SCF) in order
to mimic the conditions from mouth to colon. Coated micro-pellets of pH-dependent and
enzyme-dependent kangfuxin colon targeting delivery system were prepared; to make them
go to colon, then release, educe partial effect [111].
The ingredients for preparing the micro-pellets are 125% starch +2% CMC-Na, and add 30%
ethanol to be binder, pellets were coated with Eudragit S100 to prepare pH-dependent and
pectin-HPMC to prepare enzyme-dependent colon targeting micro-pellets.
Guar gum/ethyl cellulose mix coated pellets for potential colon-specific drug delivery were
designed [112, 113]. The coated pellets, containing 5-fluorouracil as a model drug, were pre‐
pared in a fluidized bed coater by spraying the aqueous/ethanol dispersion mixture of guar
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gum and ethyl cellulose. The lag time of drug release and release rate were adjustable by
changing the ratio of guar gum to ethyl cellulose and coat weight gain. In order to find the
optimal coating formulation that was able to achieve drug targeting to the colon and con‐
cluded that mixed coating of guar gum and ethyl cellulose is able to provide protection of
the drug load in the upper gastrointestinal tract, while allowing enzymatic breakdown of
the hybrid coat to release the drug load in the colon.A pectin-based colon specific delivery
system bearing 5-fluorouracil (5-FU) was developed for effective delivery of drug to the co‐
lon. Calcium pectinate gel (CPG) beads were prepared by ion tropic gelation method fol‐
lowed by enteric coating with Eudragit S-100 [114, 115]. The CPG beads formed were
spherical with smooth surfaces.Eudragit S-100 coated calcium pectinate beads delivered
most of its drug load (93.2+/-3.67%) to the colon after 9 h, which reflects its targeting poten‐
tial to the colon. It is concluded that orally-administered 5-FU loaded Eudragit S-100 coated
calcium pectinate beads can be used effectively for the specific delivery of drug to the co‐
lon.Colon-targeted drug delivery systems for 5-fluorouracil using pectin combined with eth‐
yl cellulose as a film coat with fluidized bed coater were de4veloped. Pellets (0.8-1.0 mm in
diameter) containing 40% 5-fluorouracil and 60% microcrystalline cellulose were prepared
by extrusion and spheronization.Eudragit-coating of pectin microspheres was performed by
oil-in-oil solvent evaporation method using coat: core ratio (5:1). The release profile of FU
from Eudragitcoated pectin microspheres was pH dependent. In acidic medium, the release
rate was much slower; however, the drug was released quickly at pH 7.4. It is concluded
from the present investigation that Eudragitcoated pectin microspheres are promising con‐
trolled release carriers for colon-targeted delivery of FU.
Guar gum-based matrix  tablets  of  rofecoxib for  their  intended use in the chemopreven‐
tion  of  colorectal  cancer  were  developed and evaluated  [116].  Matrix  tablets  containing
40% (RXL-40), 50% (RXL-50), 60% (RXL-60) or 70% (RXL-70) of guar gum were prepared
by wet granulation technique. Colon delivery of beta-lactamases by pectin beads aiming
to degrade residual beta-lactam antibiotics, in order to prevent the emergence of resistant
bacterial strains[115]. Pectin beads were prepared according to inotropic gelation method
using CaCl2  as a gelling agent[117]. Particles were then washed and soaked in polyethy‐
leneimine (PEI). Coating beads with PEI considerably improved their stability in simulat‐
ed intestinal medium.
9. Polysaccharides as a strategy for targeting colon drug delivery
A variety of delivery strategies and systems have been proposed for colonic targeting. These
generally rely on the exploitation of one or more of the following gastrointestinal features
for their functionality: pH, transit time, pressure or micro flora. Coated systems that utilise
the pH differential in the gastrointestinal tract and prodrugs that rely on colonic bacteria for
release have been commercialized. Both approaches have their own inherent limitations.
Many systems in development have progressed no further than the bench, while others are
expensive or complex to manufacture, or lack the desired site-specificity. The universal pol‐
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ysaccharide systems appear to be the most promising because of their practicality and ex‐
ploitation of the most distinctive property of the colon, abundant micro flora.
Recent research into the utilization of the metabolic activity and the colonic microenviron‐
ment in the lower gastrointestinal tract has attained great value in the design of novel colon-
targeted delivery systems based on natural biodegradable polymers. In the current articles,
special emphasis has been placed on polysaccharide systems, with minimal chemical modi‐
fication, that have been exploitedfor colon targeting. These polysaccharide based encapsula‐
tion and targeted delivery systems are envisaged to have an immense potential for the
development of food/nutraceutical formulations for colon-based diseases, including colorec‐
tal cancer [118].Pectin-ketoprofen (PT-KP) prodrug with the potential for colon targeted de‐
livery has been evaluated and showed KP distributes mainly in stomach, proximal small
intestine and distal small intestine. However, KP released from PT-KP mainly distributes in
cecum and colon. Therefore, this approach suggests that PT-KP prodrug has a good colon
targeting property [119].
Compression coatings for target drug delivery to the colon using indometacin (a water in‐
soluble drug) and paracetamol (a water soluble drug) as model drugs were evaluated. The
core tablets were compression-coated with 300 and 400 mg of 100% kayas gum, 100% albizia
gum and a mixture of kaya and albizia gum (1:1). Colon targeted drug delivery systems
were developed for tinidazole using guar gum as a carrier in the treatment of amoebiasis.
Fast-disintegrating tinidazole core tablets were compression-coated with 55, 65 and 75% of
guar gum [120]. Colon-targeted drug delivery systems for ornidazole [121]using guar gum
as a carrier are developed.The core formulation containing ornidazole was directly com‐
pressed. Compression-coated tablets of ornidazole containing various proportions of guar
gum in the coat were prepared. Compression-coated ornidazole tablets with either 65%
(OLV-65) or 75% (OLV-75) of guar gum coat are most likely to provide targeting of ornida‐
zole for local action in the colon owing to its minimal release of the drug in the first 5 hr. The
ornidazole compression-coated tablets showed no change in physical appearance, drug con‐
tent, or in dissolution pattern after storage at 40 degrees C/75% relative humidity for 6
months [122-125].
Novel tablet formulations for site-specific delivery of 5-fluorouracil to the colon without the
drug being released in the stomach or small intestine using guar gum as a carrier were de‐
veloped. Fast-disintegrating 5-fluorouracil core tablets were compression coated with 60%
(FHV-60), 70% (FHV-70) and 80% (FHV-80) of guar gum [126]. Oral colon-targeting drug de‐
livery systems for celecoxib using guar gum as a carrier were developed. Matrix tablets con‐
taining various proportions of guar gum were prepared by wet granulation technique using
starch paste as a binder.Colon targeted drug delivery systems for metronidazole using guar
gum as a carrier were developed. Matrix, multilayer and compression coated tablets of met‐
ronidazole containing various proportions of guar gum were prepared [127].The influence
of metronidazole and tinidazole on the usefulness of guar gum, a colon-specific drug carrier
based on the metabolic activity of colonic bacteria, using matrix tablets of albendazole (con‐
taining 20% of guar gum) as a model formulation is reported.Colon targeted drug delivery
systems for mebendazole using guar gum as a carrier were developed. Matrix tablets con‐
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gum and ethyl cellulose. The lag time of drug release and release rate were adjustable by
changing the ratio of guar gum to ethyl cellulose and coat weight gain. In order to find the
optimal coating formulation that was able to achieve drug targeting to the colon and con‐
cluded that mixed coating of guar gum and ethyl cellulose is able to provide protection of
the drug load in the upper gastrointestinal tract, while allowing enzymatic breakdown of
the hybrid coat to release the drug load in the colon.A pectin-based colon specific delivery
system bearing 5-fluorouracil (5-FU) was developed for effective delivery of drug to the co‐
lon. Calcium pectinate gel (CPG) beads were prepared by ion tropic gelation method fol‐
lowed by enteric coating with Eudragit S-100 [114, 115]. The CPG beads formed were
spherical with smooth surfaces.Eudragit S-100 coated calcium pectinate beads delivered
most of its drug load (93.2+/-3.67%) to the colon after 9 h, which reflects its targeting poten‐
tial to the colon. It is concluded that orally-administered 5-FU loaded Eudragit S-100 coated
calcium pectinate beads can be used effectively for the specific delivery of drug to the co‐
lon.Colon-targeted drug delivery systems for 5-fluorouracil using pectin combined with eth‐
yl cellulose as a film coat with fluidized bed coater were de4veloped. Pellets (0.8-1.0 mm in
diameter) containing 40% 5-fluorouracil and 60% microcrystalline cellulose were prepared
by extrusion and spheronization.Eudragit-coating of pectin microspheres was performed by
oil-in-oil solvent evaporation method using coat: core ratio (5:1). The release profile of FU
from Eudragitcoated pectin microspheres was pH dependent. In acidic medium, the release
rate was much slower; however, the drug was released quickly at pH 7.4. It is concluded
from the present investigation that Eudragitcoated pectin microspheres are promising con‐
trolled release carriers for colon-targeted delivery of FU.
Guar gum-based matrix  tablets  of  rofecoxib for  their  intended use in the chemopreven‐
tion  of  colorectal  cancer  were  developed and evaluated  [116].  Matrix  tablets  containing
40% (RXL-40), 50% (RXL-50), 60% (RXL-60) or 70% (RXL-70) of guar gum were prepared
by wet granulation technique. Colon delivery of beta-lactamases by pectin beads aiming
to degrade residual beta-lactam antibiotics, in order to prevent the emergence of resistant
bacterial strains[115]. Pectin beads were prepared according to inotropic gelation method
using CaCl2  as a gelling agent[117]. Particles were then washed and soaked in polyethy‐
leneimine (PEI). Coating beads with PEI considerably improved their stability in simulat‐
ed intestinal medium.
9. Polysaccharides as a strategy for targeting colon drug delivery
A variety of delivery strategies and systems have been proposed for colonic targeting. These
generally rely on the exploitation of one or more of the following gastrointestinal features
for their functionality: pH, transit time, pressure or micro flora. Coated systems that utilise
the pH differential in the gastrointestinal tract and prodrugs that rely on colonic bacteria for
release have been commercialized. Both approaches have their own inherent limitations.
Many systems in development have progressed no further than the bench, while others are
expensive or complex to manufacture, or lack the desired site-specificity. The universal pol‐
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ysaccharide systems appear to be the most promising because of their practicality and ex‐
ploitation of the most distinctive property of the colon, abundant micro flora.
Recent research into the utilization of the metabolic activity and the colonic microenviron‐
ment in the lower gastrointestinal tract has attained great value in the design of novel colon-
targeted delivery systems based on natural biodegradable polymers. In the current articles,
special emphasis has been placed on polysaccharide systems, with minimal chemical modi‐
fication, that have been exploitedfor colon targeting. These polysaccharide based encapsula‐
tion and targeted delivery systems are envisaged to have an immense potential for the
development of food/nutraceutical formulations for colon-based diseases, including colorec‐
tal cancer [118].Pectin-ketoprofen (PT-KP) prodrug with the potential for colon targeted de‐
livery has been evaluated and showed KP distributes mainly in stomach, proximal small
intestine and distal small intestine. However, KP released from PT-KP mainly distributes in
cecum and colon. Therefore, this approach suggests that PT-KP prodrug has a good colon
targeting property [119].
Compression coatings for target drug delivery to the colon using indometacin (a water in‐
soluble drug) and paracetamol (a water soluble drug) as model drugs were evaluated. The
core tablets were compression-coated with 300 and 400 mg of 100% kayas gum, 100% albizia
gum and a mixture of kaya and albizia gum (1:1). Colon targeted drug delivery systems
were developed for tinidazole using guar gum as a carrier in the treatment of amoebiasis.
Fast-disintegrating tinidazole core tablets were compression-coated with 55, 65 and 75% of
guar gum [120]. Colon-targeted drug delivery systems for ornidazole [121]using guar gum
as a carrier are developed.The core formulation containing ornidazole was directly com‐
pressed. Compression-coated tablets of ornidazole containing various proportions of guar
gum in the coat were prepared. Compression-coated ornidazole tablets with either 65%
(OLV-65) or 75% (OLV-75) of guar gum coat are most likely to provide targeting of ornida‐
zole for local action in the colon owing to its minimal release of the drug in the first 5 hr. The
ornidazole compression-coated tablets showed no change in physical appearance, drug con‐
tent, or in dissolution pattern after storage at 40 degrees C/75% relative humidity for 6
months [122-125].
Novel tablet formulations for site-specific delivery of 5-fluorouracil to the colon without the
drug being released in the stomach or small intestine using guar gum as a carrier were de‐
veloped. Fast-disintegrating 5-fluorouracil core tablets were compression coated with 60%
(FHV-60), 70% (FHV-70) and 80% (FHV-80) of guar gum [126]. Oral colon-targeting drug de‐
livery systems for celecoxib using guar gum as a carrier were developed. Matrix tablets con‐
taining various proportions of guar gum were prepared by wet granulation technique using
starch paste as a binder.Colon targeted drug delivery systems for metronidazole using guar
gum as a carrier were developed. Matrix, multilayer and compression coated tablets of met‐
ronidazole containing various proportions of guar gum were prepared [127].The influence
of metronidazole and tinidazole on the usefulness of guar gum, a colon-specific drug carrier
based on the metabolic activity of colonic bacteria, using matrix tablets of albendazole (con‐
taining 20% of guar gum) as a model formulation is reported.Colon targeted drug delivery
systems for mebendazole using guar gum as a carrier were developed. Matrix tablets con‐
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taining various proportions of guar gum were prepared by wet granulation technique using
starch paste as a binder [128, 129].
Controlling the delivery of drugs to different regions of the colon remains an elusive goal‐
was to define the diurnal variation in colonic transit and show how this influences the co‐
lonic distribution and residence time of different formulations given either in the morning
or evening. Colonic transit of small particulates and a large capsule was measured during
nocturnal sleep and daytime wakefulness. Sleep delays colonic transit and large capsules
travel faster than dispersed small particles. However, substantial inter-individual variability
in transit makes targeting specific regions of the human colon unreliable with either dis‐
persed or single unit formulations [130].
Targeting of drugs to the colon, following oral administration, can be accomplished by the
use of modified, biodegradable polysaccharides as vehicles. In a previous study, a cross‐
linked low swelling guar gum (GG) hydrogel was synthesized by reacting it with trisodium
trimetaphosphate (STMP). In the present study the functioning of GG crosslinked products
(GGP) as possible colon-specific drug carriers was analyzed by studying (a) the release ki‐
netics of pre-loaded hydrocortisone from GGP hydrogels into buffer solutions with, or with‐
out GG degrading enzymes (alpha-galactosidase and beta-mannanase) and (b) direct
measurements of the polymers' degradation [131]. Calcium pectinate preparations for drug
delivery to the colon were investigated and highlight the value of scintigraphy in focusing
the development strategy for colonic targeting preparations.
One of the review articles concluded that polysaccharide-based colon-targeted drug deliv‐
ery systems are effective when they are precisely activated by the physiological conditions
of the colon. Absence of enzymes during colonic disorders might hinder the activation of the
delivery system. To guarantee delivery of the drug to the colon, it is preferable to combine
polysaccharides with enteric or cellulose polymers [132]. The approach that is based on the
formulation of natural polysaccharides has been used as tools to deliver the drugs specially
to the colon as described in Table 1 and Table 2.
These polysaccharides remain intact in the physiological environment of stomach and small
intestine but once the dosage form enters into colon, it is acted upon by polysaccharides,
which degrades the polysaccharide and release the drug into the vicinity of bio-environment
of colon (Table 3).As shown in Figure 1 the designed drug delivery systems have been de‐
veloped that are based on the principle to prevent release of drug until 3-4 h after leaving
the stomach, which are correspond to blood concentration profile as illustrated in Figure 2.
With the respect to natural products improved drug delivery systems are required for drugs
currently in use to treat localized disease of the colon. The advantages of targeting drugs
specially to the diseased colon are reduced incidence of systemic side effects, lower dose of
drug, supply of the drug to the bio phase only when it is required and maintenance of the
drug its intact form as close as possible to target site. Thus, the natural and modified proper‐
ties of polysaccharides that are responsible for their colon targeting abilities. Among the dif‐
ferent approaches used, polysaccharides that are precisely activated by the physiological
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conditions of the colon hold great promise, as they provide improved site specificity and
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Figure 2. Blood plasma concentration profile of nifedipinetablet(top) and soft(bottom) capsule verse disintegration
time
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taining various proportions of guar gum were prepared by wet granulation technique using
starch paste as a binder [128, 129].
Controlling the delivery of drugs to different regions of the colon remains an elusive goal‐
was to define the diurnal variation in colonic transit and show how this influences the co‐
lonic distribution and residence time of different formulations given either in the morning
or evening. Colonic transit of small particulates and a large capsule was measured during
nocturnal sleep and daytime wakefulness. Sleep delays colonic transit and large capsules
travel faster than dispersed small particles. However, substantial inter-individual variability
in transit makes targeting specific regions of the human colon unreliable with either dis‐
persed or single unit formulations [130].
Targeting of drugs to the colon, following oral administration, can be accomplished by the
use of modified, biodegradable polysaccharides as vehicles. In a previous study, a cross‐
linked low swelling guar gum (GG) hydrogel was synthesized by reacting it with trisodium
trimetaphosphate (STMP). In the present study the functioning of GG crosslinked products
(GGP) as possible colon-specific drug carriers was analyzed by studying (a) the release ki‐
netics of pre-loaded hydrocortisone from GGP hydrogels into buffer solutions with, or with‐
out GG degrading enzymes (alpha-galactosidase and beta-mannanase) and (b) direct
measurements of the polymers' degradation [131]. Calcium pectinate preparations for drug
delivery to the colon were investigated and highlight the value of scintigraphy in focusing
the development strategy for colonic targeting preparations.
One of the review articles concluded that polysaccharide-based colon-targeted drug deliv‐
ery systems are effective when they are precisely activated by the physiological conditions
of the colon. Absence of enzymes during colonic disorders might hinder the activation of the
delivery system. To guarantee delivery of the drug to the colon, it is preferable to combine
polysaccharides with enteric or cellulose polymers [132]. The approach that is based on the
formulation of natural polysaccharides has been used as tools to deliver the drugs specially
to the colon as described in Table 1 and Table 2.
These polysaccharides remain intact in the physiological environment of stomach and small
intestine but once the dosage form enters into colon, it is acted upon by polysaccharides,
which degrades the polysaccharide and release the drug into the vicinity of bio-environment
of colon (Table 3).As shown in Figure 1 the designed drug delivery systems have been de‐
veloped that are based on the principle to prevent release of drug until 3-4 h after leaving
the stomach, which are correspond to blood concentration profile as illustrated in Figure 2.
With the respect to natural products improved drug delivery systems are required for drugs
currently in use to treat localized disease of the colon. The advantages of targeting drugs
specially to the diseased colon are reduced incidence of systemic side effects, lower dose of
drug, supply of the drug to the bio phase only when it is required and maintenance of the
drug its intact form as close as possible to target site. Thus, the natural and modified proper‐
ties of polysaccharides that are responsible for their colon targeting abilities. Among the dif‐
ferent approaches used, polysaccharides that are precisely activated by the physiological
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conditions of the colon hold great promise, as they provide improved site specificity and
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Polysaccharides Main Chains Side Chains Bacterial Species







Guar Gum 1) α-1,4 D-mannose
2) α-1,3 or α-1,4 D-galactose
α-1,6 D-galactose Bacteroides ,
Ruminococci
Amylose α-1,4 D-glucose -  








Cyclodextrine α-1,4 D-glucose - Bacteroides
Dextran α-1,6 D-glucose α-1,3 D-glucose Bacteroides
Xylan β-1,4 D-xylose β-1,3 L-arabinose Bacteroides ,
Bifidobacteria
Table 1. Main Structural Features of Polysaccharides
System CoLar ® CSDS Colon Delivery System
Developer Allyzyme (U.K ) Samyang Co., ( Korea ) Perio ( Israel )
Composition Amylose+Ethylcellulose Coating Tablet or Soft capsule coated
with Polysaccharide
1) Fast release: Ca.P + P
2) Slow release:Ca.P + GG



























Table 2. Microbial Degradable Colon Delivery System.
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System Targit ® Chronotopic ® CTDC ® Colon Delivery
System





Composition Starch Capsule +
Enteric Coating
1) 1st : Core Tablet
2)2nd:Low-Viscosity
HPMC
3) 3rd : Eudragit
1) 1st layer: Eudragit L
2) 2nd layer: HPMC





Coated Capsule Coated tablet Coated Capsule Coated Tablet




Indication I.B.D. I.B.D. - I.B.D.
Stage System Development Phase II ( Italy ) System Development Phase III ( Italy )
Licensee Western Pharma. - - -
Table 3. Time-Controlled &pH-Controlled Colon Delivery System
10. Protein and peptide drug targeting colon delivery
Targeted delivery to the gastrointestinal tract requires a multi-disciplinary approach to re‐
search involving contributions from polymer and material scientists, gastroenterologists,
pharmaceutical scientists and technologists. Intestinal delivery is important not only for
drugs that act locally, but also for those with systemic activity [133, 134]. In particular, there
is considerable interest in the oral delivery of peptides and it is felt that the colon may pro‐
vide an advantageous absorption site for such molecules. The different targeting mecha‐
nisms available to the pharmaceutical scientist to provide site-specific delivery in the
gastrointestinal tract will be critically assessed. Delivery systems and targeting agents,
which are being developed for the delivery of drugs, may also be exploited for the delivery
of vaccines, since many of the delivery problems are common to both areas. Recent develop‐
ments in the design of oral antigen formulations was discussed in this review [135-137].
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1. Introduction
Nanotechnology is a rapidly evolving field of research and industrial innovation with many
potentially promising applications in agriculture, healthcare, engineering, processing, pack‐
aging or delivery of drugs or food supplements. Engineered nanomaterials (ENMs) already
became part of our daily life as food packaging agents, drug delivery systems, therapeutics,
biosensors, etc. In 2011, according to the Woodrow Wilson Nanotechnology Consumer
Products Inventory, Ag nanoparticles (Ag-NPs) were the most commonly consumed ENMs,
followed by TiO2, SiO2, ZnO, Au, Pt, etc (http://www.nanotechproject.org). By the most re‐
cent definition of European Parliament and Council [1] ‘nanomaterial’ (NM) is any material
that is characterized to have at least one dimension ≤ 100 nm, or that comprises of separate
functional parts either internal or on the surface, which have one or more dimensions ≤ 100
nm, including structures, e.g. agglomerates or aggregates, which may be larger than 100 nm,
but which retain the typical properties of nanoscale.
In many countries ENMs are already used as food supplements and in food packaging: (i)
nanoclays as diffusion barriers [2]; (ii) Ag-NPs as antimicrobial agent [3,4]; (iii) silicates and
aluminosilicates (E554, E556, E559) as anti-caking and anti-clumping agents and in tooth‐
pastes, cheeses, sugars, powdered milks, etc [5]; (iv) TiO2 (E171) for whitening and brighten‐
ing, e.g. in sauces and dressings, in certain powdered foods [6], etc. According to
FAO/WHO report [7] the ENMs have several current or projected applications in the agro‐
food sector: nanostructured food ingredients; nanodelivery systems; organic and inorganic
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potentially promising applications in agriculture, healthcare, engineering, processing, pack‐
aging or delivery of drugs or food supplements. Engineered nanomaterials (ENMs) already
became part of our daily life as food packaging agents, drug delivery systems, therapeutics,
biosensors, etc. In 2011, according to the Woodrow Wilson Nanotechnology Consumer
Products Inventory, Ag nanoparticles (Ag-NPs) were the most commonly consumed ENMs,
followed by TiO2, SiO2, ZnO, Au, Pt, etc (http://www.nanotechproject.org). By the most re‐
cent definition of European Parliament and Council [1] ‘nanomaterial’ (NM) is any material
that is characterized to have at least one dimension ≤ 100 nm, or that comprises of separate
functional parts either internal or on the surface, which have one or more dimensions ≤ 100
nm, including structures, e.g. agglomerates or aggregates, which may be larger than 100 nm,
but which retain the typical properties of nanoscale.
In many countries ENMs are already used as food supplements and in food packaging: (i)
nanoclays as diffusion barriers [2]; (ii) Ag-NPs as antimicrobial agent [3,4]; (iii) silicates and
aluminosilicates (E554, E556, E559) as anti-caking and anti-clumping agents and in tooth‐
pastes, cheeses, sugars, powdered milks, etc [5]; (iv) TiO2 (E171) for whitening and brighten‐
ing, e.g. in sauces and dressings, in certain powdered foods [6], etc. According to
FAO/WHO report [7] the ENMs have several current or projected applications in the agro‐
food sector: nanostructured food ingredients; nanodelivery systems; organic and inorganic
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nanosized additives; nanocoatings on food contact surfaces; surface functionnalized NMs;
nanofiltration; nanosized agrochemicals; nanosensors; water decontamination, …
With an increasing number of ENMs present in consumer and industrial products, the risk
of human exposure increases and this may become a threat to human health and the envi‐
ronment [8]. Individual ENMs may lead to one or more endpoints, which are not unique to
NMs, but which need to be taken into account, e.g. cytotoxicity, stimulation of an inflamma‐
tory response, generation of reactive oxygen species (ROS) and/or genotoxicity. Although
the exact mechanism underlying NPs toxicity is yet to be elucidated, studies have suggested
that oxidative stress and lipid peroxidation regulate the NP-induced DNA damage, cell
membrane disruption and cell death [9-12]. It has been suggested that ROS, in turn, modu‐
late intracellular calcium concentrations, activate transcription factors, induce cytokine pro‐
duction [13], as well as lead to increased inflammation [14,15]. Small sized metallic NPs, e.g.
Ag-NPs, TiO2, Co-NPs may also cause DNA damage [16-20]. In vitro studies with different
types of NPs (metal/metal oxide, TiO2, carbon nanotubes, silica) on various cell lines have
demonstrated oxidative stress-related inflammatory reactions. It is believed that this re‐
sponse is largely driven by the specific surface area of the NPs and/or their chemical compo‐
sition [21-25]. Typically, the biological activity of particles increases with the particle size
decrease [26-29]. Moreover, depending on their chemistry, NPs show different cellular up‐
take, subcellular localization and ability to induce the ROS production [30]. On the contrary,
there are also cases reported of NPs having anti-inflammatory properties, such as certain Ce
oxide [31] and Ag-NPs [32]. Nanocrystalline Ag has been demonstrated to have antimicrobi‐
al and anti-inflammatory properties and was found to reduce colonic inflammation follow‐
ing oral administration in a rat model of ulcerative colitis, suggesting that nano-silver may
have therapeutic potential for treatment of this condition [32].
To sum up, based on the information currently available, no generic assumptions can be
made regarding the toxicity upon exposure to NMs, their endpoints and the implications of
different organs and tissues.
2. Behavior and fate of ENMs in the GIT
The gastrointestinal tract (GIT) is a complex barrier-exchange system and is one of the most
important routes for macromolecules to enter the body, as well as a key actor of the immune
system. The epithelium of the small and large intestines is in close contact with ingested ma‐
terials, which are absorbed by the villi. To date, studies on exposure, absorption and bioa‐
vailability are mainly focused on the inhalation and dermal routes, and little is known about
the toxicokinetic and toxicodynamic processes following oral exposure, particularly in rela‐
tion to ingestion of ENMs that are present in food.
ENMs can reach the GIT either after mucociliary clearance from the respiratory tract af‐
ter  being  inhaled  [33],  or  can  be  ingested  directly  in  food,  water,  drugs,  drug delivery
devices,  etc  [8,34].  The dietary consumption of  NPs in developed countries  is  estimated
around 1012  particles/person per day,  consisting mainly of  TiO2 and mixed silicates [35].
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It has been shown that several characteristics, such as (i) the particle size [36], (ii) surface
charge [37],  (iii)  attachment  of  ligands [38,39],  (iv)  coating with surfactants  [40],  as  well
as (v)  the administration time and dose [41] affect  the fate and extent of  ENMs absorp‐
tion in GIT. The published literature on the safety of oral exposure to food-related ENMs
currently  provides insufficient  reliable  data  to  allow a clear  safety assessment  of  ENMs
[42]  that  is  connected primarily  with  inadequate  characterization  of  ENMs [43].  For  in‐
stance, it has been demonstrated that smaller particles cross the colonic mucus layer fast‐
er  than  larger  ones  [37].  The  NPs  kinetics  in  the  GIT  also  depends  strongly  on  their
charge,  i.e.  positively  charged  latex  particles  remain  trapped  in  the  negatively  charged
mucus,  while  negatively charged ones diffuse across  the mucus layer  and their  interac‐
tion with epithelial cells becomes possible [41].
NPs that pass the mucus barrier may be translocated through the intestinal epithelium,
which will depend not only on physicochemical characteristics of NPs [36-41], but also on
the physiological state of the GIT [44]. The translocation of NPs potentially used as food
components through the GIТ remains to be explored [45]. Much of the current knowledge
concerning the potential toxicity of NPs has been gained from in vitro or in silico test sys‐
tems. Following ingestion, translocation of particles across the GIT can occur via different
pathways:
1. Endocytosis through ‘regular’ epithelial cells (NPs < 50 - 100 nm) [46].
2. Transcytosis via microfold (M) cell uptake at the surface of intestinal lymphoid tissue
(NPs of 20 - 100 nm and small microparticles i.e. 100 - 500 nm) [47]. M cells are special‐
ized phagocytic enterocytes that are localized in intestinal lymphatic tissue – Peyer’s
Patches (PP). This transcytotic pathway occurs via vesicle formation at the apical (i.e.
luminal) cell membrane that engulfs some extracellular material, which then moves
across the cell, escaping therefore to fusion with lysosomes, fuses with the basolateral
membrane (i.e. serosal) and releases the material at the opposite side of the intestinal
barrier. The mechanism is size-dependent - the smaller the particle, the easier is the pas‐
sage through the epithelium [48-50].
3. Persorption, where ‘old’ enterocytes are extruded from the villus into the gut lumen,
leaving ‘holes’ in the epithelium, which allow translocation of even large particles, such
as starch and pollen [51-53].
4. Another possible route by which NPs can gain access to the gastrointestinal tissue is the
paracellular route across tight junctions (TJs) of the epithelial cell layer. TJs are remarka‐
bly efficient at preventing paracellular permeation, although their integrity can be af‐
fected by diseases, e.g. inflammation, and/or by metabolites (e.g. glucose), calcium
chelators (e.g. citrate) [54] and even particle endocytosis [55].
All above-mentioned routes could be involved in NPs translocation. There are a number of
published reports stating the involvement of different types of endocytosis in the process of
NPs internalization: clathrin-mediated pathway, caveolin-mediated endocytosis and macro‐
pinocytosis for TiO2 [56], size-dependent endocytosis for Au-NPs [57]; endocytotic path‐
ways were described for SiO2 [58,59] and Ag-NPs [60], etc.
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Several studies demonstrated that the phenomenon of persorption is also true for NPs, e.g.
in the case of colloidal Au-NPs [36]. Small and large NPs gain potentially access to this
route, nevertheless its quantitative relevance remains low, as it seems to be very inefficient
compared to the active uptake of particles by M-cells. For instance, it was indicated that one
lymphoid follicle dome of the rabbit PP could transport about 105 microparticles of 460 nm
diameter in 45 min [61]. It could be assumed that for smaller particles this would be even
more efficient.
Particulate uptake may occur not only via the M-cells of the lymphoid follicle-associated ep‐
ithelium (FAE) in PP [49,62], but also via the normal intestinal enterocytes [46]. A number of
reports on intestinal uptake of micro- and nanoparticles state that the uptake of inert parti‐
cles occurs trans-cellularly through normal enterocytes and via M-cells [61,63-65], as well as,
to a lesser extent, through paracellular pathway [66].
3. Appropriate in vitro model of the intestinal barrier
There are several recognized parameters currently used for in vitro cytotoxicity assessment
of ENMs, such as cell viability, stress and inflammatory responses, genotoxicity, etc [67].
However, it should be noted that due to specific physicochemical properties of ENMs, cur‐
rently existing in vitro toxicity assays may have limited use and the methods should be care‐
fully designed in order to discard the influence of nano-sized materials on the assay itself
[28]. The risk assessment is further impaired by the lack of standardized test systems that
fulfil these criteria. According to the new European Chemicals Legislation (REACH), new
test systems for toxicity screening of ENMs should be developed, e.g. cell culture systems
that will better reflect in vivo toxicity parameters [68].
Human colon adenocarcinoma (Caco-2) cells reproducibly display a number of properties
characteristic to differentiated enterocytes and are the most popular cell culture system for
studying intestinal passage and transport [69,70]. Cultured Caco-2 cells differentiate sponta‐
neously into polarized monolayers [71] that possess an apical brush border and express
functional TJs, biotransformation enzymes and efflux pumps [72]. Caco-2 cells grow as a
monolayer and fully differentiate also on semi-permeable membranes of bicameral inserts.
This permits to separate the apical (AP) compartment from the basolateral (BL) one, reflect‐
ing the intestinal lumen and the serosal side, respectively [65]. Transport of molecules and
ions from the AP to the BL side and vice versa requires the passage either through the cells
(transcellular route) or between the cells through TJs (paracellular route).
The gut lining epithelium is for the most part impermeable to microorganisms and micro‐
particles, except for the lymphoid FAE found in PP [49,73,74]. M cells are responsible for
transport of antigens, bacteria, viruses, as well as micro- and NPs to the antigen presenting
cells within and under the epithelial barrier as the first step in developing immune respons‐
es [75]. There is only an incomplete and inadequate understanding of the development and
function of FAE, as well as of the genes and proteins responsible for their specialized func‐
tions. One potential approach to study such complex and specialized tissues is to use cell
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culture systems more precisely reproducing the features of the in vivo tissue. Kernéis et al.
[76] demonstrated that co-culturing of Caco-2 cells with murine PP lymphocytes appears to
convert Caco-2 cells into M-like cells, including enhanced transport of particles across the
epithelium monolayer. The induction of this phenotype did not require direct cell contact, as
it was also achieved via physically separated co-culturing of Caco-2 and human Burkitt's
lymphoma (Raji B) cells in bicameral culture inserts [77]. Although it is not clear whether
this model faithfully reproduces all of the features of in vivo M cell function, nevertheless
studies have confirmed that Caco-2 cells co-cultivated with Raji B cells in vitro express sever‐
al genes specifically expressed in FAE in vivo [78].
In an improved in vitro co-culture model in bicameral system Caco-2 cells were exposed to
lymphocytes from the BL chamber. In a so-called ‘inverted’ model (Figure 1) the lympho‐
cytes were shown to migrate into the monolayer and induce the conversion of the enterocyte
phenotype into the M-cells one [76,79]. Recently, des Rieux et al. [65] characterized the in‐
verted model and compared it with previously developed one [77]. According to these re‐
sults, in the inverted model, the M cell conversion rate was estimated to range between 15 -
30% (for comparison it was <10% in the human FAE [80]). The comparison of the in vitro
models revealed that the inverted model appears to be physiologically and functionally
more reproducible and efficient than the normally oriented one [65]. Thus this improved
model could be used to better characterize and understand the biological effects, absorption
and transportation mechanisms of NPs in intestinal cells.
Figure 1. Co-culture model of Caco-2 and Raji B cells [63].
4. Epithelial barrier integrity and inflammatory response under the
influence of NPs
During their differentiation epithelial cells develop junctional structures between the neigh‐
boring cells and form a tight protective barrier that restricts the absorption to some nutrients
and substances while, in the meantime, provides a physical barrier impairing the permea‐
tion of pro-inflammatory molecules, e.g. pathogens, toxins, antigens and xenobiotics from
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the luminal environment into the mucosal tissues and circulatory system. This barrier com‐
prises several structures [81], where the TJs are the most apical components of the junctional
complex and are the main gatekeepers of the epithelial paracellular passage. TJ barrier dis‐
ruption and increased paracellular permeability, followed by permeation of luminal pro-in‐
flammatory molecules can activate the mucosal immune system, resulting in chronic
inflammation and tissue damage [75]. Intestinal TJ barrier is evidenced to have a critical role
in the pathogenesis of intestinal and systemic diseases [82-84]. Under physio-pathological
conditions, pro-inflammatory cytokines, antigens and pathogens contribute to barrier im‐
pairment [85,86]. Considering the TJs integrity impairments under inflamed conditions, it
could be assumed that NPs that lead to stress and/or inflammatory responses could also in‐
fluence the TJs integrity.
Several methodological approaches allow measuring the barrier function in cell cultures,
e.g. the evaluation of the transepithelial electrical resistance (TEER) and the passage of
marker molecules, such as Lucifer Yellow (LY) [87]. Our results revealed that under the in‐
fluence of Ag-NPs < 20 nm, а disruption of the barrier integrity occurs. In figure 2A the
TEER values of both mono- and co-cultures of Caco-2 cells after 3h of incubation with differ‐
ent concentrations of Ag-NPs are shown. TEER values decreased as Ag-NPs concentration
increased, even though the reduction was less obvious in co-culture conditions – a model
that is closer to the physiological conditions of FAE.
 
A B 
Figure 2. TEER values (A) and LY passage (B) of mono- and co-cultures of Caco-2 cells upon incubation with Ag-NPs
(NM-300K, JRC repository, Ispra, IT) at 15 – 90 µg/ml. Experiments were conducted on mono- and co-cultures (i.e.
Caco-2 cells with Raji B lymphocytes) cultivated for 21 days in polycarbonate bicameral inserts with 3 µm pore size
(TranswellTM, Corning Costar, NY) to reach a full differentiation and, for co-cultures, partial conversion into M like cells.
TEER values were measured via Millicell-ERS volt-ohm meter (World Precision Instruments, Sarasota, FL) at the begin‐
ning and after 3h incubation period with Ag-NPs. The transport of LY was observed during 3h period with a 30 min
sampling time from the BL compartment. Both the changes in TEER values (P<0.0001) and the LY passage (P<0.003)
were calculated as a percentage from the initial value. Data represent the means ± SEM of 4 independent experi‐
ments. *Samples significantly different from the control (results were considered significant at P<0,05).
The passage of LY was evaluated by the amount of LY that passed from AP to BL compart‐
ment (Figure 2B). The presence of Ag-NPs increased the level of LY in the BL compartment
that was dependent on the NP concentration. These results are in correlation with the NP-
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induced reduction of TEER values. Interestingly, in contrast to TEER results, the co-cultures
had more elevated rate of LY passage than the corresponding mono-cultures.
To have an idea about the molecular mechanisms of the Ag-NPs-induced barrier integrity
disruption, an immunostaining with confocal microscopy analysis of two TJs proteins occlu‐
din and ZO-1 was realized. As illustrated on Figure 3, in Ag-NP-treated cells the continuity
of both occludin and ZO-1 was disrupted with the control comparison and the aggregation
of both proteins was observed. It should further be noted that mono-cultures were more
susceptible to the influence of Ag-NPs than co-cultures and the alterations in proteins distri‐
butions were more visible in mono-cultures. The immunostaining results in turn confirmed
the TEER data, where a more obvious reduction was estimated in the case of mono-cultures
(Figure 2).
Figure 3. Subcellular localization of the occludin and ZO-1 TJs scaffolding proteins. Mono- and co-cultures of Caco-2
cells grown on bicameral inserts were treated with Ag-NPs (45 µg/ml) for 3h and then processed for immunostaining
(B and D). Untreated cells were used as controls (A and C). In order to visualize the occludin and ZO-1 mouse anti-
Occludin and mouse anti-ZO-1 (both from Invitrogen) were used as primary antibodies, as well as Alexa Fluor 488
goat anti-mouse (Invitrogen) as the secondary antibody. Images were collected by confocal laser scanning micro‐
scope; scale bars are 15 and 25 µm for occludin and ZO-1 staining, respectively.
The observed changes were reversible at low Ag-NPs concentrations (up to 30 μg/ml): the
TEER values and TJs proteins distributions were recovered until the control level. Other
NPs were also reported to possess the ability to open the TJs. For instance, the chitosan NPs
were capable to open transiently and reversibly the epithelial TJs [88].
In contrast to Ag-NPs, we observed no change neither in TEER value and LY passage rate,
nor TJs proteins distributions upon incubation of cell mono- and co-cultures with amor‐
phous SiO2 < 25 nm (NM-200, JRC repository, Ispra, IT) (results not shown). These findings
provide additional evidence that the major input in the NPs-mediated barrier integrity dis‐
ruption seems to belong to the charge of the NPs. Particularly, it has been previously report‐
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flammatory molecules can activate the mucosal immune system, resulting in chronic
inflammation and tissue damage [75]. Intestinal TJ barrier is evidenced to have a critical role
in the pathogenesis of intestinal and systemic diseases [82-84]. Under physio-pathological
conditions, pro-inflammatory cytokines, antigens and pathogens contribute to barrier im‐
pairment [85,86]. Considering the TJs integrity impairments under inflamed conditions, it
could be assumed that NPs that lead to stress and/or inflammatory responses could also in‐
fluence the TJs integrity.
Several methodological approaches allow measuring the barrier function in cell cultures,
e.g. the evaluation of the transepithelial electrical resistance (TEER) and the passage of
marker molecules, such as Lucifer Yellow (LY) [87]. Our results revealed that under the in‐
fluence of Ag-NPs < 20 nm, а disruption of the barrier integrity occurs. In figure 2A the
TEER values of both mono- and co-cultures of Caco-2 cells after 3h of incubation with differ‐
ent concentrations of Ag-NPs are shown. TEER values decreased as Ag-NPs concentration
increased, even though the reduction was less obvious in co-culture conditions – a model
that is closer to the physiological conditions of FAE.
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Figure 2. TEER values (A) and LY passage (B) of mono- and co-cultures of Caco-2 cells upon incubation with Ag-NPs
(NM-300K, JRC repository, Ispra, IT) at 15 – 90 µg/ml. Experiments were conducted on mono- and co-cultures (i.e.
Caco-2 cells with Raji B lymphocytes) cultivated for 21 days in polycarbonate bicameral inserts with 3 µm pore size
(TranswellTM, Corning Costar, NY) to reach a full differentiation and, for co-cultures, partial conversion into M like cells.
TEER values were measured via Millicell-ERS volt-ohm meter (World Precision Instruments, Sarasota, FL) at the begin‐
ning and after 3h incubation period with Ag-NPs. The transport of LY was observed during 3h period with a 30 min
sampling time from the BL compartment. Both the changes in TEER values (P<0.0001) and the LY passage (P<0.003)
were calculated as a percentage from the initial value. Data represent the means ± SEM of 4 independent experi‐
ments. *Samples significantly different from the control (results were considered significant at P<0,05).
The passage of LY was evaluated by the amount of LY that passed from AP to BL compart‐
ment (Figure 2B). The presence of Ag-NPs increased the level of LY in the BL compartment
that was dependent on the NP concentration. These results are in correlation with the NP-
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induced reduction of TEER values. Interestingly, in contrast to TEER results, the co-cultures
had more elevated rate of LY passage than the corresponding mono-cultures.
To have an idea about the molecular mechanisms of the Ag-NPs-induced barrier integrity
disruption, an immunostaining with confocal microscopy analysis of two TJs proteins occlu‐
din and ZO-1 was realized. As illustrated on Figure 3, in Ag-NP-treated cells the continuity
of both occludin and ZO-1 was disrupted with the control comparison and the aggregation
of both proteins was observed. It should further be noted that mono-cultures were more
susceptible to the influence of Ag-NPs than co-cultures and the alterations in proteins distri‐
butions were more visible in mono-cultures. The immunostaining results in turn confirmed
the TEER data, where a more obvious reduction was estimated in the case of mono-cultures
(Figure 2).
Figure 3. Subcellular localization of the occludin and ZO-1 TJs scaffolding proteins. Mono- and co-cultures of Caco-2
cells grown on bicameral inserts were treated with Ag-NPs (45 µg/ml) for 3h and then processed for immunostaining
(B and D). Untreated cells were used as controls (A and C). In order to visualize the occludin and ZO-1 mouse anti-
Occludin and mouse anti-ZO-1 (both from Invitrogen) were used as primary antibodies, as well as Alexa Fluor 488
goat anti-mouse (Invitrogen) as the secondary antibody. Images were collected by confocal laser scanning micro‐
scope; scale bars are 15 and 25 µm for occludin and ZO-1 staining, respectively.
The observed changes were reversible at low Ag-NPs concentrations (up to 30 μg/ml): the
TEER values and TJs proteins distributions were recovered until the control level. Other
NPs were also reported to possess the ability to open the TJs. For instance, the chitosan NPs
were capable to open transiently and reversibly the epithelial TJs [88].
In contrast to Ag-NPs, we observed no change neither in TEER value and LY passage rate,
nor TJs proteins distributions upon incubation of cell mono- and co-cultures with amor‐
phous SiO2 < 25 nm (NM-200, JRC repository, Ispra, IT) (results not shown). These findings
provide additional evidence that the major input in the NPs-mediated barrier integrity dis‐
ruption seems to belong to the charge of the NPs. Particularly, it has been previously report‐
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ed that neutral and low concentrations of anionic NPs have no effect on blood-brain barrier
integrity, in contrast to anionic NPs at high concentrations and cationic NPs [89]. A number
of recent in vitro and in vivo studies highlight the importance of NPs surface charge for cellu‐
lar uptake and biodistribution [90-92], indicating that for the majority of NPs the positive
surface charge enhances cellular internalization [92-94]. The latter is likely linked to the ad‐
sorption of different bio-molecules at the surface of NPs, dependent on surface charge, as
well as on chemical characteristics of NPs [95].
Another underlying condition in the TJs disruption is likely to be the cellular oxidative
stress possibly induced by NPs [96]. Our results have shown that the fluorescence intensity
of an oxidative stress indicator dichlorofluorescein was increased upon exposure of cells to
Ag-NPs within a 3h time period (Figure 4). The ROS generation induction was dependent
on NPs concentration reaching from about 1,5 to 3-fold increase, as compared with the un‐
treated cells. Thus one mechanism of toxicity of Ag-NPs could likely be mediated by oxida‐
tive stress, already reported to be involved in the modulation of TJs integrity [97].
Figure 4. Effect of Ag-NPs (5 – 90 µg/ml) on intracellular ROS generation in Caco-2 cells. The ROS generation was
investigated using the dichlorofluorescein (DCFH) assay. After being oxidized by intracellular oxidants, DCFH becomes
DCF and emits fluorescence, quantification of which is a reliable estimation of overall oxygen species generation. The
intracellular ROS level is presented as a percentage of the corresponding initial value after incubation together with
NPs during 3h at 370C. Data represent means ± SEM of 3 experiments with 3 different samples per condition,
P<0.0001.
Altogether, the results reveal that some NPs, e.g. chitosan or Ag-NPs may enhance the epi‐
thelial barrier permeability and could therefore serve as an effective carrier for oral drug de‐
livery [44]. However, it should be noted that the epithelial permeability increase in turn
might favor the systemic absorption of ENMs, toxins and other xenobiotics, and would like‐
ly cause immune activation.
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5. Potential toxicity of ENMs in the case of altered intestinal physiology
It has been reported that the exposure to some NPs is associated with the occurrence of au‐
toimmune diseases, such as systemic lupus erythematosus, scleroderma, and rheumatoid ar‐
thritis [35]. Diseases, such as diabetes, may also lead to an increased absorption of particles
in the GIT [41]. Furthermore, inflammation may lead to the uptake and translocation of par‐
ticles of up to 20 nm [98]. Thus, an issue to be considered in relation to ENMs ingestion is a
possible increase in their intestinal absorption in the case of systemic exposures, such as in
Inflammatory Bowel Disease (IBD) and/or Crohn's disease (CD), which represent chronic
disorders characterized by recurrent and serious inflammation of the GIT [99]. Crohn’s dis‐
ease affects primarily people in developed countries, where the highest incidence rates and
prevalence for CD and ulcerative colitis (UC) have been reported from northern Europe, the
United Kingdom and North America [100] with a frequency of 1 in 1,000 people in the West‐
ern world [5]. However, reports of increasing incidence and prevalence from other areas of
the world, e.g. southern or central Europe, Asia, Africa, and Latin America state the progres‐
sive nature and worldwide rise of these diseases [100].
An abnormal intestinal barrier function plays a pivotal role in IBD [101]. Increased intestinal
permeability has been reproducibly described in patients with CD, which is likely a predis‐
posing factor to the pathogenesis and impaired epithelial resistance [102,103]. A barrier dys‐
function has been reported in the colonic mucosa of patients with Irritable Bowel Syndrome
(IBS), which results from increased paracellular permeability, presumably by an altered ex‐
pression of ZO-1 [104]. Moreover, stress is believed to contribute to induction of IBS and re‐
currence of intestinal inflammation and can increase the paracellular permeability [105]. It
should be noted that mediators of inflammation, such as ROS, endotoxins (lipopolysacchar‐
ides) and cytokines are able to provoke the disruption of TJs and thereby increase the para‐
cellular permeability [97]. Significant changes in epithelial TJs structure and function were
also observed in UC [106,107]. Thus the altered intestinal permeability could certainly be a
result of disease progression, but there is evidence that it might also be the primary causa‐
tive event.
Recently it was suggested that there could be an association between high levels of dietary
NPs uptake and CD. Experimental results indicate that the accumulation of insoluble NPs in
humans may be responsible for the compromised gastrointestinal functioning, as described
in the case of CD and UC [5]. Microscopy studies have also shown that macrophages located
in lymphoid tissue can uptake NPs, e.g. spherical anatase (TiO2) with size of 100-200 nm
from food additives, aluminosilicates of 100-400 nm typical of natural clay, and environmen‐
tal silicates of 100-700 nm [108]. According to another study, some insoluble NPs, such as
TiO2, ZnO and SiO2, upon their absorption and passage across the GIT, come into contact
with and adsorb calcium ions and lipopolysaccharides. The resulting NPs–calcium–lipopo‐
lysaccharide conjugates activate both peripheral blood mononuclear cells and intestinal
phagocytes, which are usually resistant to stimulation [109].
Despite the insufficiency of data linking the NPs consumption to the initiation of CD and
UC, it seems that particles of 0.1 – 1.0 μm may be adjuvant triggers for the exacerbation of
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these diseases [110]. Micro and NPs have been constantly found in organs, e.g. in colon tis‐
sue and blood of patients affected by cancer, CD, and UC, while in healthy subjects NPs
were absent [111]. Some evidence suggests that dietary NPs may exacerbate inflammation in
CD [6]. More precisely, some members of the population may have a genetic predisposition
where they are more affected by the intake of NPs, and therefore develop CD [9]. It has been
also reported that micro- and NPs in colon tissues may lead to cancer and CD progression
[111]. By contrast, a diet low in calcium and exogenous micro- and NPs has been shown to
alleviate the symptoms of CD [5]. This analysis is still controversial, with some proposing
that an abnormal response to dietary NPs may be the cause of this disease, and not an excess
intake [6].
Although there is a clear association between particle exposure/uptake and CD, little is
known of the exact role of the phagocytosing cells in the intestinal epithelium and particu‐
larly of the pathophysiological role of M cells. It has been shown that M cells are lost from
the epithelium in the case of CD. Other studies found that endocytotic capacity of M cells is
induced under various immunological conditions, e.g. a greater uptake of particles of 0.1 –
10 μm has been demonstrated in the inflamed colonic mucosa of rats compared to non-ul‐
cerated tissue [109,112].
Thus more vulnerable members of the population, i.e. those with pre-existing digestive dis‐
orders, may potentially be more affected by the presence of ENMs, although, in contrast,
ENMs may offer many potential routes to therapies for the same diseases. The diseases asso‐
ciated with gastrointestinal uptake of NPs, such as CD and UC have no cure and often re‐
quire surgical intervention. Treatments are aimed at maintaining the disease in remission
and mainly consist of anti-inflammatory drugs and specially formulated liquid meals [5]. If
dietary NPs are conclusively shown to cause these chronic diseases, their use in food should
be avoided or strictly regulated.
6. Potential health risks/benefits of nanotechnology-based food materials
The absorption, distribution, metabolism and excretion (ADME) parameters are likely to be
influenced by the aggregation, agglomeration, dispersability, size, solubility, and surface
area, charge and physico-chemistry of NPs [113]. Amongst these parameters the size, chemi‐
cal composition and surface treatment appear to be the most critical ones for nanotoxicity
issues [114]. Chemical composition, beside the chemical nature of the NP itself, also includes
the surface coating of the NPs [115]. Coatings can be used to stabilize the NPs in solution, to
prevent clustering or to add functionality to the NPs, depending on its intended use. Surface
coatings can influence the reactivity of the NPs in various media, including water, biological
fluids and laboratory test media [116,117]. From this point of view the interaction of NPs
with food components is another aspect that may need consideration and about which little
information is currently available. The possible interaction of food components may alter
the physicochemical properties of ENMs that in turn may influence their passage through
the GIT and their ADME properties.
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ENMs,  with  their  very  large  surface  areas,  may  adsorb  bio-molecules  on  their  surface
upon  contact  with  food  and/or  biological  fluids  to  form  a  bio-molecular  “corona”
[96,118]. Depending on the nature of the corona, the behavior of the NPs may differ, and
there  could  be  the  potential  for  novel  toxicities  non-characteristic  neither  for  the  non-
coated  NPs,  nor  for  the  adsorbed  biological  material.  These  bio-molecules  include  pro‐
teins, lipids, sugars, different secondary metabolites and it is those interactions that may
actually determine how ENMs will  interact  with living systems.  Thus,  the foregoing in‐
formation on the  food should be  considered carefully,  taking into  account  its  major  in‐
gredients  or  components,  which  have  physiological  properties  likely  to  influence  the
absorption/translocation of ENMs in the GIT.
Several studies have demonstrated that various food components provide beneficial anti-in‐
flammatory and anti-mutagenic effects in the GIT. Although the information regarding
these effects on intestinal TJ barrier integrity is limited, some results are available e.g. for
glutamine [119,120] and fatty acids [121-123]. A growing number of data suggest the poten‐
tial protective effect of phenolic compounds on the epithelial barrier function and their anti-
inflammatory properties [124,125]. In particular, certain flavonoids that represent a part of
human daily nutrition, e.g. epigallocatechin gallate, genistein, myricetin, quercetin and
kaempferol are reported to exhibit promotive and protective effects on intestinal TJ barrier
[124,126].
We have observed (unshown results) that quercetin attenuates the cytotoxic effect of Ag-
NPs on Caco-2 cells, as well as allows recovering of the epithelial barrier function, which
was evidenced by the recovery up to the initial value of the TEER and the LY passage rate in
both mono- and co-cultures. The immunostaining analysis of occludin and ZO-1 also re‐
vealed the recovery of the protein distributions in the presence of quercetin, which addition‐
ally suggests the protective effect of the latter upon the harmful effects of Ag-NPs. In a
similar study it was reported that positively charged Ni-NPs can efficiently enhance the per‐
meation and uptake of quercetin into cancer cells, which can have important biomedical and
chemotherapeutic applications [127].
A number of published reports indicate the potential application of antioxidants
[10,128-130] and anti-inflammatory drugs [6,131] that are able to treat the adverse health ef‐
fects caused by NPs. For instance, berberine, an alkaloid with a potential biomedical appli‐
cation, has been shown to attenuate TJ barrier defects induced by TNF-α, known to disrupt
TJ integrity in IBD [132]. It has been reported that rats that underwent instillation of NPs
into the lungs together with an antioxidant, i.e. nacystelin, showed an inflammation de‐
crease up to 60% in comparison to those exposed to NPs alone [10].
To have an idea about the state of Ag-NPs in the presence of quercetin, NPs were character‐
ized by transmission electron microscopy (TEM) (Figure 5). It could be seen that in the pres‐
ence of quercetin a “capping” of Ag-NPs occurs, which confirms already existing data on
Ag-NPs stabilization with reducing agents. Surface-active molecules, such as terpenoids
and/or reducing sugars are believed to stabilize the NPs in the solutions, i.e. they are be‐
lieved to react with the silver ions (Ag+) and stabilize the Ag-NPs [133,134]. Flavonoids have
been suggested to be responsible for the reduction of Ag+ to Ag-NPs [135]. Fatty acids such
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as stearic, palmitic and lauric acids are used as agents for the formation and stabilization of
Ag-NPs [136].
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Figure 5. TEM analysis of Ag-NPs < 20 nm (NM-300K) alone (A) and in the presence of quercetin (B). The average size
of Ag-NPs was about 20 nm, scale bar: 100 nm. NPs were characterized by transmission electron miscroscopy (TEM)
(Technai Spirit TEM, FEI Company, Eindhoven, NL) by Dr. J. Mast at the Electron Microscopy Unit of the Veterinary and
Agrochemical Research Centre VAR-CODA-CERVA, Uccle, BE.
Another major phenolic compound present in human diet is resveratrol, which possesses
many beneficial health effects [137-141]. Considering abundance and health-promoting ef‐
fects of resveratrol, we have also investigated its potential protective activity against the Ag-
NP-induced cytotoxicity. The results indicated no protective effect of resveratrol and
moreover, at a concentration of 100 μM, non-toxic by itself, it increased the toxic effect of
Ag-NPs, illustrating a synergistic effect.
To conclude, it could be assumed that phenolic compounds, depending on the nature and
concentration, may exhibit different effects on cells in the presence on NPs. This is not sur‐
prising, as it is known that these substances, depending on concentration, may exhibit both
beneficial and toxic effects [141].
7. Future perspectives
Nanotechnology offers a wide range of opportunities for the development of innovative
products  and applications  in  agriculture,  food  production,  processing,  preservation  and
packaging. However, the present state of knowledge still contains many gaps preventing
risk assessors from establishing the safety for many of the possible food related applica‐
tions  of  nanotechnology [142].  Currently  the  routine  assessment  of  ENMs in  situ  in  the
food or feed matrix is  not possible,  as well  as equally impossible to determine physico‐
chemical  state  of  ENMs,  which  increases  the  uncertainty  in  the  exposure  assessment.
Complex  matrices  present  in  the  food  complicate  the  detection  and  characterization  of
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ENMs in final food/feed products, which itself contain a wide range of natural structures
in the nano-size scale.  The information on the potential  of  ENMs to cross the epithelial
barriers,  such as  the GIT,  blood-brain,  placenta  and blood-milk barriers  are  also impor‐
tant for hazard identification. It is also clear that the evaluation of the pro-inflammatory
potential of ENMs is another issue of current importance, as the inflammation itself is as‐
sociated with a number of high frequency diseases, e.g. cancer, diabetes, bowel diseases,
etc.
From the above discussion and the research presented in this review, the need for more toxi‐
cology research on manufactured ENMs is clear. In addition to standard tests, there is a
need to develop appropriate and rapid screening methods to be able to control the exposure
level, as well as improved models that will permit to assess the toxicity and allow better un‐
derstanding of the mechanisms that are involved. Employment of developed and well char‐
acterized in vitro cell culture systems may be relevant for evaluation of gut and immune
responses to ENMs and to adapt conditions to specific health conditions or to consumer
groups with special needs, such as in the case of bowel diseases. Further studies are necessa‐
ry to assess whether the characteristic daily intake of ENMs may exacerbate or trigger dis‐
ease symptoms in subjects with increased susceptibility, such as inflamed state of the GIT in
the case of IBD, CD, UC, or even be its cause.
Another aspect deserving thorough investigation is the possible interaction of ENMs with
food/feed components, which in turn could influence the overall behavior and effect of not
only ENMs, but also the bioavailability of food components.
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This book is an overview of invited contributions on recent data of inflammatory 
bowel diseases. The first part of the book covers topics related to the ethiopathogenesis 
of inflammatory bowel diseases including the environmental, genetic factors and 
immunological alternations. The next chapters deal with present day management of 
disease including radiological diagnosis and surgical treatment, which consider the 
advances of most up-to-date radiological methodology including MRI techniques 
and the role of surgical procedures in the therapy. The final part presents medical 
therapy and its future directions. These chapters discuss natural products exerting 
anti-inflammatory and anti-tumour effects, methods of colon targeting drug delivery 
systems including polysaccharides, peptides and nanoparticules; as well as the 
potential risks of nanotechnology based food materials.







ISB  978-953-51-7047 1
